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Abstract 
 
 
Background 
 
Cancer is the most common non-injury cause of death after cardiovascular diseases in Iran. 
Estimation of the burden of cancer in terms of incidence, mortality, and prevalence is the 
first step to plan control measures in every country but for almost 40 years there were no 
population-based cancer statistics in Iran to reveal cancer burden. This study is designed to 
ascertain the incidence of cancers in Iran, and develop and test a new method to adjust for 
ascertainment bias in the evaluation of cancer registry data.  
 
 
Material and Methods 
 
A retrospective survey in five provinces of Iran (Ardebil, Gilan, Mazandaran and Golestan 
in the north, and Kerman in the south) carried out for five years, 1996–2000. These 
provinces composed 15.7% of about 60 million population of Iran in 1996. Available 
medical records of cancer patients in public/private hospitals and diagnostic/treatment 
facilities, and death certificates of these five provinces were compiled, computerized and 
duplicate reports were eliminated. Eighty four percent of cases were microscopically 
verified and death certificate only (DCO) cases constituted 0.1% of cases.  
 
Relative age-standardized ratio (RASR) was calculated by ASR of each cancer divided by 
ASR of leukemia. Adjusted relative age-standardized rate (ARASR with same unit as ASR) 
is calculated by multiplying the RASR for a specific cancer in a particular year by the sum 
of ASRs of that cancer over the years for which a trend is being determined and then 
dividing result by the sum of RASRs of the cancer for those years.  Two likely assumptions 
are behind use of ARASR, first, constant ASR of leukemia over time, second, if 
under/over-registration occurs, it happens to all cancers in the same extent (random 
under/over-reporting). 
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Results 
 
During the five years of study, there were 28,022 new cancer cases (57% men; 42% 
women; 1% unknown sex). The mean age at diagnosis was 55 (median age 60). In terms of 
age-standardized rate (ASR per 105), the most common cancers in men were stomach 
(22.5), esophagus (12.1), bladder (7.5), lung (6.5), colon/rectum (6.2) and prostate (5.6). 
The cumulative rate for 0–69 years of life in men was 7.8%. The leading female cancers 
were breast (13.3), stomach (9.3), esophagus (8.9), colon/rectum (6.0), leukemia (2.4) and 
cervical cancer (2.3). The cumulative rate for 0–69 years of life in women was 6.4%. In 
terms of incidence among these five provinces, stomach cancer had the highest rate in 
Ardebil province in both sexes. Highest rate of esophageal cancer was in Golestan in both 
sexes. Breast cancer was highest among Kermanian women. Highest rate of bladder and 
prostate cancer was recorded for Gilanian men whereas Gilanian women had highest rate of 
colorectal cancer. Highest rate of lung cancer found among Mazandaranian men. 
Kermanian men had the highest rate of skin or hematological neoplasms such as leukemia 
or lymphoma. It is predicted that the annual number of new cases in year 2010 in Iran 
compared to 1996 will increase 65% (women 95%; men 46%) at least to 53,000 persons. 
 
A new method was developed and tested on some complete and incomplete cancer registry 
data to adjust for ascertainment bias in cancer registry data. In registries with incomplete 
reporting, ARASR was a better estimate for time trend analysis. ARASRs in different 
countries or different times were comparable since they were already standardized for age 
structure. In addition, comparison between time trend of ASR and ARASR could be used 
to evaluate completeness of registration. 
 
 
Conclusion 
 
Generally the incidence of cancer in Iran was among lowest in the world. Cervical cancer 
was lower than even low risk countries such as China, Kuwait or Spain. Compared to 30 
years ago, the incidence of esophageal cancer declined to approximately two thirds of its 
previous level in both sexes. However, the incidence of all other cancers increased 
dramatically up to 120%. Although this increase was unrealistically high, most likely 
because of under-registration of other malignancies than esophagus 30 years ago, the real 
change seems to be in the same direction but with slower slope. 
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The 65% predicted increase in the number of new cases by year 2010 is a huge burden for 
the health care system because by adding the number of old cases to these cases, the 
number of prevalent cancer patients will be substantially higher in 2010, especially in 
women.  
 
The estimates by GLOBOCAN2002 and the results of this study were highly concordant 
because they shared the majority of their data sources except for Gilan (only available in 
this study) and Tehran (only in GLOBOCAN2002). 
 
ARASR is more accurate than ASR in studying cancer incidence trends in registries with 
incomplete reporting. ARASRs in different countries or different times are comparable 
since they are age-standardized. Moreover, comparison between trend of ASRs and 
ARASRs can be used as a test for validity of registration. 
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1. Introduction 
 
Cancers (malignant tumors) were responsible for 12 percent of the nearly 56 million deaths 
worldwide from all causes in the year 2000. In many countries, more than a quarter of 
deaths are attributable to cancer (Parkin et al. 2001). Based on recent available 
international data, there were 10.9 million new cancer cases (5.8 million men and 5.1 
million women), altogether 6.7 million died from this disease, and 24.6 million people in 
the world living with cancer in 2002 (within five years of diagnosis). The most common 
cancers in terms of new cases were lung (1.3 million), breast (1.2 million), colorectal (1.0 
million), stomach (933,000), and prostate (679,000) (Ferlay et al. 2004). The cancer profile 
varies greatly in different populations, and the evidence suggests this variation is mainly a 
consequence of different lifestyle and environmental factors, which can be influenced by 
preventive interventions (Parkin et al. 2005).  
   
Estimation of the burden of cancer in terms of prevalence, incidence, and mortality is the 
first step to plan control measures in every country. The 2000 estimate represents an 
increase of around 23% in incidence and mortality since the previous comprehensive 
estimates for 1990 (Parkin et al. 2001). World population growth and ageing imply a 
progressive increase in the cancer burden (50% increase in incidence equal to 15 million 
new cases and 10 million new deaths are expected in 2020, even if current rates remain 
unchanged) (Parkin 2001). The World Health Organization’s cancer report reveals that 
cancer has emerged as a major public health problem in developing countries, matching its 
effect in industrialized nations (WHO cancer report). The distribution of cancer between 
different populations and over time helps to define causal hypotheses, and to quantify the 
potential for prevention. Data on cancer occurrence and outcome are essential to forming 
health policy, by quantifying health problems, helping to define priorities for preventive 
and curative programs, and for evaluation of their outcomes in relation to resource inputs 
(Parkin et al. 2005). 
 
Since the burden of cancer varies between countries, each nation should find its own 
priorities to prevent this disease. Using other populations’ pattern for the countries where 
no data for cancer burden are available, not only is not always useful, but also can lead to 
wasting their scarce resources for health care. For instance, a screening program for 
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cervical cancer based on international recommendations in a country with very low cancer 
incidence and prevalence of cervix uteri diverts resources away from necessary actions for 
control of more common cancers or other diseases. Therefore, estimation of cancer burden 
is essential before starting interventions. Knowledge of regional variations of cancer 
burden will help to specify priorities and guidelines for budget and health policy. 
 
At the beginning of this study, there was no valid data available for the cancer burden of 
Iran in recent years. There were only some scattered hospital-based cancer registers which 
did not provide accurate estimates for incidence rates in the population. On the other hand, 
there was relatively reliable evidence about high incidence of esophageal cancer in the 
northern Iran from a joint study by International Agency for Research on Cancer (IARC) 
experts and Iranian researchers which dates back more than 35 years. Due to this lack of 
reliable data, as the first step to learn about the present situation, a large-scale study on the 
incidence of all cancers seemed very necessary. Therefore, this study was designed by 
Digestive Disease Research Center, an affiliate of Tehran University of Medical Sciences 
(DDRC) to quickly ascertain the recent situation of cancer incidence in Iran by a 5-year 
retrospective active registration of all accessible records of cancer patients (1996–2000) in 
a vast area of Iran (5 provinces of Ardebil, Gilan, Mazandaran, Golestan and Kerman 
which constitutes around 16% of the whole population of Iran). The role of the author of 
this dissertation started right after the data collection and includes coding, data 
management, data analysis, assessment of data quality, development of two methods to 
improve data validity, presentation of results, and interpretation of results. 
 
The rest of this chapter is about some basic concepts of descriptive epidemiology used in 
this dissertation, principles of cancer registration and health care system in Iran. 
 
 
1.1 Basic concepts  
 
There are several measures of cancer burden in a population. The following discussion is 
presented specifically in relation to cancer, though in most instances the terms discussed 
have general application. 
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1.1.1 Measures of occurrence of cancer 
 
To perform epidemiological research for quantifying the occurrence of diseases in 
population, three items must be clearly defined:  
1. What is meant by a case, i.e., an individual in a population who has the disease, or 
undergoes the event of interest (e.g., death).   
2. The population from which the cases originate.  
3. The period over which the data were collected (dos Santos Silva 1999, 57). 
 
 
1.1.1.1 Frequency 
 
Frequency is the measurement of the number of times that a repeated event occurs per unit 
time. To calculate the frequency, one fixes a time interval, counts the number of 
occurrences of the event within that interval, and then divides this count by the length of 
the time interval. In epidemiology, it can be the number of occurrences of an event such as 
new cases of cancer in a defined population over a specified period of time.  
 
 
1.1.1.2 Prevalence 
 
Point prevalence is the proportion of existing cases (old and new) in a population at a 
single point of time. Although as with any proportion, prevalence has no time unit, the 
point in time to which it refers must always be specified (dos Santos Silva 1999, 58). 
 
 
1.1.1.3 Risk 
 
Risk is the proportion of people in a population that is initially free of disease who develop 
a disease within a specified time interval. Risk is calculated by number of new cases of 
disease arising in a defined population over a given period of time divided by number of 
disease free people in that population at the beginning of that time period. This measure of 
incidence can be interpreted as the average probability or risk that an individual will 
develop a disease during a specified period of time. Risk has no time unit, however as its 
value increases with the duration of the follow-up, the time period to which it relates must 
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always be clearly specified (dos Santos Silva 1999, 60). To calculate the risk accurately, 
the population under follow-up should be closed (no new person enters and nobody exits), 
so every person free of disease at the beginning of the time period should be followed up to 
the end of the period although this is not often the case in reality. Therefore, this is a 
limitation of using risk which does not allow us to take into account information of persons 
who are called “lost to follow-up” before the end of the specified time period.  
 
 
1.1.1.4 Incidence rate 
 
Incidence rate is a measure of the frequency (also called incidence density) with which an 
event, such as a new case of illness, occurs in a population over a period of time. The 
numerator is the number of new cases of disease occurring in a defined population during a 
given time period; the denominator is the total person-time at risk during that period (dos 
Santos Silva 1999, 63). The person-time can be calculated by the number of people at risk 
multiplied by the time they were followed-up; for instance, for a source population of one 
million, when they all were followed-up for three years, the total person-time is three 
million person-years. However, sometimes the person-time is calculated for individuals 
separately (if they were not followed-up equally or entirely) and are summed to calculate 
the total person-time (e.g. in cohort studies). 
 
Incidence can be as a rate per 100,000 persons per year or even per million person-years. It 
provides an approximation of the average annual risk of developing a disease (i.e. cancer), 
which is (after age-adjustment) useful in making comparisons between populations 
(countries, ethnic groups, or different time periods within a country for example) if age-
standardized rate is used (Stewart and Kleihues 2003, 18). Ideally, we would like to know 
the risk of an individual in the population being diagnosed with cancer at a given age and 
specific point in time (xt, the instantaneous incidence rate or force of incidence at age x and 
time t).  In practice, we are only able to estimate xt by observing the rate of occurrence of 
new cases of cancer in the population over a specific time period (the incidence rate) 
(Parkin et al. 2002). 
 
Crude rate is the simplest summary measure of incidence in a population, given by number 
of cases of all ages during a specific time period divided by total population-time at risk in 
that period or ∑∑
x
x
x
x mk  where kx and mx denote, respectively, numbers of cases and 
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the person-years at risk in age group x. Actually information about the age of cases or the 
age structure of the population at risk is not needed to calculate the crude rate. The only 
data required are total number of cases in a defined period of time and the total population-
time at risk. Crude rates, however, are not satisfactory for comparing populations.  This is 
because some of the observed variation in the crude rates might be due to differences in the 
age structures of the populations being compared.  
 
In order to calculate the incidence rate, a count of the number of new cases is required 
which have occurred in the population during the period under study and an estimate of the 
person-time at risk (person-years at risk). It is important to understand that the 
denominator in the calculation of an incidence rate should be defined in terms of units of 
person-time rather than simply the number of persons in the population at a specific point 
of time -as enumerated in population censuses or estimated by national bureau of statistics- 
(Parkin et al. 2002). 
 
1.1.1.5 Age-specific rates 
 
The age-specific rate for age group x, xλ , is calculated as xxx mk=λ  where kx and mx 
denote, respectively, numbers of cases and the person-years at risk in age group x.  For 
presentational purposes, it is conventional to multiply xλ  by 100,000 to show a rate per 
100,000 person-years at risk (or multiply by million for rate per 106 person-years). To 
calculate age-specific rates, both the age group of cases and the age structure of source 
population are needed. 
 
The number of cases observed, and therefore also the rate, is subject to random variation.  
The nature of the variation in count data is dealt with by using the theoretical probability 
distribution known as the Poisson distribution. To have an accurate estimate of the 
theoretical rate x and because of random variation, the larger the number of observations of 
kx, the more accurate the estimate would become.  In descriptive cancer epidemiology we 
are restricted to a single observation of kx, but one can use the Poisson distribution to 
determine how confident one can be that the true value of x  lies within a specified range of 
values centered on our ‘best estimate’ of x which is xλ .  This is called a confidence 
interval. Another method of taking the random variation into account is to calculate and 
present p-value, which is the probability of chance in obtaining an estimate such as rate. 
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Age-specific rates provide an indication of how cancer risk develops with age in a 
population. It is also the preferred starting point when comparing incidence in two 
populations. Plots of the age-specific rates can alert the researcher to anomalies in the data 
or to features which might suggest birth cohort effects or differences in patterns of 
exposures to risk factors or other lines of investigation for further analysis. 
 
Usually, cancer incidence increases rapidly with age.  It is useful to plot age-specific curves 
on a logarithmic scale because the data points for the low incidence young age groups are 
not obscured by the large values for older age groups.  Another advantage is that 
differences in age-specific rates between populations are often approximately proportional 
on the arithmetic scale and therefore constant on the logarithmic scale.  
 
 
1.1.1.6 Age-standardized incidence rate (ASR) 
 
Age-standardization is a way of accounting for the population age structures under study 
and a number of methods of calculation are available.  The direct method involves applying 
the age-specific rates in the population of interest to a fixed reference or standard 
population.  In other words, this is incidence rate weighted with a set of external reference 
values (weights). The most frequently used standard population is the world standard 
population, so that the all ages world rate is calculated as ∑
x
xx wλ where wx  is the 
proportion of the total standard population in age group x of the standard 18 age groups and 
xλ  is the age-specific rate for age group x. Therefore, to calculate the ASR, in addition to 
age group of cases and age structure of source population, proportion of the total standard 
population in each age group is needed (Table 1). A disadvantage of using the world 
standard population for standardization of incidence data for more developed country 
populations is that a large proportion of the world standard population is in young age 
groups, whereas most cases of cancer occur in older age groups. This means that 
disproportionately more weight is attached to the incidence rates for younger as opposed to 
older age groups although it is not a real problem for comparisons.  
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Table 1. World standard population used 
for computation of age-standardized 
incidence rates 
 
 
 
 
 
 
 
 
 
 
 
 
 
Age group (yr) World (n) 
0–4 12,000 
5–9 10,000 
10–14 9,000 
15–19 9,000 
20–24 8,000 
25–29 8,000 
30–34 6,000 
35–39 6,000 
40–44 6,000 
45–49 6,000 
50–54 5,000 
55–59 4,000 
60–64 4,000 
65–69 3,000 
70–74 2,000 
75–79 1,000 
80–84 500 
85+ 500 
Total 100,000 
The age-standardized rates can be adjusted to account for the cases of unknown age. This 
can be done simply by multiplying the standardized rate, based on cases of known age, by 
T/K where T is the total number of cases of cancer of the same type in persons of the same 
sex; K is the number occurring in persons of known age. The standard errors can also be 
multiplied by the same correction factor T/K. The assumption underlying this correction is 
that the ages of cases are missing randomly; the probability that the age of a case is 
unknown does not depend on the age of the case (Parkin et al. 2002, 88). If this assumption 
is violated, it may cause bias in the results although the extent of this bias depends on the 
percentage of cases of unknown age out of all cases. 
 
An alternative form of age-standardization, known as the indirect method, involves 
calculating the ratio of the total number of cases observed in a population, O = kx, to the 
number of cases which would be expected, E, if the age-specific rates of some reference 
population applied.  The expected number of cases in a comparison population is given 
by∑
x
xxm λ where the xλ  is age-specific rate for the reference population in age group x 
and mx denotes number of persons in the population of interest in age class x.  The 
standardized incidence ratio (SIR), expressed as a percentage, can then be calculated as 
SIR=O/E × 100 (Estève et al. 1994). 
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1.1.1.7 Cumulative rate and cumulative risk 
 
A feature of both the direct and the indirect methods of standardization is the necessity of 
choosing an arbitrary reference population. This can have misleading results if the 
structures of the study and reference populations are grossly different. An alternative 
proposed by Day (1987, 787–789) is based on the sum of age-specific rates, giving equal 
weight to all age groups. In fact, each age-specific rate is multiplied by the length of the 
age group in years, which is 5 years for all age groups up to 80–84.  The oldest age groups 
are usually excluded since we are interested in the cumulative incidence up to a specific 
age.  Thus the cumulative rate up to age 70 is calculated as ∑
=
14
1
5
x
xλ  from which the 
cumulative risk, expressed as a percentage, can be estimated as 
100)1( ×− − RateCumulativee (Parkin et al. 2002, 87).  The difference between cumulative risk 
and rate is small when the value of cumulative rate is less than 10. For instance, the 
cumulative risk 100(1–e-x) for values of cumulative rate (100x) 0.5, 5 and 7% are 0.499, 
4.88 and 6.76% respectively. 
 
The cumulative risk can be interpreted as an approximation to the cumulative 'lifetime' (age 
0–69 inclusive) risk of disease for an individual if, throughout their life, they were to 
experience the same age-specific risks as the population from which the cumulative rates 
were calculated, and were free from competing causes of death. The percentage cumulative 
risk provides a statistic which is comprehensible to lay people.  For example, if someone is 
told that they have a 10% lifetime risk of lung cancer, this is more likely to dissuade them 
from smoking than the information that the ASR of lung cancer is 80 per 100,000 person-
years.  
 
 
1.1.2 Validity 
 
Validity is equivalent to lack of systematic error (bias). The validity of a study is usually 
divided into two components: the validity of the inferences drawn as they pertain to the 
members of the source population (internal validity), and the validity of the inferences as 
they pertain to people outside that population (external validity or generalizability) 
(Rothman and Greenland 1998, 118). Validity in cancer registration is defined as the 
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proportion of cases in a dataset with a given characteristic (e.g., site or age) which truly 
have the attribute (Parkin et al. 2002, 68). Data validation in the process of cancer 
registration is to ensure that the quality of data is as high as possible and no invalid codes 
are fed into the database, these may take the form of a range check (for example, that no 
patient’s age can be less than 0 or greater than, say, 110) (Jensen et al. 1991). The term 
“accuracy” is a rather similar concept which denotes the degree of conformity of a 
measured or calculated quantity to its actual, nominal, absolute, or some other reference 
value. 
 
1.1.3 Reliability   
 
Reliability, sometimes also called repeatability or reproducibility, is a measure of the 
consistency of the performance of the test when used under similar circumstances. To be 
valid, measurement must be reliable. However, reliability is not in itself sufficient for 
validity: in other words, a test may yield the same result consistently, but the result may not 
be the true (valid) one (dos Santos Silva 1999, 25). The term “precision” is a rather similar 
concept which characterizes the degree of mutual agreement or repeatability among series 
of individual measurements, values or results or in other words it is lack of random error 
(Rothman and Greenland 1998, 116). 
 
1.1.4 Confidence interval 
 
In strict terms, the confidence interval is a range of values that is likely to cover the true 
population value but we are not certain that it will. The confidence interval is based on the 
concept of repetition of the study under consideration. Thus if the study were to be repeated 
100 times, we would expect 95 of the 100 resulting 95% confidence intervals to include the 
true population value (dos Santos Silva 1999, 106).  
 
 
1.2 General principles of cancer registration 
 
Cancer registration starts with collecting data about patients with malignant diseases (and 
in some cases includes some benign tumors as well). The data collected identify the 
demographics of the patient with the disease, the type of cancer, and sometimes how it is 
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treated and the outcome of the patient. The data collected are kept in a cancer registry, a 
term which can simply mean the database or data system that manage and analyze the 
information, or data system and all of associated systems and personnel who perform 
cancer surveillance and cancer control (Gail and Benichou 2000, 127). 
 
1.2.1 Cancer registration types  
 
Hospital-based cancer registration is the process of making a cancer database maintained 
in a health care facility and providing information on all cancer patients who use the 
services of that facility for diagnosis, staging, and treatment. Hospital-based cancer registry 
records all new cases in a given hospital, usually without knowledge about the background 
of population (Jensen et al. 1991, 23). The service population for a hospital-based registry 
may not be definable and varies from facility to facility, depending on the types of 
specialty treatment it offers, the types of third-party payers it attracts, and a number of 
other factors. As a result, the number of potential patients in the facility’s customer base 
can only be estimated. A hospital-based cancer registry can calculate frequency of cases 
and measure outcomes for patients it monitors. A hospital-based cancer registry cannot 
provide incidence rate because the denominator population at risk is not known (Gail and 
Benichou 2000, 127). 
 
Population-based cancer registration is done in a centralized cancer registry with a 
database covering a known population, usually residents of a defined geographic area, such 
as a county or state. Because the population denominator can be counted or estimated by 
census, a population-based registry can provide incidence rates. Population-based registries 
are the principal source of cancer surveillance data. Population-based cancer registries must 
collect information on cancer patients from variety of sources, including registries in 
hospital and other healthcare facilities, physician offices, pathology laboratories, and 
sometimes facilities outside the defined geographic area to which residents travel for 
cancer diagnosis and treatment. The hospital registry may form the nucleus for a 
population-based cancer registration scheme (Jensen et al. 1991, 23). Population-based 
cancer registries can be of two types: (1) those that report incidence only (the first report of 
a new cancer) or (2) multipurpose registries that collect data on incidence and subsequent 
outcomes such as prognosis or death (Gail and Benichou 2000, 127). 
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Methods of data collection (notification methods) traditionally have been classified as 
active or passive. Active reporting (collection at source) involves registry personnel 
actually visiting the sources of data and abstracting the required information onto special 
forms or obtaining copies of necessary document. Passive (or self-) reporting relies upon 
other health care workers to complete notification forms and forward them to the registry, 
or to send copies of discharge abstracts etc. from which the necessary data can be obtained. 
This passive process also can be automated (computerized). In practice, a mixture of these 
two systems may be used, with, for example, active hospital visits being supplemented by 
passive receipt of copies of pathology reporting forms and death certificates mentioning 
cancer (Jensen et al. 1991, 37). 
 
1.2.2 Registry operations 
 
The four main aspects of registry operations are: case ascertainment, abstracting and 
coding, follow-up or mortality follow-back and quality control. 
 
 
Case ascertainment 
 
Case ascertainment, also called case finding, is the process of identifying patients with 
malignant disease who meet the criteria for inclusion in the registry. Because cancer 
surveillance requires monitoring of cancer incidence and mortality, case ascertainment 
must identify all cases of the disease in that defined population, regardless of where the 
cancer patient encounters the healthcare system; including hospitals, independent treatment 
centers, clinics, pathology laboratories, physician offices, and nursing homes (Gail and 
Benichou 2000, 128). The main source of information is usually hospitals, or cancer 
centers, but depending on the local circumstances, a population-based registry also involves 
private clinics, general practitioners, laboratories, coroners, hospices, health insurance 
systems, screening programs and central registers (Jensen et al. 1991, 29).  
 
Most cancer patients come to a hospital at some points in their disease process, usually for 
a biopsy or treatment; thus, hospital medical records are an important source of case-
finding. In hospitals, medical records are coded and indexed by disease and procedure so 
that patient records can be retrieved for analysis. The database containing these codes is 
one of the principal sources of case ascertainment in a healthcare facility. Specific codes 
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for cancer diagnosis and treatment permit retrieval of records related to reportable 
neoplasms that must be included in the registry (Gail and Benichou 2000, 128).   
 
A neoplasm is a “new growth’ or tumor that developed somewhere in the body. The term 
neoplasm refers to, benign, malignant (having the potential to spread from site of origin 
and ultimately kill the patient) or borderline tumors (uncertain whether benign or 
malignant). A reportable neoplasm is a tumor that meets the inclusion criteria for a registry. 
Reportable neoplasms are well defined in the International Classification of Disease for 
Oncology, a coded nomenclature published by World Health Organization (WHO).  This 
coding system defines each type of tumor and its behavior: benign, uncertain malignant 
potential, in situ, invasive, or metastatic. The reportable neoplasms collected by all general-
purpose cancer registries are those that are malignant (in situ and invasive). Metastatic 
tumors (malignancy growing in a site at a distance from origin in which started) are not 
reported individually; rather, metastases are reported as progression of the tumor at the site 
of origin. Occasionally a central registry will require that another type of tumor be 
reported, such as benign brain tumor, which cannot spread but do have the potential to be 
lethal, and tumors of uncertain malignancy, such as carcinoids of appendix. On the other 
hand, a few cancers are very common and are associated with such a good prognosis that it 
is generally not of public health importance to monitor their outcomes, such as basal cell 
and squamous cell carcinomas of the skin (Tyczynski et al. 2003, 10) and carcinoma in situ 
of the cervix.  
 
 
Abstracting and coding 
 
Abstracting is the process of deriving and recording relevant data about each reportable 
case. The resulting document, the abstract, is an abridgment or summary of what happened 
to the patient, and may be in paper or electronic form. Data items include personal 
identification and demographics of the patient (at least name, sex, date of birth or age, and 
address), a description of the disease (site of origin, type of malignancy), stage at diagnosis 
(documentation of how far the cancer had spread when it was diagnosed), and treatments 
(Jensen et al. 1991, 29) as well as incidence date and most valid bases of diagnosis 
(Tyczynski et al. 2003, 1).  
 
Parts of the abstract are encoded, such as site and type of cancer, stage, and treatment. In 
addition to the standard data items, some registries collect information on items of special 
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interest, such as smoking history, family history of cancer, or co-morbid conditions. As 
noted previously, a population-based cancer registry can be either incidence-only or 
multipurpose. If the registry is incidence-only, then the registry does no outcome 
assessments. However, outcome measurement is for describing the results of treatment and 
disease process in terms of survival rates and mortality. Abstracting rules and guidelines 
have been developed to cover nearly every situation, but human interpretation of both the 
facts of case and the rules of abstracting can sometimes cause problems, and there is 
always the danger of incorrect data entry. As a result, a series of edits have been developed 
and included in most cancer registry database systems (Gail and Benichou 2000, 128). 
 
There are several types of edits, including range checks and logic checks. The simplest 
edits are range checks or allowable codes. Logic checks are a type of inter-item edit where 
the program searches in two or more data fields to ensure that they make sense together. 
For example, an error message should be generated when ‘sex’ is male and “primary site’ 
is cervix. Inter-item edit can be quite complex, such as searching for a morphologic disease 
code as noninvasive, the corresponding stage at diagnosis coded as in situ, the method of 
diagnostic confirmation coded histologic, and the sites of distant metastasis field that 
should be left blank (Jensen et al. 1991, 104–106). Computer edits such as these are the 
first line of protection against inaccurate data. Other editing mechanisms and preventive 
measures such as training and standardization of procedures are described in the following 
on data collection and quality control (Gail and Benichou 2000, 129). 
 
An additional function of population-based central registries is case consolidation or case 
matching. Because the registry receives reports from many sources, it is necessary to 
identify multiple reports on the same patient so that the case is not counted more than once 
and there are no duplicate registrations for the same tumor (Jensen et al. 1991, 82–83).  
Case consolidation involves not only various computer algorithms but human review as 
well. For example, Hospital A might send a report on Rich Smith with a birth date of 
November 19th, 1935 and a diagnosis of sigmoid colon cancer, and Hospital B might send 
in a report on Fredric Smith with a birth date of November 18th, 1935 or November 19th, 
1935 and diagnosis of rectal cancer. The registry must decide whether these reports are 
about the same patient, and, furthermore, whether they are about the same cancer. Without 
a case consolidation operation in the registry, the numerator (newly diagnosed cases) of the 
incidence rate may be inflated (Gail and Benichou 2000, 129). 
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Occasionally a patient with cancer will be missed in the case ascertainment process and not 
be abstracted into the registry database. Missing a case leads to under-estimation of the 
incidence rate for that particular cancer. Thus high completeness is important for accurate 
cancer data. If a previously unreported cancer patient dies, a cancer diagnosis on death 
certificate may be the first and only report of the cancer case. It is good policy for a registry 
to follow-back a death certificate only (DCO) case to find out where it was missed in the 
case finding process. Trace-back is the process of contacting physicians and facilities noted 
on the death certificate to review their medical records to determine any earlier diagnosis or 
treatment of the cancer (Parkin et al. 1994, 49). In many instances, the case was simply 
missed, so the abstract is processed as a late report and reporting-source procedures are 
investigated. In other instances, death certificate diagnosis is the only identification of the 
case. These cases are tagged as DCO in database, and usually very little information is 
available about them (Gail and Benichou 2000, 130). A registry monitors its percentage of 
DCOs as part of its quality control processes; number of DCO cases as a proportion of total 
incident cases is an indicator of validity (Parkin et al. 1994, 45). 
 
  
 
Quality control 
 
Quality control encompasses all the registry activities that monitor and resolve data 
problems. Quality control usually deals with facts and data items. On the other hand, 
quality improvement or quality management usually deals with procedures and processes. 
Quality control is performed on all aspects of registry operations. Standards have been 
established for case completeness, database completeness, accuracy and reliability of data, 
and timely reporting of cases to the registry. The purpose of quality control is to determine 
whether these standards are being met (Gail and Benichou 2000, 131).  
 
Quality has been defined as “fitness for use”. Analysis of data which are not fit for use can 
result in incorrect conclusions and inappropriate cancer control and cancer surveillance 
activities. The principal components of data quality are accuracy, completeness and 
timeliness. Completeness has at least two aspects: completeness of database and 
completeness of data in each record. Completeness of database means that all cases in the 
population under investigation have been included for specified time period. Without a 
complete database, incidence rates and relative frequencies may be inaccurate. 
Completeness of the database is a function of thorough case ascertainment, described 
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above. Completeness is assessed by several techniques, including re-casefinding studies, 
projections of the number of cases reported in previous years, and the ratio of incidence to 
mortality for all cancers combined and for selected cancers (Gail and Benichou 2000, 131). 
Completeness of data in each record means that all the variables (sex, age, pace of 
residency, topography, morphology, etc.) for each record (e.g. each person) are filled. 
 
 
1.2.3 Data validity 
 
Validity is an essential component in assessing the quality of cancer registry data. It is 
operationally defined as the proportion of cases in the registry with a given characteristic 
(e.g. cancer site, or age) which truly have the attribute. Thus, the validity of recorded data 
depends upon the accuracy of data source documents (correctness and lack of error), and 
the quality in abstracting, coding and recording this information for the registry data base 
(Parkin et al. 1994, 42). 
 
Goldberg et al. (1980) identified three methods of evaluating validity: (1) diagnostic 
criteria method, (2) re-abstracting record method, and (3) internal consistency methods. To 
these might be added the percentage of registrations with missing information for indicator 
variables. The diagnostic criteria method determines the percentage of registered cases 
fulfilling criteria of diagnostic accuracy. For cancer registries, the percentage of cases 
histologically verified is considered positive indicator of data validity, while the percentage 
of cases registered on the basis of information on death certificate only is considered a 
negative correlate of validity (Parkin et al. 1994, 42). 
 
The proportion of cases with missing information for indicator variables is also an indicator 
of validity. Thus, the percentage of cases registered with an unknown or ill-defined primary 
site is clearly related to quality of diagnostic information. A high percentage of cases with 
unknown age may occur in populations with many persons unsure of their age, or 
alternatively may result from careless or incomplete record keeping or having no 
population registry. The re-abstracted record method is the most objective method of 
evaluating validity. It relies upon a careful comparison of the registry record with 
documents relating to the case, usually by an independent observer (Parkin et al. 1994, 42).  
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The internal consistency method is a checking for impossible codes or impossible and 
implausible combinations of codes for different variables in the same case record (Jensen et 
al. 1991, 212). The usefulness of internal consistency checks in evaluating validity is 
limited. Clearly, only impossible codes or combinations can be identified in a single stage. 
Unlikely combinations of codes (age vs. site/histology, site vs. histology) require 
verification via source documents to identify errors. All incorrect codes and combinations 
cannot be identified. Nevertheless, the percentage of records deemed impossible or 
unlikely, provides an approximate indication of the validity of the data. It is nonetheless 
important to monitor internal consistency of registry data, i.e. to determine whether the data 
appear to be of the type expected and whether there is coherence between the individual 
data types. The complexity of this type of quality control operation varies from a rapid 
visual scan of an abstract to check all the essential items, to extensive edit programs carried 
out by computer which are designed to flag any inconsistency (Parkin et al. 1994, 60). 
 
 
1.3 Cancer registration in developing countries 
 
At first sight, it may seem that cancer registration is a luxury that ought to occupy a lowly 
place in the priorities of health services of a developing country, given the many competing 
demands upon usually slender financial resources. Yet this would be a mistaken belief, 
firstly because cancer is already a significant health problem in the developing countries of 
the world, and one that is likely to increase in the future, and secondly because the presence 
of adequate information is an essential part of any cancer control strategy (Jensen et al. 
1991, 185).  
 
Over 10 million new cases and over 7 million deaths from cancer occurred in 2000. The 
contribution of developing countries was 53% for incidence and 56% for deaths. But the 
future is more alarming since, by 2020, the total number of new cases is expected to 
increase by 29% in developed countries whereas, in developing countries an increase of 
73% is expected, largely as a result of ageing, urbanization and change in dietary habits 
(Boutayeb 2006). The young age structure of the developing countries means that the 
overall (crude) incidence rates appear to be low, even though age-specific risk may be a 
little different from that in the developed world. The young age of the population does 
mean, though, that much of the burden falls upon individuals in the active age range of 25–
64, with a correspondingly great impact on family life. Moreover, the size of this problem 
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is bound to increase, given the rapid increase in population of many of these countries and 
with control of infectious disease and reducing of family size, and so increase in the 
proportions of the elderly (Jensen et al. 1991, 185). 
 
In general, cancer registration is a laborious task in developing countries, owing to 
shortages of medical facilities and personnel. The problem of identification of individuals, 
comprehensive case finding and definition of the reference population are most difficult to 
solve, and the risk of bias is always present. It is wise to start simply with reports of 
relative frequencies by sex and ethnic group, but the ultimate objective should be to register 
cases from a defined population so that incidence rates can be calculated, even though 
these, initially, maybe underestimates of the true rates (Jensen et al. 1991, 198).  
 
Regarding the optimal size of population covered by a cancer registry, there is no firm 
recommendation or rule. In practice, however, most cancer registries operate with a source 
population of between one and five million. With larger populations it may be difficult to 
maintain completeness or quality of the data; with smaller populations it takes longer to 
obtain meaningful figures. In countries with large populations, autonomous but linked 
regional registries may be more effective if facilities and resources allow operating this 
way. In smaller countries, national registration is feasible, such as in Kuwait with 1.9 
million people (Parkin et al. 2002). For countries in which national coverage is difficult to 
achieve, it is preferable to set up smaller registries in representative areas, as is done in the 
Indian Council of Medical Research cancer registry network (Jensen et al. 1991, 25). 
 
Based on information in latest version of the book “Cancer Incidence in Five Continents 
Vol. VIII” there are only three countries around Iran that have population-based cancer 
registry (Parkin et al. 2002). They are all in the southern part of Iran, Pakistan in the 
southeast (1995), Oman in the south with Oman Sea as the border (1985) and Kuwait in the 
southwest with Persian Gulf as border (1971; Figure 4). Oman and Kuwait are small Arab 
countries with nationwide cancer registry, but Pakistan has only cancer registry in its 
largest city, Karachi. Although these countries are different from Iran in many aspects, 
their religion, Islam, is common. 
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1.4 Cancer registration in Iran 
 
The need for cancer registration was recognized decades ago, but as the country was in 
challenging political changes four decades ago (government shifting from kingdom to 
republic and involving in a long devastating undesired war with Iraq), scarce resources for 
health care were not basically allocated to surveillances and registrations. However, in 
1984 a bill was passed by the National House of Representatives (Parliament) enacting a 
compulsory report of cancer cases to Ministry of Health and Medical Education so that any 
tissue removed from living persons (biopsy) should be sent to a pathology laboratory and 
laboratories are obliged to report neoplastic cases to the Ministry of Health. This was a 
good basic action that led to microscopic verification of the majority of cancer cases in 
recent years. Some efforts were made to start a nationwide cancer registry. As Iran is a 
relatively large country, it takes a lot of resources. Therefore, only pathologic-based cancer 
registration has been incompletely launched. Established cancer registries in Iran in the past 
and present are as follows: 
 
 
1.4.1 Babol (Mazandaran) cancer registry 
 
Cancer registration in Iran dates back to 1968 when IARC and IPHR tried to figure out the 
incidence of esophageal cancer in Caspian Littoral. This was the only population-based 
cancer registry in Iran, but unfortunately it ended after about 4 years but had a great impact 
on alarming the authorities and researchers to investigate the possible reasons for the 
highest reported incidence rate for esophageal cancer in the world in the southeastern part 
of the Caspian Sea where Turkmen live.  
 
 
1.4.2 Tehran cancer registry 
 
The first initiative came from the Cancer Institute of Tehran University (recently 
designated as a National Research Center) in 1998–9. The registry aims to collect data from 
all hospitals and laboratories in Tehran city (population more than 6 million). It is a major 
task, as there are 236 hospitals and 150 laboratories. Most cases (>80%) are from just 10–
11 hospitals, and the aim is to encourage hospital-based registries in these hospitals. A 
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major problem remains distinguishing permanent from temporary residents, and to obtain 
address of patients in cases detected in pathology laboratories. The first year data (1998) 
has been analyzed, although it is felt that this was something of a trial year and results have 
not been published anywhere. 
 
 
1.4.3 Shiraz (Fars Province) cancer registry 
 
The Shiraz registry dates from 1970’s. It is based upon registration of cancer patients 
treated in the Department of Radiotherapy in Namazi Hospital, plus cases diagnosed in the 
Pathology Department. In fact, the registry is combining these traditional two sources, 
together with case finding in four hospitals in Shiraz. Seven registry stuff (graduates in 
medical record technology) interview all patients found in patients services. The interview 
form is fairly complex and includes records of fertility variables, height, weight, smoking 
etc. The only output from this registry has been frequency data in spite of their detailed 
questionnaire for each cancer patient. 
 
 
1.4.4 Cancer registries in Ardebil and Gonbad 
 
In parallel with this study and after a feeling of need for a continuous systematic 
population-based cancer registry in the high incidence upper GI cancer areas, DDRC has 
established two active registries with permanent staff in Ardebil and Gonbad (eastern part 
of Golestan province) since 2003. 
 
 
1.4.5 National cancer registry 
 
The national registry is the responsibility of the Diseases Control Department of the 
Ministry of Health and Medical Education. The registry has undergone several 
modifications in strategy over the years. The obligation to notify the cancer registry of new 
cancer cases has been a legal requirement since 1994. But reporting to the Ministry of 
Health registry was far from complete. In the last few years, the strategy has been to 
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develop a system of national pathology registration, aiming, given the department’s limited 
budget, to automate the process as far as possible. 
 
Pathology departments throughout the country are being supplied with specially designed 
software (pathology accession and reporting system, PARS). This allows pathology 
departments to create their own database, based on specimens examined either all 
specimens or just cancer cases. It includes the facility, making it useable by beginners with 
minimal knowledge of ICD-O. A national model pathology notification form has been 
introduced, which designed to obtain demographic details of cases including full name and 
address. It is hoped that use of this form will be a prerequisite for reimbursement by 
insurance companies. A personal national unique ID has been issued for everybody in Iran 
recently but still is not completed to be used in the registries. The problems with this 
national registry are being only pathology based and the incomplete coverage of all 
pathology centers as well as having no output since establishment. 
 
 
1.5 Health care infrastructure in Iran 
 
During the 1960s and 1970s, the country experienced the expansion of health services 
through "Health Corps and Pilot Projects of Primary Health Care." However, it is since the 
Islamic Revolution in 1979 that the country’s health policy has been based on primary 
health care, with particular emphasis on expansion of health networks and programs in 
rural areas and with priority allotted to preventive over curative services.  
 
Recently, priority areas have included: reduction of population growth by use of family 
planning; control of diarrheal, respiratory and iodine deficiency diseases; integration of 
mental health, tuberculosis, leprosy, diabetes, and malaria programs into the primary health 
network system. In addition, community-oriented medical education; considerable increase 
of immunization coverage; reduction of maternal and infant mortality; increase of 
community participation; increase of basic environmental sanitation and adequate safe 
water in rural communities; and expansion of health networks, including the construction 
of district hospitals where needed. There is also the new policy of vaccination of women, 
which requires that all women of childbearing age, not only pregnant women, be 
immunized against tetanus.  
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The health budget doubled in 1991 compared with 1982–87. The declared policies have 
been made known to the different levels of government and nongovernmental sectors 
through the mass media as well as through publications and brochures. 
 
Many laws and regulations have recently been decreed which support the health for all 
policy. These include the law of economics, social and cultural development; this states 
that deprived areas should receive equal services with other areas so that, within eight 
years’ time, there should be no deprived areas in the country.  
 
Since April 1985, the expansion of health networks based on primary health care has been 
rapid. In both towns and villages, the first point of contact between the public and the 
health system is the health centre. However, in the villages, the health center performs its 
functions with the help of a large number of health houses, which effectively become the 
first point of contact. The responsibility of the rural health centre is to supervise, support 
and accept referrals from the health houses. 
 
District hospitals in towns offer services to referred cases from rural as well as urban health 
centers. District hospitals are responsible for higher level services to hospitalized and 
outpatients. The activities of the district health centers, as well as those of the district 
hospitals, are coordinated by the manager of the health network. Although, formally, this 
referral follow-up chain exists, it is somewhat weak, especially at the level of the rural 
health centre upwards.  
 
In addition, a shortage of doctors and to a lesser extent, the flight from the country of health 
professionals, including doctors, at the time of the revolution, has led to many rural health 
centers being staffed by expatriates, which affects the feedback and referral mechanisms 
and has decreased support for the health houses. This is being solved through a dramatic 
increase in the number of medical graduates and the formation of the Ministry of Health 
and Medical Education, which puts many medical facilities in service of training. Low 
literacy rates, especially in some rural areas and among girls, has made it difficult to find 
suitable candidates to be trained as community health workers and is affecting the 
expansion of the primary health care network in some parts of the country. Moreover, a 
shortage of funds and suitable facilities for health centers is also among the major obstacles 
impeding expansion of the primary health care network. 
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National health policies are decided at meetings of the Council of the Undersecretary of the 
Ministry of Health and Medical Education, headed by the Minister of Health and Medical 
Education. However, the initial information on needs for planning purposes is collected 
from the bottom up. In each district, there is a district planning council, to which each 
sector submits its planning needs in priority order. The plans approved by this council are 
referred for formal consideration to the provincial council, which, with due consideration 
of provincial priorities, coordinates the plans and ultimately sends them to the planning 
councils at the national level. The planning process is thus a two-way one: both top-down 
and bottom-up. 
 
The health network has been decentralized to district level so that implementation of 
programs is independent of central administrative and financial control. Entrusting full 
administrative and financial powers to provincial and district health centers has greatly 
facilitated the implementation of health for all strategies.  
 
An important development is the abovementioned establishment of the Ministry of Health 
and Medical Education, which combines responsibility for provision of health services and 
medical training. In each province, there is at least one university of medical sciences and 
health services. The chancellor of this university is in charge of all health affairs in the 
province, executing his duties through deputies for health, treatment, and so on. He also 
works with the deans of different health-related schools.  
 
The communities are actively involved in the planning and implementation of health 
services, mainly through the health councils in rural areas. The decentralization of 
administrative and financial management of health services has also increased community 
participation; this is in addition to the fact that all personnel working in rural health centers 
and health houses are locally recruited. Community involvement in large cities is not as 
impressive. 
 
In 1990, the Ministry of Health and Medical Education’s budget represented 12.9% of the 
total government regular budget while in 1998, expenditure of the social sectors, education, 
health and social security constituted 32.8% of total government expenditure. 
Approximately 40% of the Ministry of Health and Medical Education’s budget is spent on 
the primary health care system. The per capita total expenditure in health at international $ 
rate has been 498 in 2003. In 2004 GDP per capita has been US$ 8,367 and total health 
expenditure as percentage of GDP has been 6.5 percent in 2003 (WHO website). 
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Public health and primary health care now account for 13% of the medical curriculum. In 
2003, per 10,000 population, there were 4.5 government-employed physicians, 0.91 
dentists and 13.8 nursing/midwifery personnel. However, despite government incentives to 
attract physicians to rural, deprived areas, the distribution of physicians is very inequitable, 
with urban areas having rates of physicians more than 20 times higher than those in the 
deprived areas. 
 
As regards physical resources, there were 14.6 hospital beds per 10,000 population in 1988, 
rising to 16.3 in 2001. Available health facilities in 1988 included 8000 health houses, 3015 
health centers and 140 district health centers. The organization chart of primary health care 
system is shown in Figure 1. 
 
 
Figure 1. Primary health care system in Iran. 
 
Implementation of “health for all” strategies has improved the health status of the 
population, as indicated by the decreased mortality and increase in life expectancy (from 50 
years in 1960 to 68–72 in 2004). More than two-thirds of the population is currently 
covered by health care due to the expansion of the health centre network. Moreover, the 
expansion of water networks in towns and villages has resulted in 100% coverage of the 
urban population with safe water by year 2002 (98% covered with piped water in the home) 
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and hygienic sanitary facilities. In the same year, 83% of the rural population had access to 
safe water.  
 
There is more efficient use of human resources through the policy of local recruitment of 
staff for health centers. Although resources allocated to the health sector have doubled in 
recent years, the fact that the district health centers have become completely autonomous 
units, both administratively and financially, has also resulted in more efficient use of 
resources. 
 
 
1.5.1 Oncology care 
 
Cancer patients have different pathways for diagnosis and treatments in urban and rural 
areas (Figure 1). In rural areas a referral system exists so that first patients go to their 
nearest health house where a trained Behvarz (health worker with education at most 
diploma but trained intensively for primary health care) have a file for each household in 
the area and if they suspect serious diseases it will be referred to a physician at the rural 
health center. For further investigation, patient will be referred to district health center in 
the city where specialists are available (mainly pediatricians, gynecologists, surgeons and 
internalists). For advanced diagnostic procedure and treatment of cancer specifically, 
patients will be referred to highest level of health care system which are hospitals. All these 
usually take place within the province.  
 
This referral system is free of charge up to third level (except for drugs, for which patients 
have to use their insurance). For higher levels, the role of insurance companies is of great 
importance. There is an effort from the government to insure all rural inhabitants and it is 
going to be completed. Some non-governmental organizations such as the Special Diseases 
Foundation reimburse the expensive medicines used for treatment of cancer. Workers and 
employees, who have insurance from their employers, can use social security organization 
facilities. 
 
In urban areas, the referral system does not work as efficiently as in rural areas. Urban 
residents usually go to physicians by their choice and visit a specialist without being 
referred by general practitioners. In general, urban people have better socioeconomic status 
than rural and can use the social security organization facilities if they are workers, 
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employees or employers. Unemployed persons have to manage their needs by themselves, 
their relatives, or from charity organizations such as the Emdad Committee.  
 
Cancer cases records are best found in the hospitals (private or governmental ones). ICD 
coding is used in the hospital archive section but is not specialized for cancer so for a 
comprehensive search of cancer cases, all hospital discharge notes should be manually 
searched. Another place to find cancer cases is the pathology laboratories (governmental 
and private) which are forced by law to notify their neoplastic cases by Ministry of Health. 
Also, they have a computerized archive so it is very easy for the laboratories to send their 
data to the registry. Physicians’ offices and radiology departments usually do not archive 
the records of their patients, so they can only be used as a minor source except for 
oncologist offices which often is used for cancer registration. 
 
In this dissertation, information about cancer incidence in Iran is presented by cancer site, 
sex, age group, area of study, and year of study. Also, there are some discussions about 
quality issue and corrections made to improve the database used for this study.  In addition, 
based on incidence rates found by this investigation and considering the change in age 
structure of Iran population over the time, population growth and incidence trend, cancer 
burden in 2010 was estimated. In addition, a new method was developed and tested to 
adjust for ascertainment bias in the evaluation of cancer registry data. 
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2. Review of the literature 
 
In this chapter the magnitude of cancer burden worldwide and in national level will be 
discussed. 
 
2.1 Magnitude of cancer burden 
 
Cancer constitutes a major burden worldwide but there are marked geographical variations 
in incidence overall and at specific sites. Valid estimation of the number of new cases 
(incidence) requires population-based cancer registration. Compilation of worldwide age-
standardized cancer rates allows the identification of countries and regions where particular 
tumor types are most common. Such differences usually reflect exposure to distinct causal 
environmental factors. In addition to providing data on the distribution of neoplastic 
disease, descriptive epidemiology provides the basis for prevention, health service planning 
and resource allocation (Stewart and Kleihues 2003, 11). 
 
 
2.1.1 Global cancer burden  
 
Worldwide, cancer takes the lives of tens of millions annually. Based on recent incidence 
and mortality data available, there were 10.9 million new cases, 6.7 million deaths and 24.6 
million persons living with cancer (within five years of diagnosis) in the year 2002 (Parkin 
et al. 2005). This represents an increase of around 20% in incidence and mortality since 
1990. But the future is more alarming since, by 2020, the total number of new cases is 
expected to increase by 29% in developed countries whereas, in developing countries an 
increase of 73% is expected, largely as a result of ageing, urbanization and change in 
dietary habits (Mathers et al. 1999). 
 
In terms of incidence, the most common cancers worldwide (excluding non-melanoma skin 
cancer) are lung (12.4% of all cancers), breast (10.6%), colorectum (9.4%), stomach 
(8.6%), prostate (6.3%) and cervix uteri (4.5%) (Table 2). For any disease, the relationship 
of incidence to mortality is an indication of prognosis, similar incidence and mortality rates 
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being indicative of an essentially fatal condition. Lung cancer is the largest single cause of 
deaths due to cancer worldwide (1.1 million annually), since it has almost invariably poor 
prognosis (Figure 2). On the other hand, appropriate intervention is often effective to avoid 
death following early diagnosis of cancers such as breast cancer. Therefore, breast cancer, 
which in terms of incidence ranks second, is not among the top three causes of death from 
cancer, i.e. cancers of the lung (17.8% of all cancer deaths), stomach (10.4%) and liver 
(8.8%) (Stewart and Kleihues 2003, 11). 
 
Table 2. Age-standardized rate (ASR) for world by Globocan 2002 by sex and site. 
Male Female 
Cancer site Crude rate 
ASR 
(World) 
Cumulative rate 
(age  0–64) 
Cases 
×1000 Cancer site 
Crude 
rate 
ASR 
(World) 
Cumulative rate 
(age  0–64) 
Cases 
×1000
     All sites but skin 164.4 161.5 9.5 5,061 
All sites but skin 185.7 209.6 10.3 5,802 Breast 37.4 37.5 2.6 1,152 
Lung 30.9 35.5 1.7 965 Cervix uteri 16.0 16.2 1.3 493 
Prostate 21.7 25.3 0.8 679 Colon and rectum 15.3 14.6 0.7 472 
Stomach 19.3 22.0 1.2 603 Lung 12.6 12.1 0.6 386 
Colon and rectum 17.6 20.1 0.9 550 Stomach 10.7 10.3 0.5 330 
Liver 14.1 15.7 1.0 442 Ovary etc. 6.6 6.6 0.5 204 
Esophagus 10.1 11.5 0.6 315 Corpus uteri 6.5 6.5 0.4 198 
Bladder 8.8 10.1 0.4 273 Liver 6.0 5.8 0.3 184 
Oral cavity 5.6 6.3 0.4 176 Esophagus 4.8 4.7 0.3 146 
Non-Hodgkin lymphoma 5.6 6.1 0.3 175 Leukemia 4.2 4.1 0.2 129 
Leukemia 5.5 5.9 0.3 171 Non-Hodgkin lymphoma 4.1 3.9 0.2 125 
Larynx 4.5 5.1 0.3 139 Thyroid 3.4 3.3 0.2 103 
Kidney  4.1 4.7 0.3 129 Pancreas 3.5 3.3 0.1 107 
Pancreas 4.0 4.6 0.2 124 Oral cavity 3.2 3.2 0.2 98 
Other pharynx 3.4 3.8 0.3 106 Melanoma of skin 2.6 2.6 0.2 81 
Nervous system 3.5 3.7 0.2 108 Nervous system 2.6 2.6 0.2 81 
Melanoma of skin 2.5 2.8 0.2 79 Bladder 2.7 2.5 0.1 82 
Nasopharynx 1.8 1.9 0.1 55 Kidney  2.6 2.5 0.1 79 
Multiple myeloma 1.5 1.7 0.1 46 Multiple myeloma 1.3 1.2 0.1 39 
Testis 1.6 1.5 0.1 48 Other pharynx 0.8 0.8 0.1 24 
Thyroid 1.2 1.3 0.1 37 Hodgkin disease 0.8 0.8 0.1 24 
Hodgkin disease 1.2 1.2 0.1 38 Nasopharynx 0.8 0.8 0.1 24 
     Larynx 0.6 0.6 0 20 
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Figure 2. Global cancer incidence and mortality by sex and cancer site 
 
The most noticeable feature of the distribution of cancer between the sexes is the male 
predominance of lung cancer (Figure 2). Stomach, esophageal and bladder cancers are also 
much more common in men. Differences in distribution between the sexes are mainly 
attributable to differences in exposures rather than variation in susceptibility. For other 
tumor types, including cancers of the colorectum and pancreas, there is less difference in 
absolute sense between two sexes.  
 
The burden of cancer is distributed unequally between the developing and developed 
world, with particular cancer types exhibiting different pattern (Figure 3). All of Europe, 
Japan, Austria, New Zealand and North America are classified here as more developed 
regions, whilst Africa, Latin America and the Caribbean, Asia (excluding Japan), 
Micronesia, Polynesia and Melanesia are classified as developing or less developed regions 
(Stewart and Kleihues 2003, 11). 
  
 
 
 
Figure 3. Comparison of the most common cancers in more and less developed countries in 2002
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2.1.1.1 Lung cancer 
 
Lung cancer is the most common malignant disease worldwide, and is the major cause of 
death from cancer, particularly amongst men. It was a rare disease until the beginning of 
the 20th century. Since then, the occurrence of lung cancer has increased rapidly (Stewart 
and Kleihues 2003, 182) so that lung cancer has been the most common cancer in the world 
since 1985 (Parkin et al. 2005) and it now accounts for an estimated  965,000 new cases 
each year among men and  387,000 among women (Ferlay et al. 2004). 
 
Smoking is the most specific cause of lung cancer (Sela 2000). A causal association with 
lung cancer has been shown also for consumption of cigars, cigarillos, pipe, bidis, and 
water pipe (Blot and Fraumeni 1996, 637–665). In men, more than 80% of lung cancer 
cases are caused by smoking; in women, the attributable risk is less (about 70% in Northern 
Europe; 45% worldwide) (Stewart and Kleihues 2003, 182). Several other risk factors for 
lung cancer have been identified. Occupational exposures that increase the risk of lung 
cancer include asbestos (McDonald and McDonald 1987, 57–59). Asbestos exposure and 
cigarette smoking act synergistically, together raising the risk of lung cancer 
multiplicatively (Berry et al. 1985). Other occupational exposures related to lung cancer 
include arsenic (Blot and Fraumeni 1994, 207–218), chromium (Alderson et al. 1981), 
polycyclic aromatic hydrocarbons (IARC 1985), and radon. The latter exposure was first 
discovered among underground miners in North America, Europe, and Asia (Samet 1989), 
but is now a source of concern for the general population because many household 
basements show relatively high levels of radon. It is estimated that in the United States, 
indoor radon may be the second most important risk factor for lung cancer after cigarette 
smoking (Lubin et al. 1994). Lung cancer is also one of the major effects of exposure to 
high doses of ionizing radiation, such as in medical and atomic radiation. Various 
pollutants in urban air are implicated in lung cancer incidence rates worldwide (Blot and 
Fraumeni 1996, 637–665). 
 
In men, several populations have now passed the peak of the lung cancer epidemic, and 
incidence rates are now declining (e.g. United States and the countries of Northern and 
Western Europe). In contrast, incidence and mortality are increasing rapidly in Southern 
and Eastern European countries. In women, the epidemic is less advanced; most Western 
countries are still showing a rising trend in incidence and mortality, although in some this is 
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recent and affecting only recent generations (Spain), while for others (United Kingdom), it 
seems that the peak of risk may now have been reached.  Geographic patterns of lung 
cancer incidence and mortality are very much influenced by past exposure to tobacco 
smoking, and the geographic pattern in women reflects the rather different historical 
patterns of smoking from those in men. The proportion of lung cancer cases due to tobacco 
smoking can be estimated by comparing observed incidence (or mortality) in different areas 
with that expected based on rates in nonsmokers from several large cohort studies (Parkin 
et al. 2005). 
 
The highest incidence rates (>100 cases per 100,000 population per year) are recorded 
among Afro-Americans from New Orleans, USA and Maoris from New Zealand and are 
followed by those in the United Kingdom and Netherlands. The lowest incidence rates are 
reported from Africa and Southern Asia. Rates in women are high in the USA, Canada, 
Denmark and the UK, but are lower in the countries such as France, Japan, and Spain, in 
which the prevalence of smoking in women has increased only recently. The lowest rates 
(< 3 cases per 100,000 population per year) are recorded in Africa and India. In most 
countries, lung cancer incidence is greater in lower socioeconomic classes; to a large 
extent, this pattern is explained by differences in the prevalence of smoking. Having risen 
dramatically since the turn of the century, lung cancer mortality among males is now 
decreasing in several countries, including the USA, the UK and Finland (Stewart and 
Kleihues 2003, 182).  
 
Although this cancer is the leading cancer in terms of incidence, its rank in terms of five 
year prevalence is sixth (5.5% from all sites but skin) (Ferlay et al. 2004) because of low 
survival rate. Lung cancer remains a highly lethal disease. Survival for 5 years measured by 
the SEER program in the United States is 15%, the best recorded at the population level. 
The average survival in Europe is 10%, not much better than the 8.9% observed in 
developing countries (Parkin et al. 2005). 
 
In brief, lung cancer is the most common tumor worldwide with 965,000 new cases each 
year among men and 387,000 in women. It is the leading cause of death from cancer. In 
men, more than 80% of lung cancer cases are caused by smoking; in women, the 
attributable risk is less (70% in northern Europe, 45% worldwide).  Some occupational 
exposure and air pollution (including environmental tobacco smoke) make a minor 
contribution to incidence. 
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2.1.1.2 Breast cancer 
 
Breast cancer is by far the most frequent cancer of women (23% of all cancers) (Parkin et 
al. 2005) with more than one million cases occurring worldwide annually. Affluent 
societies carry the greatest risk, with incidence rates of >80 per 100,000 population per 
year (Stewart and Kleihues 2003, 188). The incidence rate in women worldwide is 37.5 per 
100,000 per year (Ferlay et al. 2004). 
 
One in ten of all new cancers diagnosed worldwide each year is a cancer of the female 
breast, and it is the most common cancer in women in both developing and developed 
areas. It is also the principal cause of death from cancer among women globally (Bray et al. 
2004). 
 
With an estimated 1.15 million new cases in 2002, breast cancer is in second rank overall 
when both sexes are considered together. More than half of the cases are in industrialized 
countries about 361,000 in Europe (27.3% of cancers in women) and 230,000 in North 
America (31.3%). Incidence rates are high in most of the developed areas (except for 
Japan, where it is third after colorectal and stomach cancers), with the highest age-
standardized incidence in North America (99.4 per 100,000).  Breast cancer ranks as the 
fifth cause of death from cancer overall, although still the leading cause of cancer mortality 
in women (the 411,000 annual deaths represent 14% of female cancer deaths). Incidence 
rates of breast cancer are increasing in most countries, and the changes are usually greatest 
where rates were previously low. Since the estimates for 1990, there has been an overall 
increase in incidence rates of about 0.5% annually. At this rate of growth, there would be 
around 1.4 million new cases in 2010. However, cancer registries in China are recording 
annual increases in incidence of 3% to 4%, and in those elsewhere in eastern Asia, 
increases are not much less. Assuming a 3% growth in East Asia, the world total in 2010 
would be 1.5 million (Parkin et al. 2005). 
 
Breast cancer incidence and mortality vary considerably by world region. In general, the 
incidence is high (greater than 80 per 100,000) in developed regions of the world and low 
(less than 30 per 100,000), though increasing, in developing regions; the range of mortality 
rates is much less (approximately 6–23 per 100,000) because of the more favorable 
survival of breast cancer in (high-incidence) developed regions. The incidence of breast 
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cancer is increasing almost everywhere. This unfavorable trend is due in part to increases in 
risk factors (decreased childbearing and breast-feeding, increased exogenous hormone 
exposure, and detrimental dietary and lifestyle changes, including obesity and less physical 
activity). On the other hand, mortality is now decreasing in many high-risk countries due to 
a combination of intensified early detection efforts and the introduction of mammographic 
screening, resulting in the diagnosis of more small, early stage tumors, and advances in 
treatment (Parkin and Fernandez 2006). 
 
The Netherlands is an example of the high incidence of breast cancer in developed 
countries, with an age-standardized incidence rate of 91.6 new cases per 100,000 women-
years, but there are sub-populations, such as white women in California, which exhibit age-
adjusted incidence rates of 100 or more. Overall, the incidence rate in USA is estimated at 
91.4. Such high rates are also observed in Europe, Australia and New Zealand, and in some 
parts of South America especially Uruguay and Argentina. In contrast, low rates are found 
among Africa and Asian populations. Amongst population-based cancer registries (as 
distinct from national estimates) the 30 recording the highest rates include 20 registries 
from North America, one from South America (Montevideo), two from Israel and five from 
Europe. Amongst this group, the only one from Africa is for Europeans in Harare. By 
contrast, among population-based registries with the 30 lowest rates, five are from Africa, 
18 from Asia and Israel, three from south America, two from Eastern Europe and two from 
the United States of America (American Indians in New Mexico and Koreans in Los 
Angeles, California) (Stewart and Kleihues 2003, 189). 
 
While international variations in the incidence of the disease may implicate a role for 
environmental factors, available evidence indicates that lifetime estrogen exposure may be 
a critical factor in breast carcinogenesis. While increasing age and the female sex are well-
recognized risk factors, reproductive characteristics such as age at menarche and 
menopause, menstrual irregularity, age at first and last childbirth, parity and breastfeeding 
have also been linked to breast carcinogenesis (Okobia and Bunker 2005). 
 
These large geographical differences are potentially justifiable on the basis of genetics or 
influences of lifestyle and environment. Studies of migrant population have revealed that 
when women migrate from low-risk to high-risk regions, the migrant populations acquire 
the rates of the host country after two or three generations, indicating lifestyle as primarily 
determining the geographic variations in risk (Stewart and Kleihues 2003, 189). In part, the 
high incidence in the more affluent world areas is likely because of the presence of 
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screening programs that detect early invasive cancers, some of which would otherwise have 
been diagnosed later or not at all. The incidence is more modest in Eastern Europe, South 
America, Southern Africa, and Western Asia, but it is still the most common cancer of 
women in these geographic regions (Parkin et al. 2005). 
 
The worldwide breast cancer epidemic has many etiological factors, including reproductive 
history (early menarche, later or no pregnancy), and Western lifestyle (high caloric diet, 
lack of physical activity) (Stewart and Kleihues 2003, 188). Genetic factors, including the 
major susceptibility genes (BRCA1, BRCA2), may account for up to 10% of breast cancer 
cases in developed countries but their prevalence in the population is too low to explain 
much of the international variation in risk. The majority must therefore be a consequence of 
different environmental exposures. This is evident from studies of migrants, which show 
quite clearly that incidence rises following migration from low to high incidence countries, 
particularly if this takes place at young ages. The major influences on breast cancer risk 
appear to be certain reproductive factors, body size/obesity, alcohol, physical activity, 
exogenous hormones (oral contraceptives, hormone replacement therapy), and, possibly, 
diet. There have, however, been few attempts to quantify the magnitude of risk differentials 
between populations that might be explained by such factors (Parkin et al. 2005). 
 
In some regions, including North America, Western Europe and Australia, breast cancer 
mortality rates have started to decline, mainly due to improvements in early detection and 
treatment (chemotherapy and tamoxifen). Five-year survival rates are higher than 70% in 
most developed countries. Breast cancer screening trails of mammography have shown that 
mortality can be reduced by up to 30%. However, there is limited evidence that this can be 
achieved in population-based country wide screening programs (Stewart and Kleihues 
2003, 188). 
Because of its high incidence and relatively good prognosis, breast cancer is the most 
prevalent cancer in the world today by five year prevalence of 17.5% out of all site but skin 
cancers (Ferlay et al. 2004); there are an estimated 4.4 million women alive who have had 
breast cancer diagnosed within the last 5 years (compared with just 1.4 million survivors -
male or female- from lung cancer). It has been estimated that 1.5% of the US female 
population are survivors of breast cancer (Parkin et al. 2005). 
In brief, breast cancer is the most common malignancy affecting women, with more than 
one million cases occurring worldwide annually. Wealthy societies carry the greatest risk. 
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The worldwide breast cancer epidemic has many etiological factors, including reproductive 
history (early menarche, late or no pregnancy), and western lifestyle (high caloric diet, and 
lack of physical activity). 
 
2.1.1.3 Stomach cancer 
 
Until recently, stomach cancer was the second most common cancer worldwide, but now, 
with 933,000 new cases per year in 2002 (8.6% of new cancer cases), it is in fourth place 
behind cancers of the lung, breast, and colon and rectum (Ferlay et al. 2004). It is the 
second most common cause of death from cancer (700,000 deaths annually). Almost two-
thirds of the cases occur in developing countries and 42% in China alone. The geographical 
distribution of stomach cancer is characterized by wide international variations; high-risk 
areas (ASR in men, >20 per 100,000) include East Asia (China, Japan), Eastern Europe, 
and parts of Central and South America. Incidence rates are low (<10 per 100,000 in men 
in Southern Asia, North and East Africa, North America, and Australia and New Zealand). 
Patterns in women are broadly similar to those in men. Although it has been suggested that 
gastric cancer is rare in Africa, the incidence in Central (Middle) Africa is not very low, 
with an estimated age-standardized rate in women (12.6 per 100,000) similar to that in 
Eastern Europe (Parkin et al 2005). The five-year prevalence of stomach cancer constitutes 
6% of all sites cancer but skin (Ferlay et al. 2004). 
  
Approximately 60% of all stomach cancers occur in developing countries.  There is marked 
geographical variation in incidence between countries and among different ethnic groups 
within the same locate. Migration studies show that the risk of cancer changes within two 
generations when people move from high-incidence to low-incidence areas. For example, 
Japanese immigrants to the USA retain their original risk of stomach cancer, whereas 
subsequent generations show the incidence of the host country. Incidence in men is twice 
that in women in both high and low-risk countries (Stewart and Kleihues 2003, 194). 
 
Survival for stomach cancer is moderately good only in Japan (52%), where mass screening 
by photofluoroscopy has been practised since the 1960s. Survival is also relatively high in 
North America (21% based on the SEER data, 40% age-adjusted estimate), possibly due to 
early diagnosis following a greater number of endoscopic examinations performed for 
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gastric disorders. Survival is 27% (estimated) in Western Europe while it is as low as 6% in 
sub-Saharan Africa (Parkin et al. 2005). 
 
The well-differentiated type of adenocarcinoma (which is showing the greatest decrease in 
incidence) occurs more predominantly in high risk areas, while the diffuse poorly-
differentiated type is relatively more frequent in low-risk areas. In contrast to the overall 
decreasing trend, there has been an increase of cancers localized to the cardia, documented 
by data from UK and USA, the reasons for this increase are not known. Over the last few 
decades, a steady decline in the incidence and mortality rates of gastric carcinoma has been 
observed worldwide and in particular in North America and Western Europe. However, the 
absolute number of new cases per year is increasing mainly because of ageing of the 
population. Gastric carcinoma is extremely rare below age 30; thereafter incidence 
increases rapidly and steadily to reach the highest rates in the oldest age group in both 
sexes (Stewart and Kleihues 2003, 194). 
 
The principal microbial agent causing cancer is the bacterium Helicobacter pylori (5.5% of 
all cancers) (Parkin 2006). The evidence linking H. pylori infection to cancer of the 
stomach was considered sufficient by IARC to classify this bacterium as carcinogenic in 
humans. Its action is probably indirect by provoking gastritis, a precursor of gastric 
atrophy, metaplasia, and dysplasia. Infection is acquired in childhood, and prevalence 
within populations is certainly related to socioeconomic status. The international variation 
in its prevalence bears a certain similarity to that of stomach cancer; the overall estimate of 
H. pylori prevalence in adults is 76% in developing countries and 58% in developed 
countries. However, it is clear that with such high prevalence and relatively small 
international variation, other factors than H. pylori are of major importance. Diet certainly 
plays an important role. Risk is increased by high intakes of some traditionally preserved 
salted foods, especially meats and pickles, and with salt per se. Risk is decreased by high 
intakes of fruits and vegetables, which may be in part related to their vitamin C content. 
Tobacco smoking is another risk factor which increases the risk of stomach cancer (Parkin 
et al. 2005).  
 
There has been a steady decline in the risk of gastric cancer incidence and mortality over 
several decades in most countries. The worldwide estimates of age-adjusted incidence (22.0 
per 100,000 in men and 10.3 per 100,000 in women) are about 15% lower than the values 
estimated in 1985. This decline may be related to improvements in preservation and storage 
of foods; it may also represent changes in the prevalence of H. pylori by birth cohort, 
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perhaps as a result of reduced transmission in childhood, following a trend for improved 
hygiene and reduction of crowding. If the observed secular decline continues, the expected 
number of new cases in 2010 will be around 1.1 million (an increase of 19%), rather than 
the 21% additional cases due simply to a population growth and aging (Parkin et al. 2005). 
 
In brief, cancer of the stomach is amongst the most common malignancies worldwide, with 
some 933,000 new cases every year. Infection with H. pylori causes chronic atrophic 
gastritis and is considered a factor in the development of stomach cancer. 
 
 
2.1.1.4 Colorectal cancer 
 
Colon and rectum cancers accounted for 1,023,256 new cases in 2002 (9.4% of the world 
total), and unlike most sites, numbers were not so different in men and women (ratio, 1.2:1) 
(Ferlay et al. 2004). In terms of incidence, colorectal cancers rank fourth in frequency in 
men and third in women. Survival estimates (in men) at 5 years are 65% in North America, 
54% in Western Europe, 34% in Eastern Europe, and 30% in India. The overall relatively 
good prognosis means that mortality is about one half that of incidence (about 529,000 
deaths in 2002), while prevalence is second only to that of breast cancer worldwide, with 
an estimated 2.8 million persons alive with colorectal cancer diagnosed within 5 years of 
diagnosis (Parkin et al. 2005). The five year prevalence of this cancer is 11.5% out of all 
sites cancers but skin and in third rank for both sexes worldwide (Ferlay et al. 2004). 
 
There is at least a 25-fold variation in occurrence of colorectal cancer worldwide. The 
highest incidence rates are in North America, Australia/New Zealand, Western Europe, 
and, in men especially, in Japan. Incidence tends to be low in Africa and Asia and 
intermediate in southern parts of South America. The geographical distribution of colon 
and rectal cancer is similar, although the variation between countries is more striking for 
colon cancer. In high-risk populations, the ratio of colon to rectal cancer incidence is 2:1 or 
more (rather more in females). In low-risk countries, colon and rectal cancer rates are 
generally of the same magnitude (Parkin et al. 2005).  
 
These large geographic differences for colon and rectal cancers are probably explained by 
different environmental exposures. There are strong international correlations between risk 
of large bowel cancers and per capita consumption patterns of meat (Armstrong and Doll 
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1975), fat (specifically animal fat) (Prentice and Sheppard 1990), and fiber (McKeown-
Eyssen 1994). Epidemiologic studies find consistent evidence that physical inactivity, 
excess body weight, and a central deposition of adiposity have a major influence on risk of 
colon cancer (Giovannucci 2002). That the risk of colon cancer is quite labile to 
environmental change is evident from the study of migrants; when populations moved from 
low-risk to high-risk areas, the incidence of colorectal cancer increases rapidly within the 
first generation (McMichael et al. 1980; Gelboin et al. 1980, 327–340), implying that 
dietary and other environmental factors constitute a major component of risk. Japanese 
individuals born in the United States now have higher rates than those of US Whites (38.4 
per 100,000 in men, 27.6 per 100,000 in women), and the rates in Japanese individuals 
living in Hawaii (51.2 per 100,000 in men, 30.8 per 100,000 in women) and Los Angeles 
(48.0 per 100,000 in men, 32.8 per 105 in women) are among the highest in the world 
(Parkin et al. 2002). 
 
In general, rates of incidence of colorectal cancer are increasing rather rapidly in countries 
where overall risk was formerly low (especially in Japan, but also elsewhere in Asia), while 
in high-risk countries, trends are either gradually increasing, stabilizing (North and West 
Europe), or declining with time (North America). Such moderations with time have been 
noted particularly in younger age groups (Parkin et al. 2001). 
 
A major etiological factor is lifestyle involving a diet rich in fat, refined carbohydrates and 
animal protein, combined with low physical activity. Studies suggest that risk can be 
reduced by decreasing meat consumption and increasing intake of vegetables and fruit. 
Sequential genetic alterations mediate development of colon cancer, the earliest such 
change being mutation of the APC gene. Familial clustering has usually a genetic basis. 
Typical syndromes include familial adenocarcinomatosis polyposis (FAD) and hereditary 
non-polyposis colon cancer (HNPCC). Colonoscopy is the most reliable means for early 
detection. Progressively improved treatment has resulted in a five-year survival rate of 
about 50% (Stewart and Kleihues 2003, 198). 
 
In brief, cancers of the colon and rectum are rare in developing countries, but are the 
second most frequent malignancy in affluent societies and over 940,000 cases occur 
annually worldwide. 
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2.1.1.5 Prostate cancer 
 
There were 679,100 new cases of prostate cancer worldwide in 2002, making this the fifth 
most common cancer in the world and the second most common in men  (11.7% of new 
cancer cases overall; 19% in developed countries and 5.3% in developing countries) 
(Ferlay et al. 2004). The prognosis is relatively good; it is a less prominent cause of 
mortality with 221,000 deaths (5.8% of cancer deaths in men and 3.3% of all cancer 
deaths). Three-quarters of all cases are in men aged 65 or more. Incidence rates are now 
influenced by the diagnosis of latent cancers by screening asymptomatic individuals, so 
that where this practice is common, the "incidence" may be very high (124.8 per 100,000 in 
the United States, for example, where it is now by far the most commonly diagnosed cancer 
in men). Incidence is high also in Northern and Western Europe and Australia/New 
Zealand.  
 
Survival is significantly better in high-risk countries (ratio of age-standardized rates is 87% 
in the United States versus 45% in developing countries), but much of this is a consequence 
of more latent cancer being detected by screening procedures. In fact, the relative survival 
in the United States in 1995–2000 is reported to be 99% (Ries et al. 2004). As a result, 
mortality rates are probably a better guide to the risk of invasive prostate cancer in different 
populations. Mortality rates are high in the Caribbean, Southern and Central Africa, North 
and West Europe, Australia/New Zealand, and North and South America, and low in Asian 
populations and North Africa. Variations in mortality rates between China and the United 
States are 16-fold (almost 80-fold for incidence) (Parkin et al. 2005). 
  
Migrants from low-risk countries to areas of higher risk show quite marked increases in 
incidence (for example, Japanese living in the United States). Some of this change reflects 
an elimination of the "diagnostic bias" influencing the international incidence rates, but part 
is almost certainly due to changes in environment (possibly related to diet). Nevertheless, 
the interethnic variations in incidence observed in international data are mirrored by ethnic 
variation in risk within certain countries; for example, the Black population has the highest 
incidence (and mortality) rates in the United States (Miller et al. 1996), some 70% higher 
than in Whites, who in turn have rates considerably higher than populations of Asian origin 
(e.g. Chinese, Japanese, and Korean males). Similarly, in Sao Paulo, Brazil, the risk of 
prostate cancer in black males was 1.8 times that of white men (95% CI, 1.4–2.3) 
(Bouchardy et al. 1991). The differences in ethnic-specific risk may be mediated via 
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population differences in alleles of genes coding for enzymes involved in testosterone 
metabolism (Shibata and Whittemore 1997). 
 
Until the middle of the 1980s, prostate cancer incidence (and mortality) rates in the United 
States were gradually increasing, partly due to a genuine increase in risk and partly due to 
increasing diagnosis of latent, asymptomatic cancers in prostatectomy specimens resulting 
from the increasing use of transurethral resection of the prostate. With the introduction of 
prostate-specific antigen (PSA) testing in 1986, there was a huge surge in incidence, 
especially in localized and regional stage disease, so that recorded rates doubled between 
1986 and the peak in 1992 (1993 in Blacks). Since then, incidence rates have declined, 
although they remain substantially higher than before. Prostate cancer mortality rates in the 
United States began to fall in 1992 for White men and in 1994 for Black men, and are now 
substantially lower than the rates in 1986. The recent declines in mortality are a 
consequence of declines in the incidence of distant stage disease, rather than change in 
survival, suggesting they are largely the consequence of screening (Parkin et al. 2005).  
 
Hsing et al. reviewed data on international trends in prostate cancer incidence and 
mortality. As in the United States, they observed the largest increases in incidence in high-
risk countries, especially in younger men. This is probably partly the effect of increasing 
detection following transurethral resection of the prostate and, more recently, due to the use 
of PSA. But there were also large increases in low-risk countries between 1975 and 1990: 
104% in Singapore, China; 84% in Miyagi, Japan; 55% in Hong Kong; and 44% in 
Shanghai, China. Some of this increase may be due to greater awareness of the disease, and 
diagnosis of small and latent cancers. But it is also probable that there is a genuine increase 
in risk occurring. Increases in mortality have also been substantial, although they are 
generally less marked than for incidence, especially in countries where the incidence rates 
are relatively high. However, since the 1990s, there have been declines in mortality rates of 
several developed countries, which may be the result of earlier detection and improved 
treatment (Parkin et al. 2005). 
 
The average increase in the estimated age-adjusted incidence of prostate cancer worldwide 
between 1985 and 2002 was around 1.1% annually. As noted above, a fair bit of this was 
due to the huge surge in the United States (9.5% annual increase between 1985 and 1990). 
But even if there were no further increase in the United States, a continued increase of this 
magnitude would mean that there would be almost 900,000 new cases per year by the year 
2010 (Parkin et al. 2005). 
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In brief, there are 679,100 new cases of prostate cancer worldwide every year, making this 
the fifth most common cancer in the world and the second most common in men. Risk 
factor includes high caloric intake and low physical activity. Black men have the highest, 
white men an intermediate risk and Asian men a lower risk. Recorded incidence is 
increasing in many countries, partly as a result of screening for elevated serum levels of 
prostate-specific antigen. 
 
 
2.1.1.6 Esophageal cancer 
 
Esophageal cancer is the eighth most common cancer worldwide, responsible for 462,000 
new cases in 2002 (4.2% of the total), and sixth most common cause of death from cancer 
with 386,000 deaths (5.7% of the total) (Ferlay et al. 2004). Cancer of the esophagus has a 
very poor survival: 16% of the cases in the United States (Ries et al. 2004) and 10% in 
Europe (Sant et al. 2003) survive at least five years. Geographic variation in incidence is 
very striking. Even at the level of world area, a 20-fold variation is observed between high-
risk China and low-risk western Africa (Munoz and Day 1996). Other areas of relatively 
high risk are southern and eastern Africa, south-central Asia, and (in men only) Japan. 
Esophageal cancer is more common in males in most areas—the sex ratio is 7:1 in Eastern 
Europe, for example -although in the high-risk areas of Asia and Africa, the sex ratio is 
much closer to unity (Parkin et al. 2005).  
 
This geographic variability is even more marked when smaller units are studied, for 
example, between countries or even within countries (e.g. in China, South Africa, or 
France) (Munoz and Day 1996). It seems that the environmental carcinogens responsible 
also show important geographic differences. Tobacco and alcohol are the main agents 
involved in Europe and North America, where over 90% of cases can be attributed to these 
causes. Chewing of tobacco (and betel) is important in the Indian subcontinent. Hot 
beverages have been shown to increase risk, and drinking hot mate (tea) is probably 
responsible for high rates in Uruguay, southern Brazil, and northern Argentina. Nutritional 
deficiencies (specifically of micronutrients) are thought to underlie the high risk in central 
Asia, China, and southern Africa. Here other factors such as pickled vegetables, 
nitrosamine-rich foods, and mycotoxins may also be involved, as well as consumption of 
opium residues (in Iran) or pipe stem residues (in the Transkei of southern Africa) (Munoz 
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and Day 1996). On the other hand, genetic predisposition may explain the rather high rates 
of esophageal cancer in Japan and US Japanese (Miller et al. 1996). Polymorphisms of two 
genes controlling the alcohol-metabolizing enzymes (Yokoyama et al. 2002), alcohol 
dehydrogenase 2 (ADH2) and aldehyde dehydrogenase 2, are notably frequent in 
populations in east and Southeast Asia (Goedde et al. 1992). 
 
Worldwide, most esophageal cancers are squamous cell carcinomas, arising in the middle 
and low third of the esophagus. Recently, there appears to be an increase in western 
countries in relative and absolute numbers of adenocarcinomas of the lower third of the 
esophagus (Vizcaino et al. 2002). Since both histological types are related to alcohol and 
tobacco smoking, changes in these two exposures cannot explain the differential trends. 
The most likely explanation for the increases in incidence of adenocarcinoma seems to be 
the increasing prevalence of Barrett’s esophagus as a consequence of gastroesophageal 
reflux, which is becoming more common with increasing levels of obesity (Chow et al. 
1998; Lagergren et al. 1999). 
 
In brief, cancer of the esophagus is the sixth most common cancer worldwide (more than 
460,000 cases per year). Squamous cell carcinoma is most common in developing countries 
and is typically associated with tobacco smoking and alcohol abuse. Other risk factors 
include consumption of very hot beverages and malnutrition. Adenocarcinoma occurs 
predominantly in white men from developed countries, the most important etiological 
factors being obesity and chronic gastroesophageal reflux. 
 
 
2.1.1.7 Bladder cancer   
 
An estimated 357,000 bladder cancer cases occurred in 2002, making this the ninth most 
common cause of cancer for both sexes combined. It consists 4.5% of survivors of all 
cancers for five years (five year prevalence) (Ferlay et al. 2004). There were 145,000 
deaths, with population-based five-year survival rates ranging from 40% to 80% depending 
on whether noninvasive lesions are included in the computation. It is relatively common in 
developed countries, where 63% of all incident cases occur. The majority (77%) of bladder 
tumors occur in men. The variation in international incidence is not particularly striking 
relative to other cancers, however. Rates are high in many southern and eastern European 
countries where smoking (in men) has been prevalent, and in parts of Africa and the 
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Middle East where bladder cancer, particularly of the squamous cell type, is linked to 
chronic infection with Schistosoma hematobium (IARC Monograph. 1994). Some 
occupational exposures contribute to the high risk of developed countries. The highest 
recorded incidence rate is that found in Egypt, where the estimated world-standardized rate 
in men is 37 per 100,000. In the United States, the incidence in Whites is higher than in 
Blacks -about double among men and 50% greater among women. It is unlikely that this is 
due to differences in exposure to environmental carcinogens, and explanations based on 
differential susceptibility have been proposed, including, for example, genetic 
polymorphisms of metabolic enzymes such as N-Acetyltransferase (NAT) and Glutathione 
S-transferase 1 (GSTM1) (Yu et al. 1994; Yu et al. 1995). 
 
Bladder cancer is primarily attributable to smoking, which accounts for 65% of male and 
30% of female cases in some developed countries. Other less important causes include 
analgesic abuse (phenacetin), some types of cancer chemotherapy and, historically, 
occupational exposure to chemicals such as 2-naphtahlamine. In Egypt and some Asian 
regions, chronic cystitis caused by Schistosoma hematobium infection is a major risk factor 
(Stewart and Kleihues 2003, 228). Treatment based on endoscopy, surgery, radiotherapy 
and cytotoxic drugs often permits long-term survival in developed countries, where 65% of 
patients live for at least five years after diagnosis (Stewart and Kleihues 2003, 228). 
 
In brief, around 357,000 bladder cancer cases occur worldwide every year. Smoking is the 
main known risk factor. Other less important causes include analgesic abuse, some types of 
cancer chemotherapy and, historically, occupational exposure to chemicals such as 2-
naphthylamine.  
 
 
2.1.1.8 Liver cancer 
 
About 620,000 new cases of liver cancer, usually hepatocellular carcinoma, occur annually, 
and contribute significantly to cancer mortality worldwide. More than 80% of cases occur 
in Asia and Africa and irrespective of etiology; the incidence rate is more than twice as 
high in men as in women (Stewart and Kleihues 2003, 203). Liver cancer is the sixth most 
common cancer worldwide in terms of numbers of cases (626,000 or 5.7% of new cancer 
cases) but because of the very poor prognosis, the number of deaths is almost the same 
(598,000) (Ferlay et al. 2004). It is therefore the third most common cause of death from 
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cancer. Survival rates are 3% to 5% in cancer registries for the United States and 
developing countries (Parkin et al. 2005). 82% of cases (and deaths) are in developing 
countries (55% in China alone). The areas of high incidence are sub-Saharan Africa, 
eastern and southeastern Asia, and Melanesia. The incidence is low in developed areas 
(only in southern Europe is there any substantial risk), Latin America, and south central 
Asia. The overall sex ratio (male: female) is around 2.4, much greater in the high-risk areas 
and less in low-risk areas (Parkin et al. 2005).  
 
Worldwide, the major risk factors for liver cancer are infection with the hepatitis B and C 
viruses, both of which increase the risk of liver cancer some 20-fold (Donato et al. 1998). 
Because hepatitis B virus (HBV) is more prevalent, the distribution of infection worldwide 
largely explains the patterns of liver cancer. The exception is Japan, where chronic 
infection with HBV is low, but where the generations most at risk of liver cancer have a 
relatively high rate of infection with hepatitis C virus (Tanaka et al. 1994). More than 75% 
of cases worldwide, and 85% of cases in developing countries, are caused by these two 
viruses (Parkin et al. 1999, 5–33). Exposure to aflatoxin is probably also an important 
contributor to the high incidence of liver cancer in those tropical areas of the world where 
contamination of food grains with the fungus Aspergillus fumigatus is common. There is a 
multiplicative interaction between aflatoxin exposure and chronic HBV infection, 
suggesting different carcinogenic mechanisms (Parkin et al. 2005).  
 
Cholangiocarcinoma, a tumor of the epithelium of the intrahepatic bile ducts, comprises 
10% to 25% of liver cancers in men in Europe and North America, and a much larger 
proportion in women. The incidence shows little international variation, with rates in males 
between 0.5 and 2.0, and lower in females (Parkin et al. 1993). However, the incidence is 
very much higher in some localized areas, where infection with liver flukes is common 
(e.g. Northeast Thailand) (Parkin et al. 2005).  
 
Primary prevention of the majority of liver cancer cases worldwide is now feasible, thanks 
to the development of a vaccine against HBV. This has been shown to be effective in 
preventing infection in childhood. A dramatic demonstration of the results of community 
vaccination is already available from Taiwan, where HBV immunization of newborns was 
introduced in 1984; for children aged 6 to 9 years in birth cohorts receiving vaccination, 
there was a dramatic decrease in incidence of liver cancer (Chang et al. 1997). 
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In brief, about 620,000 new cases of liver cancer, usually hepatocellular carcinoma, occur 
annually, and contribute significantly to cancer mortality worldwide. In Africa and Asia, 
hepatocellular carcinoma is most frequently caused by hepatitis B and C virus infections; 
concomitant dietary exposure to aflatoxins multiplies the risk. In Western countries, liver 
cirrhosis due to chronic alcohol abuse is the major etiological factor.   
 
 
2.1.1.9 Cervical cancer 
 
Cervical cancer is the seventh in frequency overall (Ferlay et al. 2004), but the second most 
common cancer among women worldwide (Stewart and Kleihues 2003, 215) with an 
estimated 493,000 new cases and 274,000 deaths in the year 2002 (Ferlay et al. 2004). In 
general terms, it is much more common in developing countries, where 83% of cases occur 
and where cervical cancer accounts for 15% of female cancers, with a risk before age 65 of 
1.5%. In developed countries, cervical cancer accounts for only 3.6% of new cancers, with 
a cumulative risk (0 to 64) of 0.8% (Parkin et al. 2005).  
 
The highest incidence rates are observed in sub-Saharan Africa, Melanesia, Latin America 
and the Caribbean, south-central Asia, and Southeast Asia. Incidence rates are now 
generally low in developed countries, with age-standardized rates less than 14.5 per 
100,000. This pattern is relatively recent, however; before the introduction of screening 
programs in the 1960s and 1970s, the incidence in most of Europe, North America, and 
Australia/New Zealand was similar to that in developing countries today (Gustafsson et al. 
1997). For example, incidence was 38.0 per 100,000 in the Second National Cancer Survey 
of the United States (Dorn and Cutler 1959). Very low rates are also observed in China (6.8 
per 100,000) and Western Asia (5.8 per 100,000); the lowest recorded rate is 0.4 per 
100,000 in Ardebil, northwest Iran (Sadjadi et al. 2003). 
 
Mortality rates are substantially lower than incidence. Worldwide, the ratio of mortality to 
incidence is 55%. Survival rates vary between regions with quite good prognosis in low-
risk regions (74% in SEER and 63% in the European registries). Even in developing 
countries, where many cases present at relatively advanced stage, survival rates are fair 
(Parkin et al. 2005). 
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It is quite clear that the major etiological agents are oncogenic subtypes of the human 
papilloma virus (HPV) (Bosch et al. 2002). Recent geographic studies using sensitive 
polymerase chain reaction DNA testing methods to detect a wide spectrum of HPV types 
have generally observed HPV prevalence to correlate with the population risks of cervical 
cancer, although it has not always been possible to take into account the relative efficacy of 
regional screening programs (Munoz et al. 1992; Pham et al. 2002). Other cofactors (e.g. 
high parity, tobacco smoking, and use of oral contraceptives) probably modify the risk in 
women infected with HPV (Parkin et al. 2005).  
There have been quite substantial declines in cervical cancer incidence and mortality, most 
clearly observed in Western countries where there are well-developed screening programs. 
Declines are also evident in some developing countries; this is particularly striking in 
China, where the estimated age-standardized incidence rate in 2002 was 6.8, compared 
with 17.8 in 1985. Although some of the difference reflects changing data sources, cancer 
registry results also indicate a fairly dramatic decline in rates in recent years. As a result of 
these trends, cervical cancer has ceded its place as the leading cancer in developing 
countries to breast cancer; only in sub-Saharan Africa, Central America, south-central Asia, 
and Melanesia is it now the main cancer affecting women (Parkin et al. 2005). 
 
In brief, cervical cancer is the second most common cancer among women worldwide, with 
an estimated 493,000 new cases and 274,000 deaths every year. Sexually transmitted 
infection with human papiloma virus is fundamental to the development of carcinoma of 
the cervix uteri.  
 
 
2.1.1.10 Non-Hodgkin lymphoma 
 
 The 301,000 cases of non-Hodgkin lymphoma (NH lymphoma) that occurred in 2002 
(2.8% of all cancers) (Ferlay et al. 2004) comprise an extremely heterogeneous group of 
malignancies displaying distinct behavioral, prognostic, and epidemiological 
characteristics. Advances in molecular biology, genetics, and immunology have resulted in 
extensive changes in the classification of lymphoid tumors in the last few decades. The 
WHO classification (Jaffe et al. 2001) distinguishes tumors primarily by cell lineage 
defined by immunophenotype and groups together lymphomas and leukemia, 
acknowledging that some solid tumors also pass through circulating leukemic phases. 
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Three broad categories are now recognized: B-cell neoplasms, T/NK-cell neoplasms, and 
Hodgkin disease. Lymphocytic leukemia falls within the B-cell neoplasm group (Parkin et 
al. 2005).  
 
NH lymphoma is slightly more common in developed countries (50.5% of cases 
worldwide), with rates highest in Australia and North America, intermediate in Europe 
(except Eastern Europe) and the Pacific islands, and relatively low throughout Asia and 
Eastern Europe. In most African populations, incidence of NH lymphoma is not high 
overall, but the relative frequency is above the world average in sub-Saharan Africa 
because of the high incidence of Burkitt lymphoma in children in the tropical zone of 
Africa. The relatively high estimated incidence in females in central Africa is a 
consequence of high relative frequency of such cancers in the few available datasets from 
this area (Parkin et al. 2005).  
 
Approximately 5% to 10% of HIV-infected persons will develop a lymphoma, and NH 
lymphoma is the AIDS-defining illness in about 3% of HIV-infected patients (Remick et al. 
1995). In most parts of the world, B-cell lymphomas tend to dominate, although peripheral 
T-cell tumors comprise the majority of NH lymphomas in eastern Asia and the Caribbean 
(Melbye and Trichopoulos 2002). Adult T-cell leukemia/lymphoma (ATL) accounts for a 
high proportion of NH lymphoma cases in southern Japan (Arisawa et al. 2000). 
 
There have been marked increases in the incidence of NH lymphoma in many parts of the 
world. While this may in part be due to improved diagnostic procedures and changes in 
classification, there can be little doubt that much of the change is real (Harge and Devesa 
1992) and the reasons for it have been the subject of much debate. The increase is seen in 
both sexes across Europe since the 1960s. Increases of about 1% to 2% per year in 
incidence rates in both sexes by period of diagnosis are seen in Australia and, at a lower 
level, in South America and Asia. In the United States, the rapid rises (particularly in 
younger men) may be partially attributable to the onset of the AIDS epidemic in 1981, 
while the declines during the 1990s may be due in part to a decrease in the incidence of 
HIV infection and successful antiretroviral therapies (Eltorn et al. 2002). AIDS cannot, 
however, account for all of the observed increases, as subtypes not associated with AIDS 
are continuing to increase. Other established risk factors, such as those related to disorders 
of the immune system (e.g. transplant patients, autoimmunity, congenital 
immunodeficiency), are not likely to explain more than a fraction of the observed 
incidence. The biological evidence that ultraviolet exposure to sunlight can result in 
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immune modulation and increased NH lymphoma risk is credible, but results from the 
epidemiological studies have been so far conflicting (Melbye and Trichopoulos 2002). 
 
Non-Hodgkin lymphoma is increasing worldwide. Advances in chemotherapy have led to a 
five-year survival rate for non-Hodgkin lymphoma has increased to 60–70 % (Stewart and 
Kleihues 2003, 237). 
 
In brief, 301,000 cases of non-Hodgkin lymphoma occur worldwide every year, 
predominantly in more developed countries. Non-Hodgkin lymphoma is the AIDS-defining 
illness in about 3% of HIV-infected patients. Other established risk factors are those related 
to disorders of the immune system (e.g. transplant patients, autoimmunity, congenital 
immunodeficiency) and ultraviolet exposure from sunlight which can result in immune 
modulation and non-Hodgkin. 
 
 
2.1.1.11 Leukemia 
 
Leukemia is the eleventh most common cancer worldwide with more than 250,000–
300,000 new cases each year. It typically results from malignant transformation of white 
blood cells or their precursors. Subtypes are identified on the basis of the cell of origin 
(lymphocytic or myeloid, etc.) and clinical course (acute or chronic) (Stewart and Kleihues 
2003, 242). 
 
Leukemia accounts for about 2.8% of all new cancer cases and 222,000 deaths (Ferlay et al. 
2004). This rather high ratio of deaths/cases (74%) reflects the poor prognosis of leukemia 
in many parts of the world, where the somewhat complex treatment regimes required are 
not available. There is relatively little geographic variation; the range of incidence rates is 
about five- to sevenfold, with the lowest rates in sub-Saharan Africa (probably representing 
failure of diagnosis to some extent) and the highest in North America and Australia/New 
Zealand. The geographic patterns will not be the same for different leukemia subtypes. For 
example, chronic lymphocytic leukemia (equivalent to small lymphocytic (B-cell) 
lymphoma in current classifications) is numerically the most important diagnosis in 
Western Europe, but is extremely rare in east and Southeast Asia. Variations in mortality 
are significantly less than for incidence, due to better survival (and hence lower mortality) 
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in developed countries where survival is twice that in developing countries (Parkin et al. 
2005). 
 
The etiology of leukemia is largely unknown, although a small proportion of cases is 
attributable to treatment with anticancer drugs or exposure to ionizing radiation. The 
genetic characteristics of much leukemia have been elucidated. Treatment of acute 
leukemia has made much progress and helped to establish general principles of cancer 
chemotherapy and management (Parkin et al. 2005). Survival varies greatly according to 
type, with acute lymphoblastic leukemia patients having a five-year survival rate of up to 
70%, whilst for those with acute myeloid leukemia it is only 20–30 % (Stewart and 
Kleihues 2003, 242). 
 
In brief, leukemia is the eleventh most common cancer worldwide with more than 
250,000–300,000 new cases each year. The etiology of leukemia is largely unknown 
although a small proportion of cases is attributable to treatment with anticancer drugs or 
exposure to ionizing radiation. The genetic characteristics of many leukemias have been 
elucidated. 
 
 
2.1.2 Cancer in Iran 
 
Since more than forty years, several groups have tried to assess cancer incidences in 
different areas of Iran (Mahboubi et al. 1973, Habibi 1965, Nadim and Noorai 2000). 
Among these, only the Caspian Cancer Registry in the town of Babol, which was 
established in 1969 by the joint collaboration of the Institute of Public Health Research 
(IPHR) of Tehran University and the International Agency for Research on Cancer (IARC), 
Lyon, France, provided a relatively reliable source of data on cancer incidence in the 
Caspian Littoral of Iran. Although the study area was limited to Caspian coastline (3 
provinces of Mazandaran, Golestan and Gilan as well as the district of Ardebil), data 
published by this registry alarmed the local and national health authorities by documenting 
one of the highest incidence rates of esophageal cancer in the world in the northeast of the 
Caspian Littoral, the Turkmen area (Joint Iran and IARC 1977, Cook-Mozaffari et al. 
1979). This led to an international effort to search for the risk factors of this disease in this 
region (Cook-Mozaffari et al. 1979, Salabian 1989, Mosavi-Jarrahi et al. 2001).  
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According to the statistics by the Iran Ministry of Health, crude cancer mortality rate was 
56/100,000 in year 2000 and cancer was the third most common known cause of death in 
Iran after cardiovascular diseases and accident (Naghavi 2000a, 384). In recent years, a 
demand for valid cancer incidence data was increasingly expressed, both by the national 
health officials and researchers in the field of cancer. Unfortunately, there is no accurate 
and up-to-date information about cancer incidence available in Iran. Therefore, to assess 
the cancer incidence in Iran, this investigation in five provinces seems clearly justified. 
 
 
2.1.2.1 Esophageal cancer 
 
Iran is located in the central Asian esophageal cancer belt (Kmet and Mahboubi, 1972). 
Westward from the high incidence area in northern Sinkiang, areas of extremely high 
incidence are seen in the Republics of Kazakhstan, Uzbekistan, and Turkmenistan, in the 
northeast of Iran and northern Afghanistan (Schottenfeld and Fraumeni 1996, 683). This 
belt passes the northern part of Iran especially southern coast of Caspian Sea which 
contains most of the areas of this study as well.  
 
The Babol cancer registry showed that from June 1968 to June 1971 the age-adjusted 
incidence rates of esophageal cancer for both men and women from Golestan Province who 
lived in the steppe grasslands of the Turkmen plain and neighboring hills in the north-
eastern part of the province were higher than 100/100,000 and thus among the highest rates 
in the world (Kmet and Mahboubi 1972, Mahboubi et al. 1973). The cancer registry also 
showed sharp gradients of incidence in a relatively small geographical area. Rates fell 
westward for some 300 km along the southern Caspian Littoral (a densely populated area 
inhabited largely by Persians) through Mazandaran Province and into Gilan Province where 
the incidence was lower than 10 per 100,000 in women and between 10 and 20 per 100,000 
for men. 
 
In Western countries esophageal cancer has been mainly a disease of men who smoke and 
drink alcohol heavily (Munoz and Day 1996, Brown et al. 2001), whereas in the very high 
incidence areas of Golestan Province (inhabited almost entirely by Turkmen) there were 
very low rates of smoking and drinking and esophageal cancer was slightly more common 
in women than in men. Ecological and nutritional studies conducted by IARC and IPHR to 
establish the epidemiologic features and to investigate the etiology of esophageal cancer 
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throughout the Caspian Littoral including Golestan Province (Joint Iran and IARC, 1977) 
found geographical associations of incidence with a number of variables. A subsequent 
case-control study investigated these associations further and established some risk factors, 
especially poverty and a restricted diet very low in fresh fruit and vegetables (Cook-
Mozaffari et al. 1979), factors that have since been shown to be associated with an elevated 
risk for esophageal cancer in almost all countries where diet has been studied (Munoz and 
Day 1996), but it found no clear evidence for other potential risk factors such as hot tea or 
nass consumption. However, the studies in Iran were discontinued due to the sociopolitical 
changes there in 1979, before the complete patterns of incidence and the full complement 
of risk factor results could be established. Some of the major questions that were left 
unanswered were the precise incidence of esophageal cancer and gastric cancer and the 
proportions of different histologic subtypes of esophageal tumors in the different ethnicities 
in Golestan Province, partly because population data by ethnic group were not available 
and partly because the lack of endoscopy and histological diagnoses may have led to 
incorrect designation of tumor location and histology for a proportion of patients. It was 
postulated at the time that almost all the esophageal cancer cases in this area were of 
squamous origin, but 98% of the tumors were diagnosed by radiology or by clinical 
methods alone and only 2% had histological confirmation (Mahboubi et al. 1973). 
 
The results of a recent study show that esophageal squamous cell carcinoma (ESCC) is still 
the predominant type of upper gastrointestinal (GI) cancer in high-risk areas of Golestan 
Province, and that tobacco, nass, alcohol and perhaps opium consumption are not the major 
etiological factors for ESCC in this area. ESCC seems to be distributed among both 
Turkmen and non-Turkmen, and among both city and village dwellers. Therefore, it is 
likely that the main etiologic factors for the high incidence of ESCC are factors that are 
shared by most inhabitants of this area. Further case−control and cohort studies are needed 
to explore the risk factors associated in this region with the very high rates of ESCC (Islami 
et al. 2004). 
 
 
2.1.2.2 Stomach cancer 
 
Both frequency and incident data from previous studies in 1970s and 1980s showed 
stomach cancer as the second common cancer in Iran (Parkin 1986, Mahboubi et al. 1973). 
A recent cancer surveillance study performed by the Ministry of Health of Iran revealed 
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that gastric adenocarcinoma is the most common fatal cancer in Iran with a wide variation 
of death rate in southern Iran (Persian Gulf Coast) 3.6 per 100,000 per year as compared to 
a rate of 8.4 per 100,000 in East Azarbaijan, northern Iran (Ministry of Health and Medical 
Education 2000). Of each 100 persons who die of cancer every day in Iran, 22 persons die 
from gastric (stomach) cancer, 13 from lung cancer, 9 from blood cancer, 8 from liver and 
biliary cancer, 7 from cancer of the central nervous system and 6 from esophageal cancer 
(Naghavi 2000b, 377). 
 
 
2.1.2.3 Other cancers 
 
Information on incidence of other cancers for the recent years is not available, but some 
data from more than three decades ago will be presented in Section  6.4.1. 
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3. Aims of the study 
 
 
The overall objective of this study was to identify the cancer incidence in Iran. To achieve 
this aim, several specific aims were set such as: 
1. To assess  data quality  
2. To determine incidence rate (crude rate, age-standardized rate and 5 year age-
specific incidence rates) of 10 leading cancers in five provinces of Ardebil, Gilan, 
Mazandaran, Golestan and Kerman each by sex  
3. To estimate cancer profile in the whole country of Iran  
4. To assess the time trend of incidence rates of 10 leading cancers in Iran 
5. To predict cancer burden in Iran in terms of number of cases in the year 2010 
6. To compare main results with the incidence estimates of GLOBOCAN 2000 and 
2002 for cancer in Iran as well as with those of neighboring areas 
7. To develop and test a new method to adjust for ascertainment bias in the evaluation 
of cancer registry data 
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4. Material and methods 
 
4.1 Study area 
 
All residents of five provinces of Iran including Ardebil, Gilan, Mazandaran, Golestan, and 
Kerman constitute the population at risk for the cancer registration in this study. Four of 
these provinces are located in the north of Iran named Caspian Littoral and the fifth 
(Kerman) in the south central part of Iran (Figure 4). The northern areas have been selected 
because cancer incidence in those areas has been recorded 30 years ago for comparison and 
had high incidence of some cancers. Kerman also has a homogenous population with 
different lifestyle. Information from the latter province would be suitable to be compared 
with those of northern ones to make hypotheses about cancer etiology in Iran. 
 
Figure 4. Map of Iran, study area 
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4.2 Population characteristics 
 
4.2.1 Demographic indicators of Iran 
 
Based on a World Health Organization report, the Islamic Republic of Iran, with a surface 
area of 1,648,000 km2, is a highly diverse country, not only in its ethnic variety, but also in 
topography and climate. Tehran is the capital city and the official language is Farsi 
(Persian). The population in 1994 was officially estimated at 59.6 million; in 1996 it was 
60.1 million and is now estimated at around 70 million. The population is relatively young, 
with 39.5% below the age of 15 years (Figure 5). In 1996, 4.3% of the population was aged 
above 65 years. In 1996, 61.3% of the population resided in urban areas (Iran census 1996). 
The literacy rate for the population 10 years of age and above was 80% in 1996, and the 
female literacy rate for the population 10 years of age and above was 74.2% in 1996. 
Twenty seven percent of people above the age of ten are economically active. The per 
capita income in 1997 was US$ 2118. The majority of the population is Shi’a Muslim. 
Although the reduction of the population growth rate was ratified as official policy of the 
government in 1988, the crude birth rate still remains high at 18.7 per 1000 population. The 
crude death rate was estimated at 4.2 per 1000 population, the infant mortality rate was 
estimated at 32 per 1000 live births (2004) and the under-5 mortality rate was 33 per 1000 
live births. Life expectancy at birth was calculated to be 68–72 years in 2004. Maternal 
mortality was estimated at 7.6 per 10,000 live births in 2000 (WHO website). 
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Figure 5.  Population pyramid of Iran, census 1996 
4.2.2 Five provinces 
 
Geographically, four provinces of Ardebil, Gilan, Mazandaran and Golestan are located in 
the north of Iran and form southern coast of Caspian Sea. Kerman is located in south of 
Iran and different climate than others in the north. Kerman has higher urban proportion 
especially in younger ages compared to other four provinces. In contrast, Golestan has the 
highest rural proportion in comparison with others (Table 3). The population pyramid for 
each these provinces is very similar to that of Iran (Appendix Figure 1, Appendix Figure 2, 
Appendix Figure 3, Appendix Figure 4 and Appendix Figure 5). 
 
Table 3. Demographic indicators of Iran and five provinces, census 1996 
    Province 
    Ardebil Gilan Mazandaran Golestan Kerman 
Iran 
(N) 1,128,864 2,241,896 2,602,008 1,426,288 2,004,328 60,055,488 
Population 
(%) 1.9 3.7 4.3 2.4 3.3 100 
(N) 17,953 13,952 23,833 20,380 181,714 1,648,000 
Area (km2) 
(%) 1.1 0.8 1.4 1.2 11.0 100 
Urban (%) 46.0 46.8 46.0 41.3 52.9 61.3 
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4.2.3 Ardebil province 
 
Ardebil was previously a district of East Azerbaijan Province, but became a separate 
province in 1998. It is located in northwest Iran, an area 50 km inland from the western 
Caspian coastline, with an area of about 1.09% of the total area of Iran. The province is 
mountainous with an altitude up to 4,811 m above sea level. The weather is moderate, with 
cold winters and mild summers.  
 
The total population of Ardebil Province, according to the 1996 census, was 1.1 million 
(1.94% of Iran’s total population), with 46% living in 9 cities and 54% in rural areas. The 
population is ethnically homogeneous, 95% being from the Azeri background of Aryan 
Caucasoid ancestry. They speak Azeri, which is a variant of the Turkish language. 
Consanguinity is common in both urban and rural areas (Sadjadi et al. 2003). 
 
 
4.2.4 Gilan province 
 
Covering an area of 13,952 square kilometers, Gilan province is located in the north of 
Iran, stretching between the Alborz and Talesh Mountain Ranges. Rasht is the provincial 
capital. Gilan province, shares borders with the provinces of Ardebil on the west, 
Mazandaran on the east, Zanjan to the south and the Caspian Sea and the Republic of 
Azarbayjan to the north. Gilan has a humid temperate climate with plenty of annual 
rainfall. Large parts of the province are mountainous, green and forested. Stretching from 
the east to west are the mountainous regions of Talesh, Masooleh, Poshtkooh as well as the 
Alborz Mountain Ranges. The plains of the province extend between the mountainous 
areas and the sea, reaching an altitude of 100 m above sea level. 
 
In the year 1996, this province had a population of 2.2 million, of which 46.8% were 
registered as urban and 53.2% as rural. Gilan is the most densely populated province in Iran 
after the Tehran province. Fifty four percent of people in Gilan are under 25 years old. The 
majority of the population speaks Gilaki (a Persian dialect) as their first language while 
many children, particularly in the cities, tend to use Standard Persian amongst themselves.  
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4.2.5 Mazandaran province  
 
Mazandaran province covers an area of 23,833 sq. km. The city of Sary is the center of 
Mazandaran province. Mazandaran (Khazar) Sea or the Caspian Sea is to the north, the 
provinces of Tehran and Semnan lie towards the south. Geographically, Mazandaran 
province is divided into coastal plain and the mountainous area. To the west it has common 
borders with the Gilan province, and to the east stands the province of Golestan. The 
province enjoys a moderate, semitropical climate. Mazandarani or Tabari is an Iranian 
language of the northwestern branch, another Persian dialect spoken in Mazandaran. 
 
According to the census of 1996, the population of the province was 2.6 million of which 
46% were urban and 54% rural. Young people under age 25 constitute 56.3% of 
Mazandaran population.  
 
 
4.2.6 Golestan province 
 
The province of Golestan with an area of 20,380 square km is in the southeast of the 
Caspian Sea. Golestan province is divided into the plain and mountainous parts. Gorgan 
city used to be a part of Mazandaran until recently, but is now the capital city of the new 
Iranian province of Golestan (since 1997). The Turkaman minority reside in the north of 
the province, particularly in the cities of Gonbad and Bandar Turkaman. Other minority 
communities such as Afghans and Armenians also reside in this area, and have preserved 
their traditions and rituals. Their main language is Persian but minorities speak their own 
language among themselves. 
 
The population of the province was 1.4 million in 1996, of which 41.3% were urban. Sixty 
two percent of the Golestan population are younger than 25. 
 
 
 
 
Material and methods 
72 
4.2.7 Kerman province 
 
The province of Kerman covers an area of 181,714 sq. km. and is located in the south east 
of Iran. The said province is the second largest after Khorassan, and includes 11% of the 
total area of the country. The climate in the province varies in different regions. The north, 
northwest, and central areas experience a dry and moderate climate, whereas in the south 
and southeast, the weather is warm and relatively humid. The main language of Kerman is 
Persian. 
 
In the year 1996, the province of Kerman had a population of 2 million of which 52.9% in 
the urban areas, and 46% in the rural, the remaining 1.1% counted as non residents. The 
city of Kerman is the provincial capital, and embraces about 80% of the urban population, 
being one of the most developed and largest cities of the province. Sixty three percent of 
Kerman population are younger than 25. 
 
 
4.3 Case definition and data sources 
 
All the new cancer patients (incident cases) resident in the five provinces of Ardebil, Gilan, 
Mazandaran, Golestan and Kerman diagnosed for the first time between 1996 and 2000 
who are registered with the Cancer Registry (based on the standards of cancer registry) are 
included in this study (Ardebil Province is an exception with 4 years 1996 to 1999). They 
had to have ICD-O behavior code 3 (malignant) or 2 (in situ) to be eligible to be included 
in the study. Benign tumor cases were not included in our dataset. Cancer patients with 
metastasis and unknown origin were not recorded in the database because it was impossible 
to find out their site of origin and classify them into certain tumor sites. So, metastatic 
cases were not informative for estimating incidence of each cancer site. Therefore, all 
diagnosed cases based on pathologic, radiologic confirmation, death certificate and clinical 
reports are included if they are resident in these five provinces and meet cancer registry 
criteria for registration. The study protocol has been approved by the Ethic Committee of 
Digestive Disease Research Center, Tehran University of Medical University of Medical 
Sciences (Figure 6).  
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Figure 6.  Flow chart of this study (DDRC=Digestive Disease Research Center in Tehran) 
 
This registry unit has started the first population-based cancer registry in Iran and covered 
these provinces with 15.7% of Iran population (9.4 million out of 60.1 million people, 
national census 1996). Information about migration during these study years was not 
available. This unit was collecting all reports from pathology, radiology, laboratory, clinics 
as well as death certificates. Information about death certificates has been obtained from 
graveyards which were mainly from urban areas since death registration in rural areas was 
less complete. Fortunately, cases from rural areas can use primary health care facilities free 
of charge and there is a referral system which allows them to seek for diagnosis in urban 
health centers easily. Therefore, it has been assumed that although information about 
diagnosis of cancer was not available for rural residents in rural primary health care 
facilities, their information could be found in the upper levels of health care facilities (such 
as hospitals and pathology laboratories) in urban areas instead.  
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The registry unit at DDRC consists of a gastroenterologist, epidemiologist, pathologist, and 
the survey team in each province consists of 5 general practitioners and 10 medical 
students. Five representative medical doctors from five provinces were selected, and 
trained by the central cancer registry unit in DDRC. The same instruction was given to 
them by one person in Farsi language (The only official language of Iran routinely used in 
all provinces). Each representative trained two medical students as their assistants. The data 
survey team collected the data from hospitals, pathology laboratories, diagnostic radiology 
clinics, and outpatient public and private clinics by checking all their records for reports of 
tumor cases and making one copy of documents according to which a diagnosis of cancer 
has been made and sent them to the Cancer Registry Unit in DDRC. 
 
During a period of 6 months from January to July 2001, the collectors actively collected 
and compiled data for a period of 5 years (1996–2000) from all the hospitals, most of the 
outpatient clinics, all oncologists’ private offices, all pathology laboratories, majority of the 
radiology clinics and central death registry offices in each province. Therefore, all 
pathology laboratories were included and a copy of the pathological reports was sent to the 
registry unit. 
 
The private radiology centers recorded the identifying data of subjects; and only 
occasionally they kept the reports of radiological or sonographic diagnosis of the patients. 
In public centers usually located in the hospitals, the radiology diagnosis reports were 
present for the majority of subjects. There was a good endoscopic reporting system in both 
the public and private hospitals. 
 
A minority of residents of Ardebil seeks better medical care outside their province, mainly 
in Tabriz (a large city near Ardebil) or Tehran. A thorough search was done for the records 
of these residents with a diagnosis of cancer in 5 major hospitals and 3 major pathology 
laboratories of Tabriz. Residence of other four provinces may seek more advanced medical 
care in Tehran as well. The hospital-based cancer registry of the Cancer Institute, Tehran, 
currently provides the most reliable and comprehensive data in this large city. All the 
incident cancer cases from these five provinces, recorded in Tabriz or the Cancer Institute 
of Tehran were also included for the same period of time (1996–2000).  
 
The effort was to obtain the information about diagnoses of cancer based on microscopic 
verification (see data specifications) but other sources of data were used whenever the 
pathologic reports were not available. Therefore, cancer registry recorded every cancer 
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diagnosis by any method but mentioned the means of diagnosis for each case. As the 
registry uses several sources, several reports may be found for one case from radiology, 
pathology, endoscopy etc. so, duplicates were detected by special cancer registry software 
designed supporting Farsi scripts. Elimination of duplicate records was done based on 
similar first names and family names and some other available variables such as father’s 
name, age, province, city, means of diagnosis, site of tumor and morphology code.  
 
Certain rules were used to ease the duplicate finding process, first, patients with the same 
first name and surname are different if they have different cancer site (exceptions are 
defined in Table 24 of ICD-OIII book by Fritz et al. 2000), different father’s name, different 
province, different city other than central city of each province (patients from small cities 
of each province could be found in the central city of province but not in other cities of the 
same province) and if they have more than 5 years difference in age at diagnosis. In case of 
duplicate records, the most reliable source of diagnosis (microscopically verified) were 
kept and other information in that record were completed from other records of the same 
person if any part like age or city was missing. Also, the more specific site of tumor was 
kept, for instance if there were two records for one person, one with site of tumor middle 
third of esophagus and the other one only esophagus (NOS, not otherwise specified), only 
the more specific code (lower topography code e.g. 15.2 rather than 15.9) was kept for the 
final analysis. Regarding morphology, higher number for morphology code was supposed 
to be the more specific one and was kept.  
 
 
4.4 Data analysis 
 
The obtained data were summarized in a data sheet and coded using the ICD-O, 3rd edition 
(Fritz et al. 2000). Information about population at risk for this study was available at the 
website of Statistical Center of Iran which was based on the last comprehensive census 
1996 (a national census is carried out every 10 years). 
 
Since the data were computerized, they were analyzed using SPSS software for descriptive 
purposes. A programmed sheet in Microsoft Excel was designed to calculate age-specific 
incidence rates, relative frequencies and ASRs with 95% confidence interval as well as 
cumulative incidence rates. Persian (Farsi) fonts were used in the database because 
transliteration (using English fonts for Persian names) is problematic since Persian names 
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can be transliterated in several different ways in English but they just are spelled in one 
unique way in Persian. Therefore, duplicate elimination was possible only with the Persian 
names. 
 
 
4.4.1 Relative frequency and incidence rate 
 
The term “relative frequency” used in this dissertation refers to the proportional frequency 
of each cancer site to the total of all sites excluding ICD-O code C44 (Other skin). Results 
presented as the incidence of cancers by site (ICD-O, 3rd edition), sex, age, crude, age-
specific and age-standardized rates (ASR) per 100,000 person-years, using direct method of 
standardization to the world population (Jensen et al. 1991, 131). In incomplete cancer 
registries a decline in the incidence rate can be seen at the older ages is mainly due to 
under-registration of very old cases. In this study, an attempt was made to correct this 
problem. Correction was carried out based on Finnish female age-specific rate coefficient 
for age older than 79 (using Finnish pattern for “All sites”): 
Equation 1 
Corrected Rate for age 80 to 84 = CR80–84 = 0.645083* × (R70–74+R75–79)**  
Corrected Rate for age 85 and older = CR85+ = 0.616322*** × (R75–79**+ CR80–84). 
* This is the coefficient calculated by rate of “All site” Finnish female cancers in age group 80-84 
divided by summation of Finnish rates of age 70-74 and 75-79  
** These are age-specific rates of this study 
***  This is the coefficient calculated by dividing rate of “All site” female Finnish cancers in age group 
“85+” by summation of Finnish rates of age 75-79 and 80-84. 
  
In this dissertation, the cumulative rates were also calculated and adjusted to account for 
the cases of unknown age exactly the same way as age-standardized rate that was explained 
in section  1.1.1.6 (Parkin et al. 2002, 88). 
 
 
4.4.2 Corrected incidence trends 
 
In general, using time trend analysis for ASR for such data (with doubt about completeness 
in first years of registration) was not very informative and the results were not easy to 
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interpret. To tackle this issue, time trend of relative age-standardized ratio (RASR) was 
used which seemed to be a better tool. For this novel method, leukemia was chosen as 
reference cancer with proven constant ASR during long period time. ASR of this cancer 
was constant during 50 years of registration in the Finnish Cancer Registry (Appendix 
Figure 1) similar to other valid registries such as SEER in USA (0% change from 1975–
2001). Then relative age-standardized ratio was calculated for each cancer (ASR of each 
cancer compared to ASR of leukemia). For instance, RASR of stomach cancer is calculated 
as ASR of stomach divided by ASR of leukemia. Similarly for esophageal cancer in men in 
year 1996, RASResophageal1996men = ASResophageal1996men / ASRleukemia1996men. Therefore, 
plotting RASR of each cancer against calendar year was used for trend analysis. Five points 
were in the plot for each cancer for years 1996 to 2000, so with fitting a linear regression 
line for these five points, this line showed the change of RASR over time (years of study) 
which could reflect change in ASR.  
 
The slope coefficient regression line was the change in RASR in one year which reflected 
slope of change in ASR per one year although the amount of slope was not exactly the 
same as ASR.  In order to correct for the difference in scale of ASR with RASR, the RASR 
for each year and each cancer was multiplied by sum of ASRs of the same cancer for those 
years divided by the sum of RASRs of the same cancer for those years. For example, 
instead of plotting RASRs of rectal cancer, one should plot ARASRs of rectal cancer over 
time. ARASR of rectal cancer for year 1997 (ARASRrectal1997) were calculated as follow: 
ARASRrectal1997 = RASRrectal1997 × (ASRrectal1996 + ASRrectal1997 + ASRrectal1998 + ASRrectal1999 
+ ASRrectal2000) / (RASRrectal1996 + RASRrectal1997 + RASRrectal1998 + RASRrectal1999 + 
RASRrectal2000). The empirical data showed that the slope for time trend of ARASR was 
almost the same as ASR in complete registries (Appendix Figure 7 and Appendix Figure 
8). Therefore, it supported the theory that trend of RASR over time reflects trend of ASR. 
Although results of trend by ARASR and ASR are similar in complete registries, they 
might be different in incomplete registries so that the extent of difference is hypothesized 
to be associated with the extent of incompleteness in the registry; thus, the hypothesis is 
trends by ARASR are more reliable than by ASR in the incomplete cancer registry data. 
 
The general formula for calculating RASR and ARASR are as follows (Appendix Table 
27), where “Ci” is the cancer site (C1 to Cn) and “y” is the calendar year (1 to k): 
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Equation 2. Relative age-standardized ratio                        
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Equation 3. Adjusted relative age-standardized rate 
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4.4.3 Projection 
 
A projection also was made to estimate the number of new cancer cases in Iran in the year 
2010 based on the results of this study. For this purpose, once an assumption was made that 
there will be no change in the risk factors of cancers during these 15 years (1996–2010), so 
incidence rate will not change during this period. Then the number of new cancer cases will 
only be dependent on population (both age structure and number of people). The larger the 
proportion of elderly people in the population, the more cancer cases will occur, because 
risk of cancer is age-dependent. Based on prediction made by demographists using trends 
in previous years, life expectancy of Iranian population is increasing during this 15-year 
period then proportion of elderly people will increase.  
 
To make the projection for the year 2010, crude incidence rates of these five provinces 
were adjusted for age structure of Iran population in 2010 (as predicted by the United 
Nations). Adjustment was done similar to the direct method of standardization, but the 
standard population was substituted by predicted population of Iran in 2010. So the age-
specific rates of this study were multiplied by the corresponding weight from the 
proportion of population in each age groups in 2010. Multiplying this age-adjusted 
incidence rate by projected number of people at risk in 2010 results in the number of new 
cancer cases in 2010. Using age-adjusted incidence rate for each cancer and multiplying it 
by population in 2010 gives the number of new cases of that particular cancer in 2010 
without allowing for the change in incidence during this projection period.  
 
Another estimate was number of new cases in 2010 accounting for the change in incidence. 
The slope of time trend in adjusted relative age-standardized rates (ARASR) during 5 years 
of study (1996–2000) was used as the base for the change in incidence rates. Then the 
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yearly change (increase as positive and decrease as negative) in ARASR for 12 years 
(average of 1996–2000, 1998, until 2010) was added to the adjusted incidence rate for age 
structure of Iran population in 2010. For instance, if crude rate of a cancer in 1998 was 9, 
its calculated age-adjusted rate for 2010 was “10” (as explained in previous paragraph) and 
its ARASR was decreasing annually 0.2 unit, then the final incidence rate in 2010 will be 
[10+(12×(-0.2))] which is equal to “7.6”. The final predicted number of new cancer cases 
in 2010 was then calculated by multiplying the predicted final incidence rate by population 
of Iran in 2010. The method of calculating relative age-standardized ratios (RASR) and 
relative age-standardized rates (ARASR) are in detail explained in Section  4.4.2. 
 
 
4.4.4 Confidence interval 
 
Confidence interval for age-standardized rate was calculated by the Poisson approximation 
method for estimating standard error of ASR (Jensen et al. 1991, 138). Confidence interval 
for cumulative rate was also estimated by calculation of standard error of cumulative rate 
which could be derived from expressions for the variance and standard error of a directly 
adjusted rate using appropriate weights (i.e., the length of the age interval) and the Poisson 
approximation (Jensen et al. 1991, 149). Confidence interval for the slope of time trend 
analysis (the average annual change in ASR) was calculated using standard error of 
coefficient in linear regression analysis (Jensen et al. 1991, 141). 
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5. Results 
 
 
5.1  Demographic characteristics 
 
During the five years of study, there were 28,022 new cancer cases. Of them, 56.9% were 
among men and 41.9% women (sex was unknown for 1.2% of cases). Likewise, age at 
diagnosis had been recorded for 93.3% of cases. The mean age at diagnosis was 54.88 
(95% CI 54.75 – 55.01). Numbers of cases and person-years by province and age group, 
sex and site are presented in the appendices (Appendix Table 1, Appendix Table 2 and 
Appendix Table 3). 
Table 4. Number of cancer cases by province and year of diagnosis 
Year  
Province 1996 1997 1998 1999 2000 Unknown Total 
Kerman 900 1095 1085 1271 971 95 5417 
Mazandaran 779 661 684 973 1338 3868 8303 
Gilan 807 821 1364 1340 1443 1850 7625 
Golestan 599 631 521 545 679 125 3100 
Ardebil  - - - - - 3510 3510 
Unknown 2 4 10 16 13 22 67 
Total 3088 3219 3668 4178 4454 9415 28022 
 
 
5.2  Data quality and internal validity 
 
The majority of cancer cases had been verified microscopically (MV=83.7%). Death 
certificate only (DCO) cases constituted only 0.1% of cases. About 12.7% of cases were 
diagnosed clinically only. Only 0.2% of cases had unknown province of residence although 
it was certain that they were not from outside these five provinces (Table 4). The city of 
residence was less complete, with 50.9% unknown city. Year of diagnosis had been 
recorded only for 76% of cases from four provinces of Gilan, Mazandaran, Golestan and 
Kerman, but there were no dates of diagnosis available for Ardebil (date of birth was not 
recorded so it was not possible to calculate year of diagnosis by birth year and age at 
diagnosis). 
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A few cases (125 cases out of 28,022 or 0.45%) had unlikely age/site combinations (73 
cases), unlikely age/histology combinations (42 cases), or wrong or unlikely sex/histology 
combinations (10 cases). None of them were corrected in the analysis because information 
was not available to determine which part of these mismatches (age/site/sex/histology) was 
wrong. In addition, these were just unlikely cases but not impossible ones especially for 
those unlikely young age combinations such as type A, B, C, D, or E (Table 5).  
 
Table 5. Data validation check by cancer site, histology and sex  
Province Year           Com
bination 
Type* 
Frequency 
A
rdebil 
G
ilan 
M
azandaran 
G
olestan 
K
erm
an 
1996 
1997 
1998 
1999 
2000 
No. of cases by  
age groups 
No. of cases 
by  
ICD-OC 
No. of cases by
ICD-OM 
A 9 1 1 7 0 0 0 2 2 0 2 0–4=5, 5–9=2, 20–24=2 C61=1 8140=9 
B 6 0 0 6 0 0 0 0 0 2 3 0–4=6 C53=1, C61=5 8140=5, 8900=1 
C 44 4 9 20 6 5 2 4 5 7 11 0–4=11, 5–9=8, 10–14=7, 15–19=18 
C15=16, C20=1, 
C21=1, C23=2, C24=1, 
C25=4, C38.4=1, 
C50=14, C53=1, 
C55=3 
 
D 2 1 0 1 0 0 0 0 0 0 0 5–9=1, 10–14=1 C17=2  
E 9 0 2 6 0 1 1 0 2 3 0 10–14=2, 15–19=7 C18=9  
F 3 0 1 0 0 2 0 1 0 2 0 25–29=1, 40–44=1, 85+=1 C96=1  
A
ge/site 
G 0 0 0 0 0 0 0 0 0 0 0    
H 6 0 0 2 0 4 0 4 2 0 0 5–9=1, 15–19=3, 20–24=2 C42=6  Age/ 
histology I 36 1 7 22 1 5 5 1 4 7 5 15–19=13, 20–24=6, 25–29=2, 30–74=15  
8910=3, 8960=5, 8970=2, 
8981=1, 9470=17, 9687=8 
J 0 0 0 0 0 0 0 0 0 0 0    Sex/
site K 0 0 0 0 0 0 0 0 0 0 0    
L 9 1 3 3  0 2 1 1 1 2 0 0–4=1, 20–24=1, 50–54=1, 55–59=3, 60–64=2, 70–74=1  
8380=1, 8460=2, 8470=2, 
8670=1, 9000=1, 9084=1, 
9090=1 
S
ex/ 
histology M 1  0 0  1 0  0  0  0  0  0  0  15–19=1 C56=1 9061=1 
*= The validity check type mentioned below (Parkin et al. 1994, 45): 
Presence of unlikely age/site combinations: 
A:  If age is less than 40 and site is C61 (Prostate) and histology is 814_ (Adenocarcinoma) 
B: If age is less than 5 and site is C53 (Cervix uteri) or C61 (Prostate): 
C: If age is less than 20 and site is C15 (Esophagus), 19, 20 (Rectum), 21 (Anus), 23, 24 (Gallbladder), 25 (Pancreas), 38.4 
(Pleura), 50 (Breast), 54, 55 (Uterus), or 53 (Cervix Uteri): 
D: If age is less than 20 and site is C17 (small intestine) and histology is less than 9590 (i.e. not lymphoma) 
E: If age is less than 20 and site is C33, 34 (Lung, trachea & bronchus) or 18 (Colon) and histology is not equal to 824_  
F: If age is more than 5 and histology is 9510 (Retinoblastoma) or 9512 (Retinoblastoma undif.) and site is C69 (Eye) 
G:  If age is less than 15 or more than 45 and site is C58 (Placenta) and histology is 9100 (Choriocarcinoma) 
Presence of Unlikely age/histology combinations: 
H: If age is less than or equal to 25 and histology is 9730, 9823, 9863 or 9890 
I:  If age is greater than or equal to 15 and histology is 8910, 8960, 8961–2, 8970, 8981, 8991, 9072, 9470, 9687 or 9750 
Presence of Impossible sex/site combinations: 
J:  If sex is male and site is C51–C58 
K:  If sex is female and C60–63 
Wrong or unlikely sex/histology combinations: 
L:  If sex is male and histology is 8380–1, 8441, 8460–2, 8470–3, 8600–2, 8610, 8620–3, 8632, 8660, 8670, 8931, 9000, 9013–5, 
9084 or 9090–1 
M: If sex is female and histology is 9061–3 or 9102 
 
For instance, type “A” in Table 5 denotes number of prostate cancer cases (C61) that their 
age was less than 40 years and their cancer morphology was adenocarcinoma (8140–49). 
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Half of Iran’s population is under 25 years old and among 30,000,000 young people, some 
rare (unlikely) cases may appear as was seen for colorectal cancer in young age in Iran. 
 
 
5.3 Cancer incidence   
 
 
5.3.1 Age-specific rates and curves 
 
Age-specific rates for 5 major cancers in men and women are shown Figure 7 to Figure 12. 
Details of age-specific rates for all cancer sites are tabulated in the appendix (Appendix 
Table 6 and Appendix Table 7). Occurrence of most of cancers increased by age (Figure 11 
and Figure 12).  
 
 
Figure 7. Age-specific incidence rate of five major cancers, male 
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Figure 8. Corrected age-specific incidence rate, male 
 
The decline at the older ages illustrated in the age-specific incidence curves in Figure 7 and 
Figure 10 for ages older than 79 could be due to under-registration. In this study, an 
attempt was made to correct this problem (Equation 1). Corrected curves are shown in 
Figure 8 and Figure 11.  
 
Figure 8 shows that considering the age structure of men in these five provinces together, 
stomach cancer was the leading cancer in these areas after age 25. A logarithmic scale was 
used to show leading cancers before age 25 (Figure 9). Considering all cancers, the sixth 
leading cancer in men in terms of crude incidence rate, leukemia, was the leading cancer in 
childhood until age 25. Non-Hodgkin lymphoma was the second leading cancer for the age 
0–25 followed by testis cancer as second leading cancer between age 25 to 40.  However, 
esophageal cancer was the second leading cancer after age 40. Bladder cancer was 
relatively common with third rank in terms of incidence rate followed by lung and prostate 
cancer.  
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Figure 9. Corrected age-specific incidence rate in logarithmic scale, male 
 
Among women, in four different periods of life, four different cancers were the leading 
cancer so that from birth to around the age 22, leukemia was the most common cancer (in 
terms of incidence). Thereafter, breast cancer had a remarkable increase until age 58 when 
esophageal cancer was the leading cancer for 5 years very close to stomach cancer, which 
was the most common cancer for elderly ages (Figure 10 and Figure 11). In terms of 
overall rank, breast was the first leading cancer in women while stomach and esophageal 
cancer were in second and third place. Colon cancer had the fourth rank followed by 
leukemia.     
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Figure 10. Age-specific incidence rate of five major cancers, female 
 
 
Figure 11. Corrected age-specific incidence rate, female 
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Figure 12. Corrected age-specific incidence rate in logarithmic scale, female 
 
5.3.2 Relative frequencies and incidence rates 
 
All the information and tables presented in the text of this dissertation are corrected for the 
cases of unknown age and also for under-registration of elderly ages explained in Section 
 4.4. The appendix of this dissertation gives original data without correction.  
 
Altogether during 23,063,384 man-years follow-up, 14,883 men were recorded as new 
cancer cases (Table 6). Of these cancer cases, stomach (23.1%), esophagus (12.3%), 
bladder (7.6%), lung (6.6%), and prostate (5.7%) constituted the majority of cancer cases. 
In terms of crude incidence rate, stomach (15.8), esophagus (8.4), bladder (5.3), prostate 
(4.8) and lung (4.5) were the leading cancers in men. Age-standardized rates (ASR) with 
95% confidence interval are presented in Table 6 and Table 7. These age-standardized rates 
can be used as ASR in the whole country. Crude incidence rates for whole country are 
presented in Table 23 and Table 24. 
 
Adjusting for age did not change the rank of three major cancers - stomach 22.5, esophagus 
12.1, bladder 7.5, lung 6.5 and prostate 5.6. Cumulative rates (as approximates to 
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cumulative risks) by sex and cancer site are presented in Table 6 and Table 7. For every 
man in these provinces, the risk of any kind of cancer during 0–64 and 0–69 years of their 
life was approximately 5.6 and 7.9% respectively. Of this risk around 45% was due to 
gastrointestinal tract (mostly stomach, esophagus and to some extent colon). 
 
Altogether during 22,981,260 women-years of follow-up, 10,864 women were recorded as 
new cancer cases in this study excluding other skin cancer cases (Table 7). Of these cancer 
cases, breast (19.8%), stomach (12.5%), esophagus (11.7%), colon (5.6%), and leukemia 
(4.4%) constituted the majority of female cancer cases. In terms of incidence rate (per 
100,000 person-years), breast (9.95), stomach (6.3), esophagus (5.9), colon (2.9), and 
thyroid (1.8) were the major cancers in women.  
 
In terms of age-standardized rate (per 100,000 person-years), breast 13.3, stomach 9.3, 
esophagus 8.9, colon 4.0 and thyroid 1.9 were the major incident cancers in women.  
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Table 6.  Relative frequency, crude incidence rate, age-standardized rate (ASR) and 
cumulative rate by cancer site, male  
Cumulative 
rate (percent) Site ICD-O codes No. of  cases 
Relative 
freq. % 
(excluding 
skin) 
Crude 
rate  
(per 105) 
ASR 
(per 105) 95% CI for ASR 
0–64 0–69 
95% CI for 
cumulative rate 
0–69 
Stomach C16 3432 23.1 15.8 22.54 22.29 22.79 1.12 1.76 1.64 1.88 
Esophagus C15 1835 12.3 8.36 12.13 11.94 12.31 0.58 0.86 0.77 0.95 
Other skin C44 excluding M8720–99 1593  7.44 10.46 10.28 10.63 0.56 0.79 0.71 0.87 
Bladder C67 1137 7.6 5.28 7.50 7.35 7.64 0.35 0.55 0.47 0.62 
Prostate C61 855 5.7 4.8 5.62 5.48 5.76 0.14 0.28 0.20 0.37 
Lung, trachea & bronchus C33–34 984 6.6 4.52 6.50 6.36 6.63 0.31 0.49 0.43 0.56 
Colon  C18 622 4.2 2.90 3.87 3.77 3.97 0.24 0.31 0.27 0.35 
Non-Hodgkin lymphoma M9590–5, 9670–9729, 9740–9 605 4.1 2.76 3.44 3.35 3.54 0.22 0.28 0.24 0.31 
Leukemia unspecified M9800–9 509 3.4 2.36 2.24 2.17 2.31 0.13 0.15 0.12 0.17 
Larynx C32 435 2.9 2.06 2.90 2.81 2.99 0.16 0.23 0.19 0.28 
Brain, nervous system C70–71 399 2.7 1.82 2.18 2.11 2.26 0.15 0.18 0.16 0.20 
Rectum C19–20 359 2.4 1.71 2.33 2.25 2.41 0.13 0.18 0.14 0.21 
Hodgkin disease M9650–67 246 1.7 1.13 1.21 1.16 1.26 0.09 0.09 0.08 0.11 
Pancreas C25 203 1.4 1.02 1.32 1.26 1.39 0.06 0.11 0.08 0.14 
Liver C22 210 1.4 0.99 1.36 1.3 1.42 0.07 0.1 0.07 0.13 
Kidney C64 201 1.4 0.93 1.25 1.19 1.3 0.08 0.11 0.08 0.13 
Bone C40–41 197 1.3 0.9 0.98 0.93 1.02 0.06 0.08 0.06 0.09 
Testis C62 194 1.3 0.89 0.95 0.9 0.99 0.07 0.07 0.06 0.08 
Multiple myeloma M9730–4, M9830 176 1.2 0.81 1.16 1.1 1.21 0.07 0.1 0.08 0.12 
Breast C50 160 1.1 0.73 1.05 0.99 1.10 0.08 0.08 0.06 0.10 
Thyroid C73 116 0.8 0.58 0.69 0.64 0.73 0.05 0.06 0.04 0.07 
Connective and soft tissue C47+49 114 0.8 0.57 0.66 0.62 0.70 0.05 0.06 0.05 0.07 
Lip C00 121 0.8 0.55 0.8 0.75 0.84 0.04 0.06 0.04 0.08 
Lymphoid leukemia M9820–9, M9940-1 119 0.8 0.54 0.73 0.68 0.77 0.04 0.06 0.04 0.08 
Nasopharynx C11 104 0.7 0.48 0.64 0.6 0.68 0.04 0.05 0.04 0.07 
Melanoma of skin M8720–99  95 0.6 0.43 0.6 0.56 0.64 0.03 0.04 0.02 0.06 
Gallbladder C23–24 93 0.6 0.42 0.62 0.58 0.66 0.03 0.05 0.03 0.07 
Small intestine C17 74 0.5 0.35 0.48 0.45 0.52 0.03 0.04 0.02 0.05 
Mouth C03–06 66 0.4 0.31 0.43 0.4 0.47 0.03 0.03 0.02 0.05 
Myeloid leukemia M9860–99, 9840–50, 9900, 9910, 9930–2 61 0.4 0.29 0.33 0.3 0.35 0.02 0.03 0.02 0.04 
Other thoracic organs C37–38 56 0.4 0.25 0.34 0.31 0.37 0.02 0.03 0.02 0.04 
Tongue C01–02 50 0.3 0.23 0.33 0.3 0.35 0.02 0.03 0.02 0.04 
Pharynx unspecified C14 40 0.3 0.18 0.26 0.24 0.29 0.01 0.03 0.02 0.03 
Salivary glands C07–08 41 0.3 0.18 0.24 0.22 0.27 0.02 0.03 0.01 0.04 
Anus C21 38 0.3 0.17 0.24 0.21 0.26 0.02 0.02 0.01 0.03 
Nose, sinuses C30–31 37 0.2 0.16 0.22 0.19 0.24 0.01 0.02 0.01 0.03 
Hypopharynx C12–13 27 0.2 0.13 0.18 0.16 0.20 0.01 0.01 0.01 0.02 
Kaposi sarcoma M9140 24 0.2 0.11 0.15 0.13 0.17 0.01 0.01 0.01 0.02 
Other endocrine C75 18 0.1 0.09 0.09 0.08 0.11 0.01 0.01 0.01 0.01 
Eye C69 18 0.1 0.08 0.1 0.08 0.11 0.00 0.00 0.00 0.01 
Tonsil C09 14 0.1 0.06 0.09 0.07 0.10 0.00 0.01 0.00 0.01 
Penis C60 10 0.1 0.04 0.07 0.05 0.08 0.01 0.01 0.00 0.01 
Mesothelioma M9050–9 excluding C38.4 7 0.0 0.03 0.04 0.03 0.05 0.00 0.00 0.00 0.01 
Renal pelvis C65 2 0.0 0.02 0.01 0.00 0.01 0.00 0.00 0.00 0.00 
Other urinary organs C68 3 0.0 0.01 0.02 0.01 0.03 0.00 0.00 0.00 0.00 
Other oropharynx C10 2 0.0 0.01 0.01 0.00 0.01 0.00 0.00 0.00 0.00 
Adrenal gland C74 2 0.0 0.01 0.01 0.00 0.01 0.00 0.00 0.00 0.00 
Other male genitalia C63 1 0.0 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.00 
Immunoproliferative M9760–9 1 0.0 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.00 
Other and unspecified O&U 769 5.2 3.58 4.54 4.43 4.65 0.25 0.35 0.30 0.40 
All sites All 16476  76.93 103.83 103.3 104.37 5.46 7.86 7.61 8.10 
All sites excluding skin All excluding C44 14883 100 69.49 93.38 92.87 93.89 4.90 7.07 6.84 7.30 
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Table 7.  Relative frequency, crude incidence rate, age-standardized rate (ASR) and 
cumulative rate by cancer site, female  
Cumulative rate 
(percent) Site ICD-O codes No. of  cases 
Relative 
freq. % 
(excluding 
other skin) 
Crude 
rate  
(per 105)
ASR 
(per 
105) 
95% CI for ASR
0–64 0–69 
95% CI for 
cumulative rate 
0–69 
Breast C50 2151 19.8 9.95 13.3 13.11 13.49 1.05 1.17 9.95 1.12 
Stomach C16 1362 12.5 6.32 9.33 9.17 9.50 0.54 0.78 6.32 0.72 
Esophagus C15 1267 11.7 5.89 8.89 8.73 9.06 0.55 0.76 5.89 0.70 
Other skin C44 excluding M8720–99 1160  5.37 7.87 7.72 8.02 0.45 0.59 5.37 0.53 
Colon  C18 612 5.6 2.86 4.03 3.93 4.14 0.27 0.36 2.86 0.32 
Thyroid C73 343 3.2 1.79 1.93 1.85 2 0.13 0.16 1.79 0.14 
Leukemia unspecified M9800–9 355 3.3 1.65 1.75 1.68 1.81 0.1 0.12 1.65 0.10 
Ovary C56 341 3.1 1.60 1.99 1.91 2.06 0.15 0.17 1.60 0.15 
Cervix uteri C53 341 3.1 1.54 2.25 2.17 2.33 0.18 0.21 1.54 0.19 
Brain, nervous system C70–71 319 2.9 1.43 1.73 1.66 1.79 0.13 0.15 1.43 0.13 
Rectum C19–20 295 2.7 1.39 1.98 1.90 2.05 0.15 0.17 1.39 0.15 
Non-Hodgkin lymphoma M9590–5, 9670–9729, 9740–9 293 2.7 1.37 1.65 1.58 1.71 0.11 0.13 1.37 0.11 
Lung, trachea & bronchus C33–34 241 2.2 1.12 1.63 1.56 1.70 0.08 0.12 1.12 0.09 
Bladder C67 226 2.1 1.10 1.55 1.48 1.62 0.09 0.13 1.10 0.10 
Uterus unspecified C55 164 1.5 0.79 1.05 0.99 1.10 0.08 0.10 0.79 0.09 
Gallbladder  C23–24 168 1.5 0.78 1.15 1.10 1.21 0.06 0.08 0.78 0.06 
Corpus uteri C54 150 1.4 0.70 1.04 0.99 1.10 0.08 0.11 0.70 0.10 
Hodgkin disease M9650–67 148 1.4 0.66 0.65 0.62 0.69 0.05 0.05 0.66 0.05 
Liver C22 137 1.3 0.64 0.89 0.84 0.95 0.05 0.07 0.64 0.06 
Pancreas C25 129 1.2 0.64 0.88 0.83 0.93 0.04 0.06 0.64 0.04 
Bone C40–41 135 1.2 0.60 0.63 0.6 0.67 0.04 0.04 0.60 0.03 
Kidney C64 115 1.1 0.55 0.71 0.67 0.76 0.05 0.06 0.55 0.04 
Connective and soft tissue C47+49 95 0.9 0.49 0.54 0.5 0.58 0.04 0.05 0.49 0.04 
Multiple myeloma M9730–4, M9830 83 0.8 0.39 0.56 0.52 0.6 0.04 0.05 0.39 0.04 
Tongue C01–02 71 0.7 0.34 0.49 0.45 0.52 0.03 0.03 0.34 0.02 
Melanoma of skin M8720–99 71 0.7 0.34 0.46 0.42 0.49 0.03 0.03 0.34 0.02 
Larynx C32 69 0.6 0.31 0.46 0.42 0.49 0.03 0.04 0.31 0.03 
Mouth C03–06 68 0.6 0.30 0.46 0.43 0.5 0.02 0.04 0.30 0.02 
Lymphoid leukemia M9820–9, M9940–1 61 0.6 0.29 0.39 0.36 0.42 0.02 0.03 0.29 0.02 
Lip C00 54 0.5 0.25 0.37 0.33 0.4 0.02 0.03 0.25 0.02 
Myeloid leukemia M9860–99, 9840–50, 9900, 9910, 9930–2 53 0.5 0.24 0.29 0.26 0.31 0.02 0.02 0.24 0.01 
Nasopharynx C11 47 0.4 0.23 0.28 0.26 0.31 0.02 0.03 0.23 0.02 
Vagina C52 41 0.4 0.19 0.27 0.24 0.29 0.02 0.03 0.19 0.02 
Small intestine C17 40 0.4 0.18 0.27 0.24 0.29 0.02 0.03 0.18 0.02 
Salivary glands C07–08 34 0.3 0.18 0.2 0.18 0.23 0.02 0.02 0.18 0.01 
Eye C69 36 0.3 0.16 0.22 0.20 0.24 0.01 0.01 0.16 0.00 
Hypopharynx C12–13 31 0.3 0.14 0.22 0.19 0.24 0.01 0.02 0.14 0.01 
Other thoracic organs C37–38 30 0.3 0.14 0.19 0.17 0.21 0.02 0.02 0.14 0.01 
Pharynx unspecified C14 28 0.3 0.13 0.2 0.17 0.22 0.01 0.02 0.13 0.02 
Other female genitalia C57 21 0.2 0.10 0.13 0.11 0.15 0.01 0.01 0.10 0.01 
Nose, sinuses  C30–31 18 0.2 0.09 0.12 0.10 0.14 0.01 0.01 0.09 0.00 
Anus C21 17 0.2 0.08 0.13 0.11 0.14 0.01 0.01 0.08 0.01 
Vulva C51 17 0.2 0.08 0.12 0.10 0.14 0.01 0.01 0.08 0.00 
Other endocrine C75 10 0.1 0.05 0.06 0.05 0.07 0.01 0.01 0.05 0.01 
Tonsil C09 9 0.1 0.04 0.07 0.05 0.08 0.00 0.01 0.04 0.00 
Kaposi sarcoma M9140 7 0.1 0.03 0.05 0.04 0.06 0.00 0.00 0.03 0.00 
Mesothelioma M9050–9 excluding C38.4 7 0.1 0.03 0.04 0.03 0.05 0.00 0.00 0.03 0.00 
Adrenal gland C74 4 0.0 0.02 0.02 0.01 0.03 0.00 0.00 0.02 0.00 
Other urinary organs C68 3 0.0 0.01 0.02 0.01 0.03 0.00 0.00 0.01 0.00 
Placenta C58 2 0.0 0.01 0.01 0.01 0.02 0.00 0.00 0.01 0.00 
Ureter C66 1 0.0 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.00 
Immunoproliferative  M9760–9 1 0.0 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.00 
Other and unspecified O&U 540 5.0 2.67 3.24 3.14 3.33 0.20 0.26 2.67 0.23 
All sites All 12023  56.22 76.76 76.29 77.22 5.03 6.44 56.22 6.28 
All sites excluding skin All excluding C44 10864 100 50.85 68.88 68.45 69.32 4.58 5.85 50.85 5.70 
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For every woman, the risk of any kind of cancer during 0–64 and 0–69 years of their life 
was approximately 5.0 and 6.4% respectively. Of this risk, around 38% was from 
gastrointestinal tract (mostly stomach, esophagus and colon), and about 20% was due to 
breast cancer. 
 
In all these five provinces and both sexes together, stomach was the most common cancer 
in terms of age-standardized incidence rate although it was higher in men. Esophageal 
cancer was in the second rank following by breast, bladder and lung cancers.  
 
 
Figure 13. Age-standardized rate (ASR) in all five provinces by sex 
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5.3.3 Incidence rates by provinces 
 
5.3.3.1 Ardebil 
 
Stomach cancer was the leading cancer in Ardebil both in women and men with ASR 28 
per 100,000 person-years for women and 55 for men (Figure 14). Esophageal cancer was 
the second most common cancer in this province with similar rank and rate in men and 
women (17–18 per 100,000 person-years). Third and fourth incident cancers in women 
were breast and uterus unspecified whereas in men lung and bladder came after stomach 
and esophageal cancers. Instead, there were very low ASRs for these two latter sites. 
Prostate cancer was in the 6th place after colon in men (Appendix Table 25).  
 
 
Figure 14. Age-standardized rate (ASR) in Ardebil province by sex, 1996–1999 
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The cumulative incidence of cancer (any kind) for men in Ardebil was 11.2% during 69 
years of life (Table 8). The 69-year cumulative rate for stomach cancer was 4.1% followed 
by esophagus, 1.3%. Each man in Ardebil by age 69 had 5.4% probability of upper 
gastrointestinal malignancy. 
 
Table 8. Cancer incidence rates in Ardebil province, male 
   Cumulative 
rate (percent)  Sites Cases (N) 
Relative 
freq. % 
Crude 
rate 
(/100,000) 
ASR* 
(/100,000) 95% CI for ASR 
 0–64 0–69   
95% CI for 
cumulative rate 
0–69 
Stomach 741 38.8 32.09 54.82 53.55 56.10 2.67 4.14  3.48 4.79 
Esophagus 241 12.6 10.39 18.34 17.60 19.08 0.92 1.31  0.93 1.69 
Other skin 195 0 9.00 14.23 13.56 14.91 0.80 1.02  0.70 1.35 
Lung, 120 6.3 5.13 8.60 8.11 9.10 0.44 0.71  0.49 0.94 
Bladder 117 6.1 5.04 8.58 8.07 9.08 0.44 0.61  0.35 0.87 
Colon  83 4.3 3.52 5.96 5.54 6.37 0.29 0.40  0.19 0.60 
Prostate 64 3.4 2.94 5.14 4.73 5.55 0.13 0.21  0.00 0.47 
Brain, nervous system 67 3.5 2.84 4.17 3.83 4.50 0.28 0.34  0.21 0.47 
Non-Hodgkin lymphoma 42 2.2 1.92 2.81 2.52 3.09 0.22 0.29  0.23 0.36 
Bone 37 1.9 1.66 2.35 2.10 2.61 0.15 0.18  0.07 0.29 
Kidney 37 1.9 1.61 2.41 2.15 2.67 0.19 0.22  0.13 0.31 
Liver 27 1.4 1.24 1.85 1.62 2.09 0.07 0.12  0.01 0.23 
Testis 17 0.9 0.72 0.72 0.61 0.84 0.05 0.05  0.04 0.06 
Larynx 17 0.9 0.72 1.16 0.98 1.33 0.08 0.10  0.04 0.17 
Rectum 16 0.8 0.68 0.99 0.84 1.15 0.09 0.09  0.06 0.12 
Leukemia unspecified 14 0.7 0.59 0.79 0.65 0.93 0.07 0.07  0.04 0.10 
Pancreas 12 0.6 0.51 0.87 0.72 1.03 0.04 0.07  0.00 0.15 
Pharynx unspecified 12 0.6 0.51 0.91 0.75 1.08 0.04 0.08  0.00 0.17 
Tongue 11 0.6 0.47 0.74 0.59 0.88 0.03 0.04  0.00 0.12 
Connective & soft tissue 9 0.5 0.43 0.48 0.37 0.58 0.04 0.04  0.03 0.04 
Gallbladder  10 0.5 0.42 0.63 0.50 0.75 0.03 0.04  0.00 0.09 
Thyroid 10 0.5 0.42 0.65 0.51 0.78 0.05 0.06  0.03 0.09 
Lymphoid leukemia 9 0.5 0.38 0.46 0.35 0.57 0.04 0.04  0.03 0.05 
Hodgkin disease 9 0.5 0.38 0.47 0.37 0.57 0.03 0.03  0.01 0.06 
Breast 9 0.5 0.38 0.75 0.59 0.90 0.05 0.06  0.00 0.12 
Mouth 7 0.4 0.35 0.56 0.42 0.70 0.03 0.05  0.00 0.12 
Hypopharynx 5 0.3 0.26 0.34 0.23 0.45 0.03 0.03  0.02 0.04 
Myeloid leukemia 6 0.3 0.25 0.29 0.21 0.37 0.03 0.03  0.02 0.03 
Nasopharynx 6 0.3 0.25 0.36 0.27 0.45 0.03 0.04  0.03 0.05 
Anus 6 0.3 0.25 0.40 0.29 0.50 0.03 0.03  0.02 0.04 
Multiple myeloma 4 0.2 0.23 0.25 0.16 0.34 0.02 0.03  0.02 0.05 
Other endocrine 4 0.2 0.23 0.28 0.17 0.38 0.02 0.02  0.01 0.03 
Melanoma of skin 5 0.3 0.21 0.30 0.22 0.39 0.02 0.04  0.03 0.05 
Nose, sinuses  4 0.2 0.17 0.25 0.17 0.33 0.01 0.02  0.00 0.05 
Small intestine 3 0.2 0.13 0.15 0.10 0.21 0.01 0.02  0.01 0.03 
Kaposi sarcoma 3 0.2 0.13 0.18 0.11 0.24 0.01 0.01  0.01 0.02 
Salivary glands 3 0.2 0.13 0.19 0.12 0.25 0.01 0.02  0.01 0.03 
Tonsil 3 0.2 0.13 0.21 0.13 0.28 0.02 0.02  0.00 0.04 
Eye 2 0.1 0.08 0.03 0.01 0.04 0.00 0.00  0.00 0.00 
Other thoracic organs 2 0.1 0.08 0.14 0.08 0.20 0.01 0.01  0.01 0.02 
Penis 2 0.1 0.08 0.15 0.09 0.22 0.01 0.01  0.00 0.04 
Other and unspecified 113 5.9 4.96 6.80 6.37 7.23 0.36 0.53  0.33 0.72 
All sites 2104 0 91.82 149.71 147.61 151.80 7.90 11.24  10.22 12.26 
All sites excluding skin 1909 100 82.85 135.50 133.51 137.48 7.10 10.22  9.25 11.18 
* ASR=Age-standardized rate 
 
The cumulative rate for women in Ardebil was generally lower than men; they had 8.7% 
probability of any cancer (Table 9). Similar to men, most of this risk in women was due to 
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upper GI cancer (stomach 2.3%; esophagus 1.4%) followed by skin and breast cancer 
(0.7%). 
 
Table 9. Cancer incidence rates in Ardebil province, female 
    
 
Cumulative 
rate (percent)  
Sites 
Cases 
(N) 
Relative 
freq. % 
Crude 
rate 
(/100,000) 
ASR* 
(/100,000) 95% CI for ASR 
  0–64 0–69   
95% CI for 
cumulative rate 
0–69 
Stomach 337 26.5 14.79 28.48 27.51 29.45 1.73 2.28 1.84 2.71
Esophagus 212 16.6 9.82 16.68 15.92 17.44  1.02 1.40 1.08 1.71 
Other skin 131  5.94 9.46 8.92 10.01  0.56 0.70 0.47 0.92 
Breast 108 8.5 4.80 8.43 7.92 8.95  0.52 0.62 0.39 0.85 
Uterus unspecified 51 4 2.25 3.83 3.49 4.17  0.30 0.35 0.25 0.45 
Colon  48 3.8 2.08 3.94 3.58 4.29  0.25 0.31 0.15 0.46 
Brain, nervous system 47 3.7 2.03 3.09 2.79 3.38  0.23 0.28 0.18 0.37 
Lung 42 3.3 1.86 3.27 2.95 3.59  0.17 0.24 0.11 0.38 
Liver 31 2.4 1.39 2.34 2.08 2.61  0.14 0.23 0.15 0.31 
Gallbladder 26 2.0 1.33 2.32 2.02 2.62  0.14 0.17 0.04 0.29 
Bladder 29 2.3 1.30 2.46 2.18 2.74  0.15 0.18 0.06 0.31 
Thyroid 22 1.7 1.23 1.27 1.07 1.47  0.10 0.13 0.11 0.15 
Ovary 24 1.9 1.13 1.65 1.43 1.88  0.11 0.11 0.03 0.18 
Bone 26 2.0 1.12 1.48 1.29 1.68  0.11 0.12 0.07 0.17 
Rectum 20 1.6 0.96 1.47 1.25 1.68  0.10 0.15 0.10 0.20 
Non-Hodgkin lymphoma 15 1.2 0.75 0.69 0.56 0.82  0.06 0.06 0.05 0.07 
Leukemia unspecified 15 1.2 0.70 0.96 0.79 1.12  0.07 0.08 0.05 0.12 
Tongue 9 0.7 0.58 1.21 0.95 1.48  0.02 0.02 0.00 0.20 
Cervix uteri 11 0.9 0.52 0.93 0.75 1.11  0.06 0.07 0.00 0.15 
Pancreas 12 0.9 0.52 0.93 0.76 1.10  0.08 0.10 0.06 0.14 
Hodgkin disease 11 0.9 0.48 0.46 0.37 0.55  0.03 0.04 0.03 0.05 
Anus 7 0.5 0.35 0.48 0.35 0.62  0.04 0.04 0.00 0.08 
Connective & soft tissue 7 0.5 0.30 0.34 0.25 0.44  0.03 0.03 0.02 0.04 
Pharynx unspecified 6 0.5 0.26 0.45 0.33 0.56  0.04 0.06 0.04 0.07 
Eye 6 0.5 0.26 0.34 0.25 0.43  0.01 0.01 0.00 0.05 
Lymphoid leukemia 6 0.5 0.26 0.37 0.27 0.46  0.02 0.04 0.02 0.05 
Corpus uteri 5 0.4 0.22 0.40 0.29 0.51  0.03 0.05 0.03 0.06 
Myeloid leukemia 5 0.4 0.22 0.24 0.17 0.31  0.02 0.02 0.01 0.02 
Salivary glands 4 0.3 0.17 0.27 0.18 0.35  0.02 0.03 0.02 0.04 
Larynx 4 0.3 0.17 0.24 0.17 0.32  0.02 0.02 0.01 0.03 
Melanoma of skin 4 0.3 0.17 0.19 0.13 0.26  0.02 0.02 0.01 0.02 
Tonsil 3 0.2 0.13 0.40 0.27 0.52  0.02 0.02 0.00 0.10 
Vagina 3 0.2 0.13 0.25 0.16 0.34  0.03 0.03 0.02 0.04 
Nasopharynx 2 0.2 0.09 0.13 0.07 0.19  0.01 0.01 0.01 0.01 
Hypopharynx 2 0.2 0.09 0.17 0.10 0.24  0.02 0.02 0.01 0.02 
Other thoracic organs 2 0.2 0.09 0.17 0.10 0.24  0.01 0.01 0.00 0.04 
Vulva 2 0.2 0.09 0.14 0.08 0.20  0.00 0.02 0.01 0.03 
Multiple myeloma 2 0.2 0.09 0.13 0.08 0.19  0.01 0.02 0.01 0.03 
Small intestine 1 0.1 0.04 0.08 0.03 0.14  0.01 0.01 0.00 0.01 
Nose, sinuses 1 0.1 0.04 0.24 0.13 0.34  0.00 0.00 0.00 0.08 
Placenta 1 0.1 0.04 0.05 0.02 0.08  0.00 0.00 0.00 0.01 
Other urinary organs 1 0.1 0.04 0.08 0.03 0.13  0.01 0.01 0.00 0.02 
Other endocrine 1 0.1 0.04 0.08 0.03 0.13  0.01 0.01 0.00 0.02 
Other and unspecified 102 8.0 6.25 6.86 6.33 7.38  0.42 0.52 0.31 0.73 
All sites 1405  64.63 107.72 105.83 109.60  6.75 8.66 7.89 9.43 
All sites excluding skin 1274 100 58.69 98.26 96.46 100.07   6.19 7.96 7.22 8.71 
* ASR=Age-standardized rate 
 
Figure 15 and Figure 16 show the rank and pattern of age-specific incidence rates and total 
crude incidence rate in Ardebil. Stomach cancer and esophageal cancers were the leading 
cancers in Ardebil in both sexes. Lung was the third common cancer among men. Breast 
was in the third rank in women. Brain, leukemia, and bone cancers were the most common 
cancers under age 20 in both sexes (Appendix Table 8 and Appendix Table 9). 
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Figure 15. Age-specific incidence rate in Ardebil, male 
 
 
Figure 16. Age-specific incidence rate in Ardebil, female 
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5.3.3.2 Gilan 
 
Considering ASR of both sexes together, stomach cancer was the leading cancer although 
breast cancer was the leading cancer in women (Figure 17). Esophageal cancer was the 
second most common cancer in men and third cancer in women after stomach. Bladder and 
prostate were the third and fourth common cancers in this northern province of Iran. Colon 
cancer had the fourth place in women and fifth place after lung in men. 
 
 
Figure 17. Age-standardized rate (ASR) in Gilan province by sex 
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Age-specific rates revealed that stomach cancer was the leading cancer in men at most ages 
(Figure 18). However, leukemia (age period 0–20) and testis cancer (age 20 to 30) were the 
most common cancers among boys. The age distribution among women was different so 
that after leukemia (0–15 years), Hodgkin disease and ovary were the leading cancers each 
for 5 years. Breast cancer was the leading cancer in the reproductive ages until stomach 
took first place after age 60 (Figure 19). Detailed age-specific rates can be found in 
Appendix Table 11 and Appendix Table 12. 
 
 
Figure 18. Age-specific incidence rate in Gilan, male 
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Figure 19. Age-specific incidence rate in Gilan, female 
 
In terms of cumulative rate, in Gilanian men, stomach was in the highest risk by age 69 
years with a probability of about 2% (Table 10). Bladder and esophagus had similar 
cumulative rate (0.7%); likewise lung and colon (0.4%). Risk of any kind of cancer for 
Gilanian men was 8% by age 69 years, of which the majority was due to gastrointestinal 
cancers.  
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Table 10. Cancer incidence rates in Gilan province, male 
  Cumulative rate (%)   
Sites 
Cases 
(N) 
Relative 
freq.  
(%) 
Crude 
rate 
(/105) 
ASR* 
(/105) 95% CI for ASR 
  0–64 0–69   
95% CI for 
cumulative rate 
0–69 (%) 
Stomach 1019 25.2 19.91 24.93 24.42 25.44  1.29 1.90  1.64 2.15 
Prostate 328 8.1 10.26 8.65 8.26 9.04  0.19 0.36  0.10 0.62 
Other skin 419 0.0 7.77 10.01 9.69 10.33  0.55 0.77  0.62 0.92 
Bladder 379 9.4 7.19 9.33 9.02 9.64  0.45 0.71  0.55 0.86 
Esophagus 381 9.4 7.11 9.76 9.45 10.08  0.48 0.70  0.53 0.87 
Lung 223 5.5 4.25 5.26 5.03 5.49  0.25 0.42  0.31 0.53 
Colon 216 5.3 4.16 4.83 4.62 5.05  0.30 0.42  0.34 0.51 
Leukemia unspecified 121 3.0 2.26 2.17 2.04 2.30  0.12 0.13  0.09 0.16 
Rectum 113 2.8 2.18 2.85 2.68 3.02  0.15 0.20  0.11 0.28 
Non-Hodgkin lymphoma 116 2.9 2.15 2.52 2.37 2.67  0.16 0.17  0.11 0.24 
Larynx 100 2.5 1.83 2.41 2.26 2.56  0.15 0.23  0.17 0.29 
Pancreas 68 1.7 1.48 1.73 1.59 1.87  0.09 0.15  0.09 0.22 
Testis 72 1.8 1.35 1.41 1.30 1.52  0.10 0.11  0.08 0.14 
Kidney 63 1.6 1.21 1.64 1.50 1.77  0.09 0.12  0.05 0.19 
Liver 60 1.5 1.15 1.49 1.36 1.61  0.08 0.12  0.05 0.18 
Breast 56 1.4 1.04 1.36 1.24 1.48  0.10 0.11  0.07 0.15 
Multiple myeloma 51 1.3 0.99 1.26 1.14 1.37  0.06 0.10  0.05 0.15 
Brain, nervous system 52 1.3 0.97 1.08 0.99 1.18  0.08 0.09  0.06 0.12 
Thyroid 39 1.0 0.91 0.83 0.73 0.92  0.07 0.08  0.06 0.10 
Hodgkin disease 46 1.1 0.88 0.88 0.79 0.96  0.07 0.08  0.07 0.09 
Bone 43 1.1 0.77 0.91 0.82 1.00  0.05 0.06  0.03 0.10 
Lip 37 0.9 0.66 0.87 0.78 0.95  0.06 0.08  0.06 0.11 
Small intestine 31 0.8 0.62 0.77 0.68 0.86  0.03 0.05  0.00 0.10 
Connective & soft tissue 23 0.6 0.43 0.54 0.47 0.61  0.04 0.05  0.03 0.07 
Mouth 21 0.5 0.40 0.50 0.43 0.57  0.03 0.03  0.00 0.07 
Nasopharynx 22 0.5 0.39 0.53 0.46 0.60  0.03 0.05  0.02 0.07 
Lymphoid leukemia 18 0.4 0.34 0.41 0.34 0.47  0.01 0.03  0.00 0.06 
Other thoracic organs 17 0.4 0.32 0.40 0.34 0.46  0.02 0.03  0.00 0.06 
Gallbladder 17 0.4 0.30 0.32 0.27 0.38  0.03 0.03  0.01 0.05 
Nose, sinuses 14 0.3 0.27 0.32 0.26 0.38  0.02 0.02  0.00 0.05 
Melanoma of skin 13 0.3 0.23 0.29 0.24 0.33  0.02 0.02  0.01 0.04 
Pharynx unspecified 11 0.3 0.20 0.25 0.21 0.30  0.02 0.02  0.01 0.04 
Kaposi sarcoma 10 0.2 0.20 0.25 0.19 0.30  0.00 0.02  0.00 0.05 
Salivary glands 10 0.2 0.18 0.19 0.15 0.23  0.02 0.02  0.01 0.03 
Other endocrine 3 0.1 0.16 0.06 0.02 0.10  0.00 0.00  0.00 0.01 
Anus 7 0.2 0.13 0.14 0.10 0.17  0.01 0.02  0.01 0.02 
Myeloid leukemia 6 0.1 0.11 0.14 0.10 0.17  0.01 0.01  0.01 0.01 
Hypopharynx 5 0.1 0.09 0.10 0.07 0.12  0.01 0.01  0.01 0.01 
Mesothelioma 3 0.1 0.05 0.09 0.06 0.12  0.00 0.00  0.00 0.02 
Tonsil 3 0.1 0.05 0.07 0.04 0.09  0.00 0.01  0.00 0.02 
Tongue 3 0.1 0.05 0.06 0.04 0.08  0.00 0.01  0.00 0.01 
Eye 3 0.1 0.05 0.04 0.02 0.05  0.00 0.00  0.00 0.01 
Penis 3 0.1 0.05 0.02 0.01 0.03  0.00 0.00  0.00 0.01 
Other oropharynx 1 0.0 0.02 0.02 0.01 0.04  0.00 0.00  0.00 0.01 
Immunoproliferative 1 0.0 0.02 0.00 0.00 0.00  0.00 0.00  0.00 0.00 
Ureter 1 0.0 0.00 0.00 0.00 0.00  0.00 0.00  0.00 0.00 
Other and unspecified 218 5.4 4.08 5.05 4.82 5.27  0.28 0.38  0.28 0.49 
All sites 4466  87.61 106.32 105.27 107.37  5.63 8.02  7.51 8.52 
All sites excluding skin 4047 100 79.87 96.31 95.31 97.31   5.08 7.25   6.76 7.73 
* ASR=Age-standardized rate 
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Overall risk of cancer among Gilanian women was lower than men with 6% risk of cancer 
by age 69 years (Table 11). Most of this cancer risk was firstly due to breast cancer (1.1%) 
followed by stomach (0.8%), esophagus, colon and other skin (approximately 0.5% each). 
 
Table 11. Cancer incidence rates in Gilan province, female 
  Cumulative rate (%) 
  
Sites 
Cases 
(N) 
Relative 
freq.  
(%) 
Crude 
rate 
(/105) 
ASR* 
(/105) 95% CI for ASR 
  0–64 0–69   
95% CI for 
cumulative rate 
0–69 (%) 
Breast 572 20.1 10.78 13.02 12.67 13.37  1.06 1.14  1.06 1.23 
Stomach 387 13.6 7.45 9.58 9.28 9.89  0.50 0.76  0.63 0.89 
Other skin 274 0.0 5.05 6.55 6.30 6.80  0.36 0.46  0.36 0.57 
Colon  233 8.2 4.48 5.50 5.27 5.73  0.34 0.46  0.37 0.54 
Esophagus 233 8.2 4.42 5.85 5.61 6.09  0.37 0.50  0.41 0.59 
Thyroid 137 4.8 3.47 2.82 2.64 3.00  0.20 0.23  0.18 0.28 
Rectum 100 3.5 1.97 2.37 2.21 2.52  0.16 0.18  0.13 0.24 
Ovary 105 3.7 1.94 2.28 2.14 2.42  0.18 0.21  0.17 0.25 
Leukemia unspecified 75 2.6 1.47 1.49 1.38 1.61  0.08 0.09  0.05 0.12 
Cervix uteri 80 2.8 1.46 1.84 1.70 1.97  0.16 0.18  0.15 0.21 
Brain, nervous system 73 2.6 1.31 1.47 1.36 1.58  0.11 0.13  0.11 0.15 
Corpus uteri 69 2.4 1.28 1.68 1.55 1.81  0.15 0.17  0.14 0.20 
Bladder 68 2.4 1.28 1.59 1.47 1.71  0.08 0.13  0.08 0.18 
Non-Hodgkin lymphoma 46 1.6 0.99 0.92 0.83 1.02  0.07 0.08  0.05 0.10 
Kidney 45 1.6 0.92 1.07 0.96 1.17  0.07 0.09  0.06 0.13 
Lung 46 1.6 0.89 1.12 1.02 1.23  0.06 0.10  0.06 0.14 
Pancreas 40 1.4 0.86 1.03 0.93 1.14  0.04 0.06  0.01 0.11 
Liver 44 1.5 0.84 1.04 0.94 1.14  0.06 0.09  0.06 0.12 
Connective & soft tissue 30 1.1 0.80 0.64 0.55 0.73  0.04 0.06  0.04 0.08 
Uterus unspecified 36 1.3 0.68 0.76 0.68 0.85  0.06 0.07  0.05 0.08 
Gallbladder 32 1.1 0.59 0.90 0.81 0.99  0.04 0.05  0.00 0.10 
Hodgkin disease 31 1.1 0.55 0.53 0.47 0.59  0.04 0.04  0.04 0.05 
Bone 25 0.9 0.44 0.48 0.42 0.54  0.03 0.03  0.01 0.06 
Larynx 21 0.7 0.39 0.50 0.43 0.56  0.03 0.04  0.02 0.07 
Multiple myeloma 19 0.7 0.36 0.43 0.37 0.49  0.02 0.04  0.02 0.06 
Tongue 19 0.7 0.34 0.42 0.36 0.48  0.04 0.04  0.03 0.05 
Small intestine 13 0.5 0.25 0.29 0.24 0.34  0.03 0.03  0.03 0.04 
Mouth 13 0.5 0.23 0.37 0.31 0.43  0.02 0.02  0.00 0.05 
Melanoma of skin 13 0.5 0.23 0.26 0.21 0.30  0.01 0.02  0.01 0.04 
Vagina 12 0.4 0.21 0.29 0.24 0.35  0.02 0.03  0.01 0.04 
Lymphoid leukemia 9 0.3 0.21 0.20 0.15 0.25  0.01 0.02  0.02 0.03 
Nasopharynx 11 0.4 0.20 0.25 0.20 0.30  0.02 0.03  0.02 0.03 
Hypopharynx 8 0.3 0.14 0.17 0.14 0.21  0.00 0.01  0.00 0.02 
Salivary glands 7 0.2 0.14 0.15 0.11 0.19  0.01 0.01  0.01 0.02 
Nose, sinuses 6 0.2 0.13 0.16 0.11 0.20  0.01 0.01  0.00 0.02 
Other thoracic organs 6 0.2 0.13 0.12 0.08 0.15  0.01 0.01  0.01 0.01 
Other female genitalia 6 0.2 0.13 0.12 0.09 0.16  0.01 0.01  0.00 0.02 
Pharynx unspecified 7 0.2 0.12 0.18 0.14 0.22  0.02 0.02  0.02 0.03 
Kaposi sarcoma 6 0.2 0.11 0.14 0.10 0.18  0.00 0.00  0.00 0.03 
Eye 5 0.2 0.11 0.12 0.08 0.16  0.01 0.01  0.01 0.02 
Myeloid leukemia 5 0.2 0.09 0.09 0.06 0.11  0.00 0.00  0.00 0.01 
Lip 4 0.1 0.07 0.11 0.08 0.15  0.00 0.01  0.00 0.03 
Tonsil 3 0.1 0.05 0.07 0.04 0.09  0.00 0.01  0.01 0.01 
Anus 2 0.1 0.04 0.05 0.03 0.07  0.01 0.01  0.00 0.01 
Mesothelioma 2 0.1 0.04 0.05 0.03 0.08  0.01 0.01  0.00 0.01 
Other urinary organs 2 0.1 0.04 0.05 0.03 0.08  0.01 0.01  0.00 0.01 
Other endocrine 2 0.1 0.04 0.03 0.02 0.05  0.00 0.00  0.00 0.00 
Vulva 1 0.0 0.02 0.03 0.01 0.05  0.00 0.00  0.00 0.00 
Adrenal gland 1 0.0 0.02 0.02 0.01 0.04  0.00 0.00  0.00 0.00 
Other and unspecified 132 4.6 2.46 2.85 2.69 3.01  0.17 0.25  0.19 0.30 
All sites 3116 0.0 59.83 72.13 71.30 72.97  4.75 6.00  5.71 6.28 
All sites excluding skin 2842 100.0 54.80 65.57 64.77 66.37   4.39 5.54   5.27 5.80 
* ASR=Age-standardized rate 
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5.3.3.3 Mazandaran 
 
In terms of ASR in both sexes together, stomach, esophagus, breast, lung and colon were 
the five leading cancers of this province (Figure 20). However the distribution of cancer 
was totally different between sexes. In women, breast cancer was the most common cancer 
followed by esophageal and gastric cancer, while in men the order was stomach, 
esophagus, lung, bladder and prostate. Some cancers such as esophagus, colorectal, 
leukemia, non-Hodgkin lymphoma and brain appeared roughly similar ASR among 
Mazandaranian men and women. 
 
 
Figure 20. Age-standardized rate (ASR) in Mazandaran province by sex 
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The leading cancer until age 25 was leukemia in both girls and boys, but thereafter, in 
women breast was the most common cancer until age 60, while in men after leukemia, non-
Hodgkin lymphoma and colon were the leading cancers each for 5 years and then 
esophagus was the common cancer in women and stomach cancer in men (Appendix Table 
12 and Appendix Table 13). 
 
 
Figure 21. Age-specific incidence rate in Mazandaran, male 
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Figure 22. Age-specific incidence rate in Mazandaran, female 
 
In terms of cumulative rate up to 69 years, each man in Mazandaran had approximately 
7.75% risk of cancer of any kind (Table 12). Of this risk, the majority was due to stomach 
cancer (1.6% risk until age 69) followed by esophagus (0.9%), skin (0.75%), lung (0.6%) 
and bladder (0.4%).  
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Table 12. Cancer incidence rates in Mazandaran, male 
 
 Cumulative rate (%)  Sites Cases (N) 
Relative 
freq.  
(%) 
Crude 
rate 
(/105) 
ASR* 
(/105) 95% CI for ASR 
 0–64 0–69  
95% CI for 
cumulative rate 
0–69 (%) 
Stomach 894 20.6 15.01 20.81 20.36 21.26  0.94 1.59  1.38 1.80 
Esophagus 578 13.3 9.76 13.69 13.32 14.05  0.54 0.88  0.69 1.06 
Other skin 407 0.0 6.98 9.05 8.75 9.36  0.46 0.71  0.57 0.84 
Lung 354 8.1 5.98 8.39 8.10 8.68  0.32 0.56  0.41 0.71 
Bladder 273 6.3 4.71 6.39 6.13 6.64  0.27 0.41  0.28 0.54 
Prostate 213 4.9 3.84 5.00 4.77 5.23  0.13 0.32  0.19 0.44 
Larynx 172 4.0 3.17 4.20 3.99 4.41  0.21 0.32  0.22 0.43 
Colon 181 4.2 3.14 3.82 3.63 4.01  0.26 0.30  0.23 0.37 
Leukemia unspecified 182 4.2 2.99 2.87 2.73 3.01  0.16 0.20  0.15 0.24 
Non-Hodgkin lymphoma 180 4.1 2.94 3.32 3.15 3.48  0.21 0.27  0.22 0.33 
Brain, nervous system 151 3.5 2.51 2.88 2.72 3.04  0.18 0.23  0.17 0.28 
Rectum 112 2.6 2.02 2.55 2.39 2.71  0.12 0.17  0.09 0.25 
Hodgkin disease 82 1.9 1.35 1.46 1.35 1.57  0.10 0.12  0.08 0.15 
Pancreas 55 1.3 1.08 1.35 1.22 1.47  0.04 0.12  0.06 0.17 
Nasopharynx 61 1.4 1.04 1.29 1.18 1.41  0.08 0.10  0.06 0.14 
Connective & soft tissue 50 1.2 0.96 1.02 0.91 1.12  0.07 0.09  0.05 0.12 
Testis 57 1.3 0.96 0.91 0.83 0.99  0.07 0.07  0.05 0.08 
Breast 57 1.3 0.95 1.28 1.17 1.39  0.09 0.10  0.06 0.14 
Liver 44 1.0 0.85 1.07 0.96 1.18  0.05 0.09  0.04 0.13 
Multiple myeloma 51 1.2 0.79 1.17 1.07 1.27  0.08 0.11  0.08 0.14 
Bone 43 1.0 0.73 0.65 0.58 0.72  0.05 0.05  0.04 0.07 
Kidney 42 1.0 0.70 0.83 0.74 0.91  0.05 0.07  0.04 0.10 
Gallbladder 39 0.9 0.63 0.93 0.84 1.03  0.03 0.08  0.04 0.13 
Lymphoid leukemia 37 0.9 0.60 0.75 0.66 0.83  0.04 0.07  0.03 0.10 
Lip 29 0.7 0.56 0.80 0.70 0.89  0.03 0.05  0.00 0.10 
Thyroid 27 0.6 0.49 0.55 0.48 0.62  0.04 0.05  0.03 0.07 
Melanoma of skin 25 0.6 0.40 0.58 0.50 0.65  0.03 0.04  0.00 0.07 
Tongue 22 0.5 0.36 0.51 0.44 0.58  0.03 0.04  0.02 0.07 
Small intestine 20 0.5 0.34 0.47 0.40 0.54  0.03 0.04  0.01 0.07 
Mouth 20 0.5 0.32 0.43 0.37 0.50  0.03 0.03  0.02 0.05 
Myeloid leukemia 17 0.4 0.28 0.31 0.26 0.36  0.01 0.02  0.00 0.05 
Nose, sinuses 16 0.4 0.25 0.30 0.25 0.35  0.03 0.03  0.02 0.04 
Anus 14 0.3 0.22 0.29 0.24 0.34  0.02 0.02  0.00 0.04 
Salivary glands 13 0.3 0.20 0.28 0.23 0.33  0.02 0.03  0.02 0.04 
Hypopharynx 10 0.2 0.17 0.21 0.17 0.26  0.01 0.02  0.00 0.03 
Other endocrine 9 0.2 0.14 0.15 0.12 0.19  0.01 0.01  0.01 0.02 
Other thoracic organs 8 0.2 0.12 0.18 0.14 0.22  0.01 0.02  0.00 0.03 
Pharynx unspecified 5 0.1 0.10 0.13 0.09 0.17  0.00 0.01  0.00 0.03 
Kaposi sarcoma 6 0.1 0.09 0.13 0.10 0.16  0.01 0.02  0.01 0.02 
Eye 4 0.1 0.06 0.06 0.04 0.08  0.00 0.00  0.00 0.01 
Penis 3 0.1 0.05 0.05 0.03 0.07  0.01 0.01  0.00 0.01 
Mesothelioma 2 0.0 0.03 0.04 0.02 0.05  0.00 0.00  0.00 0.01 
Other male genitalia 1 0.0 0.02 0.02 0.01 0.04  0.00 0.00  0.00 0.01 
Other urinary organs 1 0.0 0.02 0.02 0.01 0.04  0.00 0.00  0.00 0.01 
Other oropharynx 1 0.0 0.02 0.01 0.00 0.01  0.00 0.00  0.00 0.00 
Other and unspecified 186 4.3 3.38 3.99 3.79 4.19  0.23 0.32  0.25 0.40 
All sites 4754 0.0 81.15 105.01 104.00 106.01  5.11 7.75  7.30 8.21 
All sites excluding skin 4347 100.0 74.17 95.95 94.99 96.92  4.65 7.04  6.61 7.48 
* ASR=Age-standardized rate 
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In general, risk of cancer in women was lower than men in Mazandaran so that the 
cumulative rate was 6.3% for women by 69 years (Table 13).  The majority of this risk was 
attributable to breast cancer (1.3% in 0–69 years) and upper GI cancers (esophagus 0.9%; 
stomach 0.7%).  
 
Table 13. Cancer incidence rates in Mazandaran province, female 
 Cumulative rate (%)  
Sites 
Cases 
(N) 
Relative 
freq.  
(%) 
Crude 
rate 
(/105) 
ASR* 
(/105) 95% CI for ASR 
 0–64 0–69  
95% CI for 
cumulative rate 
0–69 (%) 
Breast 690 22.1 11.45 14.01 13.66 14.36  1.16 1.28  1.21 1.36 
Esophagus 436 14.0 7.12 10.78 10.46 11.11  0.61 0.91  0.78 1.03 
Stomach 354 11.3 6.12 8.16 7.87 8.45  0.46 0.71  0.60 0.82 
Other skin 280  4.64 6.75 6.49 7.01  0.38 0.51  0.41 0.62 
Colon  173 5.5 2.88 3.88 3.69 4.07  0.27 0.34  0.28 0.39 
Leukemia unspecified 110 3.5 1.84 2.00 1.87 2.13  0.10 0.13  0.08 0.17 
Non-Hodgkin lymphoma 102 3.3 1.71 2.03 1.89 2.16  0.13 0.17  0.13 0.21 
Brain, nervous system 99 3.2 1.60 1.83 1.71 1.95  0.14 0.15  0.12 0.18 
Cervix uteri 96 3.1 1.55 2.33 2.18 2.48  0.17 0.21  0.16 0.26 
Ovary 88 2.8 1.45 1.71 1.59 1.83  0.12 0.15  0.11 0.18 
Rectum 75 2.4 1.21 1.60 1.48 1.72  0.12 0.13  0.09 0.17 
Thyroid 65 2.1 1.04 1.21 1.11 1.30  0.09 0.10  0.08 0.12 
Lung 53 1.7 0.96 1.33 1.22 1.45  0.06 0.09  0.04 0.14 
Bladder 51 1.6 0.93 1.20 1.08 1.31  0.06 0.09  0.05 0.14 
Pancreas 38 1.2 0.74 0.78 0.68 0.88  0.03 0.06  0.01 0.10 
Hodgkin disease 46 1.5 0.74 0.75 0.68 0.83  0.06 0.06  0.05 0.07 
Uterus unspecified 36 1.2 0.74 0.81 0.71 0.91  0.06 0.08  0.06 0.11 
Corpus uteri 38 1.2 0.63 0.87 0.78 0.96  0.05 0.11  0.08 0.13 
Gallbladder 33 1.1 0.54 0.72 0.64 0.80  0.05 0.06  0.04 0.09 
Kidney 34 1.1 0.54 0.70 0.62 0.78  0.04 0.04  0.02 0.07 
Multiple myeloma 30 1.0 0.51 0.73 0.64 0.81  0.05 0.07  0.04 0.09 
Liver 25 0.8 0.48 0.56 0.48 0.63  0.02 0.04  0.01 0.07 
Connective & soft tissue 28 0.9 0.46 0.59 0.52 0.67  0.04 0.06  0.04 0.07 
Bone 30 1.0 0.46 0.55 0.49 0.62  0.02 0.03  0.00 0.06 
Melanoma of skin 21 0.7 0.42 0.49 0.41 0.56  0.02 0.03  0.00 0.07 
Nasopharynx 24 0.8 0.42 0.48 0.41 0.54  0.04 0.04  0.03 0.06 
Larynx 23 0.7 0.39 0.51 0.44 0.58  0.04 0.04  0.03 0.06 
Myeloid leukemia 21 0.7 0.36 0.41 0.35 0.47  0.03 0.03  0.02 0.05 
Mouth 21 0.7 0.34 0.55 0.48 0.62  0.02 0.04  0.00 0.07 
Salivary glands 16 0.5 0.30 0.31 0.26 0.37  0.03 0.03  0.02 0.04 
Tongue 18 0.6 0.28 0.43 0.37 0.49  0.01 0.02  0.00 0.05 
Lip 16 0.5 0.26 0.37 0.31 0.43  0.03 0.03  0.01 0.05 
Hypopharynx 15 0.5 0.23 0.41 0.35 0.47  0.02 0.04  0.01 0.06 
Lymphoid leukemia 14 0.4 0.23 0.31 0.26 0.36  0.02 0.02  0.00 0.05 
Small intestine 13 0.4 0.20 0.33 0.27 0.38  0.02 0.03  0.01 0.05 
Vagina 8 0.3 0.16 0.18 0.13 0.23  0.01 0.02  0.01 0.02 
Eye 7 0.2 0.13 0.18 0.13 0.22  0.01 0.01  0.00 0.03 
Nose, sinuses 8 0.3 0.12 0.15 0.11 0.18  0.01 0.01  0.00 0.02 
Other thoracic organs 5 0.2 0.10 0.13 0.09 0.17  0.01 0.02  0.01 0.02 
Pharynx unspecified 5 0.2 0.10 0.12 0.08 0.16  0.01 0.01  0.01 0.02 
Vulva 5 0.2 0.08 0.11 0.08 0.15  0.01 0.01  0.01 0.02 
Other endocrine 5 0.2 0.08 0.10 0.07 0.13  0.01 0.01  0.01 0.01 
Anus 3 0.1 0.05 0.07 0.04 0.09  0.01 0.01  0.00 0.01 
Tonsil 2 0.1 0.03 0.05 0.03 0.07  0.00 0.00  0.00 0.01 
Other female genitalia 2 0.1 0.03 0.03 0.02 0.04  0.00 0.00  0.00 0.00 
Mesothelioma 1 0.0 0.02 0.03 0.01 0.04  0.00 0.00  0.00 0.01 
Adrenal gland 1 0.0 0.02 0.01 0.00 0.02  0.00 0.00  0.00 0.00 
Other and unspecified 135 4.3 2.39 2.82 2.65 2.98  0.17 0.23  0.18 0.29 
All sites 3399  56.91 74.39 73.55 75.23  4.85 6.28  5.99 6.56 
All sites excluding skin 3119 100 52.27 67.63 66.83 68.43  4.47 5.76  5.50 6.03 
* ASR=Age-standardized rate 
 
Results 
105 
 
5.3.3.4 Golestan 
 
The leading cancer in men or women in terms of incidence in Golestan province was 
esophageal cancer (Figure 23). The second most common cancer was stomach in men and 
breast cancer in women (stomach, third leading cancer in women). Bladder and prostate 
were the third and fourth leading cancers in men while colon and cervix were the fourth 
and fifth most common cancers in Golestanian women. Lung was the ninth common cancer 
in men. 
 
 
Figure 23. Age-standardized rate (ASR) in Golestan province by sex 
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In terms of age-specific rates of cancers in Golestanian men, esophageal cancer was the 
leading cancer after age 30 (Figure 24). Leukemia was the leading cancer before age 25 in 
boys followed by testis cancer for age 25–30 (Appendix Table 14). In females, leukemia 
was the most common cancer until age 15 followed by bone cancer (age15–19), breast (20–
50) and esophageal cancer which was the leading cancer of elderly ages (Appendix Table 
15 and Figure 25). 
 
 
Figure 24. Age-specific incidence rate in Golestan, male 
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Figure 25. Age-specific incidence rate in Golestan, female 
 
Considering cumulative rate, each man in Golestan province had about 6.2% risk of cancer 
by age 69 years (Table 14). Of this risk, the largest component was esophageal cancer 
(1.8% / 69 years) followed by stomach (1.35%), skin (0.8%), bladder (0.35%) and prostate 
(0.2%).  
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Table 14. Cancer incidence rates in Golestan province, male 
  Cumulative rate (%)   
Sites 
Cases 
(N) 
Relative 
freq.  
(%) 
Crude 
rate 
(/105) 
ASR* 
(/105) 95% CI for ASR 
  0–64 0–69   
95% CI for 
cumulative rate 
0–69 (%) 
Esophagus 444 29.2 12.76 23.60 22.88 24.31  1.28 1.83  1.50 2.16 
Stomach 338 22.3 9.87 17.78 17.17 18.40  0.86 1.35  1.06 1.65 
Other skin 148  4.50 7.68 7.26 8.09  0.43 0.57  0.38 0.77 
Prostate 95 6.3 2.73 5.36 5.01 5.71  0.11 0.23  0.01 0.46 
Bladder 91 6.0 2.62 5.34 4.99 5.68  0.22 0.35  0.16 0.54 
Non-Hodgkin lymphoma 53 3.5 1.52 2.27 2.06 2.47  0.14 0.16  0.08 0.23 
Colon  47 3.1 1.48 2.48 2.24 2.72  0.12 0.15  0.02 0.28 
Leukemia unspecified 41 2.7 1.28 1.14 1.01 1.27  0.06 0.06  0.00 0.12 
Rectum 36 2.4 1.11 1.82 1.62 2.02  0.11 0.16  0.08 0.24 
Lung 31 2.0 0.93 1.48 1.30 1.66  0.09 0.11  0.02 0.19 
Lip 29 1.9 0.82 1.39 1.22 1.56  0.06 0.09  0.00 0.17 
Brain, nervous system 27 1.8 0.82 0.95 0.82 1.07  0.06 0.09  0.06 0.11 
Pancreas 23 1.5 0.68 1.25 1.08 1.41  0.06 0.08  0.00 0.16 
Kidney 21 1.4 0.65 1.01 0.87 1.16  0.06 0.10  0.05 0.15 
Hodgkin disease 20 1.3 0.63 0.71 0.60 0.82  0.05 0.05  0.00 0.10 
Bone 17 1.1 0.54 0.64 0.53 0.75  0.05 0.06  0.03 0.08 
Liver 19 1.3 0.53 0.93 0.79 1.06  0.06 0.09  0.05 0.13 
Breast 17 1.1 0.48 0.86 0.73 1.00  0.05 0.06  0.00 0.12 
Larynx 16 1.1 0.45 1.02 0.87 1.17  0.04 0.06  0.00 0.14 
Testis 15 1.0 0.42 0.57 0.47 0.66  0.05 0.05  0.04 0.06 
Thyroid 12 0.8 0.34 0.46 0.37 0.55  0.03 0.03  0.01 0.06 
Multiple myeloma 9 0.6 0.33 0.62 0.49 0.76  0.03 0.04  0.00 0.12 
Pharynx unspecified 11 0.7 0.31 0.54 0.44 0.65  0.01 0.05  0.02 0.09 
Melanoma of skin 8 0.5 0.23 0.31 0.23 0.39  0.02 0.02  0.00 0.07 
Myeloid leukemia 5 0.3 0.23 0.13 0.09 0.18  0.01 0.01  0.01 0.01 
Mouth 4 0.3 0.11 0.14 0.09 0.19  0.01 0.01  0.00 0.03 
Tonsil 3 0.2 0.08 0.18 0.12 0.24  0.01 0.01  0.00 0.05 
Anus 3 0.2 0.08 0.18 0.11 0.24  0.02 0.02  0.01 0.03 
Small intestine 3 0.2 0.08 0.12 0.07 0.16  0.01 0.01  0.00 0.03 
Connective & soft tissue 3 0.2 0.08 0.09 0.05 0.13  0.01 0.01  0.00 0.01 
Gallbladder 2 0.1 0.06 0.16 0.10 0.22  0.01 0.01  0.00 0.05 
Lymphoid leukemia 2 0.1 0.06 0.16 0.10 0.22  0.00 0.00  0.00 0.05 
Tongue 2 0.1 0.06 0.11 0.06 0.15  0.01 0.02  0.01 0.02 
Hypopharynx 2 0.1 0.06 0.11 0.06 0.16  0.01 0.01  0.01 0.01 
Nasopharynx 2 0.1 0.06 0.10 0.06 0.14  0.00 0.02  0.01 0.02 
Penis 2 0.1 0.06 0.10 0.06 0.14  0.01 0.01  0.01 0.02 
Kaposi sarcoma 2 0.1 0.06 0.09 0.05 0.13  0.01 0.01  0.00 0.01 
Other thoracic organs 1 0.1 0.03 0.05 0.02 0.08  0.00 0.01  0.00 0.01 
Nose, sinuses 1 0.1 0.03 0.03 0.01 0.04  0.00 0.00  0.00 0.00 
Mesothelioma 1 0.1 0.03 0.03 0.01 0.05  0.00 0.00  0.00 0.00 
Renal pelvis 1 0.1 0.03 0.03 0.01 0.05  0.00 0.00  0.00 0.00 
Other and unspecified 60 3.9 1.72 2.78 2.55 3.02  0.16 0.18  0.06 0.30 
All sites 1667  48.84 84.90 83.55 86.24  4.34 6.17  5.51 6.82 
All sites excluding skin 1519 100.0 44.35 77.22 75.94 78.50   3.91 5.59   4.97 6.22 
* ASR=Age-standardized rate 
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The risk of any cancer in women of Golestan was lower than men (5.7% / 69 years). The 
risk for esophageal cancer was highest (1.5%) followed by breast (0.9%), skin, stomach 
(0.4%) and cervix uteri (0.3%). 
 
Table 15. Cancer incidence rates in Golestan province, female 
  Cumulative rate (%)   
Sites 
Cases 
(N) 
Relative 
freq.  
(%) 
Crude 
rate 
(/105) 
ASR* 
(/105) 95% CI for ASR 
  0–64 0–69   
95% CI for 
cumulative rate 
0–69 (%) 
Esophagus 294 22.9 8.84 16.91 16.27 17.54  1.09 1.50 1.25 1.75 
Breast 255 19.9 7.44 10.96 10.50 11.41  0.79 0.90  0.75 1.04 
Other skin 107  3.08 5.92 5.56 6.29  0.35 0.44  0.28 0.59 
Stomach 94 7.3 2.84 5.48 5.12 5.84  0.27 0.41  0.25 0.57 
Cervix uteri 62 4.8 1.76 2.76 2.53 2.99  0.21 0.28  0.25 0.32 
Colon  56 4.4 1.65 2.91 2.65 3.16  0.19 0.28  0.20 0.36 
Ovary 52 4.0 1.54 2.12 1.92 2.32  0.18 0.20  0.17 0.23 
Leukemia unspecified 40 3.1 1.24 1.12 0.99 1.25  0.08 0.08  0.07 0.09 
Rectum 37 2.9 1.12 1.77 1.57 1.96  0.15 0.17  0.12 0.22 
Thyroid 33 2.6 0.98 1.35 1.20 1.51  0.09 0.12  0.08 0.16 
Non-Hodgkin lymphoma 35 2.7 0.98 1.30 1.15 1.45  0.09 0.09  0.03 0.15 
Lip 26 2.0 0.76 1.39 1.21 1.56  0.09 0.12  0.06 0.19 
Brain, nervous system 22 1.7 0.71 0.79 0.67 0.92  0.06 0.06  0.01 0.11 
Uterus unspecified 23 1.8 0.70 1.02 0.88 1.16  0.08 0.10  0.09 0.12 
Bladder 23 1.8 0.67 1.37 1.19 1.55  0.05 0.09  0.00 0.18 
Hodgkin disease 17 1.3 0.50 0.56 0.46 0.65  0.05 0.05  0.04 0.06 
Corpus uteri 16 1.2 0.48 0.99 0.84 1.15  0.05 0.07  0.00 0.15 
Bone 14 1.1 0.42 0.52 0.42 0.62  0.03 0.04  0.00 0.09 
Tongue 12 0.9 0.37 0.75 0.62 0.89  0.04 0.05  0.00 0.12 
Lung 12 0.9 0.37 0.73 0.60 0.86  0.03 0.04  0.00 0.12 
Kidney 13 1.0 0.36 0.59 0.48 0.70  0.05 0.06  0.05 0.07 
Vagina 11 0.9 0.34 0.62 0.50 0.74  0.03 0.06  0.01 0.11 
Gallbladder 11 0.9 0.31 0.69 0.56 0.81  0.02 0.03  0.00 0.11 
Melanoma of skin 10 0.8 0.31 0.69 0.56 0.82  0.04 0.04  0.00 0.11 
Pancreas 9 0.7 0.28 0.49 0.38 0.60  0.00 0.03  0.00 0.08 
Mouth 9 0.7 0.25 0.60 0.48 0.72  0.02 0.04  0.00 0.10 
Pharynx unspecified 8 0.6 0.22 0.44 0.34 0.54  0.02 0.04  0.00 0.07 
Liver 7 0.5 0.20 0.39 0.30 0.48  0.03 0.03  0.00 0.06 
Other thoracic organs 4 0.3 0.11 0.15 0.10 0.19  0.01 0.01  0.01 0.02 
Multiple myeloma 2 0.2 0.11 0.06 0.02 0.10  0.00 0.00  0.00 0.01 
Hypopharynx 3 0.2 0.08 0.18 0.12 0.24  0.01 0.01  0.00 0.04 
Other female genitalia 3 0.2 0.08 0.18 0.12 0.24  0.02 0.02  0.02 0.03 
Vulva 2 0.2 0.06 0.19 0.12 0.25  0.00 0.00  0.00 0.05 
Larynx 2 0.2 0.06 0.13 0.07 0.18  0.00 0.01  0.00 0.03 
Small intestine 2 0.2 0.06 0.09 0.05 0.14  0.00 0.00  0.00 0.02 
Mesothelioma 2 0.2 0.06 0.05 0.03 0.07  0.00 0.00  0.00 0.00 
Lymphoid leukemia 1 0.1 0.03 0.12 0.06 0.17  0.00 0.00  0.00 0.04 
Connective & soft tissue 1 0.1 0.03 0.06 0.02 0.10  0.01 0.01  0.00 0.01 
Ureter 1 0.1 0.03 0.06 0.02 0.09  0.00 0.01  0.00 0.00 
Placenta 1 0.1 0.03 0.05 0.02 0.08  0.00 0.00  0.00 0.01 
Kaposi sarcoma 1 0.1 0.03 0.04 0.01 0.06  0.00 0.00  0.00 0.01 
Salivary glands 1 0.1 0.03 0.03 0.01 0.05  0.00 0.00  0.00 0.00 
Myeloid leukemia 1 0.1 0.03 0.02 0.01 0.04  0.00 0.00  0.00 0.00 
Other and unspecified 56 4.4 1.72 2.42 2.19 2.66  0.14 0.17  0.07 0.27 
All sites 1391  41.19 69.05 67.83 70.28  4.39 5.68  5.21 6.15 
All sites excluding skin 1284 100 38.12 63.11 61.94 64.28   4.04 5.24   4.80 5.68 
* ASR=Age-standardized rate 
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5.3.3.5 Kerman 
 
In Kerman province, the leading cancer in men was stomach (Figure 26). In women, breast 
cancer was the most common cancer followed by stomach, leukemia, colon, non-Hodgkin 
lymphoma, and lung. The second cancer in terms of ASR in men was lung followed by 
bladder, non-Hodgkin lymphoma and leukemia.  
 
 
Figure 26. Age-standardized rate (ASR) in Kerman province by sex 
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Leukemia was the leading cancer of younger ages in men until age 35. Stomach was the 
most common cancer afterward except for two age periods 40–45 (larynx as leading 
cancer) and 50–55 (lung as leading cancer) (Figure 27 and Figure 28). The most common 
cancer in young girls in Kerman was the same as boys (leukemia) until age 25 when breast 
cancer started to increase dramatically in reproductive ages and remained the most 
common cancer for the rest of the life in Kermanian women. 
 
 
Figure 27. Age-specific incidence rate in Kerman, male
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Figure 28. Age-specific incidence rate in Kerman, female 
 
In terms of cumulative rate by 69 years of age, men in Kerman province had about 7.1% 
risk of any cancer (Table 16). Skin malignancy constituted most of this risk (1.1%) 
followed by stomach, lung, bladder, and non-Hodgkin lymphoma. 
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Table 16. Cancer incidence rates in Kerman province, male 
  Cumulative rate (%)   
Sites 
Cases 
(N) 
Relative 
freq.  
(%) 
Crude 
rate 
(/105) 
ASR* 
(/105) 95% CI for ASR 
  0–64 0–69   
95% CI for 
cumulative rate 
0–69 (%) 
Other skin 411  8.78 13.27 12.84 13.71  0.69 0.99  0.81 1.17 
Stomach 301 11.9 6.22 10.33 9.96 10.71  0.55 0.85  0.69 1.01 
Bladder 221 8.7 4.82 7.48 7.15 7.80  0.35 0.60  0.46 0.73 
Lung 212 8.4 4.35 7.62 7.29 7.95  0.47 0.65  0.52 0.78 
Non-Hodgkin lymphoma 208 8.2 4.31 5.90 5.63 6.18  0.40 0.50  0.41 0.59 
Leukemia unspecified 148 5.8 3.16 3.07 2.89 3.25  0.20 0.21  0.16 0.25 
Prostate 113 4.5 2.61 3.64 3.41 3.87  0.10 0.21  0.09 0.33 
Larynx 106 4.2 2.23 3.68 3.45 3.90  0.24 0.31  0.22 0.39 
Esophagus 99 3.9 2.16 3.13 2.93 3.34  0.13 0.17  0.07 0.27 
Brain, nervous system 96 3.8 1.97 2.64 2.45 2.82  0.20 0.24  0.19 0.28 
Hodgkin disease 85 3.4 1.73 1.88 1.74 2.02  0.14 0.14  0.11 0.17 
Colon  81 3.2 1.67 2.56 2.38 2.75  0.18 0.22  0.16 0.28 
Rectum 68 2.7 1.44 2.26 2.09 2.44  0.17 0.22  0.16 0.27 
Multiple myeloma 53 2.1 1.13 1.80 1.64 1.96  0.12 0.17  0.11 0.23 
Bone 53 2.1 1.08 1.13 1.03 1.24  0.07 0.09  0.06 0.11 
Lymphoid leukemia  52 2.1 1.06 1.68 1.53 1.83  0.11 0.14  0.09 0.20 
Liver 49 1.9 1.00 1.66 1.52 1.81  0.09 0.11  0.04 0.17 
Melanoma of skin 38 1.5 0.83 1.27 1.14 1.40  0.07 0.09  0.02 0.15 
Pancreas 37 1.5 0.79 1.04 0.93 1.16  0.06 0.09  0.04 0.13 
Testis 33 1.3 0.71 0.77 0.68 0.86  0.05 0.05  0.04 0.07 
Kidney 33 1.3 0.69 0.95 0.84 1.06  0.05 0.09  0.07 0.11 
Connective & soft tissue 31 1.2 0.67 0.76 0.67 0.86  0.05 0.07  0.05 0.08 
Myeloid leukemia 27 1.1 0.60 0.76 0.65 0.86  0.07 0.07  0.06 0.08 
Thyroid 26 1.0 0.58 0.84 0.73 0.94  0.04 0.05  0.00 0.10 
Gallbladder 28 1.1 0.57 0.88 0.77 0.99  0.05 0.07  0.03 0.12 
Other thoracic organs 27 1.1 0.55 0.79 0.69 0.88  0.06 0.08  0.04 0.11 
Breast 18 0.7 0.40 0.57 0.47 0.66  0.05 0.05  0.02 0.08 
Lip 20 0.8 0.39 0.66 0.57 0.76  0.03 0.05  0.01 0.09 
Mouth 16 0.6 0.36 0.49 0.40 0.58  0.03 0.04  0.01 0.07 
Salivary glands 16 0.6 0.34 0.47 0.40 0.55  0.04 0.05  0.04 0.06 
Tongue 12 0.5 0.26 0.41 0.33 0.49  0.04 0.04  0.02 0.05 
Small intestine 12 0.5 0.26 0.41 0.34 0.49  0.03 0.03  0.00 0.07 
Eye 12 0.5 0.26 0.31 0.25 0.37  0.01 0.01  0.00 0.04 
Nasopharynx 10 0.4 0.20 0.28 0.23 0.34  0.02 0.02  0.00 0.04 
Anus 9 0.4 0.20 0.26 0.20 0.32  0.01 0.03  0.01 0.05 
Hypopharynx 5 0.2 0.10 0.22 0.16 0.27  0.01 0.01  0.00 0.04 
Tonsil 4 0.2 0.08 0.13 0.09 0.17  0.01 0.01  0.00 0.02 
Penis 3 0.1 0.06 0.09 0.06 0.13  0.01 0.01  0.01 0.02 
Kaposi sarcoma 3 0.1 0.06 0.08 0.05 0.11  0.01 0.01  0.01 0.01 
Other urinary organs 2 0.1 0.04 0.06 0.04 0.09  0.00 0.01  0.00 0.02 
Other endocrine 2 0.1 0.04 0.05 0.03 0.07  0.01 0.01  0.00 0.01 
Adrenal gland 2 0.1 0.04 0.02 0.01 0.03  0.00 0.00  0.00 0.00 
Nose, sinuses 1 0.0 0.02 0.05 0.03 0.08  0.00 0.00  0.00 0.02 
Immunoproliferative 1 0.0 0.02 0.05 0.02 0.07  0.00 0.00  0.00 0.01 
Pharynx unspecified 1 0.0 0.02 0.00 0.00 0.00  0.00 0.00  0.00 0.00 
Other and unspecified 155 6.1 3.19 4.04 3.83 4.26  0.20 0.30  0.22 0.38 
All sites 2941  62.03 90.48 89.38 91.59  5.22 7.13  6.70 7.55 
All sites excluding skin 2530 100 53.25 77.22 76.21 78.23  4.53 6.13  5.74 6.52 
* ASR=Age-standardized rate 
 
 
The cumulative cancer risk in Kermanian women by 69 years was lower than in men 
(Table 17). Most of this risk was due to breast cancer (1.5%) followed by skin (1.1%), 
stomach (0.5%), leukemia (0.34%) and colon cancers (0.31%).  
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Table 17. Cancer incidence rates in Kerman province, female 
  Cumulative rate (%) 
  
Sites 
Cases 
(N) 
Relative 
freq.  
(%) 
Crude 
rate 
(/105) 
ASR* 
(/105) 95% CI for ASR 
  0–64 0–69   
95% CI for 
cumulative rate 
 0–69 (%) 
Breast 488 23.7 10.50 16.61 16.12 17.11  1.26 1.47  1.34 1.59 
Other skin 330 0.0 7.36 12.29 11.85 12.73  0.73 1.01  0.84 1.17 
Stomach 135 6.6 2.80 5.07 4.80 5.34  0.32 0.46  0.37 0.55 
Leukemia unspecified 109 5.3 2.25 2.62 2.45 2.79  0.17 0.20  0.16 0.23 
Non-Hodgkin lymphoma 91 4.4 1.89 2.72 2.53 2.91  0.16 0.19  0.12 0.26 
Colon  84 4.1 1.83 2.98 2.77 3.20  0.22 0.31  0.26 0.37 
Cervix uteri 83 4.0 1.75 3.02 2.80 3.23  0.24 0.27  0.22 0.33 
Thyroid 79 3.8 1.73 2.49 2.30 2.67  0.17 0.21  0.15 0.26 
Ovary 65 3.2 1.53 2.04 1.86 2.21  0.14 0.17  0.12 0.23 
Brain, nervous system 72 3.5 1.48 2.02 1.86 2.18  0.16 0.18  0.15 0.21 
Lung 69 3.3 1.44 2.62 2.42 2.81  0.12 0.20  0.13 0.28 
Rectum 63 3.1 1.36 2.29 2.10 2.48  0.20 0.25  0.20 0.29 
Bladder 49 2.4 1.22 1.83 1.64 2.01  0.13 0.16  0.10 0.23 
Gallbladder 54 2.6 1.16 2.05 1.87 2.22  0.11 0.16  0.09 0.23 
Esophagus 51 2.5 1.12 1.84 1.68 2.01  0.12 0.14  0.08 0.19 
Hodgkin disease 44 2.1 0.91 0.81 0.73 0.90  0.06 0.06  0.05 0.07 
Bone 37 1.8 0.79 0.59 0.52 0.66  0.04 0.04  0.03 0.04 
Lymphoid leukemia 31 1.5 0.67 1.01 0.89 1.13  0.05 0.10  0.06 0.13 
Connective & soft tissue 29 1.4 0.66 0.76 0.66 0.85  0.05 0.06  0.04 0.08 
Multiple myeloma 29 1.4 0.63 1.03 0.90 1.16  0.08 0.10  0.06 0.14 
Pancreas 26 1.3 0.53 0.96 0.84 1.07  0.03 0.07  0.01 0.12 
Corpus uteri 20 1.0 0.51 0.75 0.63 0.87  0.05 0.09  0.08 0.11 
Liver 24 1.2 0.49 0.88 0.77 0.99  0.06 0.06  0.02 0.11 
Melanoma of skin 23 1.1 0.49 0.69 0.59 0.79  0.05 0.05  0.02 0.09 
Kidney 20 1.0 0.45 0.55 0.46 0.63  0.03 0.05  0.03 0.07 
Myeloid leukemia 20 1.0 0.43 0.60 0.51 0.68  0.04 0.04  0.01 0.07 
Uterus unspecified 18 0.9 0.39 0.60 0.51 0.70  0.05 0.06  0.04 0.08 
Larynx 16 0.8 0.32 0.67 0.57 0.77  0.04 0.06  0.02 0.09 
Mouth 15 0.7 0.30 0.47 0.39 0.55  0.03 0.06  0.05 0.07 
Tongue 10 0.5 0.29 0.34 0.26 0.42  0.03 0.03  0.01 0.05 
Eye 14 0.7 0.28 0.52 0.44 0.61  0.02 0.03  0.00 0.07 
Other thoracic organs 13 0.6 0.26 0.47 0.38 0.55  0.05 0.05  0.03 0.06 
Small intestine 11 0.5 0.25 0.36 0.28 0.43  0.03 0.03  0.02 0.05 
Salivary glands 10 0.5 0.25 0.33 0.26 0.41  0.02 0.02  0.00 0.05 
Nasopharynx 10 0.5 0.25 0.32 0.24 0.39  0.02 0.03  0.02 0.04 
Other female genitalia 10 0.5 0.20 0.33 0.26 0.40  0.02 0.03  0.02 0.05 
Anus 8 0.4 0.16 0.24 0.18 0.30  0.02 0.02  0.01 0.04 
Vulva 6 0.3 0.15 0.17 0.12 0.22  0.01 0.01  0.00 0.03 
Lip 7 0.3 0.14 0.22 0.16 0.28  0.00 0.02  0.00 0.05 
Nose, sinuses 3 0.1 0.09 0.12 0.07 0.17  0.01 0.01  0.00 0.03 
Vagina 4 0.2 0.08 0.11 0.07 0.14  0.00 0.00  0.00 0.02 
Other endocrine 2 0.1 0.08 0.08 0.03 0.13  0.00 0.01  0.00 0.02 
Pharynx unspecified 2 0.1 0.04 0.07 0.04 0.10  0.00 0.01  0.00 0.01 
Mesothelioma 2 0.1 0.04 0.04 0.02 0.06  0.00 0.00  0.00 0.00 
Adrenal gland 2 0.1 0.04 0.04 0.02 0.06  0.00 0.00  0.00 0.00 
Hypopharynx 1 0.0 0.02 0.04 0.01 0.06  0.00 0.00  0.00 0.01 
Immunoproliferative 1 0.0 0.02 0.04 0.02 0.06  0.00 0.00  0.00 0.01 
Other and unspecified 101 4.9 2.18 3.37 3.15 3.59  0.24 0.27  0.20 0.35 
All sites 2391  51.69 79.93 78.85 81.01  5.40 6.84  6.51 7.18 
All sites excluding skin 2061 100 44.34 67.69 66.70 68.67  4.66 5.84  5.55 6.13 
* ASR=Age-standardized rate 
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5.3.4 Regional variations 
 
One goal of this study was to assess the regional variation of cancer occurrence in different 
provinces of Iran. Among men, after excluding non-melanoma skin cancer, which was the 
most common cancer in Kerman, upper gastrointestinal tract cancers (stomach and 
esophagus) were the two leading cancer sites in terms of incidence (Figure 29). Stomach 
was constantly the most common cancer although its ASR had a wide range, very high in 
the northwest of Iran (Ardebil 54.8) with a gradual decrease throughout the Caspian 
coastline to the northeast of the country (Golestan 17.8) and a further decrease in the south 
(Kerman 10.3). In contrast, esophageal cancer, as the seventh cancer site in the south 
(Kerman 3.1), was the most common cancer in Golestan and its ASR decreased from east 
(23.6) to west (12.1) of Caspian Littoral but kept its rank (second) all along the coastline. 
 
Cancer of the bladder was the third leading cancer among men in these provinces, but it 
was remarkably similar to lung cancer which preceded bladder in Ardebil, Mazandaran and 
especially Kerman (Figure 29). However, ASR of bladder and lung were rather similar in 
all geographical areas (ranging 5.3 to 9.3) except for Golestan with a lower lung cancer rate 
(1.5). Prostate cancer as fifth leading cancer had low variability between the regions 
(ranging 3.6 to 5.4) with the exception of a higher rate in Gilan province (8.6 per 100,000).   
 
In men, colon cancer as the most common lower gastrointestinal tract cancer was the sixth 
common cancer, but colorectal cancer rate was higher than prostate (5.6) when combining 
colon (3.9) and rectum (2.3).  However, it showed no considerable variation between 
provinces (Figure 29). The next common cancer after colon was non-Hodgkin lymphoma 
with a similar ASR in Northern provinces (2.3 – 3.3) but a difference in the south (ASR as 
high as 5.9). The same applied to leukemias (combined lymphoid leukemia, myeloid 
leukemia and leukemia unspecified). ASR of leukemia was comparable in Northern 
provinces (1.4 – 3.9), but higher in Kerman (5.9).  
 
In men, the provinces with the highest incidence rate for some cancers were Ardebil for 
stomach cancer, Gilan for bladder cancer, Mazandaran for lung cancer, Golestan for 
esophageal cancer and Kerman for skin cancer and hematological neoplasms such as 
lymphoma or leukemia. In women, the provinces with highest incidence rate for some 
cancers were Ardebil for stomach cancer, Gilan for colon cancer, Mazandaran for cervical 
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cancer, Golestan for esophageal cancer and Kerman for breast, skin cancer and 
hematological neoplasms such as lymphoma or leukemia.  
 
Breast cancer was the most common female cancer in these provinces but its rank was not 
stable among all five provinces. For instance, stomach cancer was preceding breast cancer 
in Ardebil and esophagus kept its first place in Golestan. ASR of breast cancer ranged from 
lowest in Ardebil (8.4) to highest in Kerman (16.6). In Ardebil excluding skin cancer, 
breast cancer was even less frequent than esophageal cancer. However, stomach cancer in 
women similar to men had a decreasing pattern from the west (28.5 in Ardebil) to the east 
(5.5 in Golestan) and south (5 in Kerman).  
 
In brief, in terms of incidence among these five provinces, stomach cancer had the highest 
rate in Ardebil province in both sexes. Highest rate of esophageal cancer was in Golestan in 
both sexes. Breast cancer was highest among Kermanian women. Highest rate of bladder 
and prostate cancer was recorded for Gilanian men whereas Gilanian women had highest 
rate of colorectal cancer. Highest rate of lung cancer found among Mazandaranian men. 
Kermanian men had the highest rate of skin or hematological neoplasms such as leukemia 
or lymphoma. 
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Figure 29. Provincial difference in age-standardized rate (ASR) by site and sex 
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Esophageal cancer in women did not have a similar pattern in men as its rate was high on 
both sides of the Caspian Sea (16.9 in Golestan and 16.7 in Ardebil) but its rate was 
medium in the middle of northern provinces (Gilan 5.9 and Mazandaran 10.8) and was 
exceptionally low in the south (Kerman 1.8). Colon with or without rectum was the fourth 
leading cancer in women and had no variation among any of the provinces.  
 
Regarding incidence of all cancer sites together excluding non-melanoma skin in the five 
provinces, the average annual ASR was 93 per 100,000 men and 69 for 100,000 women. 
ASR of all sites in Ardebil (men 135.5; women 98.2) was higher than the average while 
other provinces had rather similar ASR (especially in women 63.1–67.6). In men, Gilan 
and Mazandaran were very similar (96–96.3) same to Golestan and Kerman (77.2). The 
difference for Ardebil was mostly due to the extremely high incidence of stomach cancer 
(55.8 compared to average 22.5).    
 
 
5.3.5 Time trend 
 
In general, the number of cases increased year by year significantly for all provinces and 
also for Gilan province alone (Figure 30 and Table 18).  
 
 
Figure 30. Changes in number of new cancer cases (all sites) by province and year of 
diagnosis 
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Table 18.  Time trend analysis to test significance of annual increasing number of cases by 
province (using simple linear regression) 
Province Gilan Mazandaran Golestan Kerman 4 provinces 
Slope coefficient  179.1 143.0 7.4 31.8 361.3 
95% CI 22.4 335.8 -49.9 335.9 -65.6 80.4 -121.6 185.2 251.9 470.7 
 
Comparing slope of increase in number of cases by province revealed slower change in 
Golestan and Kerman provinces rather than two other provinces although they were not 
significant except for Gilan with a slope coefficient of 179 (95% CI: 22, 336) (Figure 25 
and Table 18). Calculating the increase of cases in each year showed that on average there 
was about 10% increase in number of cases annually (increasing 361 cancer case per year, 
95%CI: 252, 471). This means around 40% increase over 5 years, which was substantial 
and could not be real for all sites of cancers. It showed that the data in the last years of the 
study was more complete and should be closer to reality. The rates for the two last years 
(with lower under-registration) were not used as representative of the real situation because 
the ASRs calculated for 1999 and 2000 did not include Ardebil province at all (year of 
diagnosis was not reported for Ardebil) and these data, too, were based on only 75% of all 
cases from other provinces than Ardebil. Thus, ASRs for years could be more than 25% 
under-estimated.  
 
The incidence of almost all major cancer sites in both sexes had a significant increase 
during the 5 years of this study (slope coefficient averagely 7; Figure 31, Figure 32 and 
Appendix Table 26). Stomach cancer increased more rapidly than esophagus in both sexes, 
although the slow increase for esophagus in women was not significant (coefficient=0.15, 
95%CI = –0.19 – 0.48; Table 19). In women, breast cancer had a dramatic increase during 
these five years and was more than the average of other sites (slope=1.63, 95%CI=0.80 – 
2.48; highly significant). This means that each year ASR of breast cancer increased 1.63.  
Results 
120 
 
Figure 31. Changes in age standardized rate (ASR per 105) of 10 major cancers during the 
five years of the study, male 
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Figure 32. Changes in age-standardized rate (ASR per 105) of 10 major cancers during the 
five years of the study, female 
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Table 19. Time trend analysis for changes in age-standardized rate (ASR) during the five 
years of the study in four provinces by cancer site and sex (slope coefficient=annual 
change) 
Male Female 
Site Slope Coefficient 95% CI Site Slope Coefficient 95% CI 
All sites 7.09 6.19 8.00 All sites 6.77 4.62 8.91 
All sites excluding skin 6.17 5.39 6.94 All sites excluding skin 6.02 4.14 7.89 
Other skin 0.92 0.58 1.26 Breast 1.63 0.80 2.46 
Stomach 0.88 0.48 1.28 Other skin 0.75 0.46 1.04 
Bladder 0.82 0.41 1.23 Stomach 0.69 0.40 0.99 
Lung, trachea & bronchus 0.73 0.18 1.28 Colon 0.66 0.42 0.89 
Colon 0.46 0.25 0.67 Cervix uteri 0.30 0.05 0.55 
Esophagus 0.42 0.08 0.76 Ovary 0.27 0.00 0.54 
Other and unspecified 0.41 0.11 0.71 Leukemias together 0.21 -0.08 0.49 
Non-Hodgkin lymphoma 0.38 0.12 0.65 Non-Hodgkin lymphoma 0.20 0.02 0.39 
Rectum 0.34 0.11 0.56 Uterus unspecified 0.18 0.10 0.27 
Leukemia unspecified 0.29 0.14 0.43 Other and unspecified 0.18 0.09 0.27 
Leukemias together 0.25 -0.09 0.58 Rectum 0.17 0.06 0.29 
Multiple myeloma 0.18 0.03 0.34 Bladder 0.17 0.04 0.29 
Kidney 0.18 0.01 0.35 Leukemia unspecified 0.16 0.02 0.30 
Other thoracic organs 0.15 0.06 0.25 Esophagus 0.15 -0.19 0.48 
Testis 0.15 0.01 0.28 Multiple myeloma 0.15 0.07 0.22 
Larynx 0.13 -0.21 0.48 Liver 0.13 0.03 0.24 
Pancreas 0.13 -0.10 0.36 Pancreas 0.13 0.04 0.22 
Prostate 0.13 -0.28 0.54 Hodgkin disease 0.13 0.01 0.24 
Lip 0.09 -0.09 0.26 Lung, trachea & bronchus 0.12 -0.12 0.35 
Mouth 0.08 -0.02 0.18 Kidney 0.11 0.07 0.16 
Bone 0.07 -0.01 0.15 Nasopharynx 0.09 0.03 0.15 
Brain, nervous system 0.07 -0.08 0.23 Melanoma of skin 0.08 0.00 0.16 
Hodgkin disease 0.06 0.02 0.10 Lymphoid Leukemia 0.05 -0.05 0.16 
Nasopharynx 0.05 0.00 0.11 Corpus uteri 0.05 -0.03 0.12 
Liver 0.04 -0.09 0.17 Salivary glands 0.05 -0.02 0.11 
Gallbladder 0.04 -0.02 0.09 Tongue 0.04 -0.08 0.15 
Hypopharynx 0.03 0.00 0.05 Vagina 0.04 0.00 0.07 
Kaposi sarcoma 0.02 -0.02 0.05 Larynx 0.03 0.01 0.06 
Myeloid Leukemia 0.02 -0.02 0.05 Mouth 0.03 -0.05 0.12 
Thyroid 0.01 -0.12 0.14 Small intestine 0.03 -0.01 0.08 
Renal pelvis 0.01 0.00 0.02 Eye 0.03 -0.02 0.08 
Eye 0.01 -0.03 0.05 Hypopharynx 0.03 -0.03 0.09 
Other male genitalia 0.01 0.00 0.02 Vulva 0.02 -0.02 0.07 
Breast 0.00 -0.16 0.16 Connective & soft tissue 0.02 -0.18 0.22 
Tongue 0.00 -0.05 0.05 Kaposi sarcoma 0.02 0.01 0.04 
Small intestine 0.00 -0.05 0.05 Bone 0.01 -0.13 0.15 
Nose, sinuses 0.00 -0.07 0.07 Nose, sinuses 0.01 -0.02 0.04 
Other female genitalia 0.00 0.00 0.00 Other thoracic organs 0.01 -0.05 0.07 
Adrenal gland 0.00 -0.01 0.01 Placenta 0.01 0.00 0.02 
Ureter 0.00 0.00 0.00 Mesothelioma 0.01 -0.02 0.03 
Placenta 0.00 0.00 0.00 Anus 0.01 -0.02 0.03 
Vulva 0.00 0.00 0.00 Testis 0.00 0.00 0.00 
Vagina 0.00 0.00 0.00 Prostate 0.00 0.00 0.00 
Corpus uteri 0.00 0.00 0.00 Renal pelvis 0.00 0.00 0.00 
Uterus unspecified 0.00 0.00 0.00 Other male genitalia 0.00 0.00 0.00 
Ovary 0.00 0.00 0.00 Ureter 0.00 -0.01 0.01 
Cervix uteri 0.00 0.00 0.00 Penis 0.00 0.00 0.00 
Penis 0.00 -0.04 0.03 Other urinary organs 0.00 0.00 0.00 
Other urinary organs 0.00 -0.02 0.01 Other oropharynx 0.00 0.00 0.00 
Mesothelioma 0.00 -0.02 0.01 Tonsil 0.00 -0.02 0.02 
Connective & soft tissue -0.01 -0.17 0.16 Pharynx unspecified 0.00 -0.03 0.03 
Other oropharynx -0.01 -0.02 0.00 Gallbladder 0.00 -0.14 0.13 
Immunoproliferative -0.01 -0.02 0.00 Other endocrine 0.00 -0.04 0.03 
Pharynx unspecified -0.02 -0.06 0.03 Immunoproliferative 0.00 -0.02 0.01 
Tonsil -0.02 -0.03 -0.01 Adrenal gland -0.01 -0.03 0.01 
Salivary glands -0.03 -0.06 0.01 Myeloid Leukemia -0.01 -0.07 0.06 
Anus -0.03 -0.13 0.06 Lip -0.02 -0.12 0.09 
Melanoma of skin -0.03 -0.12 0.05 Other female genitalia -0.02 -0.04 0.00 
Other endocrine -0.04 -0.06 -0.01 Brain, nervous system -0.05 -0.27 0.16 
Lymphoid Leukemia -0.06 -0.25 0.13 Thyroid -0.06 -0.24 0.12 
 
 
5.3.5.1 Corrected incidence trends using relative age-standardized ratio 
 
Using adjusted relative age-standardized rate for trend analysis showed that there were 
slight changes in incidence of cancers annually as expected for this short period of time, 
but the annual change shown in the incidence of these cancers were not statistically 
significant (Table 20).  
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Table 20. Time trend analysis of adjusted relative age-standardized rate (ARASR per 105) 
by calendar year, site and sex (slope coefficient=annual change) 
Male Female 
ARASR ARASR Site 
1996 1997 1998 1999 2000 
Slope 
coefficient 95% CI 1996 1997 1998 1999 2000 
Slope 
coefficient 95% CI 
Stomach 17.23 10.93 15.30 12.20 14.32 -0.45 -2.17 1.26 4.96 6.28 4.05 5.74 6.12 0.18 -0.45 0.81 
Esophagus 10.47 6.92 8.45 7.35 8.38 -0.38 -1.26 0.51 7.96 6.93 3.76 5.65 5.87 -0.55 -1.48 0.39 
Breast 0.59 0.41 1.03 0.56 0.32 -0.04 -0.23 0.15 11.83 8.98 7.03 12.43 12.72 0.52 -1.16 2.20 
Other skin 7.46 4.94 8.94 7.24 7.72 0.28 -0.71 1.27 6.06 5.26 3.81 6.39 6.36 0.17 -0.58 0.93 
Bladder 5.99 3.76 7.48 5.36 6.65 0.29 -0.66 1.24 1.16 1.09 1.15 1.24 1.36 0.06 0.01 0.10 
Colon 2.75 1.87 2.50 2.72 3.41 0.22 -0.09 0.53 2.64 3.00 2.26 4.20 3.93 0.38 -0.03 0.79 
Other and unspecified 3.69 1.88 3.97 2.82 3.68 0.09 -0.51 0.70 2.78 2.34 1.58 2.18 2.50 -0.07 -0.38 0.24 
Lung 3.81 4.07 5.62 3.74 5.92 0.39 -0.22 1.00 1.01 1.89 0.75 1.09 1.41 0.00 -0.31 0.31 
NH lymphoma 3.13 1.67 2.83 3.10 2.97 0.11 -0.31 0.53 1.64 0.99 0.91 1.76 1.54 0.06 -0.21 0.33 
Prostate 5.09 3.94 6.08 3.84 3.89 -0.25 -0.90 0.40 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Rectum 1.73 1.38 1.84 2.42 2.10 0.18 -0.01 0.37 1.69 1.67 1.40 1.52 1.83 0.01 -0.11 0.13 
Brain, nervous system 1.95 1.10 1.46 1.63 1.30 -0.08 -0.29 0.14 2.15 1.01 0.98 1.39 0.90 -0.21 -0.49 0.07 
Thyroid 0.69 0.36 0.80 0.23 0.56 -0.04 -0.20 0.12 2.04 1.85 1.30 1.63 1.02 -0.23 -0.37 -0.08 
Larynx 3.26 1.06 2.24 2.12 2.14 -0.12 -0.66 0.42 0.42 0.31 0.28 0.38 0.37 0.00 -0.04 0.04 
Cervix uteri 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.79 1.39 1.06 2.39 1.94 0.13 -0.21 0.47 
Ovary 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.59 1.22 0.99 2.28 1.66 0.12 -0.21 0.45 
Pancreas 0.78 1.37 1.21 1.06 1.25 0.06 -0.08 0.21 0.49 0.79 0.35 0.71 0.87 0.07 -0.07 0.20 
Liver 1.23 0.76 1.50 1.00 0.86 -0.05 -0.25 0.16 0.60 0.30 0.59 0.65 0.82 0.08 -0.02 0.18 
Kidney 0.71 0.57 1.42 1.19 0.93 0.11 -0.11 0.32 0.52 0.59 0.52 0.78 0.73 0.06 0.01 0.11 
Hodgkin disease 1.25 0.79 1.24 0.98 0.96 -0.04 -0.17 0.09 0.67 0.24 0.34 0.65 0.79 0.07 -0.09 0.22 
Gallbladder 0.62 0.34 0.38 0.43 0.51 -0.01 -0.09 0.06 1.08 1.18 0.68 1.08 0.63 -0.10 -0.24 0.04 
Multiple myeloma 0.83 0.83 1.54 0.83 1.35 0.11 -0.11 0.32 0.23 0.59 0.30 0.71 0.72 0.11 0.00 0.22 
Bone 0.84 0.36 0.75 0.73 0.67 0.00 -0.13 0.13 0.82 0.33 0.15 0.35 0.56 -0.05 -0.23 0.13 
Lip 0.79 0.54 0.42 0.40 0.97 0.02 -0.15 0.20 0.73 0.19 0.19 0.30 0.34 -0.07 -0.21 0.07 
Connective & soft tissue 0.95 0.22 0.19 0.44 0.47 -0.07 -0.28 0.13 0.50 0.39 0.68 0.12 0.53 -0.02 -0.17 0.13 
Corpus uteri 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.94 0.68 0.49 0.87 0.68 -0.03 -0.16 0.09 
Melanoma of skin 0.57 0.58 0.46 0.43 0.30 -0.07 -0.09 -0.05 0.40 0.24 0.45 0.45 0.50 0.04 -0.01 0.10 
Uterus unspecified 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.53 0.26 0.48 0.80 0.94 0.14 0.02 0.25 
Mouth 0.09 0.32 0.30 0.15 0.51 0.07 -0.02 0.16 0.42 0.34 0.36 0.19 0.47 0.00 -0.08 0.07 
Small intestine 0.47 0.43 0.40 0.41 0.32 -0.03 -0.05 -0.02 0.22 0.23 0.07 0.26 0.26 0.01 -0.04 0.06 
Nasopharynx 0.46 0.26 0.54 0.51 0.40 0.01 -0.06 0.09 0.09 0.00 0.25 0.25 0.40 0.09 0.03 0.14 
Testis 0.71 0.26 0.61 0.91 0.79 0.08 -0.07 0.23 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Tongue 0.31 0.08 0.08 0.19 0.15 -0.02 -0.08 0.04 0.57 0.16 0.11 0.30 0.46 -0.01 -0.15 0.13 
Other thoracic organs 0.13 0.14 0.23 0.29 0.74 0.14 0.05 0.23 0.07 0.26 0.17 0.24 0.08 0.00 -0.06 0.06 
Salivary glands 0.38 0.11 0.19 0.16 0.11 -0.05 -0.11 0.01 0.10 0.16 0.03 0.32 0.18 0.03 -0.03 0.10 
Hypopharynx 0.08 0.07 0.22 0.12 0.14 0.02 -0.02 0.06 0.12 0.12 0.13 0.31 0.11 0.02 -0.04 0.07 
Vagina 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.28 0.20 0.12 0.29 0.29 0.01 -0.04 0.06 
Pharynx unspecified 0.18 0.25 0.16 0.15 0.09 -0.03 -0.05 0.00 0.17 0.09 0.13 0.13 0.08 -0.02 -0.04 0.01 
Eye 0.10 0.02 0.17 0.14 0.04 0.00 -0.04 0.04 0.10 0.18 0.14 0.30 0.13 0.02 -0.03 0.07 
Anus 0.14 0.12 0.39 0.04 0.00 -0.04 -0.14 0.06 0.06 0.15 0.03 0.10 0.07 0.00 -0.04 0.03 
Nose, sinuses 0.09 0.03 0.26 0.12 0.01 -0.01 -0.08 0.06 0.00 0.06 0.10 0.04 0.07 0.01 -0.01 0.03 
Other female genitalia 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.23 0.13 0.06 0.06 0.08 -0.04 -0.07 0.00 
Other endocrine 0.21 0.05 0.02 0.01 0.02 -0.04 -0.08 -0.01 0.12 0.00 0.07 0.08 0.02 -0.01 -0.04 0.02 
Kaposi sarcoma 0.05 0.11 0.09 0.17 0.09 0.01 -0.01 0.04 0.00 0.00 0.07 0.08 0.07 0.02 0.01 0.04 
Vulva 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.04 0.07 0.21 0.04 0.02 -0.02 0.07 
Tonsil 0.13 0.04 0.07 0.03 0.00 -0.03 -0.04 -0.01 0.00 0.05 0.00 0.04 0.00 0.00 -0.02 0.02 
Mesothelioma 0.03 0.00 0.05 0.00 0.00 -0.01 -0.02 0.01 0.06 0.05 0.02 0.00 0.09 0.00 -0.02 0.03 
Penis 0.04 0.07 0.00 0.10 0.00 -0.01 -0.04 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Adrenal gland 0.00 0.00 0.03 0.00 0.00 0.00 -0.01 0.01 0.00 0.08 0.02 0.00 0.00 -0.01 -0.03 0.01 
Immunoproliferative 0.05 0.00 0.00 0.00 0.00 -0.01 -0.02 0.00 0.00 0.05 0.00 0.00 0.00 0.00 -0.02 0.01 
Other urinary organs 0.00 0.03 0.04 0.00 0.00 0.00 -0.02 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Placenta 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.04 0.01 0.00 0.02 
Other oropharynx 0.04 0.00 0.00 0.00 0.00 -0.01 -0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Renal pelvis 0.00 0.00 0.00 0.00 0.05 0.01 0.00 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Ureter 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.04 0.00 0.00 0.00 -0.01 0.01 
Other male genitalia 0.00 0.00 0.00 0.00 0.04 0.01 0.00 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
All sites 83.33 55.88 84.60 69.28 78.11 0.30 -8.22 8.81 62.44 54.41 40.56 63.04 62.67 0.91 -5.94 7.76 
All sites excluding skin 75.87 50.93 75.66 62.04 70.39 0.01 -7.56 7.59 56.37 49.16 36.75 56.66 56.30 0.74 -5.36 6.83 
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Gender-specific trends showed a slight decrease in stomach, esophagus and prostate and 
slight increase in bladder, lung and stability in non-Hodgkin lymphoma in men while in 
women breast, colon, stomach and cervical cancers were increasing and there was a decline 
in incidence of esophageal and thyroid cancer (Figure 33 and Figure 34). 
 
 
 
Figure 33. Time trend of adjusted relative age-standardized rate (ARASR per 105) for 
leading cancers, male, 1996–2000 
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Figure 34. Time trend of adjusted relative age-standardized rate (ARASR per 105) for 
leading cancers, female, 1996–2000 
 
Calculating ARASR using mean ASR of men and women for each cancer in each year 
provided an estimate for the time trend for incidence of each cancer including the slope and 
confidence interval (Table 21).  
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Table 21. Time trend analysis of adjusted relative age-standardized rate (ARASR per 105) 
by calendar year and site 
Both sexes 
ARASR Site 
1996 1997 1998 1999 2000 
Slope 
coefficient 95% CI 
Stomach 11.27 8.83 8.93 9.14 10.39 -0.14 -0.89 0.60 
Esophagus 9.34 6.84 5.90 6.58 7.22 -0.45 -1.23 0.33 
Other skin 6.86 5.03 6.16 6.89 7.14 0.24 -0.31 0.79 
Breast 6.27 4.01 4.89 6.32 6.47 0.27 -0.45 0.99 
Bladder 3.64 2.60 3.86 3.41 4.11 0.17 -0.19 0.54 
Lung, trachea & bronchus 2.46 3.12 2.82 2.49 3.76 0.20 -0.11 0.51 
Colon 2.72 2.31 2.47 3.44 3.69 0.31 0.04 0.57 
Prostate 2.60 2.25 2.55 2.01 2.01 -0.14 -0.26 -0.02 
Non-Hodgkin lymphoma 2.41 1.36 1.75 2.46 2.29 0.09 -0.24 0.42 
Rectum 1.72 1.47 1.64 1.98 1.97 0.10 0.00 0.21 
Brain, nervous system 2.06 1.04 1.22 1.51 1.11 -0.14 -0.39 0.11 
Larynx 1.87 0.73 1.11 1.29 1.28 -0.06 -0.35 0.22 
Thyroid 1.38 0.99 1.16 0.91 0.80 -0.13 -0.21 -0.04 
Pancreas 0.64 1.11 0.72 0.90 1.07 0.06 -0.06 0.19 
Cervix uteri 0.91 0.58 0.67 1.16 0.96 0.07 -0.08 0.22 
Liver 0.93 0.56 1.00 0.84 0.84 0.01 -0.11 0.13 
Kidney 0.63 0.58 0.93 1.01 0.84 0.09 -0.01 0.18 
Multiple myeloma 0.54 0.73 0.85 0.79 1.07 0.11 0.06 0.16 
Hodgkin disease 0.97 0.55 0.73 0.83 0.88 0.01 -0.11 0.12 
Ovary 0.80 0.51 0.63 1.11 0.82 0.06 -0.08 0.21 
Gallbladder 0.86 0.69 0.59 0.75 0.58 -0.05 -0.11 0.01 
Bone 0.85 0.35 0.41 0.55 0.63 -0.02 -0.16 0.12 
Lip 0.77 0.38 0.29 0.35 0.65 -0.03 -0.17 0.12 
Connective & soft tissue 0.72 0.27 0.47 0.29 0.49 -0.05 -0.17 0.07 
Melanoma of skin 0.48 0.42 0.47 0.43 0.39 -0.02 -0.03 0.00 
Corpus uteri 0.48 0.29 0.31 0.42 0.34 -0.01 -0.07 0.04 
Testis 0.36 0.15 0.25 0.47 0.40 0.04 -0.04 0.12 
Nasopharynx 0.28 0.15 0.37 0.38 0.39 0.05 -0.01 0.10 
Mouth 0.26 0.32 0.35 0.16 0.49 0.03 -0.05 0.11 
Small intestine 0.35 0.34 0.21 0.34 0.29 -0.01 -0.05 0.03 
Uterus unspecified 0.26 0.11 0.30 0.38 0.46 0.07 0.01 0.12 
Tongue 0.44 0.12 0.11 0.24 0.30 -0.02 -0.11 0.08 
Other thoracic organs 0.10 0.19 0.20 0.27 0.42 0.07 0.05 0.10 
Salivary glands 0.25 0.13 0.10 0.24 0.15 -0.01 -0.06 0.04 
Pharynx unspecified 0.18 0.17 0.15 0.14 0.09 -0.02 -0.03 -0.01 
Hypopharynx 0.10 0.09 0.17 0.21 0.13 0.02 -0.01 0.05 
Eye 0.10 0.09 0.16 0.22 0.09 0.01 -0.03 0.05 
Vagina 0.14 0.09 0.08 0.14 0.14 0.01 -0.02 0.03 
Anus 0.11 0.14 0.19 0.07 0.04 -0.02 -0.06 0.01 
Nose, sinuses 0.05 0.04 0.18 0.09 0.04 0.00 -0.04 0.04 
Kaposi sarcoma 0.03 0.06 0.07 0.12 0.08 0.02 0.00 0.03 
Other endocrine 0.16 0.03 0.05 0.04 0.02 -0.03 -0.05 0.00 
Other female genitalia 0.12 0.05 0.04 0.03 0.04 -0.02 -0.03 0.00 
Tonsil 0.07 0.05 0.03 0.03 0.00 -0.02 -0.02 -0.01 
Vulva 0.00 0.02 0.04 0.10 0.02 0.01 -0.01 0.04 
Mesothelioma 0.05 0.02 0.04 0.00 0.05 0.00 -0.02 0.01 
Penis 0.02 0.03 0.00 0.05 0.00 0.00 -0.02 0.01 
Adrenal gland 0.00 0.03 0.02 0.00 0.00 0.00 -0.01 0.01 
Immunoproliferative 0.03 0.02 0.00 0.00 0.00 -0.01 -0.01 0.00 
Other urinary organs 0.00 0.02 0.02 0.00 0.00 0.00 -0.01 0.00 
Renal pelvis 0.00 0.00 0.00 0.00 0.02 0.00 0.00 0.01 
Placenta 0.00 0.00 0.00 0.00 0.02 0.00 0.00 0.01 
Ureter 0.00 0.00 0.02 0.00 0.00 0.00 -0.01 0.01 
Other male genitalia 0.00 0.00 0.00 0.00 0.02 0.00 0.00 0.01 
Other oropharynx 0.02 0.00 0.00 0.00 0.00 0.00 -0.01 0.00 
Other and unspecified 3.29 2.06 2.67 2.54 3.15 0.02 -0.33 0.37 
All sites 73.80 54.56 60.92 66.68 71.19 0.69 -4.83 6.22 
All sites excluding skin 66.92 49.53 54.76 59.80 64.05 0.45 -4.54 5.44 
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Figure 35. Comparison of trend in age-standardized rate (ASR per 105) and adjusted 
relative age-standardized rate (ARASR per 105) of some selected cancers  
 
ASR of all three cancers (leukemia, esophageal and rectal cancer in male) increased in the 
five years of registration (1996–2000; Part A, Figure 35). However, ARASR of esophageal 
cancer did not show any increase, it was annually decreasing 0.38 per 100,000 persons 
(Part B). In the same parts, comparing slope of change in ASR and ARASR of rectal cancer 
in men showed that both ASR and ARASR of rectal cancer were increasing, but the slope 
of increase in ARASR was around half of the slope for ASR. ASR of rectal cancer in 
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women (Part C in Figure 35) increased 0.17 per 105 each year and the shape and slope of 
trend was very similar to those of leukemia. However, ARASR of rectal cancer in women 
in Part D showed almost no change over time, which seemed more realistic for this short 
period of time. The same happened to “All sites excluding skin” in men (compare Part E 
and F in Figure 35).   
 
In general, trends of RASR and ARASR are similar with the difference that their Y axis 
scale is different and ARASR is closer to ASR. 
 
5.3.5.2 Comparison between past and present 
 
The only comparable information available for the incidence of cancers in the past is 
results of an effort to find out the esophageal cancer incidence in the Caspian Littoral part 
of Iran in the 1960’s. Compared to 3–4 decades ago, the incidence of esophageal cancer 
declined to approximately two thirds of its previous level in both women and men (Figure 
36). On the other hand, incidence of all cancer sites during this 25–31 year period of time 
increased substantially (54% increase in men and 63% in women, Figure 36).  
 
 
Figure 36. Age-standardized rate (ASR per 105) in the four northern provinces of Ardebil, 
Gilan, Mazandaran and Golestan, comparison between 1969–71 and 1996–2000 
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5.3.6 Cancer burden prediction for year 2010 
 
Based on information from the United Nations, the population of Iran is predicted to 
increase from 60,055,488 in 1996 to 74,282,000 in 2010 (23.7% growth). With the 
assumption of no change in the risk factors of cancer from 1996 to 2010 and therefore a 
constant incidence rate during this period of time, the number of cases will increase due to 
population growth alone (column “Without any adjustment” in Table 23, Table 24 and 
Table 25). In addition, over this 10–15 year period of time, the age structure of population 
will change so that the proportion of older age groups will increase (Figure 5 and Figure 
37). Thus, the incidence for 2010 should be adjusted for the age structure in that year. 
Adjustment for age will affect (mostly increase) the annual number of new cases (column 
“Only age adjusted” in Table 23, Table 24 and Table 25). Ignoring the change in incidence 
of cancers, it is estimated that in the year 2010, there will be 47,059 new cancer cases for 
all cancer sites excluding skin whereas mean annual new cancer cases in 1996–2000 was 
32,320 (45.6% increase after 10–15 years; Table 25). Half of this increase will be due to 
increase in population over time (23.7%) and the other half will be because of ageing in the 
population. The increase in annual number of new cancer cases during this 10–15 years 
will be different among women and men so that women will have more incident cancer 
cases in 2010 (women 58.5% vs. men 36.5%).  
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Figure 37. Population pyramid for Iran 2010 
 
The annual number of new cancer cases will increase from 1996 to 2010 for all leading 
cancers (Figure 38). In general, the increase will be greater in women than men with the 
largest amount in breast cancer. The percent of increase for each cancer is shown in Table 
23, Table 24 and Table 25.  
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Figure 38. Annual number of new cases in 1996–2000 and predicted for 2010 by sex 
 
Table 22 shows the results of projected adjusted relative age-standardized rate for year 
2010 which approximates ASR in 2010.  Based on this projection, the ranking of leading 
cancers will change over 10–15 years from 1996. For instance, esophageal cancer will 
decrease whereas breast cancer will increase substantially. 
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Table 22. Projected adjusted relative age-standardized rate (ARASR per 105) for year 2010 
as alternative for age-standardized rate (ASR) in 2010 
Site Male Site Female 
Bladder 9.35 Breast 15.18 
Lung 9.29 Colon 8.19 
Stomach 8.54 Stomach 6.63 
Colon 5.26 Lung 2.68 
NH lymphoma 4.09 Rectum 2.51 
Rectum 4.05 Bladder 2.46 
Esophagus 3.80 Cervix uteri 1.41 
Prostate 1.58 NH lymphoma 1.06 
All sites 77.79 All sites 68.09 
All sites excluding skin 67.15 All sites excluding skin 61.26 
 
 
Considering change in the incidence rate of cancers from 1996 to 2000 using annual 
changes in adjusted relative age-standardized rate as an approximation of change in 
incidence, incidence rates in the year 2010 will change, so that the number of new cases 
will change accordingly (column “Final” in Table 23, Table 24 and Table 25). The 
predicted number of cases has been adjusted for change in age structure of population, 
population growth and change in incidence rate during this 10–15 year period of time.  The 
number of new cases in 2010 will increase by around 50% in men and about 100% in 
women. The total number of new cases, excluding non-melanoma skin cancer in 2010, will 
be more than 53,000 (about 28,000 men and 25,000 women).  
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Table 23. Estimated number of new cases and incidence rate for Iran in year 1996 and 2010 
by cancer site, male 
1996–2000  2010 
Incidence rate Annual no. of new cases (Iran)  
Incidence 
rate  No. of new cases 
Site 
C
rude 5 provinces 
A
ge-adjusted for Iran 
age structure 
Total no. of new
 cases 
 (5 P
rovinces, 5 years) 
N
ot adjusted for Iran 
age structure 
A
ge-adjusted for Iran 
age structure 
 
A
ge-adjusted for Iran 
age structure 2010 
Final* 
  
W
ithout any adjustm
ent 
for age structure 
A
ge-adjusted for Iran 
age structure 2010 
Final* 
Increase (%
) 
Stomach 15.80 14.21 3432 4537 4332  15.45 9.99  5940 5809 3756 -13.3
Esophagus 8.36 7.62 1835 2426 2323  8.44 3.93  3143 3172 1476 -36.4
Other skin 7.44 6.66 1593 2106 2031  7.8 11.17  2799 2934 4201 106.8
Bladder 5.28 4.73 1137 1503 1441  5.27 8.77  1986 1982 3299 128.9
Lung 4.52 4.07 984 1301 1241  4.41 9.08  1701 1656 3412 175.0
Prostate 4.80 3.57 855 1130 1089  3.81 0.82  1805 1431 309 -71.6
Other and unspecified 3.58 3.24 769 1017 989  3.6 4.69  1346 1355 1765 78.5
Colon 2.90 2.61 622 823 795  3.06 5.66  1091 1149 2129 167.8
Non-Hodgkin lymphoma 2.76 2.56 605 800 782  2.86 4.21  1036 1076 1585 102.6
Leukemia unspecified 2.36 2.20 509 673 672  2.07 3.45  886 778 1298 93.1
Larynx 2.06 1.81 435 576 552  2.05 0.62  776 769 233 -57.8
Brain, nervous system 1.82 1.70 399 528 517  1.91 1.00  684 717 375 -27.5
Rectum 1.71 1.51 359 475 460  1.8 3.96  643 677 1488 223.5
Hodgkin disease 1.13 1.06 246 325 323  1.19 0.71  425 447 268 -16.9
Liver 0.99 0.87 210 278 267  0.98 0.39  373 370 147 -45.0
Pancreas 1.02 0.84 203 268 256  0.91 1.67  384 342 629 145.7
Kidney 0.93 0.84 201 266 257  0.9 2.17  349 337 817 218.0
Bone 0.90 0.84 197 260 257  0.92 0.96  338 345 361 40.5
Testis 0.89 0.84 194 256 256  1.07 2.02  335 401 759 196.6
Multiple myeloma 0.81 0.73 176 232 222  0.82 2.09  305 310 786 254.1
Breast 0.73 0.67 160 212 205  0.85 0.37  275 319 138 -32.5
Lip 0.55 0.50 121 160 154  0.58 0.86  207 217 322 109.4
Lymphoid leukemia 0.54 0.50 119 158 153  0.54 0.00  203 202 0 -100.0
Thyroid 0.58 0.49 116 153 150  0.61 0.13  219 229 47 -68.6
Connective & soft tissue 0.57 0.48 114 151 147  0.56 0.00  214 209 0 -100.0
Nasopharynx 0.48 0.44 104 138 134  0.52 0.68  180 197 257 92.0
Melanoma of skin 0.43 0.40 95 125 121  0.44 0.00  163 167 0 -100.0
Gallbladder 0.42 0.38 93 123 117  0.42 0.27  156 158 103 -12.2
Small intestine 0.35 0.31 74 98 95  0.37 0.00  132 137 0 -100.0
Mouth 0.31 0.27 66 87 84  0.33 1.14  116 124 428 409.3
Myeloid leukemia 0.29 0.26 61 81 80  0.32 0.16  111 119 61 -24.3
Other thoracic organs 0.25 0.24 56 74 72  0.26 1.90  94 98 713 890.8
Tongue 0.23 0.21 50 67 63  0.23 0.00  86 86 0 -100.0
Salivary glands 0.18 0.17 41 55 53  0.19 0.00  69 73 0 -100.0
Pharynx unspecified 0.18 0.17 40 53 51  0.17 0.00  68 65 0 -100.0
Anus 0.17 0.16 38 50 49  0.2 0.00  64 75 0 -100.0
Nose, sinuses 0.16 0.16 37 49 47  0.17 0.09  62 66 36 -24.3
Hypopharynx 0.13 0.11 27 36 35  0.15 0.35  48 56 131 275.6
Kaposi sarcoma 0.11 0.10 24 32 31  0.11 0.28  41 43 105 240.3
All sites except other skin 69.49 62.22 14883 19680 18974   68.88 73.92   26127 25899 27790 46.5
All sites 76.93 68.88 16476 21786 21005  76.69 83.9  28925 28832 31546 50.2
* Adjusted for change in Iran age structure in 2010 and change in adjusted relative age-standardized rate during this period. 
Estimations for sites with number of new cases lower than 20 are not presented. 
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 Table 24. Estimated number of new cancer cases and incidence rate for Iran in year 1996 
and 2010 by cancer site, female 
1996–2000  2010 
Incidence Rate No. of new cases (Iran)  Incidence Rate  
No. of new 
cases 
Site 
C
rude  5 P
rovinces 
A
ge-adjusted for Iran 
age structure  
Total no. of new
 cases 
 (5 P
rovinces, 5 years) 
N
ot A
djusted for Iran 
age structure 
A
ge-adjusted for Iran 
age structure 
  
A
ge-adjusted for Iran 
age structure 2010 
Final* 
  
W
ithout any adjustm
ent 
for age structure 
A
ge-adjusted for Iran 
age structure 2010 
Final* 
Increase (%
) 
Breast 13.3 9.95 2151 2764 2661  11.98 18.24  3651 4395 6692 151.5
Stomach 9.33 6.32 1362 1750 1650  7.22 9.36  2319 2649 3433 108.1
Esophagus 8.89 5.89 1267 1628 1531  6.81 0.25  2161 2498 93 -93.9
Other skin 7.87 5.37 1160 1490 1419  6.39 8.47  1970 2343 3109 119.1
Colon 4.03 2.86 612 787 749  3.32 7.85  1047 1220 2880 284.5
Other and unspecified 3.24 2.67 540 694 669  2.77 1.92  980 1017 704 5.3
Leukemia unspecified 1.75 1.65 355 456 453  1.55 1.59  605 570 582 28.5
Thyroid 1.93 1.79 343 441 427  1.84 0.00  657 674 0 -100.0
Ovary 1.99 1.6 341 438 423  1.82 3.24  586 668 1189 181.0
Cervix uteri 2.25 1.54 341 438 419  1.93 3.49  565 710 1281 205.6
Brain, nervous system 1.73 1.43 319 409 399  1.57 0.00  525 575 0 -100.0
Rectum 1.98 1.39 295 378 359  1.64 1.79  510 601 658 83.4
Non-Hodgkin lymphoma 1.65 1.37 293 376 364  1.46 2.14  503 536 785 115.6
Lung 1.63 1.12 241 309 292  1.26 1.26  412 461 462 58.3
Bladder 1.55 1.1 226 291 274  1.2 1.87  402 439 685 150.0
Gallbladder 1.15 0.78 168 216 203  0.87 0.00  285 321 0 -100.0
Uterus unspecified 1.05 0.79 164 211 201  0.91 2.54  288 332 932 363.9
Corpus uteri 1.04 0.7 150 193 182  0.83 0.43  258 304 156 -14.1
Hodgkin disease 0.65 0.66 148 190 188  0.7 1.49  243 258 547 190.8
Liver 0.89 0.64 137 176 167  0.69 1.63  234 254 600 259.1
Bone 0.63 0.6 135 174 171  0.61 0.01  221 224 3 -98.1
Pancreas 0.88 0.64 129 166 157  0.68 1.48  235 249 542 245.5
Kidney 0.71 0.55 115 148 144  0.58 1.31  201 214 480 233.5
Connective & soft tissue 0.54 0.49 95 121 118  0.49 0.24  179 180 89 -24.7
Multiple myeloma 0.56 0.39 83 106 99  0.41 1.74  144 152 637 543.2
Tongue 0.49 0.34 71 92 86  0.37 0.25  126 137 91 5.4
Melanoma of skin 0.46 0.34 71 92 87  0.38 0.88  126 141 324 272.1
Larynx 0.46 0.31 69 88 83  0.36 0.32  114 134 116 39.9
Mouth 0.46 0.3 68 88 84  0.36 0.30  111 133 111 32.7
Lymphoid leukemia 0.39 0.29 61 79 75  0.31 0.66  106 113 242 222.9
Lip 0.37 0.25 54 70 66  0.28 0.00  90 104 0 -100.0
Myeloid leukemia 0.29 0.24 53 68 66  0.27 0.00  90 100 0 -100.0
Nasopharynx 0.28 0.23 47 61 59  0.25 1.30  85 93 475 705.2
Vagina 0.27 0.19 41 53 50  0.21 0.33  70 77 119 138.5
Small intestine 0.27 0.18 40 52 49  0.22 0.34  68 82 124 153.6
Eye 0.22 0.16 36 46 45  0.19 0.42  60 68 154 242.7
Salivary glands 0.2 0.18 34 44 43  0.19 0.58  66 71 214 397.0
Hypopharynx 0.22 0.14 31 40 38  0.17 0.37  50 62 136 256.7
Other thoracic organs 0.19 0.14 30 39 37  0.16 0.18  52 61 65 75.7
Pharynx unspecified 0.2 0.13 28 36 34  0.15 0.00  47 56 0 -100.0
Other female genitalia 0.13 0.1 21 27 26  0.12 0.00  36 42 0 -100.0
Nose, sinuses 0.12 0.09 18 24 22  0.1 0.24  33 36 88 301.2
Vulva 0.12 0.08 17 22 21  0.09 0.39  29 33 141 572.7
Anus 0.13 0.08 17 22 21  0.1 0.07  29 36 25 17.6
All sites excluding skin 68.88 50.85 10864 13958 13347  57.68 66.51  18655 21160 26048 95.2
All sites 76.76 56.22 12023 15448 14766  64.07 74.97   20625 23504 29156 97.5
* Adjusted for change in Iran age structure in 2010 and change in adjusted relative age-standardized rate during this period. 
Estimations for sites with number of new cases lower than 20 are not presented. 
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Table 25. Predicted number of new cancer cases in year 2010 for both sexes by site  
Number of new cases in year 
1996–2000  2010 
Cancer site Five 
provinces 5 
years 
Iran estim
ate  
not adjusted 
for age 
structure 
A
ge-adjusted 
to Iran 
structure in 
1996 
 
W
ithout any 
adjustm
ent 
A
ge-adjusted 
to Iran 
structure in 
2010 
Final* 
Increase (%
) 
Stomach 4794 6287 5982  8259 8458 7189 20.2 
Esophagus 3102 4054 3854  5304 5670 1570 -59.3 
Other skin 2752 3596 3451  4769 5277 7309 111.8 
Breast 2311 2976 2866  3926 4714 6830 138.3 
Bladder 1363 1794 1716  2388 2421 3983 132.1 
Other and unspecified 1309 1711 1658  2327 2371 2469 48.9 
Colon 1234 1609 1544  2139 2368 5009 224.4 
Lung 1225 1610 1533  2112 2117 3874 152.7 
Non-Hodgkin lymphoma 898 1176 1145  1539 1612 2369 106.9 
Leukemia unspecified 864 1129 1125  1491 1347 1880 67.1 
Prostate 855 1130 1089  1805 1431 309 -71.6 
Brain 718 938 917  1209 1292 375 -59.1 
Rectum 654 853 819  1153 1278 2146 162.1 
Larynx 504 664 636  890 903 349 -45.1 
Thyroid 459 594 577  876 903 47 -91.8 
Hodgkin disease 394 515 511  668 704 815 59.5 
Liver 347 454 433  607 624 747 72.4 
Bone 332 434 428  559 568 364 -14.9 
Ovary 341 438 423  586 668 1189 181.0 
Cervix uteri 341 438 419  565 710 1281 205.6 
Pancreas 332 434 413  619 591 1172 183.7 
Kidney 316 414 401  550 551 1297 223.5 
Multiple myeloma 258 338 322  450 462 1423 341.9 
Gallbladder 261 338 320  441 479 103 -67.9 
Connective & soft tissue 209 273 265  394 389 89 -66.5 
Testis 194 256 256  335 401 759 196.6 
Lymphoid leukemia 181 236 228  309 315 242 6.2 
Lip 175 230 220  297 321 322 46.5 
Melanoma of skin 166 217 209  289 308 324 54.9 
Uterus unspecified 164 211 201  288 332 932 363.9 
Nasopharynx 151 198 193  265 290 732 279.5 
Corpus uteri 150 193 182  258 304 156 -14.1 
Mouth 134 175 167  227 257 539 222.9 
Tongue 122 158 149  212 224 91 -39.1 
Myeloid leukemia 114 149 147  200 219 61 -58.8 
Small intestine 115 150 144  200 219 124 -13.7 
Other thoracic organs 86 113 109  146 158 778 614.1 
Salivary glands 76 99 95  135 144 214 125.0 
Pharynx unspecified 69 90 85  115 121 0 -100.0 
Hypopharynx 58 76 73  98 119 267 265.8 
Nose, sinuses  55 72 70  95 102 124 76.9 
Anus 56 73 70  93 111 25 -64.7 
Eye 54 70 69  92 98 186 169.8 
Vagina 41 53 50  70 77 119 138.5 
Kaposi sarcoma 31 41 39  52 57 220 463.4 
Other endocrine 28 37 36  53 54 0 -100.0 
Tonsil 23 30 29  38 41 13 -55.7 
Other female genitalia 21 27 26  36 42 0 -100.0 
All sites except other skin 25747 33638 32320  44782 47059 53393 65.2 
All sites 28499 37234 35771   49550 52336 60703 69.7 
* Adjusted for change in Iran age structure in 2010 and change in adjusted relative age-standardized rate during this period. 
Estimations for sites with number of new cases lower than 20 are not presented. 
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6. Discussion 
 
The decreasing burden of infectious diseases and increasing non-communicable diseases 
during the last century are not limited to developed countries, developing countries have 
experienced such changes too (Lopez and Murray, 1998). It is predicted that, by 2020, non-
communicable diseases will cause seven out of every ten deaths in developing countries. 
Among non-communicable diseases, special attention is devoted to cardiovascular diseases, 
diabetes, cancer and chronic pulmonary disease (Boutayeb 2006). A recent report from the 
Iran Ministry of Health demonstrated that more than 70% of deaths were caused by 
cardiovascular diseases, accidents and cancers whereas less than 3% of deaths were due to 
infectious diseases. Therefore, understanding and quantifying the burden of cancer as the 
second cause of non-injury death in the country is clearly justified. On the other hand, 
when there is no surveillance for cancer in developing countries such as Iran, research in 
the cancer epidemiology field is difficult. One of the crucial tools in cancer control is the 
cancer registry which can provide not only information for epidemiological research on 
cancer determinants, but also for planning and evaluating cancer control programs (Jensen 
et al. 1991). In the absence of a continuous systematic population-based cancer registry, 
this type of retrospective survey seemed feasible to determine the cancer incidence.  
 
 
6.1 Strengths of this study 
 
The trained survey team had access to all patient records, with close monitoring of expert 
pathologists and epidemiologists at the registry branch of DDRC in Tehran. The survey 
team obtained copies of pathology reports, imaging reports and endoscopy documents for 
the majority of cases. These data provide the most complete and accurate estimates of 
cancer occurrence that have been reported so far from Iran. Including new diagnosed 
cancer cases of five large provinces of Iran (including 15.7% of Iran; almost 9.5 million)  
for five years in this study allowed precise estimates of incidence for all cancers (even rare 
cancers).  
 
This is the first time that cumulative incidence rates for men and women separately have 
been calculated for 0–64 and 0–69 years of life in Iran, which is a very tangible measure to 
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explain the burden of cancer in the region. Moreover, two novel methods have been 
presented in this study, one for correcting under-registration of elderly ages by modeling 
while the other uses adjusted relative age-standardized rate for estimating time trend of 
cancer incidence in incomplete developing cancer registries. This is a new method using 
time trend analysis of adjusted relative age-standardized rates instead of trend in ASR, 
which accounts for variation in completeness of registration over time and can be used as 
an indicator of validity for cancer registries. 
 
 
The first prediction of the number of new cancer cases in Iran for 2010 is another aspect of 
this study. Altogether, using retrospective registration of cancer cases in these five 
provinces resulted in an overview of cancer burden in Iran. Some other provinces such as 
Semnan province have also tried to use this method to ascertain the cancer profile in their 
regions (Babaei et al. 2005).  
 
 
6.2 Shortcomings of this study 
 
One of the shortcomings of this study was its retrospective nature in the setting of 
suboptimal quality medical records kept in private and to some extent in public hospitals 
and other medical centers. Also, not using the ICD coding system in some of the medical 
facilities at the time of diagnosis made it impossible to classify all cancer cases from the 
topographic point of view. Not using a national unique code for each person at the time of 
diagnosis made duplicate elimination difficult. Metastatic cancer cases were not included in 
the registration, i.e. tumors with unknown origin have been excluded. Therefore, there is a 
slight under-estimation for those cases. However it was impossible to classify them into 
certain tumor sites.  
 
This study was designed for regional purposes (provinces) and also provided estimates for 
the whole country of Iran. Therefore, these five provinces may not be representative of all 
of Iran, which questions the external validity of results.  
 
The results of a study of cancer patterns among inpatients of public hospitals in Iran in 
2000–2 showed that only 22.3% of all inpatient cancer cases are from rural areas, while the 
proportion of rural population was 35.5% in the latest census (Mehrabi et al. 2004). It is 
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also less probable that rural patients go to the private hospital because the private sector is 
very expensive. This may show that rural residents are less diagnosed or referred to the 
urban hospitals and our main source of data of this study has been from urban facilities. 
This may have resulted in an underestimation of about 10% for all cancers, especially for 
breast cancer, since the contribution of rural breast cancer cases in inpatient public 
hospitals was only 10.6% of all breast cancer cases (25% less than their proportion in the 
whole population). In general, the results of this study should be taken as the minimum 
incidence rates of cancers in Iran. Despite all these shortcomings, data from the first years 
of two continuous active population-based cancer registries in Ardebil and Golestan in 
2004–5 show similar rates to those in the current study (Babai and Malih, unpublished 
data).  
 
 
6.3 Corrected incidence rates 
 
The decline at older ages in the age-specific incidence curves could be due to under-
registration (Figure 7 and Figure 10). In this study, an attempt was made to correct this 
problem. Correction was carried out based on the Finnish female age-specific rate pattern 
for age older than 79 years using the Finnish pattern for all sites. This was chosen because 
Finnish cancer cases are believed to be correctly registered with a very high level of 
completeness in their population-based cancer registry (Teppo et al. 1994). As Finnish 
population is much older than that in Iran, using the pattern of their age-specific rates, 
especially female pattern with higher life expectancy, would be the best choice as a model 
for correction of under-registration of old cancer cases in Iran. Since the proportion of 
Iranian population over 79 in 1996 is very low (male 0.45%, female 0.54%), the correction 
does not substantially affect the rates and number of cases in that year. However, with 
increase of life expectancy, this proportion increases (predicted for 2010; 0.71% of all ages 
for men or 0.73% for women). This may affect the results because if the calculation of 
future rates is done without correction, results will be underestimated (Table 25).     
 
Comparing the corrected figures of age-specific curves with the original ones showed how 
well this correction took care of the problem of under-registration in elderly ages. Other 
ways to solve this problem include using a truncated incidence rate which omits cases 
below 35 years in addition to ages over 74). Another way is to ignore this fact and only 
report the elderly ages as sums of all age groups over a certain age such as 65+ or 75+. This 
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will hide the defect in the age-specific curve. In this dissertation, it was preferred to try to 
improve the data rather than hiding or ignoring the problem. Therefore, this correction was 
used. The correction does not mean adjustment based on Finnish age structure, age-
standardization or using Finnish incidence rates; it is only compensation for the under-
registration of elderly cancer cases in incomplete registries. This correction is based on 
using data from cancer cases aged 70–79 in the incomplete registry multiplied by a 
coefficient from a complete registry to estimate incidence in those aged 80 or more 
(Equation 1). Corrected figures of age-specific curves seem more interpretable and realistic 
because they do not show any false decline in the incidence of common cancers in elderly 
ages while cancer is known to be a highly age-dependant disease increasing in elderly ages 
(except for some childhood cancers).   
 
Opportunistic breast cancer screening is common among urban Iranian women and may be 
one of the causes of a rise at age 35 to 44 and a rather flat situation from 45 to 54, with a 
decrease in the incidence of breast cancer afterwards from 55 to 69 (possibly due to the 
diagnosis of this cancer earlier than what it used to be without screening; Figure 10). 
However, the curve returns to logarithmic increase after age 69, but again it is hampered by 
under-registration of elderly cases (80 and above). This phenomenon was seen in all the 
provinces, so it is not a random error. Similar phenomenon was seen in Osaka Prefecture in 
Japan and with further longitudinal analysis the reason for decline in the elderly ages 
appeared to be the birth cohort effect (Rothman 1998). So the birth cohort effect can partly 
justify the shape of age-specific curve for breast cancer. Longer period of study is needed 
to find the birth cohort effect (at least 15 years). 
 
Using ASR is a good tool for comparison, but it is an artificial rate. Cumulative rate was 
therefore used to show how great the risk of a particular cancer is for this population in 70 
years of life. Cumulative rate approximates cumulative risk and the interpretation is more 
tangible. For instance, the risk of cancer of any kind in men during 0–69 years of life was 
approximately 7.9%. Of this, around 45% was due to gastrointestinal tract (mostly 
stomach, esophagus and to some extent colon). For women, risk of any cancer during 0–69 
years of life was approximately 6.4%. Of this risk, around 38% was for gastrointestinal 
tract (mostly stomach, esophagus and colon), and about 20% was due to breast cancer. 
 
The cancer site “Uterus” as the fourth leading cancer in women was misleading because it 
only showed the topography code for uterine unspecified (ICD-O code C55). It was not 
certain whether it was corpus uteri or cervix uteri (page 91 Figure 14). Based on 
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unpublished data from an ongoing cancer registry in Ardebil, the majority of uterine 
unspecified is attributable to cervix uteri rather than corpus uteri. However, in spite of this, 
cervical cancer is very rare in Ardebil. 
 
6.4 Comparisons 
 
 
6.4.1 Past and present 
 
An effort was made to ascertain the esophageal cancer incidence in the Caspian Littoral 
part of Iran in 1960’s (Kmet and Mahboubi 1972). That large-scale survey showed a very 
high incidence rate for esophageal cancer in Northeastern Iran. The interesting finding in 
that study is the 10-fold variation in esophageal cancer rates between eastern and western 
parts of the Caspian Littoral in areas less than 500 km apart. Unfortunately, there was no 
information on the overall ASR of each cancer site in this region to compare with present 
data. In this study, the overall ASR for this region was estimated by ASRs of esophageal 
cancer and all cancer sites in these northern cities of Iran which included cities of Ardebil, 
Gilan, Mazandaran and Golestan provinces. 
 
The incidence of esophageal cancer has declined to approximately two thirds of its 
previous rate in both females and males. This may reflect partly a real decrease in the 
incidence of this cancer due to overall improvement in socioeconomic status after the 
revolution of 1979 (Pourshams et al. 2005). It may be due to a change in risk factors of 
esophageal cancer such as poor nutrition (Cook-Mozaffari et al. 1979) and bad oral hygiene 
(Sepehr et al. 2005). Another explanation for this decrease might be the change in the 
classification of the lowest part of esophagus to the cardia of stomach which is done 
nowadays. However, the decline in the incidence of esophageal cancer is in line with the 
decrease found over years of study using ARASR (Figure 33 and Figure 34) and in another 
study with Shiraz and Tehran data (Yazdizadeh et al. 2005). 
 
On the other hand, the incidence of all cancer sites during this 25–31 year period of time 
has increased substantially (54% increase in males and 63% in female, Figure 36). This 
increase does not seem to be real. However, there seems to be an overall increase in all 
sites of cancer at a slower pace in the society with change in some risk factors such as 
higher obesity (60% overweight in Golestan and 25% obese, BMI>30) and a tendency 
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toward western diet (Pourshams et al. 2005). Refrigerator ownership in rural areas has 
increased from less than 5% in 1970 to more than 90% at present. The change in lifestyle 
toward westernized fashions with less physical activity may be the reason behind overall 
increase in all cancer sites. Therefore, with current lifestyle, it is reasonable to expect 
higher incidence rates in the future. With the increase in population over time and with 
longer life expectancy, the cancer burden will make a major contribution to disease 
prevalence, mortality and the health budget. With the increasing proportion of high risk age 
group female population, population growth, and increasing incidence and survival rate in 
breast cancer, this cancer will have the highest number of survivors in the near future. 
 
 
6.4.2 Present and future (time trend) 
 
Studying time trends in the incidence of cancers is helpful to understand the present 
situation and the results can also be projected to the future. For a five-year study, the time 
trend was difficult to interpret especially when data on year of diagnosis was available only 
for three fourths of subjects. For cases with unknown year of diagnosis, which year they 
were diagnosed with cancer was not noted, but they were selected from medical records 
with a diagnosis of cancer in 1996 to 2000. However, the analysis was done for those cases 
with a known year of diagnosis. Time trend analysis and projection based on just five-year 
data is not optimal because of random variation in a short period of time.  
 
Figure 30 illustrated changes in the number of new cases over time by province. In general, 
these trends should be interpreted quite cautiously because first, the duration of the study 
was quite short for these kinds of interpretations. Second, year of diagnosis was not 
reported for all cancer cases. Third, the increase may be due to the improvement of case 
ascertainment over time or real increase in incidence of cancers which was unlikely to have 
such a high annual increase. As this increase was seen in almost all cancer sites and all 
provinces, the reason was more likely to be improvement of case finding rather than real 
change in incidence.  Also, cases with missing information on year of diagnosis may be 
more likely from the first years of study which would overestimate the increase in 
incidence rates over time.  
 
In general, the results of the time trend analysis were uncertain (with doubt about 
completeness in first years of registration) and not easy to interpret. To tackle this issue, the 
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time trend of relative age-standardized ratio (RASR) was developed, tested and used. For 
this alternative method, leukemia was chosen as a reference cancer with constant ASR 
during time. The ASR of this cancer was constant for 50 years of registration in the Finnish 
Cancer Registry, like other valid registries such as SEER in USA (0% change from 1975–
2001). Then relative age-standardized ratio for each cancer (ASR of each cancer relative to 
ASR of leukemia) was calculated.  
 
Using ASR for trend analysis on the data of this study resulted in an unrealistically strong 
increase over a short time period. Thus, ARASR may be preferable to ASR in situations 
where completeness of registration is not 100% and is variable over time because it takes 
the ascertainment bias into account. Of course, use of ARASR involves two assumptions. 
First, incidence of leukemia cancer is constant over time, and second, if under-registration 
or over-registration occurs, it happens in all cancers to the same extent. For instance, if 
there was 15% under-registration in a registry in 1996, each and every cancer would be 
15% under-registered in that year. If the under-registration in 2000 was 10%, then the 
change in ASR from 1996 to 2000 would show a 5% increase. In this situation, ARASR is 
more reliable because it is not affected by under/over-registration. If there was no real 
change in ASR, the change in completeness of registration would distort the ASR trend but 
not affect the ARASR trend.  
 
Using adjusted relative age-standardized rate (ARASR) in the time trend analysis resulted 
in a slope coefficient in the linear regression which approximated the slope of time trend in 
incidence. Using ASR in the calculation of RASR or ARASR also accounted for the 
change in the age structure of population over time since it was already age-standardized. 
Using other measures such as crude incidence rate or number of cancer patients (morbidity 
odds ratio) in settings with incomplete registration could result in incorrect estimates.  
 
The time trend analysis of ARASR for cancers in both sexes together demonstrated that 
incidence of ‘all sites’ was showing a slight increase over this 5-year period, but this 
increase was not statistically significant. The direction and amount of change in ARASR of 
different cancers as an approximate for incidence of cancers were different. The highest 
incidence change among leading cancers in both sexes was in esophagus, which decreased 
0.45 units of ASR per year. This was in line with findings from the comparison of past and 
present data and from another study which showed change in morbidity odds ratio for the 
frequency data of Shiraz and Tehran 1972–1995 (Yazdizadeh et al. 2005). In contrast, 
using ASR in the trend analysis showed that the incidence of esophageal cancer is 
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increasing in both sexes (annually 0.15 units increase in women and 0.42 units in men) 
which is not consistent with current knowledge and practice. Using ARASR revealed that 
the incidence of stomach cancer was decreasing as well but at a slower pace. Yet the Shiraz 
and Tehran study showed an increase in stomach cancer similar to the change in women of 
our study. On the other hand, the incidences of breast and colon cancers were increasing 
while prostate was significantly decreasing. The increase in colon cancer was in line with 
the study by Yazdizadeh et al. (2005). Bladder and lung cancer incidences were increasing 
to the same extent over this period. The incidence of cervical cancer was almost constant 
over time. In general, using ASR in the trend analysis of this data showed an increase in all 
leading cancer sites, which does not seem realistic while the results of ARASR were more 
interpretable.  
 
ARASR has the same unit as ASR because it is a ratio with no unit (RASR) multiplied by a 
rate with a unit of number per person-time (∑ASR) divided by another ratio with no unit 
(∑RASR). Therefore, adjusted relative age-standardized rate is not a ratio after adjustment 
and it has the same unit as rates. ARASR has another advantage as it takes the change in 
population age structure over time into account because the ASRs used in the calculation of 
ARASR have been already directly standardized by a standard population such as the 
World Standard Population. Therefore, ARASRs from countries are comparable to each 
other.  
 
Using ARASR instead of ASR in trend analysis is new and should be tested in other cancer 
registries although it seems to work wherever the assumptions behind it are met. A similar 
concept has been used in another study where morbidity odds ratios (MOR) were compared 
between past and present situation of a cancer in the absence of accurate incidence 
estimates (Yazdizadeh et al. 2005). Yazdizadeh et al. used the number of childhood cancers 
as the reference group for cases of each cancer. They referred to another similar concept, 
morbidity or mortality odds ratio, as an alternative to proportional mortality ratio to assess 
cancer risk in the absence of denominators (Miettinen and Wang 1981). The concept of 
MOR does not seem an appropriate method for time trend analysis because the age 
structure of a population changes over time and MOR does not take the age structure into 
account while ARASR does. ARASR can also be used to evaluate completeness of 
registration. When ARASRs and ASRs and their trends are similar, it indicates correct 
registration (no under/over-registration) and if they are very different it may show a 
problem in validity of registration (under-registration or over-registration).  
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Using time trend analysis of ARASR and considering population growth and change in age 
structure of population, it is predicted that the number of new cases in year 2010 will 
increase 50% in men and 100% in women. The total number of new cases in 2010 will be 
more than 53,000 (about 28,000 men and 25,000 women). This increase will be a major 
burden for the health care system. With increased survival rate, the number of prevalent 
cancer patients will be substantially higher in 2010, especially in women.  
 
The dramatic increase in breast cancer (2.5 times) may be partly due to the increase in 
population, aging of population and partly due to the fact that younger girls at the peak of 
the baby boom after the Iran revolution reach the age of breast cancer. In other words, 
those 10–30 year old women who composed the majority of female population in 1996 will 
be 25–45 years old in 2010 and will be at risk of breast cancer although in younger ages 
most of the breast cancers may be caused by inherited susceptibility. Given a good survival 
rate for breast cancer, survivors of this cancer will compose a remarkable portion of female 
population after 2010, similar to what is now seen in developed countries. 
 
 
6.4.3 GLOBOCAN and this study 
 
International Agency for Research on Cancer (IARC) estimated the cancer profile of every 
country in the world to assess the global burden of cancer. They used real data for countries 
with cancer registries, but for countries without any registry, cancer burden was estimated 
based on frequency data and estimates from neighboring similar countries. The results of 
this have been organized in the GLOBOCAN database. At the time of creating 
GLOBOCAN2000, there was no population-based cancer registry in Iran and the only 
available data was frequency data from hospitals in different provinces. They included data 
from Register of the Iranian Cancer Organization (1998–1982, Tehran, Tabriz and Isfahan 
hospitals) and Fars Province Cancer Registry (1978–1981, Shiraz hospitals) (Parkin et al. 
1986). The source data for GLOBOCAN2002 came partly from this study (Ardebil, 
Golestan, Kerman and Mazandaran) and another part from Tehran metropolitan area (1997) 
by Tehran Cancer Institute. They used the mean of estimates from these two sources. The 
estimates by GLOBOCAN2002 and the result of this study were highly concordant because 
they shared the majority of their data sources except for Gilan (only available in this study) 
and Tehran (only in GLOBOCAN2002; Figure 39).  
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Figure 39. Iran, age-standardized rate (ASR per 105) by GLOBOCAN2000, GLOBOCAN2002 and 5 provinces 1996–2000 
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In general, the results of GLOBOCAN2002 and this study were very similar, and the only 
difference was higher incidence in almost all cancer sites in GLOBOCAN2002. This 
difference may be due to the fact that duplicate cases in shared parts of GLOBOCAN2002 
and this study, were not eradicated completely at the time of creating GLOBOCAN2002 
because there was a hurry to use all available data for the latest version of GLOBOCAN 
(2002). Nevertheless, the over-estimation in GLOBOCAN2002 was not substantial and 
only the incidence of cervical cancer was remarkably higher in GLOBOCAN2002, which 
may reflect higher cervical cancer incidence in Tehran. In addition, the results of the 
Tehran registry (with very large population at risk around 6,760,000) have been generally 
similar to those in this study.  
 
 
6.4.4 Neighboring countries 
 
Based on “Cancer Incidence in Five Continents Vol. VIII” there were only three countries 
around Iran with population-based cancer registries. They were all south of Iran: Pakistan 
in the southeast, Oman in the south and Kuwait in the southwest. Generally the incidence 
of cancer in Iran was lower than other neighbors in both men and women (Figure 40). The 
reason is unknown, but largely due to difference in the incidence of breast and lung cancers 
(higher in Pakistan) possibly a reflection of differences in risk factors, such as obesity and 
smoking, between these countries. 
 
 
Figure 40. Age-standardized rate (/100,000 person-years) of Iran (1996–2000) and 
neighbors (Pakistan 1995–97, Kuwait 1994–97, Oman 1993–97) 
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The incidence of stomach and esophageal cancer in Iran in both women and men was 
moderately higher than Pakistan, Kuwait and Oman (Figure 41). On the other hand, the 
incidence of breast cancer was very high in Pakistan (ASR=53/100,000) and Kuwait, more 
than twice that in Iran or Oman. Bladder cancer was not very different in these 4 countries. 
Lung cancer was 2–3 times more common in Pakistan or Kuwait than in Oman or Iran.  
This may reflect the pattern of smoking in these countries. Pakistan and Iran (with similar 
incidence of prostate cancer) had lower incidence of prostate cancer than the two other 
countries. 
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Figure 41. Age-standardized rate (/100,000 person-years) of leading cancers in countries 
around Iran that have cancer registries 
 
 
6.4.5 Developing and developed countries 
 
As demonstrated in Figure 42, in general, the incidence of all cancers in Iran was lower 
than the world average or even the average of less developed countries. The resulting 
overall estimated ASR of 93.4 in males and 68.9 in females was among the lowest in the 
world. ASR of cancers in Iran was less than half of the incidence of the world and less than 
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one third of more developed countries in both women and men. This is not due to the 
younger age structure in Iran because these numbers are already adjusted for age 
(standardized by world standard population). This low incidence in Iran does not apply to 
every cancer (Figure 43 and Appendix Figure 9).  
 
 
Figure 42. Age-standardized rate (/100,000 person-years) of all site cancers excluding non-
melanoma skin in the world, developed countries, developing countries (2002) and Iran 
(1996–2000) 
 
There were only a few cancers in Iran which have higher or similar ASR compared to the 
rest of the world. Hodgkin disease in men and women, and esophageal cancer in Iranian 
women were higher than the world average. Stomach cancer was very similar in all four 
categories. This comparison was made irrespective of regional variations within the 
country (for instance very high ASR of stomach cancer in Ardebil province (54/100,000 
men) or very high ASR of esophageal cancer in Golestan province (24/100,000) well 
beyond the world average. The low incidence of lung cancer in Iran may reflect lower 
prevalence of smoking, especially in women (12.9% in males over 15 years old; Noorbala 
and Mohammad, 1999). Other explanations might be due to possible under-reporting, 
under-registration and difficulty in tissue diagnosis.  
 
One interesting finding was the very low incidence of cervical cancer in Iran compared to 
any other parts of the world. This may be due to the fact that Iranians are very strict in their 
marital relationships, and, because of their religion, have almost no extra-marital 
partnerships. Information from neighboring Muslim countries supports this theory of lower 
incidence of cervical cancer associated with religion and sexual monogamy (Draini et al. 
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2002). The ASR of cervical cancer in Pakistan (6.8) Kuwait (5.6) and Oman (7.7) was also 
lower than the world average (16.2/105). 
 
 
Figure 43. Age-standardized rate (/100,000 person-years) of leading cancers in the world, 
developed countries, developing countries (2002) and Iran (1996–2000) 
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6.5 Strategic targets for prevention and control 
 
The most important human carcinogens include tobacco, asbestosis, aflatoxins and 
ultraviolet rays. Almost 20% of cancers are associated with chronic infections (hepatitis B 
and C viruses, HIV, HPV, Helicobacter pylori, schistosomiasis etc.). There is increasing 
recognition of the causative role of lifestyle factors including diet, physical activity and 
alcohol consumption. Genetic susceptibility may significantly alter the risk from 
environmental exposure (Stewart and Kleihues 2003, 21). These are the main strategic 
targets for the prevention and control of human cancer (Schottenfeld and Fraumeni 1996, 
1404–1406). Since other common non-communicable diseases share the same lifestyle-
related risk factors, action to prevent cancer should focus on controlling these risk factors 
in an integrated manner. This requires close coordination with programs for the prevention 
of other related non-communicable diseases mainly cardiovascular diseases, chronic 
obstructive pulmonary diseases and diabetes (Stewart and Kleihues 2003, 307).  
 
The investigation of risk factors of cancer and preventive measures are beyond the scope of 
this study. However, since the estimation of the burden of cancer in terms of incidence, 
mortality, and prevalence is the first step to plan control measures and define priorities for 
preventive strategy, the results of this study can be used to prioritize the preventive 
measures based on the current status of cancer incidence in Iran.  
 
Based on the results of this study stomach cancer is the most common cancer among 
Iranian men in terms of incidence higher than the world average. Helicobacter pylori is a 
causal agent for chronic atrophic gastritis, a precursor of gastric carcinoma. Prevalence of 
infection with H. pylori is positively correlated with stomach cancer mortality rate in 
countries throughout the world (Schottenfeld and Fraumeni 1996, 1406). Eradication of H. 
pylori interrupts the malignant pathway and reduces the cancer risk (Parsonnet  et al. 1996). 
As the rate of H. pylori infection in Iran reaches 85% (Latifi-Navid et al. 2007), it seems 
necessary to allocate some research budget to study cost-effectiveness of screening 
program for H. pylori infection in high risk groups by a noninvasive test, such as serology 
or breath testing (i.e. in Ardebil).  
 
Iran, like every other country, should give high priority to tobacco control in its fight 
against cancer. Given the multi-faceted impact of diet on cancer, the aim must also be to 
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encourage consumption of available vegetables, fruits and other agricultural products, and 
avoid the adoption of Western style eating habits. Dietary policy and measures to increase 
physical exercise and reduce obesity should be developed based on the local context. Thus 
there is a great need for effective and carefully evaluated school education programs in Iran 
for tobacco abstinence and healthy dietary habits.  
 
The strategy for the early diagnosis of cancer should be a public and health professional 
activity. The public health education campaign should teach people to recognize early signs 
of cancers and urge them to seek prompt medical attention. Health professionals, especially 
primary health workers should be trained to identify cases that are suspicious and refer 
them for rapid diagnosis. Because of the considerable resources involved, population 
screening programs should be undertaken as a component of early detection where their 
effectiveness has been demonstrated (Stewart and Kleihues 2003, 307).  
 
This study showed that breast cancer is the most common cancer in Iranian women in terms 
of incidence. On the other hand, the incidence of cervical cancer is substantially lower than 
in other parts of the world, especially in Ardebil, which has the lowest reported cervical 
cancer incidence in the world. Therefore, it seems more beneficial and rational to shift the 
national screening program in Iran from screening for cervical cancer to breast cancer if 
resources are limited. As mammography is a high cost procedure, in the first step it can be 
done only for high risk groups. Establishing a breast self-examination educational program 
and encouraging women to self-examine can be done for all women in order to detect 
cancer earlier and increase survival of patients (Hadi et al. 2002). 
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7. Summary 
 
During the five years of study, 1996–2000, there were 28,022 new cancer cases in these 
five provinces of Iran: Ardebil, Gilan, Mazandaran, and Golestan in the north and Kerman 
in the south. In terms of age-standardized rate (ASR per 105), the most common cancers in 
males were stomach (22.5), esophagus (12.1), bladder (7.5), lung (6.5), colon/rectum (6.2) 
and prostate (5.6). The cumulative rate for 0–69 years of life in men was 7.8%. The most 
common female cancers were breast (13.3), stomach (9.3), esophagus (8.9), colon/rectum 
(6.0), leukemia (2.4) and cervical cancer (2.3). The cumulative rate for 0–69 years of life in 
women was 6.4%. In terms of incidence among these five provinces, stomach cancer had 
the highest rate in Ardebil province in both sexes. Highest rate of esophageal cancer was in 
Golestan in both sexes. Breast cancer was highest among Kermanian women. Highest rate 
of bladder and prostate cancer was recorded for Gilanian men whereas Gilanian women 
had highest rate of colorectal cancer. Highest rate of lung cancer found among 
Mazandaranian men. Kermanian men had the highest rate of skin or hematological 
neoplasms such as leukemia or lymphoma. 
 
Generally the incidence of cancer in Iran was among lowest in the world. Cervical cancer 
was lower than even low risk countries such as China, Kuwait or Spain. Compared to 30 
years ago, incidence of esophageal cancer declined to approximately two thirds of its 
previous level in both sexes. However, incidence of all other cancers including stomach 
cancer and breast cancer increased dramatically up to 120%. Although this increase was 
unrealistically high, most likely because of under-registration of other malignancies than 
esophagus 30 years ago, the real change seems to be in the same direction but with slower 
slope.  
 
The estimates by GLOBOCAN2002 and the results of this study were highly concordant 
because they shared the majority of their data sources except for Gilan (only available in 
this study) and Tehran (only in GLOBOCAN2002). 
 
It is predicted that the annual number of new cases excluding non-melanoma skin cancer in 
year 2010 in Iran compared to 1996 will increase 65% (women 95%; men 46%) to at least 
53,000 persons. This increase in the number of new cases is a huge burden for the health 
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care system because by adding the number of old cases to these cases, the number of 
cancer patients will be substantially higher in 2010, especially in women.  
 
A new method was developed and tested on some complete and incomplete cancer registry 
data to adjust for ascertainment bias in cancer registry data. In registries with incomplete 
reporting, ARASR was a better estimate for time trend analysis. ARASRs in different 
countries or different times were comparable since they were already standardized for age 
structure. In addition, comparison between time trend of ASR and ARASR could be used 
to evaluate completeness of registration. 
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Appendix Figure 1. Population pyramid of Ardebil 
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Appendix Figure 2. Population pyramid of Gilan province 
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Appendix Figure 3. Population pyramid of Mazandaran 
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Appendix Figure 4. Population pyramid of Golestan 
Kerman
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Appendix Figure 5.  Population pyramid of Kerman 
  
 
 
 
Appendix Table 1. Number of cases and person-years by province and age group 
      Age group 
  Province Sex 0–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85+ Unknown Total 
Male 8 28 23 21 38 39 47 51 66 97 136 193 343 358 357 167 38 33 61 2104 Ardebil 
Female 12 16 18 30 31 32 41 60 93 107 137 127 195 152 160 61 30 19 84 1405 
Male 35 60 46 56 60 63 118 122 161 250 289 339 662 632 691 367 86 45 384 4466 Gilan 
Female 29 26 37 41 61 89 148 186 250 259 252 266 365 314 311 169 50 28 235 3116 
Male 62 83 88 98 83 95 132 112 203 234 284 306 506 604 756 422 148 79 459 4754 Mazandaran 
Female 44 55 57 66 54 87 150 216 294 263 309 256 374 307 285 175 62 57 288 3399 
Male 14 13 16 25 23 33 36 56 87 80 128 120 243 214 283 145 62 24 65 1667 Golestan 
Female 11 13 23 23 32 46 77 108 136 125 113 108 149 126 132 59 16 15 79 1391 
Male 62 84 88 63 73 56 93 107 150 147 185 207 354 326 382 233 95 34 202 2941 
N
o. of cases (all sites) 
Kerman 
Female 28 46 57 80 61 88 109 127 191 202 238 161 260 209 216 103 47 20 148 2391 
                       
Male 268836 369108 371792 296008 192236 179488 134064 114960 82008 67232 57876 54476 59596 55168 37232 10572 4200 4740 192 2359784 Ardebil 
Female 252552 349324 359736 298148 213920 172232 134708 117452 94104 73152 58876 49368 49332 42304 29256 7780 3516 6400 100 2312260 
Male 493590 678110 801580 643745 406385 446785 400870 357420 290785 223485 169050 163950 183165 144935 110280 37650 13615 11365 190 5576955 Gilan 
Female 472970 652515 773095 672750 502610 465130 400895 361295 294455 225765 170900 158100 164400 135965 103240 42430 15895 20100 15 5632525 
Male 565365 839785 995920 748055 503885 524395 477380 419245 323395 251135 179585 164815 173265 126625 109820 46730 17060 14435 3310 6484205 Mazandaran 
Female 541175 812645 971125 760545 586045 544285 482795 427340 336865 263280 183285 158970 158780 117885 96330 43150 18570 19985 2780 6525835 
Male 418015 562305 558460 410735 279660 254100 229860 206915 152155 107520 82590 71645 80635 60950 46210 17100 5840 6380 360 3551435 Golestan 
Female 401700 534325 547430 441780 337730 264660 233935 202330 156045 120675 86715 65945 69275 51645 36800 15620 5495 7615 285 3580005 
Male 569315 766040 811655 631430 433615 349040 300695 284890 228100 150120 108650 107640 117125 91895 80490 34025 12940 12615 725 5091005 Kerman 
Female 543060 745415 797785 601965 424285 353470 307470 279345 218510 154525 108085 98840 100350 77030 66435 28560 12365 12770 370 4930635 
Male 2315121 3215348 3539407 2729973 1815781 1753808 1542869 1383430 1076443 799492 597751 562526 613786 479573 384032 146077 53655 49535 4777 23063384
Female 2211457 3094224 3449171 2775188 2064590 1799777 1559803 1387762 1099979 837397 607861 531223 542137 424829 332061 137540 55841 66870 3550 22981260
P
erson-years 
5 Provinces 
Both 4526578 6309572 6988578 5505161 3880371 3553585 3102672 2771192 2176422 1636889 1205612 1093749 1155923 904402 716093 283617 109496 116405 8327 46044644
 
  
 
Appendix Table 2. Number of cases by site and age group, male 
Age group Site 
0–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85+ Unknown Total 
Lip 0 0 0 1 2 1 3 3 3 5 10 11 15 18 21 12 3 1 6 115 
Tongue 0 0 0 0 1 0 1 2 2 5 3 4 11 6 9 2 1 1 2 50 
Mouth 0 1 0 0 0 1 3 1 4 5 9 5 10 3 11 4 2 4 5 68 
Salivary glands 1 0 0 1 3 1 1 5 3 4 1 4 8 6 2 0 1 0 1 42 
Tonsil 0 1 0 0 0 0 0 0 1 2 0 1 2 1 4 1 0 0 0 13 
Other oropharynx 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 2 
Nasopharynx 3 0 2 4 6 3 4 4 9 11 9 5 11 10 8 5 1 0 6 101 
Hypopharynx 0 0 0 0 0 1 0 3 3 5 6 0 0 2 3 1 1 0 2 27 
Pharynx unspecified 0 0 0 0 0 0 0 0 5 0 2 3 6 13 5 3 1 1 1 40 
Esophagus 3 1 2 3 1 17 25 31 54 68 134 121 295 257 381 189 54 26 89 1751 
Stomach 7 6 7 8 13 29 40 57 77 128 198 282 578 581 640 310 100 36 200 3297 
Small intestine 0 1 1 0 1 1 2 3 4 4 6 8 7 9 9 7 2 0 6 71 
Colon 4 1 6 9 21 18 27 31 42 46 42 52 71 65 77 35 12 7 44 610 
Rectum 0 0 0 0 5 12 10 18 26 24 30 26 40 38 43 31 8 3 32 346 
Anus 0 0 0 0 1 2 4 3 1 3 4 6 4 3 4 1 2 0 1 39 
Liver 1 1 0 0 2 5 3 5 12 10 14 14 28 29 37 17 2 2 17 199 
Gallbladder  0 0 0 0 0 0 0 2 7 4 6 5 16 19 13 10 5 6 3 96 
Pancreas 0 2 0 0 1 2 1 3 10 10 10 13 26 39 30 15 4 1 28 195 
Nose, sinuses 1 1 2 0 1 0 3 3 1 2 2 5 3 3 5 2 1 0 1 36 
Larynx 0 2 0 0 1 4 3 7 27 26 30 34 73 63 57 40 4 4 37 412 
Lung 1 2 0 2 2 6 13 7 19 33 59 71 171 168 196 95 31 11 56 943 
Other thoracic organs 1 2 0 0 2 0 3 4 4 1 1 8 10 7 4 4 2 0 2 55 
Bone 3 2 19 44 16 13 7 5 6 6 8 13 13 12 9 6 1 0 10 193 
Melanoma of skin 1 0 1 0 1 1 5 4 8 3 2 4 20 8 11 12 3 1 5 90 
Other skin 6 8 10 10 13 21 33 41 107 126 131 123 158 208 218 148 69 39 115 1584 
Mesothelioma 0 0 0 1 0 0 1 1 0 0 0 0 0 0 2 1 0 0 0 6 
Kaposi sarcoma 0 0 0 1 1 0 2 1 2 1 2 0 4 6 0 2 0 1 1 24 
Connective & soft tissue 5 3 5 6 4 4 6 5 6 11 9 5 13 8 4 3 3 1 15 116 
Breast 1 0 0 1 1 1 7 9 23 25 19 11 18 6 14 9 2 2 8 157 
Penis 0 0 0 0 0 0 0 0 1 0 1 1 4 2 1 0 0 3 0 13 
Prostate 5 5 1 1 6 4 1 4 3 5 16 24 75 107 195 114 37 17 195 815 
Testis 5 1 2 13 18 27 37 29 15 12 7 3 5 1 4 2 2 0 11 194 
Other male genitalia 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 
Kidney 12 13 2 3 3 0 5 3 5 10 14 17 35 25 22 11 2 2 12 196 
Renal pelvis 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1 2 
Ureter 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 
Bladder 2 1 8 2 9 7 16 23 26 66 61 85 154 176 203 122 27 18 76 1082 
Other urinary organs 0 0 0 0 0 0 0 0 0 0 0 0 0 1 2 0 0 0 0 3 
Eye 2 2 1 0 1 0 2 0 0 0 1 0 1 0 5 1 2 2 1 21 
Brain, nervous system 9 33 25 18 19 13 31 22 23 33 27 32 24 29 22 11 2 2 19 394 
Thyroid 1 1 0 1 6 4 12 10 9 7 9 8 9 7 7 5 1 1 16 114 
Adrenal gland 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 
Other endocrine 0 2 0 1 2 2 1 1 1 1 0 2 2 0 0 0 0 0 3 18 
Hodgkin disease 6 18 23 22 26 16 16 20 14 12 12 14 11 8 5 5 1 0 14 243 
Non-Hodgkin lymphoma 20 28 34 23 24 24 22 32 46 27 43 57 46 48 59 22 11 8 29 603 
Immunoproliferative 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0 2 
Multiple myeloma 2 1 2 2 1 2 3 4 3 14 14 15 34 26 17 14 2 1 11 168 
Lymphoid leukemia 0 9 8 4 2 1 1 1 3 9 9 9 15 15 11 10 4 2 5 118 
Myeloid leukemia 1 3 0 5 5 3 9 3 6 3 3 3 5 3 0 2 0 1 6 61 
Leukemia unspecified 54 90 72 54 31 21 24 12 14 13 8 15 19 13 20 9 4 2 32 507 
Other and unspecified 27 26 26 24 27 19 39 29 34 30 50 51 69 91 86 48 19 8 53 756 
All sites 184 267 262 264 279 286 426 452 669 810 1023 1170 2119 2140 2478 1341 429 216 1177 15992 
All sites excluding skin 178 259 252 254 266 265 393 411 562 684 892 1047 1961 1932 2260 1193 360 177 1062 14408 
 
  
Appendix Table 3. Number of cases by site and age group, female 
  Age group 
Site 0–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85+ Unknown Total 
Lip 1 0 0 2 0 1 1 2 2 2 2 5 12 7 7 4 2 1 2 53 
Tongue 0 0 0 1 0 0 3 2 2 6 5 1 17 3 13 5 1 2 7 68 
Mouth 0 1 2 1 0 2 3 1 2 1 9 2 9 12 7 8 1 0 1 62 
Salivary glands 0 1 0 1 1 4 3 2 1 3 4 3 2 1 2 0 0 0 6 34 
Tonsil 0 0 0 0 0 0 0 0 0 0 0 2 1 2 2 1 0 0 0 8 
Other oropharynx 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Nasopharynx 0 1 1 0 3 4 1 5 5 4 6 1 5 4 2 0 0 0 5 47 
Hypopharynx 0 0 0 0 0 0 2 0 0 2 7 2 1 5 9 1 0 0 0 29 
Pharynx unspecified 0 0 0 0 0 0 0 1 4 1 4 5 4 6 2 0 0 0 1 28 
Esophagus 1 1 0 4 2 8 14 22 65 83 117 125 224 170 175 81 33 24 81 1230 
Stomach 2 4 3 11 9 13 35 37 68 68 108 112 221 197 187 95 30 24 85 1309 
Small intestine 0 0 0 0 0 3 2 2 3 4 5 3 6 5 3 1 0 1 2 40 
Colon 3 0 2 8 14 16 16 45 42 53 54 63 68 71 55 29 7 7 41 594 
Rectum 0 0 0 0 6 9 10 16 20 21 30 38 45 21 29 12 11 5 23 296 
Anus 0 0 0 0 0 0 0 0 1 3 2 3 5 0 2 0 1 2 1 20 
Liver 4 1 3 2 1 4 2 5 7 14 11 3 20 19 21 4 0 1 9 131 
Gallbladder 1 0 1 1 0 3 2 2 8 7 10 8 32 18 34 14 4 1 10 156 
Pancreas 0 1 1 0 0 3 0 5 4 5 11 8 7 20 24 11 4 6 16 126 
Nose, sinuses 0 0 1 0 0 1 0 0 0 3 1 2 3 0 3 1 1 0 2 18 
Larynx 2 0 0 0 2 0 2 5 3 4 7 8 8 8 11 2 1 0 3 66 
Lung 0 0 3 2 4 2 2 8 11 15 14 20 25 36 43 18 4 1 16 224 
Other thoracic organs 0 0 0 1 1 0 3 1 5 1 3 4 5 2 2 0 0 0 2 30 
Bone 2 7 26 18 18 7 7 4 3 5 6 0 8 6 4 6 2 0 3 132 
Melanoma of skin 0 1 1 1 1 0 5 3 6 4 2 9 6 4 9 6 4 2 7 71 
Other skin 4 5 4 6 10 31 33 43 70 103 126 84 116 114 139 100 38 26 70 1122 
Mesothelioma 1 0 1 0 0 0 1 1 0 0 1 0 2 0 0 0 0 0 0 7 
Kaposi sarcoma 0 0 0 0 0 0 0 0 1 0 1 0 0 0 1 2 2 0 0 7 
Connective & soft tissue 3 4 1 6 4 7 4 5 8 4 11 3 4 9 4 1 1 1 15 95 
Breast 3 1 1 7 22 73 176 261 364 299 225 154 143 97 89 52 15 10 128 2120 
Vulva 2 0 0 0 0 0 1 0 0 0 1 2 3 2 3 1 1 0 1 17 
Vagina 2 0 1 2 1 0 2 1 0 4 3 3 5 8 2 2 0 0 3 39 
Cervix uteri 1 0 0 0 2 3 23 38 35 37 52 41 32 26 11 14 3 2 13 333 
Corpus uteri 0 0 0 0 0 3 5 6 9 9 20 20 26 25 6 5 2 1 11 148 
Uterus unspecified 0 0 1 1 3 10 10 9 19 20 18 11 20 14 8 2 1 2 15 164 
Ovary 1 2 8 20 16 21 24 32 30 28 24 26 33 18 17 8 0 2 24 334 
Other female genitalia 0 0 0 0 3 2 2 0 1 0 1 3 2 4 2 0 0 0 1 21 
Placenta 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 2 
Kidney 15 7 1 2 2 2 3 4 8 9 9 7 11 9 6 5 3 0 10 113 
Renal pelvis 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Ureter 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 
Bladder 1 1 0 2 2 3 4 6 8 9 15 19 35 30 34 16 6 6 23 220 
Other urinary organs 0 0 0 0 0 0 0 0 0 0 1 0 2 0 0 0 0 0 0 3 
Eye 5 3 0 1 0 1 1 1 3 0 4 2 1 1 3 4 0 0 2 32 
Brain, nervous system 10 27 22 19 17 16 20 24 19 20 21 25 32 13 14 4 0 1 10 314 
Thyroid 0 0 7 7 14 25 35 33 42 27 17 14 14 20 19 5 1 0 57 337 
Adrenal gland 0 1 0 0 1 1 0 0 0 0 0 0 1 0 0 0 0 0 0 4 
Other endocrine 0 0 1 0 0 1 1 1 0 0 1 2 1 1 0 0 0 0 1 10 
Hodgkin disease 1 4 13 41 17 12 14 9 6 3 6 6 8 3 1 0 0 1 4 149 
Non-Hodgkin lymphoma 2 19 15 15 14 16 21 13 15 14 20 15 29 15 29 8 6 3 21 290 
Immunoproliferative 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 
Multiple myeloma 0 0 2 1 1 0 0 3 4 1 7 5 21 13 12 2 3 0 7 82 
Lymphoid leukemia 3 0 3 0 1 1 0 4 5 5 2 4 7 10 5 3 3 0 5 61 
Myeloid leukemia 3 1 3 6 3 7 3 1 2 3 3 2 6 1 2 2 1 0 3 52 
Leukaemia unspecified 43 44 45 30 20 9 9 12 20 16 16 11 11 12 15 9 5 0 23 350 
Other and unspecified 9 19 19 22 24 19 22 22 35 39 29 35 46 48 38 24 8 7 65 530 
All sites 125 156 192 241 239 343 527 698 966 960 1052 921 1346 1111 1106 568 205 139 835 11730 
All sites excluding skin 121 151 188 235 229 312 494 655 896 857 926 837 1230 997 967 468 167 113 765 10608 
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Age-specific incidence rates after correction 
 
Corrections mentioned in the appendix have been explained on pages 76. 
 
Appendix Table 4. Age-specific incidence rates, male (corrected for cases of unknown ages 
and under-registration in elderly ages) 
Age-specific incidence rates (per 100,000 person-years) 
Sites 0–4 
5–9 
10–14 
15–19 
20–24 
25–29 
30–34 
35–39 
40–44 
45–49 
50–54 
55–59 
60–64 
65–69 
70–74 
75–79 
80–84 
85+ 
C
rude rate 
(/100,000) 
Lip 0.00 0.00 0.00 0.04 0.11 0.06 0.19 0.22 0.28 0.63 1.67 1.96 2.44 3.75 5.47 8.21 8.83 10.50 0.52 
Tongue 0.00 0.00 0.00 0.00 0.06 0.00 0.06 0.14 0.19 0.63 0.50 0.71 1.79 1.25 2.34 1.37 2.39 2.32 0.22 
Mouth 0.00 0.03 0.00 0.00 0.00 0.06 0.19 0.07 0.37 0.63 1.51 0.89 1.63 0.63 2.86 2.74 3.61 3.92 0.29 
Salivary glands 0.04 0.00 0.00 0.04 0.17 0.06 0.06 0.36 0.28 0.50 0.17 0.71 1.30 1.25 0.52 0.00 0.34 0.21 0.18 
Tonsil 0.00 0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.09 0.25 0.00 0.18 0.33 0.21 1.04 0.68 1.11 1.11 0.06 
Other oropharynx 0.00 0.00 0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.26 0.00 0.17 0.10 0.01 
Nasopharynx 0.13 0.00 0.06 0.15 0.33 0.17 0.26 0.29 0.84 1.38 1.51 0.89 1.79 2.09 2.08 3.42 3.55 4.30 0.45 
Hypopharynx 0.00 0.00 0.00 0.00 0.00 0.06 0.00 0.22 0.28 0.63 1.00 0.00 0.00 0.42 0.78 0.68 0.95 1.00 0.12 
Pharynx unspecified 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.46 0.00 0.33 0.53 0.98 2.71 1.30 2.05 2.16 2.60 0.18 
Esophagus 0.13 0.03 0.06 0.11 0.06 0.97 1.62 2.24 5.02 8.51 22.42 21.51 48.06 53.59 99.21 129.38 147.46 170.63 7.95 
Stomach 0.30 0.19 0.20 0.29 0.72 1.65 2.59 4.12 7.15 16.01 33.12 50.13 94.17 121.15 166.65 212.22 244.40 281.42 14.88 
Small intestine 0.00 0.03 0.03 0.00 0.06 0.06 0.13 0.22 0.37 0.50 1.00 1.42 1.14 1.88 2.34 4.79 4.60 5.79 0.32 
Colon 0.17 0.03 0.17 0.33 1.16 1.03 1.75 2.24 3.90 5.75 7.03 9.24 11.57 13.55 20.05 23.96 28.39 32.26 2.70 
Rectum 0.00 0.00 0.00 0.00 0.28 0.68 0.65 1.30 2.42 3.00 5.02 4.62 6.52 7.92 11.20 21.22 20.91 25.97 1.56 
Anus 0.00 0.00 0.00 0.00 0.06 0.11 0.26 0.22 0.09 0.38 0.67 1.07 0.65 0.63 1.04 0.68 1.11 1.11 0.17 
Liver 0.04 0.03 0.00 0.00 0.11 0.29 0.19 0.36 1.11 1.25 2.34 2.49 4.56 6.05 9.63 11.64 13.72 15.63 0.91 
Gallbladder 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.14 0.65 0.50 1.00 0.89 2.61 3.96 3.39 6.85 6.60 8.29 0.40 
Pancreas 0.00 0.06 0.00 0.00 0.06 0.11 0.06 0.22 0.93 1.25 1.67 2.31 4.24 8.13 7.81 10.27 11.66 13.52 0.88 
Nose, sinuses 0.04 0.03 0.06 0.00 0.06 0.00 0.19 0.22 0.09 0.25 0.33 0.89 0.49 0.63 1.30 1.37 1.72 1.91 0.16 
Larynx 0.00 0.06 0.00 0.00 0.06 0.23 0.19 0.51 2.51 3.25 5.02 6.04 11.89 13.14 14.84 27.38 27.24 33.66 1.89 
Lung 0.04 0.06 0.00 0.07 0.11 0.34 0.84 0.51 1.77 4.13 9.87 12.62 27.86 35.03 51.04 65.03 74.88 86.23 4.27 
Other thoracic organs 0.04 0.06 0.00 0.00 0.11 0.00 0.19 0.29 0.37 0.13 0.17 1.42 1.63 1.46 1.04 2.74 2.44 3.19 0.24 
Bone 0.13 0.06 0.54 1.61 0.88 0.74 0.45 0.36 0.56 0.75 1.34 2.31 2.12 2.50 2.34 4.11 4.16 5.10 0.85 
Melanoma of skin 0.04 0.00 0.03 0.00 0.06 0.06 0.32 0.29 0.74 0.38 0.33 0.71 3.26 1.67 2.86 8.21 7.15 9.47 0.41 
Other skin 0.26 0.25 0.28 0.37 0.72 1.20 2.14 2.96 9.94 15.76 21.92 21.87 25.74 43.37 56.77 101.32 101.98 125.29 6.91 
Mesothelioma 0.00 0.00 0.00 0.04 0.00 0.00 0.06 0.07 0.00 0.00 0.00 0.00 0.00 0.00 0.52 0.68 0.78 0.90 0.03 
Kaposi sarcoma 0.00 0.00 0.00 0.04 0.06 0.00 0.13 0.07 0.19 0.13 0.33 0.00 0.65 1.25 0.00 1.37 0.88 1.39 0.10 
Connective & soft tissue 0.22 0.09 0.14 0.22 0.22 0.23 0.39 0.36 0.56 1.38 1.51 0.89 2.12 1.67 1.04 2.05 2.00 2.50 0.50 
Breast 0.04 0.00 0.00 0.04 0.06 0.06 0.45 0.65 2.14 3.13 3.18 1.96 2.93 1.25 3.65 6.16 6.33 7.70 0.69 
Vulva 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Vagina 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Cervix uteri 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Corpus uteri 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Kidney 0.52 0.40 0.06 0.11 0.17 0.00 0.32 0.22 0.46 1.25 2.34 3.02 5.70 5.21 5.73 7.53 8.55 9.91 0.87 
Renal pelvis 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.07 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 
Ureter 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Bladder 0.09 0.03 0.23 0.07 0.50 0.40 1.04 1.66 2.42 8.26 10.20 15.11 25.09 36.70 52.86 83.52 87.97 105.69 4.93 
Other urinary organs 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.21 0.52 0.00 0.34 0.21 0.01 
Eye 0.09 0.06 0.03 0.00 0.06 0.00 0.13 0.00 0.00 0.00 0.17 0.00 0.16 0.00 1.30 0.68 1.28 1.21 0.08 
Brain, nervous system 0.39 1.03 0.71 0.66 1.05 0.74 2.01 1.59 2.14 4.13 4.52 5.69 3.91 6.05 5.73 7.53 8.55 9.91 1.73 
Thyroid 0.04 0.03 0.00 0.04 0.33 0.23 0.78 0.72 0.84 0.88 1.51 1.42 1.47 1.46 1.82 3.42 3.38 4.20 0.50 
Adrenal gland 0.00 0.00 0.06 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 
Other endocrine 0.00 0.06 0.00 0.04 0.11 0.11 0.06 0.07 0.09 0.13 0.00 0.36 0.33 0.00 0.00 0.00 0.00 0.00 0.08 
Hodgkin disease 0.26 0.56 0.65 0.81 1.43 0.91 1.04 1.45 1.30 1.50 2.01 2.49 1.79 1.67 1.30 3.42 3.05 3.99 1.06 
NH lymphoma 0.86 0.87 0.96 0.84 1.32 1.37 1.43 2.31 4.27 3.38 7.19 10.13 7.49 10.01 15.36 15.06 19.63 21.38 2.62 
Immunoproliferative 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.17 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Multiple myeloma 0.09 0.03 0.06 0.07 0.06 0.11 0.19 0.29 0.28 1.75 2.34 2.67 5.54 5.42 4.43 9.58 9.04 11.48 0.76 
Lymphoid leukemia 0.00 0.28 0.23 0.15 0.11 0.06 0.06 0.07 0.28 1.13 1.51 1.60 2.44 3.13 2.86 6.85 6.26 8.08 0.52 
Myeloid leukemia 0.04 0.09 0.00 0.18 0.28 0.17 0.58 0.22 0.56 0.38 0.50 0.53 0.81 0.63 0.00 1.37 0.88 1.39 0.27 
Leukemia unspecified 2.33 2.80 2.03 1.98 1.71 1.20 1.56 0.87 1.30 1.63 1.34 2.67 3.10 2.71 5.21 6.16 7.33 8.32 2.21 
Other and unspecified 1.17 0.81 0.73 0.88 1.49 1.08 2.53 2.10 3.16 3.75 8.36 9.07 11.24 18.98 22.39 32.86 35.64 42.22 3.33 
All sites 7.95 8.30 7.40 9.67 15.37 16.31 27.61 32.67 62.15 101.31 171.14 207.99 345.23 446.23 645.26 918.01 1008.44 1187.31 71.44 
All sites excluding skin 7.69 8.06 7.12 9.30 14.65 15.11 25.47 29.71 52.21 85.55 149.23 186.12 319.49 402.86 588.49 816.69 906.46 1062.02 64.53 
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Appendix Table 5. Age-specific incidence rates, female (corrected for cases of unknown 
ages and elderly ages) 
Age-specific incidence rates (per 100,000 person-years) 
Sites 0–4 
5–9 
10–14 
15–19 
20–24 
25–29 
30–34 
35–39 
40–44 
45–49 
50–54 
55–59 
60–64 
65–69 
70–74 
75–79 
80–84 
85+ 
Crude 
rate 
(/100,000) 
Lip 0.05 0.00 0.00 0.07 0.00 0.06 0.06 0.14 0.18 0.24 0.33 0.94 2.21 1.65 2.11 2.91 3.24 3.79 0.24 
Tongue 0.00 0.00 0.00 0.04 0.00 0.00 0.19 0.14 0.18 0.72 0.82 0.19 3.14 0.71 3.91 3.64 4.87 5.24 0.31 
Mouth 0.00 0.03 0.06 0.04 0.00 0.11 0.19 0.07 0.18 0.12 1.48 0.38 1.66 2.82 2.11 5.82 5.11 6.74 0.30 
Salivary glands 0.00 0.03 0.00 0.04 0.05 0.22 0.19 0.14 0.09 0.36 0.66 0.56 0.37 0.24 0.60 0.00 0.39 0.24 0.15 
Tonsil 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.38 0.18 0.47 0.60 0.73 0.86 0.98 0.04 
Other oropharynx 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Nasopharynx 0.00 0.03 0.03 0.00 0.15 0.22 0.06 0.36 0.45 0.48 0.99 0.19 0.92 0.94 0.60 0.00 0.39 0.24 0.21 
Hypopharynx 0.00 0.00 0.00 0.00 0.00 0.00 0.13 0.00 0.00 0.24 1.15 0.38 0.18 1.18 2.71 0.73 2.22 1.81 0.14 
Pharynx unspecified 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.07 0.36 0.12 0.66 0.94 0.74 1.41 0.60 0.00 0.39 0.24 0.12 
Esophagus 0.05 0.03 0.00 0.14 0.10 0.44 0.90 1.59 5.91 9.91 19.25 23.53 41.32 40.02 52.70 58.89 71.99 80.66 5.51 
Stomach 0.09 0.13 0.09 0.40 0.44 0.72 2.24 2.67 6.18 8.12 17.77 21.08 40.76 46.37 56.31 69.07 80.88 92.42 5.93 
Small intestine 0.00 0.00 0.00 0.00 0.00 0.17 0.13 0.14 0.27 0.48 0.82 0.56 1.11 1.18 0.90 0.73 1.05 1.10 0.18 
Colon 0.14 0.00 0.06 0.29 0.68 0.89 1.03 3.24 3.82 6.33 8.88 11.86 12.54 16.71 16.56 21.08 24.29 27.96 2.66 
Rectum 0.00 0.00 0.00 0.00 0.29 0.50 0.64 1.15 1.82 2.51 4.94 7.15 8.30 4.94 8.73 8.72 11.26 12.32 1.28 
Anus 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.09 0.36 0.33 0.56 0.92 0.00 0.60 0.00 0.39 0.24 0.08 
Liver 0.18 0.03 0.09 0.07 0.05 0.22 0.13 0.36 0.64 1.67 1.81 0.56 3.69 4.47 6.32 2.91 5.96 5.46 0.60 
Gallbladder 0.05 0.00 0.03 0.04 0.00 0.17 0.13 0.14 0.73 0.84 1.65 1.51 5.90 4.24 10.24 10.18 13.17 14.39 0.73 
Pancreas 0.00 0.03 0.03 0.00 0.00 0.17 0.00 0.36 0.36 0.60 1.81 1.51 1.29 4.71 7.23 8.00 9.82 10.98 0.56 
Nose, sinuses 0.00 0.00 0.03 0.00 0.00 0.06 0.00 0.00 0.00 0.36 0.16 0.38 0.55 0.00 0.90 0.73 1.05 1.10 0.08 
Larynx 0.09 0.00 0.00 0.00 0.10 0.00 0.13 0.36 0.27 0.48 1.15 1.51 1.48 1.88 3.31 1.45 3.07 2.79 0.30 
Lung 0.00 0.00 0.09 0.07 0.19 0.11 0.13 0.58 1.00 1.79 2.30 3.76 4.61 8.47 12.95 13.09 16.80 18.42 1.05 
Other thoracic organs 0.00 0.00 0.00 0.04 0.05 0.00 0.19 0.07 0.45 0.12 0.49 0.75 0.92 0.47 0.60 0.00 0.39 0.24 0.13 
Bone 0.09 0.23 0.75 0.65 0.87 0.39 0.45 0.29 0.27 0.60 0.99 0.00 1.48 1.41 1.20 4.36 3.59 4.90 0.59 
Melanoma of skin 0.00 0.03 0.03 0.04 0.05 0.00 0.32 0.22 0.55 0.48 0.33 1.69 1.11 0.94 2.71 4.36 4.56 5.50 0.31 
Other skin 0.18 0.16 0.12 0.22 0.48 1.72 2.12 3.10 6.36 12.30 20.73 15.81 21.40 26.83 41.86 72.71 73.90 90.36 5.05 
Mesothelioma 0.05 0.00 0.03 0.00 0.00 0.00 0.06 0.07 0.00 0.00 0.16 0.00 0.37 0.00 0.00 0.00 0.00 0.00 0.03 
Kaposi sarcoma 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.09 0.00 0.16 0.00 0.00 0.00 0.30 1.45 1.13 1.59 0.03 
Connective & soft tissue 0.14 0.13 0.03 0.22 0.19 0.39 0.26 0.36 0.73 0.48 1.81 0.56 0.74 2.12 1.20 0.73 1.25 1.22 0.41 
Breast 0.14 0.03 0.03 0.25 1.07 4.06 11.28 18.81 33.09 35.71 37.02 28.99 26.38 22.83 26.80 37.81 41.68 48.99 9.36 
Vulva 0.09 0.00 0.00 0.00 0.00 0.00 0.06 0.00 0.00 0.00 0.16 0.38 0.55 0.47 0.90 0.73 1.05 1.10 0.08 
Vagina 0.09 0.00 0.03 0.07 0.05 0.00 0.13 0.07 0.00 0.48 0.49 0.56 0.92 1.88 0.60 1.45 1.33 1.71 0.18 
Cervix uteri 0.05 0.00 0.00 0.00 0.10 0.17 1.47 2.74 3.18 4.42 8.55 7.72 5.90 6.12 3.31 10.18 8.70 11.64 1.48 
Corpus uteri 0.00 0.00 0.00 0.00 0.00 0.17 0.32 0.43 0.82 1.07 3.29 3.76 4.80 5.88 1.81 3.64 3.51 4.40 0.65 
Uterus unspecified 0.00 0.00 0.03 0.04 0.15 0.56 0.64 0.65 1.73 2.39 2.96 2.07 3.69 3.30 2.41 1.45 2.49 2.43 0.71 
Ovary 0.05 0.06 0.23 0.72 0.77 1.17 1.54 2.31 2.73 3.34 3.95 4.89 6.09 4.24 5.12 5.82 7.05 7.93 1.48 
Other female genitalia 0.00 0.00 0.00 0.00 0.15 0.11 0.13 0.00 0.09 0.00 0.16 0.56 0.37 0.94 0.60 0.00 0.39 0.24 0.09 
Placenta 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.07 0.00 0.12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 
Kidney 0.68 0.23 0.03 0.07 0.10 0.11 0.19 0.29 0.73 1.07 1.48 1.32 2.03 2.12 1.81 3.64 3.51 4.40 0.50 
Renal pelvis 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Ureter 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.24 0.00 0.00 0.00 0.00 0.00 
Bladder 0.05 0.03 0.00 0.07 0.10 0.17 0.26 0.43 0.73 1.07 2.47 3.58 6.46 7.06 10.24 11.63 14.11 15.87 0.99 
Other urinary organs 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.16 0.00 0.37 0.00 0.00 0.00 0.00 0.00 0.01 
Eye 0.23 0.10 0.00 0.04 0.00 0.06 0.06 0.07 0.27 0.00 0.66 0.38 0.18 0.24 0.90 2.91 2.46 3.31 0.15 
Brain, nervous system 0.45 0.87 0.64 0.68 0.82 0.89 1.28 1.73 1.73 2.39 3.45 4.71 5.90 3.06 4.22 2.91 4.60 4.62 1.39 
Thyroid 0.00 0.00 0.20 0.25 0.68 1.39 2.24 2.38 3.82 3.22 2.80 2.64 2.58 4.71 5.72 3.64 6.04 5.96 1.49 
Adrenal gland 0.00 0.03 0.00 0.00 0.05 0.06 0.00 0.00 0.00 0.00 0.00 0.00 0.18 0.00 0.00 0.00 0.00 0.00 0.02 
Other endocrine 0.00 0.00 0.03 0.00 0.00 0.06 0.06 0.07 0.00 0.00 0.16 0.38 0.18 0.24 0.00 0.00 0.00 0.00 0.04 
Hodgkin disease 0.05 0.13 0.38 1.48 0.82 0.67 0.90 0.65 0.55 0.36 0.99 1.13 1.48 0.71 0.30 0.00 0.19 0.12 0.64 
NH lymphoma 0.09 0.61 0.43 0.54 0.68 0.89 1.35 0.94 1.36 1.67 3.29 2.82 5.35 3.53 8.73 5.82 9.39 9.37 1.27 
Immunoproliferative 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.18 0.00 0.00 0.00 0.00 0.00 0.00 
Multiple myeloma 0.00 0.00 0.06 0.04 0.05 0.00 0.00 0.22 0.36 0.12 1.15 0.94 3.87 3.06 3.61 1.45 3.27 2.91 0.36 
Lymphoid leukemia 0.14 0.00 0.09 0.00 0.05 0.06 0.00 0.29 0.45 0.60 0.33 0.75 1.29 2.35 1.51 2.18 2.38 2.81 0.27 
Myeloid leukemia 0.14 0.03 0.09 0.22 0.15 0.39 0.19 0.07 0.18 0.36 0.49 0.38 1.11 0.24 0.60 1.45 1.33 1.71 0.23 
Leukemia unspecified 1.94 1.42 1.30 1.08 0.97 0.50 0.58 0.86 1.82 1.91 2.63 2.07 2.03 2.82 4.52 6.54 7.14 8.43 1.54 
Other and unspecified 0.41 0.61 0.55 0.79 1.16 1.06 1.41 1.59 3.18 4.66 4.77 6.59 8.48 11.30 11.44 17.45 18.64 22.24 2.35 
All sites 5.65 5.04 5.57 8.68 11.58 19.06 33.79 50.30 87.82 114.64 173.07 173.37 248.28 261.52 333.07 412.97 481.26 551.13 52.32 
All sites excluding skin 5.47 4.88 5.45 8.47 11.09 17.34 31.67 47.20 81.46 102.34 152.34 157.56 226.88 234.68 291.21 340.26 407.35 460.77 47.27 
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Age-specific incidence rates before correction 
 
Appendix Table 6. Age-specific incidence rates, male (before correction for elderly ages) 
Age-specific incidence rates (per 100,000 person-years) 
Sites 0–4 
5–9 
10–14 
15–19 
20–24 
25–29 
30–34 
35–39 
40–44 
45–49 
50–54 
55–59 
60–64 
65–69 
70–74 
75–79 
80–84 
85+ 
Total 
Lip 0.0 0.0 0.0 0.0 0.1 0.1 0.2 0.2 0.3 0.6 1.7 2.0 2.4 3.8 5.5 8.2 5.6 2.0 0.5 
Tongue 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.2 0.6 0.5 0.7 1.8 1.3 2.3 1.4 1.9 2.0 0.2 
Mouth 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.1 0.4 0.6 1.5 0.9 1.6 0.6 2.9 2.7 3.7 8.1 0.3 
Salivary glands 0.0 0.0 0.0 0.0 0.2 0.1 0.1 0.4 0.3 0.5 0.2 0.7 1.3 1.3 0.5 0.0 1.9 0.0 0.2 
Tonsil 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.0 0.2 0.3 0.2 1.0 0.7 0.0 0.0 0.1 
Other oropharynx 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 
Nasopharynx 0.1 0.0 0.1 0.1 0.3 0.2 0.3 0.3 0.8 1.4 1.5 0.9 1.8 2.1 2.1 3.4 1.9 0.0 0.4 
Hypopharynx 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.3 0.6 1.0 0.0 0.0 0.4 0.8 0.7 1.9 0.0 0.1 
Pharynx unspecified 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.3 0.5 1.0 2.7 1.3 2.1 1.9 2.0 0.2 
Esophagus 0.1 0.0 0.1 0.1 0.1 1.0 1.6 2.2 5.0 8.5 22.4 21.5 48.1 53.6 99.2 129.4 100.6 52.5 7.6 
Stomach 0.3 0.2 0.2 0.3 0.7 1.7 2.6 4.1 7.2 16.0 33.1 50.1 94.2 121.1 166.7 212.2 186.4 72.7 14.3 
Small intestine 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.2 0.4 0.5 1.0 1.4 1.1 1.9 2.3 4.8 3.7 0.0 0.3 
Colon 0.2 0.0 0.2 0.3 1.2 1.0 1.7 2.2 3.9 5.8 7.0 9.2 11.6 13.6 20.1 24.0 22.4 14.1 2.6 
Rectum 0.0 0.0 0.0 0.0 0.3 0.7 0.6 1.3 2.4 3.0 5.0 4.6 6.5 7.9 11.2 21.2 14.9 6.1 1.5 
Anus 0.0 0.0 0.0 0.0 0.1 0.1 0.3 0.2 0.1 0.4 0.7 1.1 0.7 0.6 1.0 0.7 3.7 0.0 0.2 
Liver 0.0 0.0 0.0 0.0 0.1 0.3 0.2 0.4 1.1 1.3 2.3 2.5 4.6 6.0 9.6 11.6 3.7 4.0 0.9 
Gallbladder 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.7 0.5 1.0 0.9 2.6 4.0 3.4 6.8 9.3 12.1 0.4 
Pancreas 0.0 0.1 0.0 0.0 0.1 0.1 0.1 0.2 0.9 1.3 1.7 2.3 4.2 8.1 7.8 10.3 7.5 2.0 0.8 
Nose, sinuses 0.0 0.0 0.1 0.0 0.1 0.0 0.2 0.2 0.1 0.3 0.3 0.9 0.5 0.6 1.3 1.4 1.9 0.0 0.2 
Larynx 0.0 0.1 0.0 0.0 0.1 0.2 0.2 0.5 2.5 3.3 5.0 6.0 11.9 13.1 14.8 27.4 7.5 8.1 1.8 
Lung, trachea & bronchus 0.0 0.1 0.0 0.1 0.1 0.3 0.8 0.5 1.8 4.1 9.9 12.6 27.9 35.0 51.0 65.0 57.8 22.2 4.1 
Other thoracic organs 0.0 0.1 0.0 0.0 0.1 0.0 0.2 0.3 0.4 0.1 0.2 1.4 1.6 1.5 1.0 2.7 3.7 0.0 0.2 
Bone 0.1 0.1 0.5 1.6 0.9 0.7 0.5 0.4 0.6 0.8 1.3 2.3 2.1 2.5 2.3 4.1 1.9 0.0 0.8 
Melanoma of skin 0.0 0.0 0.0 0.0 0.1 0.1 0.3 0.3 0.7 0.4 0.3 0.7 3.3 1.7 2.9 8.2 5.6 2.0 0.4 
Other skin 0.3 0.2 0.3 0.4 0.7 1.2 2.1 3.0 9.9 15.8 21.9 21.9 25.7 43.4 56.8 101.3 128.6 78.7 6.9 
Mesothelioma 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.7 0.0 0.0 0.0 
Kaposi sarcoma 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.2 0.1 0.3 0.0 0.7 1.3 0.0 1.4 0.0 2.0 0.1 
Connective &  soft tissue 0.2 0.1 0.1 0.2 0.2 0.2 0.4 0.4 0.6 1.4 1.5 0.9 2.1 1.7 1.0 2.1 5.6 2.0 0.5 
Breast 0.0 0.0 0.0 0.0 0.1 0.1 0.5 0.7 2.1 3.1 3.2 2.0 2.9 1.3 3.6 6.2 3.7 4.0 0.7 
Vulva 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Vagina 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Cervix uteri 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Corpus uteri 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Uterus unspecified 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Ovary 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Other female genital org. 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Placenta 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Penis 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.2 0.7 0.4 0.3 0.0 0.0 6.1 0.1 
Prostate 0.2 0.2 0.0 0.0 0.3 0.2 0.1 0.3 0.3 0.6 2.7 4.3 12.2 22.3 50.8 78.0 69.0 34.3 3.5 
Testis 0.2 0.0 0.1 0.5 1.0 1.5 2.4 2.1 1.4 1.5 1.2 0.5 0.8 0.2 1.0 1.4 3.7 0.0 0.8 
Other male genital organ 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 
Kidney 0.5 0.4 0.1 0.1 0.2 0.0 0.3 0.2 0.5 1.3 2.3 3.0 5.7 5.2 5.7 7.5 3.7 4.0 0.8 
Renal pelvis 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Ureter 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.0 0.0 
Bladder 0.1 0.0 0.2 0.1 0.5 0.4 1.0 1.7 2.4 8.3 10.2 15.1 25.1 36.7 52.9 83.5 50.3 36.3 4.7 
Other urinary organs 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.5 0.0 0.0 0.0 0.0 
Eye 0.1 0.1 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.2 0.0 1.3 0.7 3.7 4.0 0.1 
Brain, nervous system 0.4 1.0 0.7 0.7 1.0 0.7 2.0 1.6 2.1 4.1 4.5 5.7 3.9 6.0 5.7 7.5 3.7 4.0 1.7 
Thyroid 0.0 0.0 0.0 0.0 0.3 0.2 0.8 0.7 0.8 0.9 1.5 1.4 1.5 1.5 1.8 3.4 1.9 2.0 0.5 
Adrenal gland 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Other endocrine 0.0 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.4 0.3 0.0 0.0 0.0 0.0 0.0 0.1 
Hodgkin disease 0.3 0.6 0.6 0.8 1.4 0.9 1.0 1.4 1.3 1.5 2.0 2.5 1.8 1.7 1.3 3.4 1.9 0.0 1.1 
Non-Hodgkin lymphoma 0.9 0.9 1.0 0.8 1.3 1.4 1.4 2.3 4.3 3.4 7.2 10.1 7.5 10.0 15.4 15.1 20.5 16.2 2.6 
Immunoproliferative 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 2.0 0.0 
Multiple myeloma 0.1 0.0 0.1 0.1 0.1 0.1 0.2 0.3 0.3 1.8 2.3 2.7 5.5 5.4 4.4 9.6 3.7 2.0 0.7 
Lymphoid leukemia 0.0 0.3 0.2 0.1 0.1 0.1 0.1 0.1 0.3 1.1 1.5 1.6 2.4 3.1 2.9 6.8 7.5 4.0 0.5 
Myeloid leukemia 0.0 0.1 0.0 0.2 0.3 0.2 0.6 0.2 0.6 0.4 0.5 0.5 0.8 0.6 0.0 1.4 0.0 2.0 0.3 
Leukemia unspecified 2.3 2.8 2.0 2.0 1.7 1.2 1.6 0.9 1.3 1.6 1.3 2.7 3.1 2.7 5.2 6.2 7.5 4.0 2.2 
Other and unspecified 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
All sites 6.8 7.5 6.7 8.8 13.9 15.2 25.1 30.6 59.0 97.6 162.8 198.9 334.0 427.3 622.9 885.1 764.1 419.9 66.1 
All sites excluding skin 6.5 7.2 6.4 8.4 13.2 14.0 22.9 27.6 49.1 81.8 140.9 177.1 308.3 383.9 566.1 783.8 635.5 341.2 59.2 
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Appendix Table 7. Age-specific incidence rates, female (before correction for elderly ages) 
Age-specific incidence rates (per 100,000 person-years) 
Sites 0–4 
5–9 
10-14 
15-19 
20-24 
25-29 
30-34 
35-39 
40-44 
45-49 
50-54 
55-59 
60-64 
65-69 
70-74 
75-79 
80-84 
85+ 
Total 
Lip 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.1 0.2 0.2 0.3 0.9 2.2 1.6 2.1 2.9 3.6 1.5 0.2 
Tongue 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.2 0.7 0.8 0.2 3.1 0.7 3.9 3.6 1.8 3.0 0.3 
Mouth 0.0 0.0 0.1 0.0 0.0 0.1 0.2 0.1 0.2 0.1 1.5 0.4 1.7 2.8 2.1 5.8 1.8 0.0 0.3 
Salivary glands 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.1 0.1 0.4 0.7 0.6 0.4 0.2 0.6 0.0 0.0 0.0 0.1 
Tonsil 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.2 0.5 0.6 0.7 0.0 0.0 0.0 
Other oropharynx 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Nasopharynx 0.0 0.0 0.0 0.0 0.1 0.2 0.1 0.4 0.5 0.5 1.0 0.2 0.9 0.9 0.6 0.0 0.0 0.0 0.2 
Hypopharynx 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 1.2 0.4 0.2 1.2 2.7 0.7 0.0 0.0 0.1 
Pharynx unspecified 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.4 0.1 0.7 0.9 0.7 1.4 0.6 0.0 0.0 0.0 0.1 
Esophagus 0.0 0.0 0.0 0.1 0.1 0.4 0.9 1.6 5.9 9.9 19.2 23.5 41.3 40.0 52.7 58.9 59.1 35.9 5.4 
Stomach 0.1 0.1 0.1 0.4 0.4 0.7 2.2 2.7 6.2 8.1 17.8 21.1 40.8 46.4 56.3 69.1 53.7 35.9 5.7 
Small intestine 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.1 0.3 0.5 0.8 0.6 1.1 1.2 0.9 0.7 0.0 1.5 0.2 
Colon 0.1 0.0 0.1 0.3 0.7 0.9 1.0 3.2 3.8 6.3 8.9 11.9 12.5 16.7 16.6 21.1 12.5 10.5 2.6 
Rectum 0.0 0.0 0.0 0.0 0.3 0.5 0.6 1.2 1.8 2.5 4.9 7.2 8.3 4.9 8.7 8.7 19.7 7.5 1.3 
Anus 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.4 0.3 0.6 0.9 0.0 0.6 0.0 1.8 3.0 0.1 
Liver 0.2 0.0 0.1 0.1 0.0 0.2 0.1 0.4 0.6 1.7 1.8 0.6 3.7 4.5 6.3 2.9 0.0 1.5 0.6 
Gallbladder 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.1 0.7 0.8 1.6 1.5 5.9 4.2 10.2 10.2 7.2 1.5 0.7 
Pancreas 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.4 0.4 0.6 1.8 1.5 1.3 4.7 7.2 8.0 7.2 9.0 0.5 
Nose, sinuses 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.4 0.2 0.4 0.6 0.0 0.9 0.7 1.8 0.0 0.1 
Larynx 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.4 0.3 0.5 1.2 1.5 1.5 1.9 3.3 1.5 1.8 0.0 0.3 
Trachea, bronchus & lung 0.0 0.0 0.1 0.1 0.2 0.1 0.1 0.6 1.0 1.8 2.3 3.8 4.6 8.5 12.9 13.1 7.2 1.5 1.0 
Other thoracic organs 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.5 0.1 0.5 0.8 0.9 0.5 0.6 0.0 0.0 0.0 0.1 
Bone 0.1 0.2 0.8 0.6 0.9 0.4 0.4 0.3 0.3 0.6 1.0 0.0 1.5 1.4 1.2 4.4 3.6 0.0 0.6 
Melanoma of skin 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.2 0.5 0.5 0.3 1.7 1.1 0.9 2.7 4.4 7.2 3.0 0.3 
Other skin 0.2 0.2 0.1 0.2 0.5 1.7 2.1 3.1 6.4 12.3 20.7 15.8 21.4 26.8 41.9 72.7 68.1 38.9 4.9 
Mesothelioma 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.2 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 
Kaposi sarcoma 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.3 1.5 3.6 0.0 0.0 
Connective & soft tissue 0.1 0.1 0.0 0.2 0.2 0.4 0.3 0.4 0.7 0.5 1.8 0.6 0.7 2.1 1.2 0.7 1.8 1.5 0.4 
Breast 0.1 0.0 0.0 0.3 1.1 4.1 11.3 18.8 33.1 35.7 37.0 29.0 26.4 22.8 26.8 37.8 26.9 15.0 9.2 
Vulva 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.4 0.6 0.5 0.9 0.7 1.8 0.0 0.1 
Vagina 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.5 0.5 0.6 0.9 1.9 0.6 1.5 0.0 0.0 0.2 
Cervix uteri 0.0 0.0 0.0 0.0 0.1 0.2 1.5 2.7 3.2 4.4 8.6 7.7 5.9 6.1 3.3 10.2 5.4 3.0 1.4 
Corpus uteri 0.0 0.0 0.0 0.0 0.0 0.2 0.3 0.4 0.8 1.1 3.3 3.8 4.8 5.9 1.8 3.6 3.6 1.5 0.6 
Uterus unspecified 0.0 0.0 0.0 0.0 0.1 0.6 0.6 0.6 1.7 2.4 3.0 2.1 3.7 3.3 2.4 1.5 1.8 3.0 0.7 
Ovary 0.0 0.1 0.2 0.7 0.8 1.2 1.5 2.3 2.7 3.3 3.9 4.9 6.1 4.2 5.1 5.8 0.0 3.0 1.5 
Other female genital org. 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.0 0.2 0.6 0.4 0.9 0.6 0.0 0.0 0.0 0.1 
Placenta 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Kidney 0.7 0.2 0.0 0.1 0.1 0.1 0.2 0.3 0.7 1.1 1.5 1.3 2.0 2.1 1.8 3.6 5.4 0.0 0.5 
Renal pelvis 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Ureter 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 
Bladder 0.0 0.0 0.0 0.1 0.1 0.2 0.3 0.4 0.7 1.1 2.5 3.6 6.5 7.1 10.2 11.6 10.7 9.0 1.0 
Other urinary organs 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 
Eye 0.2 0.1 0.0 0.0 0.0 0.1 0.1 0.1 0.3 0.0 0.7 0.4 0.2 0.2 0.9 2.9 0.0 0.0 0.1 
Brain, nervous system 0.5 0.9 0.6 0.7 0.8 0.9 1.3 1.7 1.7 2.4 3.5 4.7 5.9 3.1 4.2 2.9 0.0 1.5 1.4 
Thyroid 0.0 0.0 0.2 0.3 0.7 1.4 2.2 2.4 3.8 3.2 2.8 2.6 2.6 4.7 5.7 3.6 1.8 0.0 1.5 
Adrenal gland 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 
Other endocrine 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.2 0.4 0.2 0.2 0.0 0.0 0.0 0.0 0.0 
Hodgkin disease 0.0 0.1 0.4 1.5 0.8 0.7 0.9 0.6 0.5 0.4 1.0 1.1 1.5 0.7 0.3 0.0 0.0 1.5 0.6 
Non-Hodgkin lymphoma 0.1 0.6 0.4 0.5 0.7 0.9 1.3 0.9 1.4 1.7 3.3 2.8 5.3 3.5 8.7 5.8 10.7 4.5 1.3 
Immunoproliferative 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 
Multiple myeloma 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.4 0.1 1.2 0.9 3.9 3.1 3.6 1.5 5.4 0.0 0.4 
Lymphoid leukemia 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.3 0.5 0.6 0.3 0.8 1.3 2.4 1.5 2.2 5.4 0.0 0.3 
Myeloid leukemia 0.1 0.0 0.1 0.2 0.1 0.4 0.2 0.1 0.2 0.4 0.5 0.4 1.1 0.2 0.6 1.5 1.8 0.0 0.2 
Leukemia unspecified 1.9 1.4 1.3 1.1 1.0 0.5 0.6 0.9 1.8 1.9 2.6 2.1 2.0 2.8 4.5 6.5 9.0 0.0 1.5 
Other and unspecified 0.4 0.6 0.6 0.8 1.2 1.1 1.4 1.6 3.2 4.7 4.8 6.6 8.5 11.3 11.4 17.4 14.3 10.5 2.3 
All sites 5.7 5.0 5.6 8.7 11.6 19.1 33.8 50.3 87.8 114.6 173.1 173.4 248.3 261.5 333.1 413.0 367.1 207.9 51.0 
All sites excluding skin 5.5 4.9 5.5 8.5 11.1 17.3 31.7 47.2 81.5 102.3 152.3 157.6 226.9 234.7 291.2 340.3 299.1 169.0 46.2 
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Appendix Table 8. Age-specific incidence rates in Ardebil, male (corrected) 
Crude age-specific incidence rates (per 100,000 person-years) 
Sites 0–4 
5–9 
10-14 
15-19 
20-24 
25-29 
30-34 
35-39 
40-44 
45-49 
50-54 
55-59 
60-64 
65-69 
70-74 
75-79 
80-84 
85+ 
C
rude 
rate 
/100,000 
Lip 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Tongue 0.00 0.00 0.00 0.00 0.00 0.00 0.75 0.00 1.22 0.00 0.00 0.00 3.36 3.63 8.06 9.46 11.30 12.79 0.47 
Mouth 0.00 0.00 0.00 0.00 0.00 0.00 0.75 0.00 0.00 0.00 0.00 1.84 3.36 1.81 0.00 9.46 6.10 9.59 0.35 
Salivary glands 0.00 0.00 0.00 0.00 0.52 0.00 0.00 0.00 0.00 1.49 0.00 0.00 0.00 1.81 0.00 0.00 0.00 0.00 0.13 
Tonsil 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.84 1.68 0.00 2.69 0.00 1.73 1.07 0.13 
Other oropharynx 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Nasopharynx 0.00 0.00 0.00 0.00 0.00 0.56 0.00 0.87 0.00 0.00 0.00 1.84 3.36 1.81 0.00 0.00 0.00 0.00 0.25 
Hypopharynx 0.00 0.00 0.00 0.00 0.00 0.56 0.00 0.87 0.00 0.00 3.46 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.26 
Pharynx unspecified 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.67 5.03 7.25 0.00 18.92 12.20 19.18 0.51 
Esophagus 0.00 0.00 0.00 0.00 0.00 0.56 1.49 1.74 9.76 14.87 31.10 34.88 85.58 77.94 136.98 227.01 234.81 284.63 10.39 
Stomach 0.00 0.00 0.27 0.00 2.60 2.79 6.71 9.57 12.19 34.21 84.66 124.83 244.98 286.40 370.65 681.04 678.43 837.87 32.09 
Small intestine 0.00 0.27 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.84 0.00 1.81 0.00 0.00 0.00 0.00 0.13 
Colon 0.00 0.00 0.00 0.00 0.52 2.79 2.98 1.74 4.88 13.39 5.18 9.18 16.78 21.75 45.66 66.21 72.17 85.29 3.52 
Rectum 0.00 0.00 0.00 0.00 0.52 1.67 1.49 0.87 1.22 1.49 3.46 1.84 5.03 0.00 2.69 0.00 1.73 1.07 0.68 
Anus 0.00 0.00 0.00 0.00 0.00 0.56 0.00 1.74 1.22 1.49 1.73 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.25 
Liver 0.00 0.00 0.00 0.00 0.00 1.11 0.75 1.74 0.00 5.95 0.00 0.00 3.36 9.06 21.49 9.46 19.96 18.13 1.24 
Gallbladder 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.22 0.00 1.73 1.84 1.68 1.81 10.74 0.00 6.93 4.27 0.42 
Pancreas 0.00 0.00 0.00 0.00 0.00 0.56 0.00 0.00 0.00 0.00 1.73 3.67 1.68 7.25 5.37 9.46 9.57 11.73 0.51 
Nose, sinuses 0.00 0.00 0.00 0.00 0.52 0.00 0.00 0.00 0.00 0.00 1.73 0.00 0.00 1.81 2.69 0.00 1.73 1.07 0.17 
Larynx 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.22 0.00 1.73 7.34 5.03 5.44 13.43 0.00 8.66 5.34 0.72 
Lung, trachea & bronchus 0.00 0.00 0.00 0.68 0.00 0.56 2.24 0.87 0.00 10.41 13.82 20.19 38.59 54.38 61.77 75.67 88.66 101.28 5.13 
Other thoracic organs 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.87 0.00 0.00 1.73 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.08 
Bone 0.00 0.00 0.81 0.68 1.56 1.67 0.75 1.74 2.44 2.97 1.73 7.34 6.71 5.44 8.06 18.92 17.40 22.38 1.66 
Melanoma of skin 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.87 0.00 0.00 0.00 1.84 1.68 3.63 0.00 0.00 0.00 0.00 0.21 
Other skin 0.37 1.08 0.00 0.34 0.52 0.56 3.73 5.22 17.07 16.36 22.46 33.04 46.98 39.88 77.89 151.34 147.87 184.41 9.00 
Mesothelioma 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Kaposi sarcoma 0.00 0.00 0.00 0.00 0.52 0.00 0.75 0.00 0.00 1.49 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.13 
Connective & soft tissue 0.00 0.00 0.00 0.34 1.04 0.56 0.75 0.00 3.66 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.43 
Breast 0.00 0.00 0.00 0.00 0.52 0.00 0.00 0.00 1.22 2.97 1.73 1.84 1.68 1.81 0.00 9.46 6.10 9.59 0.38 
Vulva 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Vagina 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Cervix uteri 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Corpus uteri 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Uterus unspecified 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Ovary 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Other female genitalia 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Placenta 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Penis 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.73 0.00 0.00 0.00 2.69 0.00 1.73 1.07 0.08 
Prostate 0.00 0.00 0.00 0.00 1.04 0.56 0.00 0.00 1.22 0.00 5.18 5.51 10.07 14.50 59.09 94.59 99.14 119.40 2.94 
Testis 0.00 0.00 0.54 0.34 1.56 2.23 2.24 3.48 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.72 
Other male genitalia 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Kidney 0.37 0.27 0.27 0.34 0.52 0.00 0.75 2.61 1.22 2.97 6.91 11.01 10.07 5.44 8.06 9.46 11.30 12.79 1.61 
Renal pelvis 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Ureter 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Bladder 0.00 0.27 0.27 0.34 0.52 0.00 0.75 1.74 6.10 5.95 15.55 20.19 35.24 32.63 61.77 104.05 106.97 130.06 5.04 
Other urinary organs 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Eye 0.00 0.27 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.08 
Brain, nervous system 0.37 1.90 0.54 0.34 2.60 0.56 2.24 3.48 6.10 8.92 5.18 12.85 11.75 10.88 10.74 28.38 25.24 33.04 2.84 
Thyroid 0.00 0.27 0.00 0.00 0.00 0.00 0.00 1.74 0.00 2.97 0.00 3.67 1.68 1.81 2.69 0.00 1.73 1.07 0.42 
Adrenal gland 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Other endocrine 0.00 0.00 0.00 0.00 0.00 0.56 0.00 0.00 1.22 1.49 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.23 
Hodgkin disease 0.00 0.00 0.00 0.00 1.04 1.67 0.75 0.00 0.00 0.00 1.73 0.00 0.00 1.81 2.69 0.00 1.73 1.07 0.38 
Non-Hodgkin lymphoma 0.37 0.00 0.27 0.34 1.04 0.00 0.00 0.00 2.44 2.97 8.64 22.03 3.36 12.69 10.74 0.00 6.93 4.27 1.92 
Immunoproliferative 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Multiple myeloma 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.36 1.81 0.00 0.00 0.00 0.00 0.23 
Lymphoid leukemia 0.00 0.81 0.27 0.00 0.52 0.00 0.00 0.00 0.00 0.00 3.46 1.84 1.68 0.00 0.00 0.00 0.00 0.00 0.38 
Myeloid leukemia 0.37 0.27 0.00 0.34 0.00 0.00 0.00 0.87 0.00 0.00 0.00 0.00 3.36 0.00 0.00 0.00 0.00 0.00 0.25 
Leukemia unspecified 0.00 0.54 0.27 0.00 1.04 0.00 1.49 0.00 1.22 1.49 1.73 5.51 0.00 0.00 2.69 0.00 1.73 1.07 0.59 
Other and unspecified 1.12 1.63 2.69 3.04 1.04 1.67 3.73 1.74 3.66 10.41 6.91 12.85 18.46 32.63 29.54 56.75 55.67 69.29 4.96 
All sites 2.98 7.59 6.19 7.09 19.77 21.73 35.06 44.36 80.48 144.28 234.99 354.28 575.54 648.93 958.85 1579.64 1637.54 1982.82 91.82 
All sites excluding skin 2.60 6.50 6.19 6.76 19.25 21.17 31.33 39.14 63.41 127.92 212.52 321.24 528.56 609.05 880.96 1428.30 1489.67 1798.41 82.85 
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Appendix Table 9. Age-specific incidence rates in Ardebil, female (corrected) 
Age-specific incidence rates (per 100,000 person-years) 
Sites 0–4 
5-9 
10–14 
15-19 
20–24 
25-29 
30–34 
35-39 
40–44 
45-49 
50–54 
55-59 
60–64 
65-69 
70–74 
75-79 
80–84 
85+ 
Crude 
rate 
(/100,000) 
Lip 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Tongue 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.03 0.00 10.25 25.71 23.20 30.14 0.39 
Mouth 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Salivary glands 0.00 0.29 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.70 0.00 2.03 2.36 0.00 0.00 0.00 0.00 0.17 
Tonsil 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.05 0.00 0.00 0.00 12.85 8.29 13.03 0.13 
Other oropharynx 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Nasopharynx 0.00 0.00 0.00 0.00 0.00 0.58 0.00 0.00 0.00 1.37 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.09 
Hypopharynx 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.40 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.09 
Pharynx unspecified 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.06 0.00 0.00 0.00 6.08 4.73 0.00 0.00 0.00 0.00 0.26 
Esophagus 0.00 0.00 0.00 0.67 0.47 1.16 2.23 2.55 10.63 21.87 49.26 34.44 66.89 70.92 85.45 128.53 138.04 164.30 9.17 
Stomach 0.00 0.29 0.28 1.34 0.93 0.58 3.71 6.81 24.44 23.24 69.64 87.10 121.62 108.74 140.14 308.48 289.40 368.49 14.57 
Small intestine 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.70 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.04 
Colon 0.00 0.00 0.00 0.34 0.00 1.16 0.74 2.55 1.06 5.47 11.89 8.10 18.24 11.82 20.51 38.56 38.10 47.25 2.08 
Rectum 0.00 0.00 0.00 0.00 0.00 0.58 0.74 0.85 1.06 2.73 3.40 2.03 6.08 9.46 6.84 0.00 4.41 2.72 0.86 
Anus 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.37 1.70 2.03 2.03 0.00 3.42 0.00 2.20 1.36 0.30 
Liver 0.00 0.00 0.00 0.00 0.00 0.58 0.00 1.70 2.13 5.47 1.70 2.03 14.19 16.55 17.09 0.00 11.02 6.79 1.34 
Gallbladder 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.10 5.10 4.05 10.14 4.73 20.51 12.85 21.52 21.19 1.12 
Pancreas 0.00 0.00 0.00 0.00 0.00 0.58 0.00 0.00 0.00 1.37 3.40 8.10 2.03 4.73 3.42 0.00 2.20 1.36 0.52 
Nose, sinuses 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 12.85 8.29 13.03 0.04 
Larynx 0.40 0.00 0.00 0.00 0.00 0.00 0.00 0.85 1.06 0.00 0.00 2.03 0.00 0.00 0.00 0.00 0.00 0.00 0.17 
Lung 0.00 0.00 0.00 0.00 0.47 0.00 0.00 1.70 2.13 4.10 6.79 10.13 8.11 14.18 37.60 12.85 32.55 27.98 1.82 
Other thoracic organs 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.70 0.00 0.00 0.00 3.42 0.00 2.20 1.36 0.09 
Bone 0.40 0.29 1.39 0.67 0.93 0.58 0.74 0.00 1.06 2.73 6.79 0.00 6.08 2.36 6.84 0.00 4.41 2.72 1.12 
Melanoma of skin 0.00 0.00 0.00 0.34 0.47 0.00 0.74 0.00 0.00 0.00 0.00 2.03 0.00 0.00 0.00 0.00 0.00 0.00 0.17 
Other skin 0.40 0.00 0.28 0.34 2.34 5.23 2.97 7.66 7.44 9.57 20.38 22.28 28.38 26.00 75.20 51.41 81.68 82.03 5.67 
Mesothelioma 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Kaposi sarcoma 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Connective & soft tissue 0.40 0.29 0.00 0.00 0.00 0.58 0.00 0.85 0.00 0.00 3.40 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.30 
Breast 0.00 0.00 0.00 0.67 1.40 1.16 3.71 10.22 18.07 17.77 8.49 16.20 24.32 18.91 27.34 89.97 75.68 102.10 4.67 
Vulva 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.73 0.00 0.00 0.00 0.00 0.09 
Vagina 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.70 0.00 4.05 0.00 0.00 0.00 0.00 0.00 0.13 
Cervix uteri 0.00 0.00 0.00 0.00 0.00 0.00 1.48 0.85 1.06 1.37 3.40 2.03 0.00 2.36 0.00 12.85 8.29 13.03 0.48 
Corpus uteri 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.73 0.00 4.05 0.00 2.36 0.00 0.00 0.00 0.00 0.22 
Uterus unspecified 0.00 0.00 0.00 0.00 0.00 2.32 2.97 1.70 6.38 13.67 3.40 10.13 18.24 9.46 10.25 12.85 14.91 17.11 2.21 
Ovary 0.00 0.00 0.28 0.34 0.00 0.58 2.23 0.00 3.19 5.47 1.70 2.03 4.05 0.00 17.09 0.00 11.02 6.79 1.04 
Other female genitalia 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Placenta 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.85 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.04 
Kidney 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.04 
Renal pelvis 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Ureter 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Bladder 0.00 0.00 0.00 0.00 0.00 0.00 0.74 0.85 0.00 2.73 1.70 6.08 16.22 7.09 27.34 12.85 25.93 23.90 1.25 
Other urinary organs 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.03 0.00 0.00 0.00 0.00 0.00 0.04 
Eye 0.40 0.29 0.00 0.34 0.00 0.00 0.00 0.00 1.06 0.00 0.00 0.00 0.00 0.00 6.84 0.00 4.41 2.72 0.26 
Brain, nervous system 0.40 1.43 0.83 0.34 0.93 0.00 2.23 3.41 2.13 2.73 5.10 12.15 14.19 9.46 10.25 12.85 14.91 17.11 2.03 
Thyroid 0.00 0.00 0.00 0.34 0.47 0.58 2.97 2.55 1.06 1.37 1.70 4.05 0.00 4.73 0.00 0.00 0.00 0.00 0.95 
Adrenal gland 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Other endocrine 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.03 0.00 0.00 0.00 0.00 0.00 0.04 
Hodgkin disease 0.00 0.29 0.28 1.01 0.47 0.58 0.74 0.85 1.06 0.00 0.00 0.00 0.00 2.36 0.00 0.00 0.00 0.00 0.48 
Non-Hodgkin lymphoma 0.40 0.29 0.83 0.67 0.47 0.00 0.00 1.70 0.00 0.00 1.70 4.05 0.00 0.00 0.00 0.00 0.00 0.00 0.65 
Immunoproliferative 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Multiple myeloma 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.06 0.00 0.00 0.00 0.00 2.36 0.00 0.00 0.00 0.00 0.09 
Lymphoid leukemia 0.40 0.00 0.00 0.00 0.47 0.00 0.00 0.00 2.13 0.00 1.70 0.00 0.00 2.36 0.00 0.00 0.00 0.00 0.26 
Myeloid leukemia 0.79 0.00 0.00 0.67 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.03 0.00 0.00 0.00 0.00 0.00 0.22 
Leukemia unspecified 0.00 0.29 0.28 0.00 0.93 0.00 0.00 0.00 3.19 2.73 3.40 0.00 2.03 2.36 3.42 0.00 2.20 1.36 0.65 
Other and unspecified 0.79 0.86 0.56 2.01 3.74 1.74 1.48 2.55 6.38 12.30 6.79 8.10 12.16 14.18 13.67 38.56 33.69 44.53 4.41 
All sites 4.75 4.58 5.00 10.06 14.49 18.58 30.44 51.08 98.83 146.27 232.69 257.25 395.28 359.30 546.90 784.06 858.58 1012.40 60.76 
All sites excluding skin 4.36 4.58 4.73 9.73 12.15 13.35 27.47 43.42 91.39 136.70 212.31 234.97 366.90 333.30 471.70 732.65 776.90 930.37 55.10 
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Gilan 
 
 
Appendix Table 10. Age-specific incidence rates in Gilan, male (corrected) 
Age-specific incidence rates (per 100,000 person-years) 
Sites 0-4 
5-9 
10-14 
15-19 
20-24 
25-29 
30-34 
35-39 
40-44 
45-49 
50-54 
55-59 
60-64 
65-69 
70-74 
75-79 
80-84 
85+ 
C
rude rate 
(/100,000) 
Lip 0.00 0.00 0.00 0.00 0.00 0.00 0.25 0.00 0.34 0.89 2.96 4.27 2.73 5.52 7.25 0.00 4.68 2.88 0.66 
Tongue 0.00 0.00 0.00 0.00 0.25 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.55 0.69 0.00 0.00 0.00 0.00 0.05 
Mouth 0.00 0.00 0.00 0.00 0.00 0.00 0.25 0.00 0.69 0.45 0.00 1.83 2.73 0.00 4.53 5.31 6.35 7.19 0.38 
Salivary glands 0.00 0.00 0.00 0.00 0.49 0.22 0.00 0.00 0.00 0.00 0.00 1.22 1.09 0.69 0.91 0.00 0.58 0.36 0.18 
Tonsil 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.55 0.69 0.91 0.00 0.58 0.36 0.05 
Other oropharynx 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.91 0.00 0.58 0.36 0.02 
Nasopharynx 0.00 0.00 0.00 0.00 0.49 0.00 0.50 0.00 0.34 0.45 2.96 0.61 1.64 2.76 1.81 2.66 2.88 3.41 0.39 
Hypopharynx 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.34 0.89 0.00 0.00 0.00 0.69 0.00 0.00 0.00 0.00 0.09 
Pharynx unspecified 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.69 0.00 1.18 0.00 1.64 1.38 1.81 0.00 1.17 0.72 0.20 
Esophagus 0.00 0.15 0.25 0.16 0.25 0.90 1.00 3.36 1.72 7.16 17.15 17.08 43.13 42.78 58.03 132.80 123.11 157.72 6.83 
Stomach 0.00 0.00 0.00 0.31 0.25 2.01 5.24 6.16 8.25 21.48 36.08 49.41 107.01 111.77 176.82 236.39 266.56 309.97 18.27 
Small intestine 0.00 0.00 0.00 0.00 0.00 0.00 0.50 0.28 0.69 0.45 1.18 0.61 2.18 3.45 6.35 7.97 9.23 10.60 0.56 
Colon 0.41 0.15 0.37 0.78 1.23 0.90 1.25 1.40 5.16 8.95 5.92 14.03 14.74 23.46 24.48 21.25 29.50 31.28 3.87 
Rectum 0.00 0.00 0.00 0.00 0.49 1.34 0.75 0.84 2.41 4.92 5.32 5.49 5.46 9.66 15.42 31.87 30.50 38.44 2.03 
Anus 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.28 0.00 0.00 0.59 0.61 1.09 0.69 0.00 0.00 0.00 0.00 0.13 
Liver 0.00 0.00 0.00 0.00 0.00 0.00 0.25 0.28 0.34 1.34 2.96 1.83 7.64 7.59 6.35 18.59 16.09 21.37 1.08 
Gallbladder 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.56 0.00 0.45 1.18 0.61 2.73 0.69 0.00 2.66 1.71 2.69 0.30 
Pancreas 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.03 1.34 4.14 2.44 6.55 9.66 7.25 13.28 13.25 16.35 1.22 
Nose, sinuses 0.00 0.15 0.12 0.00 0.00 0.00 0.00 0.56 0.00 0.45 0.00 1.83 0.00 0.69 2.72 2.66 3.47 3.77 0.25 
Larynx 0.00 0.15 0.00 0.00 0.25 0.00 0.25 0.28 1.03 2.68 7.10 5.49 12.01 15.18 12.69 13.28 16.76 18.51 1.79 
Lung 0.00 0.00 0.00 0.00 0.00 0.22 0.75 1.12 1.38 4.47 5.32 11.59 21.84 33.12 43.53 42.50 55.49 60.39 4.00 
Other thoracic organs 0.00 0.15 0.00 0.00 0.25 0.00 0.00 0.00 0.34 0.45 0.00 0.61 2.73 1.38 2.72 2.66 3.47 3.77 0.30 
Bone 0.00 0.15 0.25 1.24 0.98 0.67 0.50 0.28 0.00 0.45 2.37 1.22 2.73 2.07 2.72 7.97 6.89 9.16 0.77 
Melanoma of skin 0.00 0.00 0.00 0.00 0.00 0.00 0.25 0.00 0.69 0.00 0.59 0.00 3.28 0.00 2.72 0.00 1.75 1.08 0.23 
Other skin 0.41 0.15 0.37 0.47 0.98 0.90 1.75 4.20 11.00 21.93 18.34 22.57 22.38 42.78 49.87 98.27 95.57 119.47 7.51 
Mesothelioma 0.00 0.00 0.00 0.16 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.91 2.66 2.30 3.05 0.05 
Kaposi sarcoma 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.34 0.00 0.00 0.00 0.55 2.76 0.00 5.31 3.43 5.39 0.18 
Connective & soft tissue 0.00 0.15 0.12 0.16 0.00 0.00 0.25 0.00 0.34 0.89 2.37 1.22 2.73 1.38 0.91 2.66 2.30 3.05 0.41 
Breast 0.00 0.00 0.00 0.16 0.00 0.22 1.50 1.12 2.41 4.03 5.92 2.44 2.18 1.38 2.72 7.97 6.89 9.16 1.00 
Penis 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.69 0.00 0.00 0.00 0.00 0.05 
Prostate 0.00 0.00 0.00 0.16 0.49 0.00 0.25 0.00 0.00 0.45 1.77 4.27 14.19 19.32 58.03 108.90 107.68 133.48 5.88 
Testis 0.20 0.00 0.00 0.62 1.97 1.79 2.99 3.36 1.72 2.68 2.37 0.61 1.64 0.69 0.00 5.31 3.43 5.39 1.29 
Other male genitalia 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Kidney 0.20 0.44 0.00 0.00 0.00 0.00 1.00 0.00 0.34 0.89 4.14 3.05 7.10 4.83 7.25 21.25 18.39 24.43 1.13 
Renal pelvis 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Ureter 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 
Bladder 0.20 0.00 0.37 0.16 0.49 0.00 0.25 2.24 2.06 8.05 14.20 20.74 37.12 47.61 67.10 98.27 106.68 126.32 6.80 
Other urinary organs 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Eye 0.00 0.00 0.00 0.00 0.00 0.00 0.25 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.91 0.00 0.58 0.36 0.05 
Brain, nervous system 0.61 0.74 0.25 0.16 0.49 0.45 1.25 0.56 1.38 2.68 1.77 3.05 1.09 2.76 1.81 2.66 2.88 3.41 0.93 
Thyroid 0.00 0.00 0.00 0.00 0.25 0.22 1.50 0.84 0.34 0.89 1.77 3.05 2.18 1.38 1.81 0.00 1.17 0.72 0.70 
Adrenal gland 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Other endocrine 0.00 0.00 0.00 0.00 0.25 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.05 
Hodgkin disease 0.00 0.29 0.37 1.09 1.23 0.00 0.75 1.40 0.34 0.45 1.77 3.66 1.64 2.07 0.91 0.00 0.58 0.36 0.82 
Non-Hodgkin lymphoma 0.81 0.88 0.62 0.62 0.49 1.34 0.75 2.52 4.13 2.24 3.55 8.54 3.82 3.45 13.60 15.94 19.05 21.57 2.08 
Immunoproliferative 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 
Multiple myeloma 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.28 0.69 1.79 2.37 1.22 5.46 6.21 10.88 7.97 12.16 12.41 0.91 
Lymphoid leukemia 0.00 0.29 0.12 0.16 0.00 0.22 0.00 0.00 0.00 0.45 1.18 0.00 0.00 2.76 1.81 5.31 4.60 6.11 0.32 
Myeloid leukemia 0.00 0.00 0.00 0.00 0.49 0.22 0.00 0.00 0.00 0.89 0.00 0.61 0.00 0.00 0.00 0.00 0.00 0.00 0.11 
Leukemia unspecified 3.85 3.83 2.00 1.71 1.23 1.12 2.00 0.56 1.03 0.45 1.18 2.44 1.64 1.38 6.35 2.66 5.81 5.22 2.17 
Other and unspecified 0.41 1.18 0.50 0.62 1.48 1.34 3.24 1.68 3.78 5.82 11.24 8.54 13.65 20.01 21.76 47.81 44.88 57.13 3.91 
All sites 7.09 8.85 5.74 8.70 14.76 14.10 29.44 34.13 55.37 111.86 170.96 206.77 361.42 436.06 626.59 974.77 1033.01 1237.44 80.08 
All sites excluding skin 6.69 8.70 5.36 8.23 13.78 13.21 27.69 29.94 44.36 89.94 152.62 184.20 339.04 393.28 576.71 876.49 937.44 1117.97 72.57 
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Appendix Table 11. Age-specific incidence rates in Gilan, female (corrected) 
Age-specific incidence rates (per 100,000 person-years) 
Sites 0-4 
5-9 
10-14 
15-19 
20-24 
25-29 
30-34 
35-39 
40-44 
45-49 
50-54 
55-59 
60-64 
65-69 
70-74 
75-79 
80-84 
85+ 
C
rude rate 
(/100,000) 
Lip 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.63 0.00 0.74 0.97 2.36 2.15 2.77 0.07 
Tongue 0.00 0.00 0.00 0.00 0.00 0.00 0.50 0.28 0.34 1.33 0.59 0.00 5.47 0.00 0.97 0.00 0.62 0.39 0.34 
Mouth 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.28 0.00 0.00 0.59 0.00 3.65 0.00 1.94 7.07 5.81 7.94 0.23 
Salivary glands 0.00 0.00 0.00 0.00 0.20 0.21 0.25 0.00 0.00 0.00 0.59 0.63 0.61 0.00 0.00 0.00 0.00 0.00 0.12 
Tonsil 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.61 1.47 0.00 0.00 0.00 0.00 0.05 
Other oropharynx 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Nasopharynx 0.00 0.00 0.00 0.00 0.20 0.00 0.00 0.28 0.68 0.89 0.59 0.63 0.61 1.47 0.00 0.00 0.00 0.00 0.20 
Hypopharynx 0.00 0.00 0.00 0.00 0.00 0.00 0.50 0.00 0.00 0.00 0.00 0.00 0.00 0.74 4.84 0.00 3.12 1.93 0.14 
Pharynx unspecified 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.34 0.00 1.76 0.63 0.61 0.74 0.00 0.00 0.00 0.00 0.12 
Esophagus 0.00 0.00 0.00 0.00 0.00 0.43 0.50 1.66 3.40 6.20 12.87 13.28 30.41 24.27 34.87 40.07 48.34 54.49 4.14 
Stomach 0.00 0.00 0.00 0.59 0.80 1.29 2.49 3.32 5.43 10.63 12.29 15.81 39.54 48.54 60.05 82.49 91.95 107.51 6.87 
Small intestine 0.00 0.00 0.00 0.00 0.00 0.21 0.00 0.55 0.34 0.89 0.00 0.63 2.43 0.74 0.00 0.00 0.00 0.00 0.23 
Colon 0.21 0.00 0.26 0.45 1.39 1.50 0.75 4.71 4.75 8.42 8.78 13.92 17.03 22.06 24.22 37.71 39.95 47.86 4.14 
Rectum 0.00 0.00 0.00 0.00 0.60 0.64 0.50 0.55 2.04 3.54 6.44 6.33 8.52 3.68 15.50 11.78 17.60 18.11 1.78 
Anus 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.44 0.00 0.63 0.00 0.00 0.00 0.00 0.00 0.00 0.04 
Liver 0.21 0.00 0.26 0.00 0.00 0.21 0.25 0.55 0.68 3.54 1.76 1.27 2.43 5.88 5.81 2.36 5.27 4.70 0.78 
Gallbladder 0.00 0.00 0.00 0.00 0.00 0.21 0.00 0.00 1.36 0.44 1.17 2.53 1.22 2.94 5.81 16.50 14.39 19.04 0.57 
Pancreas 0.00 0.00 0.00 0.00 0.00 0.21 0.00 0.28 1.02 1.33 0.59 1.27 1.22 4.41 9.69 9.43 12.33 13.41 0.71 
Nose, sinuses 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.89 0.59 0.63 0.00 0.00 0.97 0.00 0.62 0.39 0.11 
Larynx 0.00 0.00 0.00 0.00 0.20 0.00 0.50 0.28 0.34 0.89 0.59 1.90 1.22 2.21 2.91 2.36 3.39 3.54 0.37 
Lung 0.00 0.00 0.00 0.00 0.00 0.00 0.25 0.00 0.00 0.44 1.76 5.06 4.26 6.62 7.75 7.07 9.56 10.25 0.82 
Other thoracic organs 0.00 0.00 0.00 0.00 0.20 0.00 0.25 0.00 0.68 0.00 0.00 0.00 0.61 0.00 0.00 0.00 0.00 0.00 0.11 
Bone 0.00 0.31 0.39 0.59 0.80 0.00 0.50 0.28 0.34 0.89 0.00 0.00 1.22 1.47 0.00 4.71 3.04 4.78 0.44 
Melanoma of skin 0.00 0.00 0.00 0.00 0.00 0.00 0.25 0.83 0.00 0.89 0.00 0.00 0.61 2.21 1.94 0.00 1.25 0.77 0.23 
Other skin 0.42 0.31 0.13 0.30 0.20 0.86 3.49 2.49 5.09 11.96 16.97 10.12 16.42 20.59 35.84 70.70 68.73 85.94 4.86 
Mesothelioma 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.59 0.00 0.61 0.00 0.00 0.00 0.00 0.00 0.04 
Kaposi sarcoma 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.59 0.00 0.00 0.00 0.97 4.71 3.67 5.16 0.11 
Connective & soft tissue 0.21 0.31 0.00 0.15 0.00 0.00 0.25 0.00 0.34 0.89 1.17 0.00 1.82 2.94 1.94 0.00 1.25 0.77 0.53 
Breast 0.00 0.00 0.00 0.30 0.60 3.44 11.72 17.99 32.26 36.32 35.69 38.58 23.72 14.71 24.22 37.71 39.95 47.86 10.16 
Vulva 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.59 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 
Vagina 0.21 0.00 0.13 0.00 0.00 0.00 0.25 0.00 0.00 0.89 0.59 0.63 0.61 2.21 0.00 2.36 1.52 2.39 0.21 
Cervix uteri 0.00 0.00 0.00 0.00 0.00 0.21 1.25 2.77 2.72 4.87 4.68 8.86 6.69 3.68 0.97 4.71 3.67 5.16 1.42 
Corpus uteri 0.00 0.00 0.00 0.00 0.00 0.21 0.50 1.11 1.36 2.21 5.85 8.22 8.52 4.41 3.87 4.71 5.54 6.32 1.23 
Uterus unspecified 0.00 0.00 0.13 0.00 0.20 0.64 0.50 0.55 2.38 1.33 2.34 0.63 1.82 2.21 2.91 0.00 1.87 1.16 0.64 
Ovary 0.00 0.15 0.13 0.45 1.79 1.72 2.24 2.21 3.06 2.66 4.10 8.86 7.91 5.15 2.91 7.07 6.44 8.32 1.86 
Other female genitalia 0.00 0.00 0.00 0.00 0.00 0.00 0.50 0.00 0.00 0.00 0.00 0.63 0.00 0.74 0.97 0.00 0.62 0.39 0.11 
Placenta 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Kidney 0.21 0.00 0.00 0.00 0.20 0.21 0.25 0.28 1.70 1.33 1.76 1.90 4.26 3.68 4.84 4.71 6.16 6.70 0.80 
Renal pelvis 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Ureter 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Bladder 0.21 0.15 0.00 0.00 0.20 0.43 0.25 0.28 0.68 1.33 2.34 3.80 6.08 9.56 7.75 14.14 14.12 17.42 1.21 
Other urinary organs 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.59 0.00 0.61 0.00 0.00 0.00 0.00 0.00 0.04 
Eye 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.68 0.00 0.59 0.63 0.00 0.00 0.00 0.00 0.00 0.00 0.09 
Brain, nervous system 0.63 0.77 1.03 0.59 0.60 1.29 0.75 1.11 2.04 0.89 4.10 3.80 4.26 2.94 3.87 0.00 2.50 1.54 1.30 
Thyroid 0.00 0.00 0.00 0.45 0.99 1.93 3.49 3.32 4.08 3.10 2.93 3.80 3.65 4.41 9.69 2.36 7.77 6.24 2.43 
Adrenal gland 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.61 0.00 0.00 0.00 0.00 0.00 0.02 
Other endocrine 0.00 0.00 0.00 0.00 0.00 0.21 0.25 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.04 
Hodgkin disease 0.21 0.00 0.13 1.04 1.19 0.86 0.25 0.83 0.68 0.00 0.59 1.27 0.61 0.74 0.00 0.00 0.00 0.00 0.55 
Non-Hodgkin lymphoma 0.00 0.15 0.13 0.15 0.20 0.86 0.75 0.28 0.68 0.44 2.93 1.90 3.04 1.47 4.84 0.00 3.12 1.93 0.82 
Immunoproliferative 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Multiple myeloma 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.28 0.00 0.00 1.17 1.27 1.82 3.68 3.87 0.00 2.50 1.54 0.34 
Lymphoid leukemia 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.55 0.00 0.44 0.00 1.27 0.00 1.47 0.00 0.00 0.00 0.00 0.16 
Myeloid leukemia 0.00 0.15 0.00 0.00 0.00 0.00 0.50 0.28 0.00 0.00 0.00 0.00 0.00 0.00 0.97 0.00 0.62 0.39 0.09 
Leukemia unspecified 3.38 1.38 1.55 0.59 0.60 0.64 0.75 0.00 0.68 1.33 0.59 1.90 0.61 1.47 1.94 7.07 5.81 7.94 1.33 
Other and unspecified 0.21 0.31 0.52 0.45 0.99 0.64 1.50 3.32 4.75 3.10 5.85 4.43 6.08 14.71 10.65 14.14 16.00 18.57 2.34 
All sites 6.13 3.98 4.79 6.09 12.14 19.13 36.92 51.48 84.90 114.72 147.45 168.25 222.02 230.94 301.24 398.30 451.26 523.61 55.32 
All sites excluding skin 5.71 3.68 4.66 5.80 11.94 18.27 33.43 48.99 79.81 102.76 130.49 158.13 205.60 210.35 265.40 327.60 382.53 437.67 50.46 
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Mazandaran 
 
Appendix Table 12. Age-specific incidence rates in Mazandaran, male (corrected) 
Age-specific incidence rates (per 100,000 person-years) 
Sites 0-4 
5-9 
10-14 
15-19 
20-24 
25-29 
30-34 
35-39 
40-44 
45-49 
50-54 
55-59 
60-64 
65-69 
70-74 
75-79 
80-84 
85+ 
C
rude rate 
(/100,000) 
Lip 0.00 0.00 0.00 0.00 0.00 0.19 0.00 0.48 0.00 0.40 1.11 1.21 1.73 2.37 1.82 14.98 10.84 15.91 0.45 
Tongue 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.31 1.59 0.56 1.21 2.89 1.58 3.64 2.14 3.73 3.62 0.34 
Mouth 0.00 0.12 0.00 0.00 0.00 0.00 0.21 0.00 0.31 1.19 2.23 0.61 1.73 0.00 3.64 0.00 2.35 1.45 0.31 
Salivary glands 0.18 0.00 0.00 0.13 0.00 0.00 0.21 0.24 0.00 0.40 0.56 1.21 1.15 1.58 0.91 0.00 0.59 0.36 0.20 
Tonsil 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Other oropharynx 0.00 0.00 0.10 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 
Nasopharynx 0.53 0.00 0.20 0.27 0.79 0.19 0.42 0.48 1.86 3.58 2.23 1.82 2.89 2.37 4.55 6.42 7.08 8.32 0.94 
Hypopharynx 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.48 0.62 0.00 1.11 0.00 0.00 0.79 1.82 0.00 1.17 0.72 0.15 
Pharynx unspecified 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.31 0.00 0.00 0.00 0.00 1.58 0.00 2.14 1.38 2.17 0.08 
Esophagus 0.53 0.00 0.00 0.27 0.00 0.76 1.68 1.91 4.33 7.57 18.38 18.20 45.59 60.81 137.50 145.52 182.57 202.21 8.91 
Stomach 0.71 0.48 0.60 0.53 0.79 1.72 1.05 2.39 7.73 11.55 28.40 46.72 69.84 119.25 173.01 179.76 227.56 251.04 13.79 
Small intestine 0.00 0.00 0.10 0.00 0.00 0.19 0.00 0.24 0.62 0.00 1.11 2.43 1.15 1.58 0.91 4.28 3.35 4.70 0.31 
Colon 0.35 0.00 0.30 0.40 1.39 0.95 2.72 2.86 4.64 3.98 8.91 12.13 7.50 7.11 18.21 19.26 24.17 26.77 2.79 
Rectum 0.00 0.00 0.00 0.00 0.20 0.57 0.84 1.19 3.40 3.19 5.01 1.82 4.62 8.69 10.02 32.10 27.17 36.53 1.73 
Anus 0.00 0.00 0.00 0.00 0.20 0.19 0.84 0.00 0.00 0.80 0.00 1.82 0.00 0.00 1.82 2.14 2.56 2.89 0.22 
Liver 0.00 0.12 0.00 0.00 0.20 0.19 0.21 0.00 0.00 0.40 3.34 3.03 0.58 5.53 5.46 8.56 9.05 10.85 0.68 
Gallbladder 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.24 0.80 0.56 0.00 2.89 10.27 4.55 10.70 9.84 12.66 0.60 
Pancreas 0.00 0.00 0.00 0.00 0.00 0.19 0.00 0.48 0.62 1.59 0.00 1.21 2.89 11.06 7.28 10.70 11.60 13.74 0.85 
Nose, sinuses 0.18 0.00 0.10 0.00 0.00 0.00 0.42 0.24 0.31 0.40 0.56 1.21 1.73 0.79 0.91 0.00 0.59 0.36 0.25 
Larynx 0.00 0.00 0.00 0.00 0.00 0.57 0.21 0.48 2.16 3.58 3.34 6.67 17.89 18.95 20.03 47.08 43.29 55.70 2.65 
Lung 0.18 0.24 0.00 0.00 0.20 0.38 1.05 0.24 2.47 4.38 10.02 9.10 29.43 45.01 74.67 98.44 111.67 129.49 5.46 
Other thoracic organs 0.18 0.12 0.00 0.00 0.00 0.00 0.21 0.00 0.00 0.00 0.00 1.82 0.00 0.79 0.00 2.14 1.38 2.17 0.12 
Bone 0.18 0.00 0.70 2.14 0.20 0.19 0.42 0.00 0.31 0.00 0.56 2.43 1.15 1.58 0.91 0.00 0.59 0.36 0.66 
Melanoma of skin 0.00 0.00 0.00 0.00 0.00 0.19 0.42 0.00 1.24 1.19 0.00 0.61 1.15 2.37 2.73 8.56 7.28 9.76 0.39 
Other skin 0.35 0.12 0.30 0.40 0.79 1.53 1.89 0.95 6.80 10.75 24.50 16.38 17.31 45.01 44.62 85.60 84.00 104.53 6.28 
Mesothelioma 0.00 0.00 0.00 0.00 0.00 0.00 0.21 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.91 0.00 0.59 0.36 0.03 
Kaposi sarcoma 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.24 0.31 0.00 0.56 0.00 1.15 0.79 0.00 0.00 0.00 0.00 0.09 
Connective & soft tissue 0.18 0.00 0.10 0.40 0.40 0.00 0.21 0.48 0.62 2.79 2.23 0.61 2.89 3.16 1.82 4.28 3.94 5.06 0.77 
Breast 0.18 0.00 0.00 0.00 0.00 0.00 0.21 0.95 2.78 4.78 2.23 1.82 4.04 1.58 5.46 6.42 7.67 8.68 0.88 
Vulva 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Vagina 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Cervix uteri 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Corpus uteri 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Uterus unspecified 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Ovary 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Other female genitalia 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Placenta 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Penis 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.61 0.58 0.00 0.00 0.00 0.00 0.00 0.05 
Prostate 0.88 0.48 0.10 0.00 0.00 0.19 0.00 0.48 0.62 1.19 2.78 3.03 12.70 31.59 45.53 59.92 68.02 78.85 3.28 
Testis 0.18 0.12 0.00 0.80 0.79 1.53 2.72 1.43 1.55 0.80 1.11 0.61 0.58 0.00 1.82 0.00 1.17 0.72 0.88 
Other male genitalia 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.91 0.00 0.59 0.36 0.02 
Kidney 0.18 0.95 0.10 0.27 0.00 0.00 0.00 0.00 0.31 1.19 0.56 1.82 3.46 3.95 3.64 4.28 5.11 5.79 0.65 
Renal pelvis 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Ureter 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Bladder 0.00 0.00 0.20 0.00 0.79 0.38 0.84 1.43 2.16 10.35 6.13 9.71 16.16 25.27 49.17 74.90 80.04 95.49 4.21 
Other urinary organs 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.91 0.00 0.59 0.36 0.02 
Eye 0.18 0.00 0.10 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.56 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.06 
Brain, nervous system 0.18 0.95 1.10 1.47 1.98 0.95 2.30 1.67 2.78 4.78 6.13 6.07 3.46 7.90 10.93 10.70 13.95 15.19 2.33 
Thyroid 0.18 0.00 0.00 0.00 0.79 0.57 0.42 0.24 0.93 0.00 1.67 0.61 0.58 2.37 0.00 2.14 1.38 2.17 0.42 
Adrenal gland 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Other endocrine 0.00 0.24 0.00 0.00 0.20 0.19 0.21 0.24 0.00 0.00 0.00 1.21 0.58 0.00 0.00 0.00 0.00 0.00 0.14 
Hodgkin disease 0.35 0.48 0.60 0.67 1.19 1.53 1.68 1.19 2.47 1.59 2.23 1.82 2.89 3.16 0.91 6.42 4.73 6.87 1.26 
Non-Hodgkin lymphoma 1.24 0.48 1.31 1.20 1.19 2.29 2.30 2.62 3.71 3.19 6.13 6.07 7.50 12.64 11.84 10.70 14.54 15.55 2.78 
Immunoproliferative 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Multiple myeloma 0.35 0.00 0.10 0.13 0.20 0.00 0.21 0.24 0.00 2.39 3.34 3.64 5.77 5.53 3.64 6.42 6.49 7.96 0.79 
Lymphoid leukemia 0.00 0.36 0.30 0.27 0.20 0.00 0.00 0.00 0.31 0.40 1.67 1.21 2.89 4.74 3.64 4.28 5.11 5.79 0.57 
Myeloid leukemia 0.00 0.12 0.00 0.40 0.20 0.00 0.63 0.00 0.62 0.00 0.00 0.00 0.58 1.58 0.00 4.28 2.76 4.34 0.26 
Leukemia unspecified 1.95 4.05 2.21 3.21 2.98 1.72 1.26 1.19 1.55 1.59 0.00 3.64 4.62 7.11 6.37 8.56 9.63 11.21 2.81 
Other and unspecified 1.59 0.48 0.20 0.13 0.79 0.76 1.68 1.67 2.78 0.80 8.35 11.53 7.50 16.58 21.85 19.26 26.52 28.22 2.87 
All sites ### 9.88 8.84 13.10 16.47 18.12 27.65 26.71 62.77 93.18 158.14 185.66 292.04 477.00 688.40 903.06 1026.62 1189.31 73.32 
All sites excluding skin 10.61 9.76 8.53 12.70 15.68 16.59 25.77 25.76 55.97 82.43 133.64 169.28 274.72 431.98 643.78 817.46 942.62 1084.78 67.04 
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Appendix Table 13. Age-specific incidence rates in Mazandaran province, female 
(corrected) 
Age-specific incidence rates (per 100,000 person-years) 
Sites 0-4 
5-9 
10-14 
15-19 
20-24 
25-29 
30-34 
35-39 
40-44 
45-49 
50-54 
55-59 
60-64 
65-69 
70-74 
75-79 
80-84 
85+ 
C
rude rate 
(/100,000) 
Lip 0.00 0.00 0.00 0.00 0.00 0.00 0.21 0.00 0.30 0.76 0.00 1.26 2.52 0.85 2.08 2.32 2.83 3.18 0.25 
Tongue 0.00 0.00 0.00 0.13 0.00 0.00 0.00 0.00 0.00 0.76 1.09 0.63 0.00 1.70 6.23 4.63 7.01 7.18 0.28 
Mouth 0.00 0.00 0.00 0.13 0.00 0.18 0.21 0.00 0.30 0.00 2.18 0.00 0.63 3.39 4.15 6.95 7.16 8.70 0.32 
Salivary glands 0.00 0.00 0.00 0.13 0.00 0.37 0.21 0.47 0.30 0.38 1.64 0.00 0.63 0.85 0.00 0.00 0.00 0.00 0.25 
Tonsil 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.08 0.00 1.34 0.83 0.03 
Other oropharynx 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Nasopharynx 0.00 0.00 0.00 0.00 0.34 0.37 0.21 0.94 0.59 0.38 1.09 0.00 2.52 0.85 2.08 0.00 1.34 0.83 0.37 
Hypopharynx 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.73 0.63 0.63 3.39 3.11 2.32 3.50 3.59 0.23 
Pharynx unspecified 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.38 0.00 1.89 0.00 0.00 0.00 0.00 0.00 0.00 0.08 
Esophagus 0.18 0.00 0.00 0.26 0.00 0.18 0.83 1.17 6.23 7.98 19.10 27.68 51.64 55.14 73.70 78.79 98.38 109.19 6.68 
Stomach 0.37 0.12 0.21 0.39 0.51 0.18 2.07 1.64 2.97 6.08 14.73 17.61 35.27 43.26 46.71 53.30 64.52 72.62 5.42 
Small intestine 0.00 0.00 0.00 0.00 0.00 0.18 0.00 0.00 0.59 0.00 1.64 0.00 1.26 2.54 1.04 2.32 2.16 2.76 0.20 
Colon 0.37 0.00 0.00 0.26 0.34 0.37 1.86 4.68 5.05 6.08 10.91 11.32 8.82 11.88 16.61 13.90 19.68 20.70 2.65 
Rectum 0.00 0.00 0.00 0.00 0.34 0.37 0.83 0.47 2.08 2.28 4.36 6.29 5.04 2.54 6.23 11.59 11.49 14.22 1.15 
Anus 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.30 0.00 0.00 0.63 0.63 0.00 0.00 0.00 0.00 0.00 0.05 
Liver 0.18 0.12 0.10 0.00 0.17 0.18 0.00 0.00 0.30 0.00 1.09 0.00 1.26 2.54 5.19 2.32 4.84 4.41 0.38 
Gallbladder 0.18 0.00 0.10 0.13 0.00 0.37 0.21 0.00 0.30 0.38 0.00 0.00 6.93 3.39 5.19 2.32 4.84 4.41 0.51 
Pancreas 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.47 0.00 0.00 2.73 0.63 1.26 4.24 3.11 9.27 7.99 10.64 0.58 
Nose, sinuses 0.00 0.00 0.10 0.00 0.00 0.18 0.00 0.00 0.00 0.38 0.00 0.00 1.89 0.00 1.04 0.00 0.67 0.41 0.12 
Larynx 0.18 0.00 0.00 0.00 0.17 0.00 0.00 0.47 0.30 0.38 0.55 1.26 3.15 1.70 4.15 0.00 2.68 1.65 0.35 
Lung 0.00 0.00 0.21 0.13 0.17 0.00 0.00 0.70 0.89 1.14 1.09 1.89 3.15 5.94 9.34 13.90 15.00 17.81 0.81 
Other thoracic organs 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.26 0.00 1.70 0.00 0.00 0.00 0.00 0.08 
Bone 0.18 0.12 0.62 0.13 0.68 0.18 0.21 0.70 0.30 0.38 1.09 0.00 0.00 1.70 2.08 6.95 5.82 7.87 0.46 
Melanoma of skin 0.00 0.00 0.00 0.00 0.00 0.00 0.62 0.00 0.89 0.00 0.00 1.26 0.63 0.85 2.08 6.95 5.82 7.87 0.32 
Other skin 0.00 0.12 0.10 0.13 0.34 0.73 0.83 1.87 6.53 10.64 19.64 12.58 17.63 23.75 30.10 69.52 64.27 82.46 4.29 
Mesothelioma 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.63 0.00 0.00 0.00 0.00 0.00 0.02 
Kaposi sarcoma 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Connective & soft tissue 0.18 0.12 0.00 0.26 0.17 0.37 0.41 0.23 0.89 0.38 3.27 0.63 0.00 3.39 0.00 2.32 1.49 2.35 0.43 
Breast 0.55 0.12 0.10 0.26 0.85 4.59 12.01 21.53 37.40 39.12 36.01 31.45 30.23 22.90 17.65 20.86 24.84 28.16 10.57 
Vulva 0.00 0.00 0.00 0.00 0.00 0.00 0.21 0.00 0.00 0.00 0.00 1.26 1.26 0.00 0.00 0.00 0.00 0.00 0.08 
Vagina 0.18 0.00 0.00 0.00 0.00 0.00 0.00 0.23 0.00 0.38 0.00 1.26 0.00 0.85 0.00 0.00 0.00 0.00 0.12 
Cervix uteri 0.18 0.00 0.00 0.00 0.00 0.00 0.21 2.81 2.97 1.52 8.18 9.44 7.56 6.79 4.15 18.54 14.64 20.45 1.47 
Corpus uteri 0.00 0.00 0.00 0.00 0.00 0.00 0.62 0.47 0.89 0.38 2.73 1.26 3.78 9.33 0.00 2.32 1.49 2.35 0.58 
Uterus unspecified 0.00 0.00 0.00 0.00 0.00 0.00 0.41 0.47 0.89 0.76 1.64 1.89 3.15 3.39 1.04 2.32 2.16 2.76 0.55 
Ovary 0.00 0.12 0.10 1.45 0.17 0.73 1.24 2.11 2.37 4.56 3.82 1.26 5.04 4.24 2.08 6.95 5.82 7.87 1.35 
Other female genitalia 0.00 0.00 0.00 0.00 0.17 0.18 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.03 
Placenta 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Kidney 1.11 0.74 0.00 0.13 0.17 0.18 0.00 0.70 0.59 0.76 1.64 0.63 1.89 0.00 0.00 6.95 4.48 7.05 0.52 
Renal pelvis 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Ureter 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Bladder 0.00 0.00 0.00 0.26 0.17 0.18 0.00 0.00 0.59 0.76 2.18 3.15 3.15 5.09 9.34 6.95 10.51 10.76 0.78 
Other urinary organs 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Eye 0.37 0.12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.55 0.63 0.00 0.00 0.00 2.32 1.49 2.35 0.11 
Brain, nervous system 0.55 0.98 0.72 0.79 1.02 1.29 1.45 1.87 1.48 3.04 2.73 4.40 6.30 1.70 3.11 4.63 5.00 5.94 1.52 
Thyroid 0.00 0.00 0.21 0.26 0.51 1.47 1.45 1.40 3.56 2.28 1.09 1.89 2.52 2.54 3.11 2.32 3.50 3.59 1.00 
Adrenal gland 0.00 0.12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 
Other endocrine 0.00 0.00 0.10 0.00 0.00 0.00 0.00 0.23 0.00 0.00 0.55 1.26 0.00 0.00 0.00 0.00 0.00 0.00 0.08 
Hodgkin disease 0.00 0.12 0.41 1.18 0.51 0.55 1.04 1.17 0.59 0.38 2.18 1.26 1.89 0.85 1.04 0.00 0.67 0.41 0.70 
Non-Hodgkin lymphoma 0.18 0.86 0.31 0.66 0.68 0.73 1.45 1.40 1.48 3.04 5.46 3.77 4.41 6.79 8.30 4.63 8.35 8.00 1.56 
Immunoproliferative 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Multiple myeloma 0.00 0.00 0.10 0.00 0.17 0.00 0.00 0.23 0.59 0.38 1.64 0.63 5.04 3.39 4.15 2.32 4.17 4.00 0.46 
Lymphoid leukemia 0.18 0.00 0.10 0.00 0.00 0.00 0.00 0.47 0.30 0.00 0.00 0.63 1.89 0.85 0.00 4.63 2.99 4.70 0.21 
Myeloid leukemia 0.18 0.00 0.31 0.26 0.00 0.37 0.00 0.00 0.30 0.38 1.64 0.63 1.26 0.85 0.00 2.32 1.49 2.35 0.32 
Leukemia unspecified 1.85 1.97 1.34 1.18 0.68 0.18 0.62 0.94 2.08 0.76 3.82 2.52 1.26 4.24 5.19 13.90 12.32 16.16 1.69 
Other and unspecified 0.92 0.98 0.62 0.13 0.85 1.29 1.66 0.70 2.08 2.66 3.82 4.40 8.82 11.03 10.38 13.90 15.67 18.23 2.07 
All sites 8.13 6.77 5.87 8.68 9.21 15.98 31.07 50.55 87.28 99.89 168.59 161.04 235.55 260.42 295.86 405.56 452.47 528.83 52.09 
All sites excluding skin 8.13 6.64 5.77 8.55 8.87 15.25 30.24 48.67 80.74 89.26 148.95 148.46 217.91 236.67 265.75 336.04 388.20 446.37 47.79 
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Golestan 
 
Appendix Table 14. Age-specific incidence rates in Golestan, male (corrected) 
Age-specific incidence rates (per 100,000 person-years) 
Sites 0-4 
5-9 
10-14 
15-19 
20-24 
25-29 
30-34 
35-39 
40-44 
45-49 
50-54 
55-59 
60-64 
65-69 
70-74 
75-79 
80-84 
85+ 
C
rude rate 
(/100,000) 
Lip 0.00 0.00 0.00 0.24 0.36 0.00 0.44 0.00 1.31 0.00 3.63 1.40 4.96 4.92 17.31 11.70 18.71 18.74 0.82 
Tongue 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.40 0.00 1.64 0.00 0.00 0.00 0.00 0.06 
Mouth 0.00 0.00 0.00 0.00 0.00 0.39 0.00 0.00 0.00 0.93 0.00 0.00 0.00 0.00 2.16 0.00 1.40 0.86 0.11 
Salivary glands 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Tonsil 0.00 0.18 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.93 0.00 0.00 0.00 0.00 0.00 5.85 3.77 5.93 0.08 
Other oropharynx 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Nasopharynx 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.28 0.00 0.00 0.00 0.00 0.06 
Hypopharynx 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.86 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.06 
Pharynx unspecified 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.31 0.00 0.00 1.40 0.00 8.20 6.49 0.00 4.19 2.58 0.31 
Esophagus 0.00 0.00 0.00 0.00 0.00 1.18 2.61 3.87 16.43 18.60 58.12 54.44 95.49 108.29 179.61 210.53 251.67 284.86 12.50 
Stomach 0.72 0.18 0.00 0.49 0.72 0.79 1.31 1.45 7.23 10.23 24.22 37.69 80.61 95.16 162.30 152.05 202.78 218.69 9.52 
Small intestine 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.21 0.00 0.00 0.00 2.16 0.00 1.40 0.86 0.08 
Colon 0.00 0.00 0.00 0.00 1.07 0.39 1.74 1.93 1.97 1.86 2.42 2.79 7.44 4.92 12.98 35.09 31.01 40.74 1.32 
Rectum 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.87 1.31 1.86 6.05 4.19 3.72 8.20 6.49 11.70 11.73 14.44 1.01 
Anus 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.42 1.40 0.00 0.00 0.00 0.00 0.00 0.00 0.08 
Liver 0.00 0.00 0.00 0.00 0.00 0.39 0.00 0.48 1.31 0.00 0.00 5.58 4.96 4.92 8.66 0.00 5.58 3.44 0.53 
Gallbladder 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.24 0.00 0.00 5.85 3.77 5.93 0.06 
Pancreas 0.00 0.00 0.00 0.00 0.36 0.00 0.00 0.00 0.66 0.93 2.42 2.79 4.96 3.28 12.98 11.70 15.92 17.02 0.65 
Nose, sinuses 0.00 0.00 0.00 0.00 0.00 0.00 0.44 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.03 
Larynx 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.66 2.79 2.42 1.40 1.24 3.28 6.49 17.54 15.51 20.37 0.45 
Lung 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.97 0.93 2.42 0.00 11.16 3.28 12.98 11.70 15.92 17.02 0.87 
Other thoracic organs 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.64 0.00 0.00 0.00 0.00 0.03 
Bone 0.24 0.18 0.18 0.24 0.36 0.79 0.00 0.48 0.66 0.93 0.00 2.79 1.24 1.64 2.16 0.00 1.40 0.86 0.48 
Melanoma of skin 0.00 0.00 0.00 0.00 0.00 0.00 0.44 0.48 0.00 0.00 0.00 0.00 3.72 0.00 0.00 5.85 3.77 5.93 0.23 
Other skin 0.00 0.00 0.18 0.73 0.00 1.57 0.87 3.38 5.26 13.02 13.32 18.15 23.56 26.25 36.79 81.87 76.55 97.64 4.17 
Mesothelioma 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.48 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.03 
Kaposi sarcoma 0.00 0.00 0.00 0.00 0.00 0.00 0.44 0.00 0.00 0.00 1.21 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.06 
Connective & soft tissue 0.00 0.00 0.00 0.00 0.00 0.39 0.00 0.00 0.00 0.00 0.00 1.40 0.00 0.00 0.00 0.00 0.00 0.00 0.08 
Breast 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.63 0.00 2.42 2.79 2.48 1.64 8.66 5.85 9.36 9.37 0.48 
Vulva 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Vagina 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Cervix uteri 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Corpus uteri 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Uterus unspecified 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Ovary 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Other female genitalia 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Placenta 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Penis 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.48 0.00 0.00 0.00 0.00 0.00 0.06 
Prostate 0.00 0.00 0.00 0.00 0.72 0.39 0.00 0.00 0.00 0.93 3.63 5.58 9.92 24.61 56.26 116.96 111.74 140.95 2.67 
Testis 0.24 0.00 0.00 0.00 0.36 2.36 0.00 0.97 0.66 0.93 1.21 1.40 1.24 0.00 0.00 0.00 0.00 0.00 0.42 
Other male genitalia 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Kidney 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.66 0.93 1.21 0.00 8.68 6.56 8.66 0.00 5.58 3.44 0.59 
Renal pelvis 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.48 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.03 
Ureter 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Bladder 0.00 0.00 0.00 0.00 0.00 1.18 0.87 1.93 2.63 6.51 8.48 8.37 12.40 26.25 25.97 93.57 77.11 105.19 2.56 
Other urinary organs 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Eye 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Brain, nervous system 0.00 0.00 0.36 0.49 0.72 0.79 2.18 1.45 0.66 0.00 2.42 0.00 2.48 4.92 2.16 0.00 1.40 0.86 0.76 
Thyroid 0.00 0.00 0.00 0.24 0.00 0.00 0.00 1.93 0.66 2.79 1.21 0.00 0.00 0.00 2.16 0.00 1.40 0.86 0.34 
Adrenal gland 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Other endocrine 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Hodgkin disease 0.00 0.36 0.36 0.73 0.36 0.39 0.00 1.45 1.31 0.00 1.21 2.79 0.00 0.00 0.00 5.85 3.77 5.93 0.56 
Non-Hodgkin lymphoma 0.24 0.36 0.18 0.97 1.07 1.18 0.44 0.48 4.60 3.72 6.05 5.58 2.48 3.28 19.48 5.85 16.34 13.67 1.49 
Immunoproliferative 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Multiple myeloma 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.93 1.21 1.40 1.24 1.64 0.00 11.70 7.54 11.86 0.25 
Lymphoid leukemia 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.16 5.85 5.17 6.79 0.06 
Myeloid leukemia 0.00 0.00 0.00 0.00 0.36 0.00 0.87 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.14 
Leukemia unspecified 1.67 0.71 1.43 0.97 1.07 0.00 1.31 0.97 0.00 0.00 0.00 1.40 1.24 0.00 4.33 5.85 6.56 7.65 1.15 
Other and unspecified 0.24 0.36 0.18 0.97 0.72 0.79 1.74 0.97 3.29 2.79 6.05 1.40 12.40 3.28 12.98 35.09 31.01 40.74 1.69 
All sites 3.35 2.31 2.87 6.09 8.22 12.99 15.66 27.06 57.18 74.40 154.98 167.49 301.36 351.11 612.42 847.95 942.06 1103.23 46.94 
All sites excluding skin 3.35 2.31 2.69 5.36 8.22 11.41 14.79 23.68 51.92 61.38 141.66 149.35 277.80 324.86 575.63 766.08 865.52 1005.59 42.77 
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Appendix Table 15. Age-specific incidence rates in Golestan, female (corrected) 
Age-specific incidence rates (per 100,000 person-years) 
Sites 0-4 
5-9 
10-14 
15-19 
20-24 
25-29 
30-34 
35-39 
40-44 
45-49 
50-54 
55-59 
60-64 
65-69 
70-74 
75-79 
80-84 
85+ 
C
rude rate 
(/100,000) 
Lip 0.25 0.00 0.00 0.45 0.00 0.38 0.00 0.99 0.64 0.00 2.31 3.03 10.10 5.81 8.15 6.40 9.39 9.73 0.73 
Tongue 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.64 0.83 2.31 0.00 4.33 1.94 5.43 6.40 7.64 8.65 0.34 
Mouth 0.00 0.00 0.00 0.00 0.00 0.00 0.43 0.00 0.64 0.00 1.15 0.00 1.44 3.87 2.72 12.80 10.01 14.06 0.25 
Salivary glands 0.00 0.00 0.00 0.00 0.00 0.38 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.03 
Tonsil 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Other oropharynx 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Nasopharynx 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Hypopharynx 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.83 0.00 1.52 0.00 0.00 2.72 0.00 1.75 1.08 0.08 
Pharynx unspecified 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.49 0.64 0.00 1.15 1.52 0.00 3.87 5.43 0.00 3.51 2.16 0.22 
Esophagus 0.00 0.00 0.00 0.00 0.30 1.13 0.85 2.97 12.82 18.23 32.29 56.11 77.95 75.52 89.67 108.83 128.05 146.00 8.21 
Stomach 0.00 0.19 0.00 0.00 0.00 0.00 2.14 1.98 2.56 0.83 5.77 10.61 25.98 25.17 59.78 32.01 59.21 56.22 2.63 
Small intestine 0.00 0.00 0.00 0.00 0.00 0.00 0.43 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.72 0.00 1.75 1.08 0.06 
Colon 0.00 0.00 0.00 0.00 0.30 0.38 0.85 0.99 3.20 6.63 2.31 12.13 8.66 17.43 16.30 6.40 14.65 12.97 1.56 
Rectum 0.00 0.00 0.00 0.00 0.30 1.13 0.43 2.47 1.28 0.83 3.46 10.61 7.22 3.87 8.15 0.00 5.26 3.24 1.03 
Anus 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Liver 0.00 0.00 0.00 0.00 0.00 0.00 0.43 0.00 0.00 0.83 1.15 0.00 2.89 0.00 5.43 0.00 3.51 2.16 0.20 
Gallbladder 0.00 0.00 0.00 0.00 0.00 0.00 0.43 0.49 0.64 0.83 1.15 0.00 1.44 1.94 5.43 12.80 11.77 15.14 0.31 
Pancreas 0.00 0.19 0.00 0.00 0.00 0.00 0.00 0.49 0.00 0.00 0.00 0.00 0.00 3.87 10.87 0.00 7.01 4.32 0.25 
Nose, sinuses 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Larynx 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.94 2.72 0.00 1.75 1.08 0.06 
Lung 0.00 0.00 0.00 0.00 0.00 0.38 0.00 0.99 0.00 1.66 0.00 1.52 1.44 1.94 2.72 12.80 10.01 14.06 0.34 
Other thoracic organs 0.00 0.00 0.00 0.23 0.00 0.00 0.43 0.00 0.64 0.00 0.00 1.52 0.00 0.00 0.00 0.00 0.00 0.00 0.11 
Bone 0.00 0.19 0.18 0.91 0.00 0.00 1.28 0.00 0.00 0.00 0.00 0.00 2.89 1.94 0.00 6.40 4.13 6.49 0.39 
Melanoma of skin 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.64 1.66 1.15 3.03 0.00 0.00 2.72 12.80 10.01 14.06 0.28 
Other skin 0.25 0.19 0.00 0.45 0.30 0.76 0.43 2.47 8.33 9.12 17.30 16.68 11.55 17.43 40.76 44.81 55.20 61.64 2.99 
Mesothelioma 0.25 0.00 0.18 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.06 
Kaposi sarcoma 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.64 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.03 
Connective & soft tissue 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.52 0.00 0.00 0.00 0.00 0.00 0.00 0.03 
Breast 0.00 0.00 0.00 0.00 2.07 4.91 13.25 21.75 28.84 29.83 21.91 9.10 18.77 21.30 29.89 38.41 44.06 50.83 7.12 
Vulva 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.72 6.40 5.88 7.57 0.06 
Vagina 0.00 0.00 0.00 0.00 0.30 0.00 0.43 0.00 0.00 0.83 1.15 0.00 2.89 5.81 0.00 6.40 4.13 6.49 0.31 
Cervix uteri 0.00 0.00 0.00 0.00 0.30 0.76 4.27 2.97 5.77 8.29 9.23 6.07 4.33 13.55 2.72 0.00 1.75 1.08 1.73 
Corpus uteri 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.64 0.00 3.46 1.52 4.33 3.87 5.43 12.80 11.77 15.14 0.45 
Uterus unspecified 0.00 0.00 0.00 0.23 0.30 0.00 0.85 0.99 1.92 3.31 5.77 0.00 1.44 3.87 0.00 0.00 0.00 0.00 0.64 
Ovary 0.25 0.00 0.18 0.45 0.59 1.89 0.43 5.44 4.49 3.31 5.77 7.58 2.89 3.87 2.72 0.00 1.75 1.08 1.45 
Other female genitalia 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.03 0.00 1.94 0.00 0.00 0.00 0.00 0.08 
Placenta 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.83 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.03 
Kidney 0.50 0.00 0.00 0.00 0.00 0.00 0.43 0.00 0.00 2.49 3.46 3.03 0.00 1.94 0.00 0.00 0.00 0.00 0.36 
Renal pelvis 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Ureter 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.94 0.00 0.00 0.00 0.00 0.03 
Bladder 0.00 0.00 0.00 0.00 0.00 0.00 0.43 0.99 1.92 0.00 0.00 1.52 4.33 7.75 16.30 12.80 18.78 19.46 0.64 
Other urinary organs 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Eye 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Brain, nervous system 0.25 0.37 0.55 0.00 0.30 0.38 0.43 1.48 0.00 0.83 1.15 1.52 2.89 0.00 0.00 6.40 4.13 6.49 0.61 
Thyroid 0.00 0.00 0.37 0.23 0.00 0.76 0.43 2.97 4.49 3.31 1.15 1.52 1.44 5.81 5.43 0.00 3.51 2.16 0.92 
Adrenal gland 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Other endocrine 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Hodgkin disease 0.00 0.00 0.18 0.68 0.89 0.76 0.85 0.00 0.64 0.83 1.15 1.52 1.44 0.00 0.00 0.00 0.00 0.00 0.47 
Non-Hodgkin lymphoma 0.00 0.37 0.55 0.00 1.18 1.51 2.14 0.49 1.92 0.83 0.00 1.52 7.22 0.00 8.15 6.40 9.39 9.73 0.98 
Immunoproliferative 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Multiple myeloma 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.49 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.06 
Lymphoid leukemia 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6.40 4.13 6.49 0.03 
Myeloid leukemia 0.00 0.00 0.00 0.00 0.30 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.03 
Leukemia unspecified 1.00 0.94 1.28 0.23 1.18 0.76 0.43 0.99 2.56 2.49 2.31 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.12 
Other and unspecified 0.00 0.00 0.73 1.36 0.89 1.13 0.43 0.49 0.64 4.14 2.31 6.07 7.22 5.81 13.59 19.21 21.15 24.88 1.56 
All sites 2.74 2.43 4.20 5.21 9.48 17.38 32.92 53.38 87.15 103.58 130.31 163.77 215.08 243.97 358.70 377.72 475.05 525.58 38.85 
All sites excluding skin 2.49 2.25 4.20 4.75 9.18 16.63 32.49 50.91 78.82 94.47 113.01 147.09 203.54 226.55 317.93 332.91 419.85 463.94 35.87 
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Appendix Table 16. Age-specific incidence rates in Kerman, male (corrected) 
Age-specific incidence rates (per 100,000 person-years) 
Sites 0-4 
5-9 
10-14 
15-19 
20-24 
25-29 
30-34 
35-39 
40-44 
45-49 
50-54 
55-59 
60-64 
65-69 
70-74 
75-79 
80-84 
85+ 
C
rude rate 
(/100,000) 
Lip 0.00 0.00 0.00 0.00 0.23 0.00 0.33 0.35 0.00 1.33 0.00 0.93 2.56 4.35 3.73 8.82 8.09 10.42 0.39 
Tongue 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.70 0.00 0.67 1.84 0.93 2.56 0.00 2.48 0.00 1.60 0.99 0.24 
Mouth 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.35 0.44 0.00 4.60 0.00 0.00 2.18 1.24 2.94 2.70 3.47 0.31 
Salivary glands 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.40 1.32 1.33 0.00 0.00 3.42 2.18 0.00 0.00 0.00 0.00 0.31 
Tonsil 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.44 0.67 0.00 0.00 0.00 0.00 2.48 0.00 1.60 0.99 0.08 
Other oropharynx 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Nasopharynx 0.00 0.00 0.00 0.32 0.00 0.29 0.00 0.35 0.88 0.67 0.00 0.00 0.85 0.00 1.24 2.94 2.70 3.47 0.20 
Hypopharynx 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.67 1.84 0.00 0.00 0.00 1.24 2.94 2.70 3.47 0.10 
Pharynx unspecified 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 
Esophagus 0.00 0.00 0.00 0.00 0.00 1.43 1.66 0.35 0.88 2.00 5.52 4.65 6.83 7.62 36.03 29.39 42.20 44.12 1.94 
Stomach 0.00 0.13 0.00 0.00 0.23 1.15 0.67 3.51 3.07 11.32 15.65 26.94 42.69 55.50 49.70 114.62 106.00 135.97 5.91 
Small intestine 0.00 0.00 0.00 0.00 0.23 0.00 0.00 0.35 0.00 1.33 0.92 1.86 0.00 1.09 0.00 5.88 3.79 5.96 0.24 
Colon 0.00 0.00 0.00 0.16 1.15 0.86 0.33 2.81 2.19 3.33 10.12 1.86 11.10 7.62 8.70 14.70 15.09 18.36 1.59 
Rectum 0.00 0.00 0.00 0.00 0.23 0.00 0.33 0.35 2.19 1.33 4.60 9.29 12.81 8.71 13.67 5.88 12.61 11.39 1.34 
Anus 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.93 1.71 2.18 2.48 0.00 1.60 0.99 0.18 
Liver 0.18 0.00 0.00 0.00 0.23 0.29 0.00 0.35 3.95 1.33 2.76 1.86 5.98 3.26 14.91 14.70 19.10 20.83 0.96 
Gallbladder 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.88 0.67 1.84 2.79 3.42 4.35 4.97 8.82 8.89 10.92 0.55 
Pancreas 0.00 0.26 0.00 0.00 0.00 0.00 0.33 0.35 1.75 1.33 0.00 2.79 3.42 5.44 7.45 5.88 8.60 8.92 0.73 
Nose, sinuses 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.94 1.90 2.98 0.02 
Larynx 0.00 0.13 0.00 0.00 0.00 0.29 0.33 1.40 6.58 5.33 8.28 8.36 13.66 13.06 16.15 26.45 27.48 33.24 2.08 
Lung 0.00 0.00 0.00 0.00 0.23 0.57 0.67 0.35 1.75 2.66 20.25 24.15 40.13 33.73 44.73 64.66 70.56 83.34 4.16 
Other thoracic organs 0.00 0.00 0.00 0.00 0.23 0.00 0.67 1.05 1.32 0.00 0.00 3.72 4.27 3.26 1.24 5.88 4.59 6.45 0.53 
Bone 0.18 0.00 0.74 2.69 1.61 1.15 0.67 0.35 0.88 1.33 1.84 0.93 0.85 3.26 1.24 2.94 2.70 3.47 1.04 
Melanoma of skin 0.18 0.00 0.12 0.00 0.23 0.00 0.33 0.70 0.88 0.00 0.92 1.86 6.83 3.26 6.21 17.63 15.38 20.35 0.75 
Other skin 0.18 0.26 0.37 0.00 0.92 1.15 3.33 3.16 12.71 16.65 29.45 25.08 34.15 55.50 83.24 120.50 131.43 155.27 8.07 
Mesothelioma 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Kaposi sarcoma 0.00 0.00 0.00 0.16 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.85 1.09 0.00 0.00 0.00 0.00 0.06 
Connective & soft tissue 0.70 0.26 0.37 0.16 0.00 0.57 1.00 1.05 0.00 1.33 0.92 0.93 2.56 2.18 1.24 0.00 0.80 0.49 0.61 
Breast 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.35 0.88 1.33 1.84 0.93 3.42 0.00 1.24 2.94 2.70 3.47 0.35 
Vulva 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Vagina 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Cervix uteri 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Corpus uteri 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Uterus unspecified 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Ovary 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Other female genitalia 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Placenta 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Kidney 1.58 0.13 0.00 0.00 0.46 0.00 0.00 0.00 0.44 1.33 0.92 2.79 2.56 6.53 3.73 0.00 2.40 1.48 0.65 
Renal pelvis 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 
Ureter 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Bladder 0.18 0.00 0.25 0.00 0.46 0.57 2.66 1.05 1.75 6.66 9.20 16.72 23.05 44.62 49.70 67.60 75.66 88.29 4.34 
Other urinary organs 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.09 1.24 0.00 0.80 0.49 0.04 
Eye 0.18 0.13 0.00 0.00 0.23 0.00 0.33 0.00 0.00 0.00 0.00 0.00 0.85 0.00 4.97 2.94 5.10 4.96 0.24 
Brain, nervous system 0.70 1.70 0.99 0.48 0.00 0.86 2.33 2.11 1.75 6.00 7.36 9.29 5.12 6.53 3.73 5.88 6.20 7.44 1.89 
Thyroid 0.00 0.00 0.00 0.00 0.23 0.00 1.33 0.00 1.75 0.00 1.84 0.00 2.56 1.09 3.73 11.76 9.99 13.40 0.51 
Adrenal gland 0.00 0.00 0.25 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.04 
Other endocrine 0.00 0.00 0.00 0.16 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.85 0.00 0.00 0.00 0.00 0.00 0.04 
Hodgkin disease 0.70 1.31 1.48 1.11 2.77 1.15 1.33 2.46 1.32 4.66 2.76 2.79 2.56 0.00 2.48 2.94 3.50 3.97 1.67 
Non-Hodgkin lymphoma 1.23 2.09 1.60 0.79 2.54 0.86 2.33 3.16 5.70 5.33 14.73 15.79 18.78 19.59 22.36 26.45 31.49 35.71 4.09 
Immunoproliferative 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.92 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 
Multiple myeloma 0.00 0.13 0.12 0.16 0.00 0.57 0.67 0.70 0.44 2.00 2.76 5.57 9.39 8.71 1.24 17.63 12.18 18.37 1.04 
Lymphoid leukemia 0.00 0.13 0.37 0.16 0.00 0.00 0.33 0.35 0.88 4.66 1.84 5.57 7.68 5.44 4.97 14.70 12.69 16.88 1.02 
Myeloid leukemia 0.00 0.13 0.00 0.16 0.23 0.57 1.33 0.70 1.75 0.67 2.76 1.86 1.71 1.09 0.00 0.00 0.00 0.00 0.53 
Leukemia unspecified 2.99 3.13 3.08 2.22 1.38 2.01 1.66 1.05 2.19 4.66 4.60 0.93 5.98 2.18 3.73 8.82 8.09 10.42 2.91 
Other and unspecified 1.58 0.91 1.11 0.95 2.54 1.15 2.99 3.86 2.63 3.33 5.52 6.50 5.12 19.59 24.85 20.57 29.30 30.74 3.04 
All sites 10.89 10.97 10.84 9.98 16.84 16.04 30.93 37.56 65.76 97.92 170.27 192.31 302.24 354.75 474.59 684.79 747.90 883.00 57.77 
All sites excluding skin 10.71 10.70 10.47 9.98 15.91 14.90 27.60 34.40 53.05 81.27 140.82 167.22 268.09 299.25 391.35 564.29 616.47 727.73 49.70 
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Appendix Table 17. Age-specific incidence rates in Kerman, female (corrected) 
Age-specific incidence rates (per 100,000 person-years) 
Sites 0-4 
5-9 
10-14 
15-19 
20-24 
25-29 
30-34 
35-39 
40-44 
45-49 
50-54 
55-59 
60-64 
65-69 
70-74 
75-79 
80-84 
85+ 
C
rude rate 
(/100,000) 
Lip 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 2.60 1.51 3.50 3.23 4.15 0.14 
Tongue 0.00 0.00 0.00 0.00 0.00 0.00 0.33 0.36 0.00 0.00 0.00 0.00 3.99 0.00 1.51 0.00 0.97 0.60 0.20 
Mouth 0.00 0.00 0.25 0.00 0.00 0.28 0.33 0.00 0.00 0.65 1.85 2.02 0.00 6.49 0.00 0.00 0.00 0.00 0.30 
Salivary glands 0.00 0.13 0.00 0.00 0.00 0.00 0.33 0.00 0.00 1.29 0.00 2.02 0.00 0.00 3.01 0.00 1.94 1.20 0.20 
Tonsil 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Other oropharynx 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Nasopharynx 0.00 0.13 0.13 0.00 0.00 0.28 0.00 0.00 0.46 0.00 2.78 0.00 0.00 1.30 0.00 0.00 0.00 0.00 0.20 
Hypopharynx 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.65 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 
Pharynx unspecified 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.46 0.00 0.00 0.00 0.00 1.30 0.00 0.00 0.00 0.00 0.04 
Esophagus 0.00 0.13 0.00 0.00 0.00 0.00 0.98 0.72 1.83 5.82 2.78 4.05 4.98 3.89 15.05 7.00 14.23 13.08 1.03 
Stomach 0.00 0.13 0.00 0.00 0.00 1.13 1.63 2.15 6.86 6.47 12.95 9.11 21.92 27.26 24.08 28.01 33.61 37.98 2.74 
Small intestine 0.00 0.00 0.00 0.00 0.00 0.28 0.33 0.00 0.00 1.29 0.93 2.02 0.00 1.30 1.51 0.00 0.97 0.60 0.22 
Colon 0.00 0.00 0.00 0.33 0.94 1.13 0.33 1.07 2.29 3.88 9.25 11.13 10.96 16.88 3.01 10.50 8.72 11.85 1.70 
Rectum 0.00 0.00 0.00 0.00 0.00 0.00 0.65 2.15 1.83 2.59 4.63 10.12 14.95 9.09 3.01 7.00 6.46 8.30 1.28 
Anus 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.65 0.93 0.00 2.99 0.00 1.51 0.00 0.97 0.60 0.16 
Liver 0.37 0.00 0.00 0.33 0.00 0.28 0.00 0.36 0.92 0.65 3.70 0.00 4.98 1.30 4.52 7.00 7.43 8.90 0.49 
Gallbladder 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.36 0.92 0.65 3.70 2.02 12.95 9.09 22.58 10.50 21.34 19.63 1.10 
Pancreas 0.00 0.00 0.13 0.00 0.00 0.28 0.00 0.36 0.46 0.65 2.78 1.01 1.00 6.49 9.03 10.50 12.60 14.24 0.53 
Nose, sinuses 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.01 0.00 0.00 1.51 0.00 0.97 0.60 0.06 
Larynx 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.36 0.00 0.65 4.63 2.02 1.00 2.60 4.52 3.50 5.17 5.35 0.32 
Lung 0.00 0.00 0.13 0.17 0.47 0.28 0.33 0.36 2.75 3.88 4.63 3.04 7.97 15.58 19.57 21.01 26.18 29.08 1.40 
Other thoracic organs 0.00 0.00 0.00 0.00 0.00 0.00 0.33 0.36 0.92 0.65 1.85 1.01 3.99 0.00 1.51 0.00 0.97 0.60 0.26 
Bone 0.00 0.27 1.38 1.16 1.89 1.41 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.75 
Melanoma of skin 0.00 0.13 0.13 0.00 0.00 0.00 0.00 0.00 0.92 0.00 0.93 4.05 3.99 0.00 6.02 3.50 6.14 5.94 0.47 
Other skin 0.00 0.13 0.13 0.00 0.24 3.39 3.25 4.30 5.95 19.41 31.46 26.31 38.86 49.33 54.19 101.54 100.46 124.50 6.69 
Mesothelioma 0.00 0.00 0.00 0.00 0.00 0.00 0.33 0.36 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.04 
Kaposi sarcoma 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Connective & soft tissue 0.00 0.00 0.13 0.50 0.71 1.13 0.33 1.07 1.83 0.65 0.93 1.01 1.00 1.30 3.01 0.00 1.94 1.20 0.59 
Breast 0.00 0.00 0.00 0.17 0.94 4.81 11.38 17.18 36.61 40.77 66.61 28.33 29.90 40.24 42.15 49.02 58.81 66.46 9.90 
Vulva 0.18 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 3.01 0.00 1.94 1.20 0.12 
Vagina 0.00 0.00 0.00 0.33 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.01 0.00 1.94 1.20 0.08 
Cervix uteri 0.00 0.00 0.00 0.00 0.24 0.00 1.63 3.22 3.20 7.12 17.58 7.08 5.98 6.49 7.53 10.50 11.63 13.64 1.68 
Corpus uteri 0.00 0.00 0.00 0.00 0.00 0.57 0.00 0.00 0.46 0.65 1.85 2.02 2.99 6.49 0.00 0.00 0.00 0.00 0.41 
Uterus unspecified 0.00 0.00 0.00 0.00 0.24 0.85 0.00 0.36 0.00 0.65 3.70 2.02 1.99 1.30 1.51 0.00 0.97 0.60 0.37 
Ovary 0.00 0.00 0.50 0.50 0.94 0.85 1.63 1.43 1.37 1.29 3.70 4.05 7.97 5.19 9.03 7.00 10.34 10.69 1.32 
Other female genitalia 0.00 0.00 0.00 0.00 0.47 0.28 0.00 0.00 0.46 0.00 0.93 0.00 1.99 2.60 1.51 0.00 0.97 0.60 0.20 
Placenta 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Kidney 1.10 0.13 0.13 0.17 0.00 0.00 0.33 0.00 0.46 0.65 0.00 1.01 1.00 3.89 1.51 0.00 0.97 0.60 0.41 
Renal pelvis 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Ureter 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Bladder 0.00 0.00 0.00 0.00 0.00 0.00 0.33 0.72 0.46 1.29 5.55 4.05 8.97 5.19 4.52 14.01 11.95 16.00 0.99 
Other urinary organs 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Eye 0.37 0.13 0.00 0.00 0.00 0.28 0.33 0.36 0.00 0.00 1.85 0.00 1.00 1.30 1.51 10.50 7.75 11.25 0.28 
Brain, nervous system 0.37 0.94 0.13 1.16 1.18 0.57 1.95 1.79 2.75 4.53 4.63 5.06 5.98 3.89 6.02 0.00 3.88 2.39 1.46 
Thyroid 0.00 0.00 0.38 0.00 1.18 1.41 2.60 2.15 4.58 5.82 7.40 2.02 2.99 7.79 6.02 10.50 10.66 13.04 1.60 
Adrenal gland 0.00 0.00 0.00 0.00 0.24 0.28 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.04 
Other endocrine 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.30 0.00 0.00 0.00 0.00 0.04 
Hodgkin disease 0.00 0.27 0.75 3.16 0.94 0.57 1.63 0.00 0.00 0.65 0.00 1.01 2.99 0.00 0.00 0.00 0.00 0.00 0.89 
Non-Hodgkin lymphoma 0.00 1.07 0.63 1.16 0.94 1.13 1.95 1.07 2.29 2.59 3.70 3.04 10.96 6.49 19.57 17.51 23.92 25.53 1.85 
Immunoproliferative 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.02 
Multiple myeloma 0.00 0.00 0.13 0.17 0.00 0.00 0.00 0.00 0.46 0.00 1.85 2.02 9.97 3.89 6.02 3.50 6.14 5.94 0.59 
Lymphoid leukemia 0.18 0.00 0.25 0.00 0.00 0.28 0.00 0.00 0.92 2.59 0.93 1.01 3.99 7.79 7.53 0.00 4.85 2.99 0.63 
Myeloid leukemia 0.00 0.00 0.00 0.33 0.47 1.41 0.33 0.00 0.46 1.29 0.00 1.01 2.99 0.00 1.51 3.50 3.23 4.15 0.41 
Leukemia unspecified 2.39 1.74 1.50 2.66 1.65 0.85 0.65 1.79 1.83 3.88 3.70 4.05 6.98 5.19 10.54 0.00 6.80 4.19 2.21 
Other and unspecified 0.18 0.80 0.38 1.00 0.71 0.85 1.30 1.07 2.75 6.47 5.55 13.15 10.96 6.49 12.04 21.01 21.32 26.09 2.05 
All sites 5.16 6.17 7.14 13.29 14.38 24.90 35.45 45.46 87.41 130.72 220.20 162.89 259.09 271.32 325.13 360.64 442.38 494.92 48.49 
All sites excluding skin 5.16 6.04 7.02 13.29 14.14 21.50 32.20 41.17 81.46 111.31 188.74 136.58 220.23 221.99 270.94 259.10 341.92 370.43 41.80 
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Appendix Table 18. Relative frequency, crude incidence rate, age-standardized rate (ASR) 
and cumulative rate by cancer site and sex (before correction for elderly ages or unknown 
age cases) 
Male Female 
Cumulative rate 
(percent) 
Cumulative rate 
(percent) 
Sites No. of 
cases 
Relative 
freq. % 
Crude 
rate (per 
100,000) 
ASR* (per 
100,000) 0–64 0–69 
No. of 
cases 
Relative 
freq. % 
Crude 
rate (per 
100,000) 
ASR (per 
100,000) 0–64 0–69 
Lip 115 0.84 0.50 0.70 0.04 0.06 53 0.50 0.23 0.34 0.02 0.03 
Tongue 50 0.37 0.22 0.31 0.02 0.03 68 0.64 0.30 0.41 0.03 0.03 
Mouth 68 0.50 0.29 0.42 0.03 0.03 62 0.58 0.27 0.40 0.02 0.04 
Salivary glands 42 0.31 0.18 0.24 0.02 0.02 34 0.32 0.15 0.16 0.01 0.01 
Tonsil 13 0.10 0.06 0.08 0.00 0.01 8 0.08 0.03 0.06 0.00 0.01 
Other oropharynx 2 0.01 0.01 0.01 0.00 0.00 0 0.00 0.00 0.00 0.00 0.00 
Nasopharynx 101 0.74 0.44 0.57 0.04 0.05 47 0.44 0.20 0.25 0.02 0.02 
Hypopharynx 27 0.20 0.12 0.17 0.01 0.01 29 0.27 0.13 0.20 0.01 0.02 
Pharynx unspecified 40 0.29 0.17 0.25 0.01 0.03 28 0.26 0.12 0.19 0.01 0.02 
Esophagus 1751 12.83 7.59 10.71 0.55 0.82 1230 11.60 5.35 8.04 0.52 0.72 
Stomach 3297 24.15 14.30 19.89 1.05 1.66 1309 12.34 5.70 8.33 0.50 0.74 
Small intestine 71 0.52 0.31 0.41 0.02 0.03 40 0.38 0.17 0.25 0.02 0.02 
Colon 610 4.47 2.64 3.48 0.22 0.29 594 5.60 2.58 3.62 0.25 0.33 
Rectum 346 2.53 1.50 1.99 0.12 0.16 296 2.79 1.29 1.84 0.14 0.16 
Anus 39 0.29 0.17 0.24 0.02 0.02 20 0.19 0.09 0.14 0.01 0.01 
Liver 199 1.46 0.86 1.14 0.06 0.09 131 1.23 0.57 0.79 0.05 0.07 
Gallbladder 96 0.70 0.42 0.63 0.03 0.05 156 1.47 0.68 0.99 0.06 0.08 
Pancreas 195 1.43 0.85 1.06 0.05 0.10 126 1.19 0.55 0.75 0.03 0.05 
Nose, sinuses 36 0.26 0.16 0.20 0.01 0.02 18 0.17 0.08 0.11 0.01 0.01 
Larynx 412 3.02 1.79 2.43 0.15 0.21 66 0.62 0.29 0.42 0.03 0.04 
Lung, trachea & bronchus 943 6.91 4.09 5.72 0.29 0.47 224 2.11 0.97 1.39 0.07 0.12 
Other thoracic organs 55 0.40 0.24 0.32 0.02 0.03 30 0.28 0.13 0.18 0.02 0.02 
Bone 193 1.41 0.84 0.89 0.06 0.07 132 1.24 0.57 0.59 0.04 0.04 
Melanoma of skin 90 0.66 0.39 0.52 0.03 0.04 71 0.67 0.31 0.41 0.02 0.03 
Other skin 1584 0.00 6.87 9.60 0.52 0.73 1122 0.00 4.88 7.11 0.42 0.56 
Mesothelioma 6 0.04 0.03 0.03 0.00 0.00 7 0.07 0.03 0.04 0.00 0.00 
Kaposi sarcoma 24 0.18 0.10 0.14 0.01 0.01 7 0.07 0.03 0.05 0.00 0.00 
Connective and soft tissue 116 0.85 0.50 0.59 0.04 0.05 95 0.90 0.41 0.46 0.03 0.04 
Breast 157 1.15 0.68 0.96 0.07 0.08 2120 19.98 9.22 12.26 0.98 1.10 
Vulva 0 0.00 0.00 0.00 0.00 0.00 17 0.16 0.07 0.11 0.01 0.01 
Vagina 0 0.00 0.00 0.00 0.00 0.00 39 0.37 0.17 0.23 0.01 0.02 
Cervix uteri 0 0.00 0.00 0.00 0.00 0.00 333 3.14 1.45 2.10 0.17 0.20 
Corpus uteri 0 0.00 0.00 0.00 0.00 0.00 148 1.40 0.64 0.95 0.07 0.10 
Uterus unspecified 0 0.00 0.00 0.00 0.00 0.00 164 1.55 0.71 0.95 0.07 0.09 
Ovary 0 0.00 0.00 0.00 0.00 0.00 334 3.15 1.45 1.79 0.14 0.16 
Other female genitalia 0 0.00 0.00 0.00 0.00 0.00 21 0.20 0.09 0.12 0.01 0.01 
Placenta 0 0.00 0.00 0.00 0.00 0.00 2 0.02 0.01 0.01 0.00 0.00 
Penis 13 0.10 0.06 0.10 0.01 0.01 0 0.00 0.00 0.00 0.00 0.00 
Prostate 815 5.97 3.53 3.94 0.11 0.22 0 0.00 0.00 0.00 0.00 0.00 
Testis 194 1.42 0.84 0.89 0.07 0.07 0 0.00 0.00 0.00 0.00 0.00 
Other male genitalia 1 0.01 0.00 0.01 0.00 0.00 0 0.00 0.00 0.00 0.00 0.00 
Kidney 196 1.44 0.85 1.12 0.07 0.10 113 1.07 0.49 0.64 0.04 0.05 
Renal pelvis 2 0.01 0.01 0.00 0.00 0.00 0 0.00 0.00 0.00 0.00 0.00 
Ureter 1 0.01 0.00 0.01 0.00 0.00 1 0.01 0.00 0.01 0.00 0.00 
Bladder 1082 7.93 4.69 6.46 0.33 0.51 220 2.07 0.96 1.34 0.08 0.11 
Other urinary organs 3 0.02 0.01 0.02 0.00 0.00 3 0.03 0.01 0.02 0.00 0.00 
Eye 21 0.15 0.09 0.12 0.00 0.00 32 0.30 0.14 0.18 0.01 0.01 
Brain, nervous system 394 2.89 1.71 2.03 0.14 0.17 314 2.96 1.37 1.63 0.13 0.14 
Thyroid 114 0.84 0.49 0.57 0.04 0.05 337 3.18 1.47 1.56 0.11 0.13 
Adrenal gland 2 0.01 0.01 0.01 0.00 0.00 4 0.04 0.02 0.02 0.00 0.00 
Other endocrine 18 0.13 0.08 0.08 0.01 0.01 10 0.09 0.04 0.05 0.00 0.01 
Hodgkin disease 243 1.78 1.05 1.11 0.08 0.09 149 1.40 0.65 0.64 0.05 0.05 
Non-Hodgkin lymphoma 603 4.42 2.61 3.26 0.21 0.26 290 2.73 1.26 1.51 0.10 0.12 
Immunoproliferative 2 0.01 0.01 0.02 0.00 0.00 1 0.01 0.00 0.01 0.00 0.00 
Multiple myeloma 168 1.23 0.73 1.01 0.07 0.09 82 0.77 0.36 0.51 0.03 0.05 
Lymphoid leukemia 118 0.86 0.51 0.68 0.04 0.06 61 0.58 0.27 0.36 0.02 0.03 
Myeloid leukemia 61 0.45 0.26 0.29 0.02 0.02 52 0.49 0.23 0.26 0.02 0.02 
Leukemia unspecified 507 3.71 2.20 2.08 0.12 0.14 350 3.30 1.52 1.60 0.10 0.11 
Other and unspecified 0 0.00 0.00 0.00 0.00 0.00 530 5.00 2.31 2.77 0.18 0.23 
All sites 15236 0.00 66.06 87.52 4.83 6.97 11730 0.00 51.04 69.14 4.68 5.99 
All sites excluding skin 13652 100.00 59.19 77.92 4.32 6.24 10608 100.00 46.16 62.03 4.26 5.43 
* ASR=Age-standardized rate 
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Provinces 
 
Appendix Table 19. Age-standardized rate (ASR) by province and sex (before correction 
for elderly ages or unknown age cases) 
ASR (per 100,000) by province and sex 
All 5 provinces Ardebil Kerman Mazandaran Gilan Golestan Site 
Both Male Female Male Female Male Female Male Female Male Female Male Female
Lip 0.54 0.70 0.34 0.00 0.00 0.61 0.26 0.50 0.34 0.83 0.09 1.46 1.24 
Tongue 0.36 0.31 0.41 0.47 0.54 0.36 0.23 0.48 0.41 0.06 0.44 0.11 0.61 
Mouth 0.42 0.42 0.40 0.30 0.00 0.52 0.51 0.42 0.45 0.45 0.30 0.21 0.48 
Salivary glands 0.22 0.24 0.16 0.13 0.27 0.44 0.25 0.27 0.25 0.23 0.13 0.00 0.03 
Tonsil 0.08 0.08 0.06 0.13 0.29 0.12 0.00 0.00 0.04 0.06 0.07 0.13 0.00 
Other oropharynx 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.02 0.00 0.00 0.00 
Nasopharynx 0.42 0.57 0.25 0.25 0.13 0.25 0.25 1.12 0.41 0.50 0.25 0.10 0.00 
Hypopharynx 0.18 0.17 0.20 0.21 0.17 0.19 0.04 0.18 0.37 0.13 0.15 0.11 0.16 
Pharynx unspecified 0.22 0.25 0.19 0.51 0.45 0.04 0.07 0.09 0.10 0.24 0.18 0.51 0.41 
Esophagus 9.54 10.71 8.04 10.21 16.10 2.70 1.60 11.56 9.68 8.28 5.10 22.44 15.20 
Stomach 14.43 19.89 8.33 31.40 26.52 9.31 4.64 18.17 7.30 20.92 8.04 16.47 4.65 
Small intestine 0.34 0.41 0.25 0.13 0.08 0.37 0.36 0.38 0.30 0.60 0.27 0.19 0.08 
Colon 3.54 3.48 3.62 3.52 3.73 2.42 2.79 3.27 3.39 4.48 4.81 1.86 2.77 
Rectum 1.92 1.99 1.84 0.68 1.28 2.06 2.15 2.09 1.59 2.38 2.11 1.53 1.67 
Anus 0.20 0.24 0.14 0.25 0.48 0.26 0.31 0.26 0.07 0.17 0.05 0.18 0.00 
Liver 0.98 1.14 0.79 1.14 2.18 1.39 0.80 0.78 0.42 1.33 0.92 0.88 0.36 
Gallbladder 0.81 0.63 0.99 0.42 1.75 0.91 1.85 0.84 0.69 0.46 0.70 0.11 0.55 
Pancreas 0.92 1.06 0.75 0.51 0.91 1.03 0.90 0.92 0.73 1.28 0.72 1.12 0.38 
Nose, sinuses 0.16 0.20 0.11 0.17 0.13 0.03 0.07 0.33 0.17 0.26 0.13 0.03 0.00 
Larynx 1.47 2.43 0.42 0.72 0.24 3.17 0.62 3.21 0.47 2.23 0.44 0.84 0.11 
Lung, trachea & bronchus 3.66 5.72 1.39 5.09 3.11 6.72 2.31 7.16 0.97 4.68 0.99 1.56 0.55 
Other thoracic organs 0.25 0.32 0.18 0.08 0.15 0.78 0.46 0.16 0.10 0.34 0.10 0.05 0.15 
Bone 0.75 0.89 0.59 1.57 1.45 1.06 0.60 0.59 0.51 0.86 0.44 0.55 0.43 
Melanoma of skin 0.47 0.52 0.41 0.21 0.19 1.00 0.76 0.50 0.33 0.27 0.28 0.43 0.50 
Other skin 8.46 9.60 7.11 8.26 9.14 12.06 10.77 8.32 5.95 9.48 6.12 6.91 5.33 
Mesothelioma 0.03 0.03 0.04 0.00 0.00 0.00 0.04 0.03 0.03 0.06 0.05 0.03 0.05 
Kaposi sarcoma 0.10 0.14 0.05 0.13 0.00 0.08 0.00 0.13 0.00 0.22 0.16 0.09 0.04 
Connective and soft tissue 0.53 0.59 0.46 0.38 0.42 0.68 0.66 0.86 0.53 0.49 0.45 0.17 0.06 
Breast 6.62 0.96 12.26 0.38 7.61 0.55 15.40 1.15 12.77 1.23 12.03 0.85 10.14 
Vulva    0.11   0.14   0.16   0.11   0.03   0.12 
Vagina    0.23   0.25   0.09   0.13   0.27   0.51 
Cervix uteri    2.10   0.74   2.86   2.06   1.80   2.70 
Corpus uteri    0.95   0.40   0.60   0.81   1.58   0.86 
Uterus unspecified    0.95   3.59   0.60   0.61   0.73   0.93 
Ovary    1.79   1.42   1.65   1.57   2.12   1.98 
Other female genitalia    0.12   0.00   0.32   0.03   0.10   0.18 
Placenta    0.01   0.05   0.00   0.00   0.00   0.05 
Penis  0.10   0.08   0.09   0.08   0.11   0.10   
Prostate  3.94   2.71   2.91   3.99   4.29   5.06   
Testis  0.89   0.72   0.69   0.82   1.38   0.57   
Other male genitalia  0.01   0.00   0.00   0.02   0.00   0.00   
Kidney 0.89 1.12 0.64 1.57 0.00 0.88 0.49 0.78 0.65 1.32 0.89 0.95 0.68 
Renal pelvis 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.03 0.00 
Ureter 0.01 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.04 0.00 0.00 0.06 
Bladder 4.01 6.46 1.34 4.96 2.12 6.22 1.51 5.37 0.98 8.11 1.48 4.48 1.12 
Other urinary organs 0.02 0.02 0.02 0.00 0.08 0.06 0.00 0.02 0.00 0.00 0.05 0.00 0.00 
Eye 0.15 0.12 0.18 0.08 0.31 0.28 0.43 0.09 0.13 0.07 0.10 0.00 0.00 
Brain, nervous system 1.84 2.03 1.63 2.84 2.93 2.46 1.96 2.56 1.68 1.05 1.43 0.86 0.70 
Thyroid 1.07 0.57 1.56 0.42 0.98 0.66 2.22 0.45 1.12 0.63 1.91 0.53 1.24 
Adrenal gland 0.01 0.01 0.02 0.00 0.00 0.02 0.04 0.00 0.01 0.00 0.02 0.00 0.00 
Other endocrine 0.06 0.08 0.05 0.17 0.08 0.05 0.04 0.15 0.10 0.02 0.03 0.00 0.00 
Hodgkin disease 0.88 1.11 0.64 0.38 0.46 1.78 0.80 1.34 0.71 0.82 0.55 0.59 0.52 
Non-Hodgkin lymphoma 2.40 3.26 1.51 1.78 0.60 5.45 2.50 3.26 1.82 2.34 0.83 2.23 1.36 
Immunoproliferative 0.01 0.02 0.01 0.00 0.00 0.05 0.04 0.00 0.00 0.04 0.00 0.00 0.00 
Multiple myeloma 0.77 1.01 0.51 0.17 0.13 1.55 0.98 1.15 0.61 1.03 0.42 0.39 0.03 
Lymphoid leukemia 0.53 0.68 0.36 0.38 0.37 1.58 0.99 0.71 0.28 0.37 0.15 0.10 0.06 
Myeloid leukemia 0.28 0.29 0.26 0.25 0.24 0.67 0.53 0.29 0.38 0.14 0.08 0.08 0.02 
Leukemia unspecified 1.87 2.08 1.60 0.59 0.87 2.81 2.52 2.65 1.77 2.07 1.32 1.04 1.10 
Other and unspecified 3.41 0.00 2.77 4.79 4.59 3.83 2.97 3.33 2.35 4.59 2.69 2.63 2.38 
All sites 81.43 87.52 69.14 89.16 97.67 81.13 72.98 90.86 66.28 90.97 64.09 78.55 62.57 
All sites excluding skin 72.96 77.92 62.03 80.90 88.53 69.07 62.21 82.54 60.32 81.49 57.97 71.63 57.24 
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Appendix Table 20. Age-standardized rate (ASR) by province, male (before correction for 
elderly ages or unknown age cases) 
 ASR (per 100,000) 
Rank All 5 Provinces Ardebil Kerman Mazandaran Gilan Golestan 
1 Stomach 19.89 Stomach 31.40 Other skin 12.06 Stomach 18.17 Stomach 20.92 Esophagus 22.44
2 Esophagus 10.71 Esophagus 10.21 Stomach 9.31 Esophagus 11.56 Other skin 9.48 Stomach 16.47
3 Other skin 9.60 Other skin 8.26 Lung, trachea & bronchus 6.72 Other skin 8.32 Esophagus 8.28 Other skin 6.91 
4 Bladder 6.46 Lung 5.09 Bladder 6.22 Lung 7.16 Bladder 8.11 Prostate 5.06 
5 Lung, trachea & bronchus 5.72 Bladder 4.96 Non-Hodgkin lymphoma 5.45 Bladder 5.37 Lung 4.68 Bladder 4.48 
6 Prostate 3.94 Colon 3.52 Larynx 3.17 Prostate 3.99 Colon 4.48 Non-Hodgkin lymphoma 2.23 
7 Colon 3.48 Brain, nervous system 2.84 Prostate 2.91 Colon 3.27 Prostate 4.29 Colon 1.86 
8 Non-Hodgkin lymphoma 3.26 Prostate 2.71 Leukemia unspecified 2.81 Non-Hodgkin lymphoma 3.26 Rectum 2.38 Lung 1.56 
9 Larynx 2.43 Non-Hodgkin lymphoma 1.78 Esophagus 2.70 Larynx 3.21 Non-Hodgkin lymphoma 2.34 Rectum 1.53 
10 Leukemia unspecified 2.08 Bone 1.57 Brain, nervous system 2.46 Leukemia unspecified 2.65 Larynx 2.23 Lip 1.46 
11 Brain, nervous system 2.03 Kidney 1.57 Colon 2.42 Brain, nervous system 2.56 Leukemia unspecified 2.07 Pancreas 1.12 
12 Rectum 1.99 Liver 1.14 Rectum 2.06 Rectum 2.09 Testis 1.38 Leukemia unspecified 1.04 
13 Liver 1.14 Larynx 0.72 Hodgkin disease 1.78 Hodgkin disease 1.34 Liver 1.33 Kidney 0.95 
14 Kidney 1.12 Testis 0.72 Lymphoid leukemia 1.58 Multiple myeloma 1.15 Kidney 1.32 Liver 0.88 
15 Hodgkin disease 1.11 Rectum 0.68 Multiple myeloma 1.55 Breast 1.15 Pancreas 1.28 Brain, nervous system 0.86 
16 Pancreas 1.06 Leukemia unspecified 0.59 Liver 1.39 Nasopharynx 1.12 Breast 1.23 Breast 0.85 
17 Multiple myeloma 1.01 Pharynx unspecified 0.51 Bone 1.06 Pancreas 0.92 Brain, nervous system 1.05 Larynx 0.84 
18 Breast 0.96 Pancreas 0.51 Pancreas 1.03 Connective & soft tissue 0.86 Multiple myeloma 1.03 Hodgkin disease 0.59 
19 Testis 0.89 Tongue 0.47 Melanoma of skin 1.00 Gallbladder 0.84 Bone 0.86 Testis 0.57 
20 Bone 0.89 Gallbladder 0.42 Gallbladder 0.91 Testis 0.82 Lip 0.83 Bone 0.55 
21 Lip 0.70 Thyroid 0.42 Kidney 0.88 Liver 0.78 Hodgkin disease 0.82 Thyroid 0.53 
22 Lymphoid leukemia 0.68 Connective & soft tissue 0.38 Other thoracic organs 0.78 Kidney 0.78 Thyroid 0.63 Pharynx unspecified 0.51 
23 Gallbladder 0.63 Breast 0.38 Testis 0.69 Lymphoid leukemia 0.71 Small intestine 0.60 Melanoma of skin 0.43 
24 Connective & soft tissue 0.59 Hodgkin disease 0.38 Connective& soft tissue 0.68 Bone 0.59 Nasopharynx 0.50 Multiple myeloma 0.39 
25 Thyroid 0.57 Lymphoid leukemia 0.38 Myeloid leukemia 0.67 Melanoma of skin 0.50 Connective & soft tissue 0.49 Mouth 0.21 
26 Nasopharynx 0.57 Mouth 0.30 Thyroid 0.66 Lip 0.50 Gallbladder 0.46 Small intestine 0.19 
27 Melanoma of skin 0.52 Nasopharynx 0.25 Lip 0.61 Tongue 0.48 Mouth 0.45 Anus 0.18 
28 Mouth 0.42 Anus 0.25 Breast 0.55 Thyroid 0.45 Lymphoid leukemia 0.37 Connective& soft tissue 0.17 
29 Small intestine 0.41 Myeloid leukemia 0.25 Mouth 0.52 Mouth 0.42 Other thoracic organs 0.34 Tonsil 0.13 
30 Other thoracic organs 0.32 Hypopharynx 0.21 Salivary glands 0.44 Small intestine 0.38 Melanoma of skin 0.27 Hypopharynx 0.11 
31 Tongue 0.31 Melanoma of skin 0.21 Small intestine 0.37 Nose, sinuses 0.33 Nose, sinuses 0.26 Gallbladder 0.11 
32 Myeloid leukemia 0.29 Nose, sinuses 0.17 Tongue 0.36 Myeloid leukemia 0.29 Pharynx unspecified 0.24 Tongue 0.11 
33 Pharynx unspecified 0.25 Other endocrine 0.17 Eye 0.28 Salivary glands 0.27 Salivary glands 0.23 Lymphoid leukemia 0.10 
34 Salivary glands 0.24 Multiple myeloma 0.17 Anus 0.26 Anus 0.26 Kaposi sarcoma 0.22 Penis 0.10 
35 Anus 0.24 Salivary glands 0.13 Nasopharynx 0.25 Hypopharynx 0.18 Anus 0.17 Nasopharynx 0.10 
36 Nose, sinuses 0.20 Tonsil 0.13 Hypopharynx 0.19 Other thoracic organs 0.16 Myeloid leukemia 0.14 Kaposi sarcoma 0.09 
37 Hypopharynx 0.17 Small intestine 0.13 Tonsil 0.12 Other endocrine 0.15 Hypopharynx 0.13 Myeloid leukemia 0.08 
38 Kaposi sarcoma 0.14 Kaposi sarcoma 0.13 Penis 0.09 Kaposi sarcoma 0.13 Penis 0.11 Other thoracic organs 0.05 
39 Eye 0.12 Other thoracic organs 0.08 Kaposi sarcoma 0.08 Eye 0.09 Eye 0.07 Mesothelioma 0.03 
40 Penis 0.10 Penis 0.08 Other urinary organs 0.06 Pharynx unspecified 0.09 Tongue 0.06 Renal pelvis 0.03 
41 Tonsil 0.08 Eye 0.08 Other endocrine 0.05 Penis 0.08 Tonsil 0.06 Nose, sinuses 0.03 
42 Other endocrine 0.08 Lip 0.00 Immunoproliferative 0.05 Mesothelioma 0.03 Mesothelioma 0.06 Salivary glands 0.00 
43 Mesothelioma 0.03 Other oropharynx 0.00 Pharynx unspecified 0.04 Other male genitalia 0.02 Ureter 0.04 Other oropharynx 0.00 
44 Immunoproliferative 0.02 Mesothelioma 0.00 Nose, sinuses 0.03 Other urinary organs 0.02 Immunoproliferative 0.04 Other male genitalia 0.00 
45 Other urinary organs 0.02 Other male genitalia 0.00 Adrenal gland 0.02 Other oropharynx 0.01 Other endocrine 0.02 Ureter 0.00 
46 Ureter 0.01 Renal pelvis 0.00 Other oropharynx 0.00 Tonsil 0.00 Other oropharynx 0.02 Other urinary organs 0.00 
47 Other oropharynx 0.01 Ureter 0.00 Mesothelioma 0.00 Renal pelvis 0.00 Other male genitalia 0.00 Eye 0.00 
48 Other male genitalia 0.01 Other urinary organs 0.00 Other male genitalia 0.00 Ureter 0.00 Renal pelvis 0.00 Adrenal gland 0.00 
49 Adrenal gland 0.01 Adrenal gland 0.00 Renal pelvis 0.00 Adrenal gland 0.00 Other urinary organs 0.00 Other endocrine 0.00 
50 Renal pelvis 0.00 Immunoproliferative 0.00 Ureter 0.00 Immunoproliferative 0.00 Adrenal gland 0.00 Immunoproliferative 0.00 
 Other & unspecified 0.00 Other & unspecified 4.79 Other & unspecified 3.83 Other & unspecified 3.33 Other & unspecified 4.59 Other & unspecified 2.63 
 All sites 87.52 All sites 89.16 All sites 81.13 All sites 90.86 All sites 90.97 All sites 78.55
 All sites excluding skin 77.92 All sites excluding skin 80.90 All sites excluding skin 69.07 All sites excluding skin 82.54 All sites excluding skin 81.49 All sites excluding skin 71.63
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Appendix Table 21. Age-standardized rate (ASR) by province, female (before correction 
for elderly ages or unknown age cases) 
ASR (per 100,000) Rank All 5 Provinces Ardebil Kerman Mazandaran Gilan Golestan 
1 Breast 12.26 Stomach 26.52 Breast 15.40 Breast 12.77 Breast 12.03 Esophagus 15.20
2 Stomach 8.33 Esophagus 16.10 Other skin 10.77 Esophagus 9.68 Stomach 8.04 Breast 10.14
3 Esophagus 8.04 Other skin 9.14 Stomach 4.64 Stomach 7.30 Other skin 6.12 Other skin 5.33 
4 Other skin 7.11 Breast 7.61 Cervix uteri 2.86 Other skin 5.95 Esophagus 5.10 Stomach 4.65 
5 Colon 3.62 Colon 3.73 Colon 2.79 Colon 3.39 Colon 4.81 Colon 2.77 
6 Cervix uteri 2.10 Uterus unspecified 3.59 Leukemia unspecified 2.52 Cervix uteri 2.06 Ovary 2.12 Cervix uteri 2.70 
7 Rectum 1.84 Lung, trachea & bronchus 3.11 Non-Hodgkin lymphoma 2.50 Non-Hodgkin lymphoma 1.82 Rectum 2.11 Ovary 1.98 
8 Ovary 1.79 Brain, nervous system 2.93 Lung, trachea & bronchus 2.31 Leukemia unspecified 1.77 Thyroid 1.91 Rectum 1.67 
9 Brain, nervous system 1.63 Liver 2.18 Thyroid 2.22 Brain, nervous system 1.68 Cervix uteri 1.80 Non-Hodgkin lymphoma 1.36 
10 Leukemia unspecified 1.60 Bladder 2.12 Rectum 2.15 Rectum 1.59 Corpus uteri 1.58 Thyroid 1.24 
11 Thyroid 1.56 Gallbladder 1.75 Brain, nervous system 1.96 Ovary 1.57 Bladder 1.48 Lip 1.24 
12 Non-Hodgkin lymphoma 1.51 Bone 1.45 Gallbladder 1.85 Thyroid 1.12 Brain, nervous system 1.43 Bladder 1.12 
13 Lung, trachea & bronchus 1.39 Ovary 1.42 Ovary 1.65 Bladder 0.98 Leukemia unspecified 1.32 Leukemia unspecified 1.10 
14 Bladder 1.34 Rectum 1.28 Esophagus 1.60 Lung 0.97 Lung, trachea & bronchus 0.99 Uterus unspecified 0.93 
15 Gallbladder 0.99 Thyroid 0.98 Bladder 1.51 Corpus uteri 0.81 Liver 0.92 Corpus uteri 0.86 
16 Corpus uteri 0.95 Pancreas 0.91 Lymphoid leukemia 0.99 Pancreas 0.73 Kidney 0.89 Brain, nervous system 0.70 
17 Uterus unspecified 0.95 Leukemia unspecified 0.87 Multiple myeloma 0.98 Hodgkin disease 0.71 Non-Hodgkin lymphoma 0.83 Kidney 0.68 
18 Liver 0.79 Cervix uteri 0.74 Pancreas 0.90 Gallbladder 0.69 Uterus unspecified 0.73 Tongue 0.61 
19 Pancreas 0.75 Non-Hodgkin lymphoma 0.60 Hodgkin disease 0.80 Kidney 0.65 Pancreas 0.72 Gallbladder 0.55 
20 Hodgkin disease 0.64 Tongue 0.54 Liver 0.80 Multiple myeloma 0.61 Gallbladder 0.70 Lung 0.55 
21 Kidney 0.64 Anus 0.48 Melanoma of skin 0.76 Uterus unspecified 0.61 Hodgkin disease 0.55 Hodgkin disease 0.52 
22 Bone 0.59 Hodgkin disease 0.46 Connective& soft tissue 0.66 Connective& soft tissue 0.53 Connective& soft tissue 0.45 Vagina 0.51 
23 Multiple myeloma 0.51 Pharynx unspecified 0.45 Larynx 0.62 Bone 0.51 Bone 0.44 Melanoma of skin 0.50 
24 Connective& soft tissue 0.46 Connective& soft tissue 0.42 Uterus unspecified 0.60 Larynx 0.47 Tongue 0.44 Mouth 0.48 
25 Larynx 0.42 Corpus uteri 0.40 Bone 0.60 Mouth 0.45 Larynx 0.44 Bone 0.43 
26 Melanoma of skin 0.41 Lymphoid leukemia 0.37 Corpus uteri 0.60 Liver 0.42 Multiple myeloma 0.42 Pharynx unspecified 0.41 
27 Tongue 0.41 Eye 0.31 Myeloid leukemia 0.53 Tongue 0.41 Mouth 0.30 Pancreas 0.38 
28 Mouth 0.40 Tonsil 0.29 Mouth 0.51 Nasopharynx 0.41 Melanoma of skin 0.28 Liver 0.36 
29 Lymphoid leukemia 0.36 Salivary glands 0.27 Kidney 0.49 Myeloid leukemia 0.38 Vagina 0.27 Other female genital org. 0.18 
30 Lip 0.34 Vagina 0.25 Other thoracic organs 0.46 Hypopharynx 0.37 Small intestine 0.27 Hypopharynx 0.16 
31 Myeloid leukemia 0.26 Larynx 0.24 Eye 0.43 Lip 0.34 Nasopharynx 0.25 Other thoracic organs 0.15 
32 Small intestine 0.25 Myeloid leukemia 0.24 Small intestine 0.36 Melanoma of skin 0.33 Pharynx unspecified 0.18 Vulva 0.12 
33 Nasopharynx 0.25 Melanoma of skin 0.19 Other female genitalia 0.32 Small intestine 0.30 Kaposi sarcoma 0.16 Larynx 0.11 
34 Vagina 0.23 Hypopharynx 0.17 Anus 0.31 Lymphoid leukemia 0.28 Lymphoid leukemia 0.15 Small intestine 0.08 
35 Hypopharynx 0.20 Other thoracic organs 0.15 Lip 0.26 Salivary glands 0.25 Hypopharynx 0.15 Lymphoid leukemia 0.06 
36 Pharynx unspecified 0.19 Vulva 0.14 Nasopharynx 0.25 Nose, sinuses 0.17 Nose, sinuses 0.13 Connective& soft tissue 0.06 
37 Eye 0.18 Multiple myeloma 0.13 Salivary glands 0.25 Vagina 0.13 Salivary glands 0.13 Ureter 0.06 
38 Other thoracic organs 0.18 Nose, sinuses 0.13 Tongue 0.23 Eye 0.13 Other female genital org. 0.10 Placenta 0.05 
39 Salivary glands 0.16 Nasopharynx 0.13 Vulva 0.16 Vulva 0.11 Other thoracic org. 0.10 Mesothelioma 0.05 
40 Anus 0.14 Small intestine 0.08 Vagina 0.09 Other thoracic organs 0.10 Eye 0.10 Kaposi sarcoma 0.04 
41 Other female genital org. 0.12 Other urinary organs 0.08 Nose, sinuses 0.07 Other endocrine 0.10 Lip 0.09 Salivary glands 0.03 
42 Vulva 0.11 Other endocrine 0.08 Pharynx unspecified 0.07 Pharynx unspecified 0.10 Myeloid leukemia 0.08 Multiple myeloma 0.03 
43 Nose, sinuses 0.11 Placenta 0.05 Adrenal gland 0.04 Anus 0.07 Tonsil 0.07 Myeloid leukemia 0.02 
44 Tonsil 0.06 Lip 0.00 Mesothelioma 0.04 Tonsil 0.04 Mesothelioma 0.05 Tonsil 0.00 
45 Other endocrine 0.05 Mouth 0.00 Immunoproliferative 0.04 Other female genitalia 0.03 Other urinary org. 0.05 Other oropharynx 0.00 
46 Kaposi sarcoma 0.05 Other oropharynx 0.00 Other endocrine 0.04 Mesothelioma 0.03 Anus 0.05 Nasopharynx 0.00 
47 Mesothelioma 0.04 Mesothelioma 0.00 Hypopharynx 0.04 Adrenal gland 0.01 Other endocrine 0.03 Anus 0.00 
48 Other urinary organs 0.02 Kaposi sarcoma 0.00 Tonsil 0.00 Other oropharynx 0.00 Vulva 0.03 Nose, sinuses 0.00 
49 Adrenal gland 0.02 Other female genitalia 0.00 Other oropharynx 0.00 Kaposi sarcoma 0.00 Adrenal gland 0.02 Renal pelvis 0.00 
50 Placenta 0.01 Kidney 0.00 Kaposi sarcoma 0.00 Placenta 0.00 Other oropharynx 0.00 Other urinary organs 0.00 
51 Immunoproliferative 0.01 Renal pelvis 0.00 Placenta 0.00 Renal pelvis 0.00 Placenta 0.00 Eye 0.00 
52 Ureter 0.01 Ureter 0.00 Renal pelvis 0.00 Ureter 0.00 Renal pelvis 0.00 Adrenal gland 0.00 
53 Renal pelvis 0.00 Adrenal gland 0.00 Ureter 0.00 Other urinary organs 0.00 Ureter 0.00 Other endocrine 0.00 
54 Other oropharynx 0.00 Immunoproliferative 0.00 Other urinary organs 0.00 Immunoproliferative 0.00 Immunoproliferative 0.00 Immunoproliferative 0.00 
 Other& unspecified 2.77 Other& unspecified 4.59 Other& unspecified 2.97 Other& unspecified 2.35 Other& unspecified 2.69 Other& unspecified 2.38 
 All sites 69.14 All sites 97.67 All sites 72.98 All sites 66.28 All sites 64.09 All sites 62.57
 All sites excluding skin 62.03 All sites excluding skin 88.53 All sites excluding skin 62.21 All sites excluding skin 60.32 All sites excluding skin 57.97 All sites excluding skin 57.24
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Appendix Table 22. Age-standardized rate (ASR) by cancer site, year and sex in Gilan, 
Mazandaran, Golestan and Kerman but not Ardebil (before correction for elderly ages or 
unknown age cases) 
ASR by year and sex in 4 provinces  (Gilan, Mazandaran, Golestan and Kerman) 
1996 1997 1998 1999 2000 Site 
Male Female Male Female Male Female Male Female Male Female 
Lip 0.58 0.52 0.60 0.16 0.35 0.23 0.31 0.29 0.93 0.45 
Tongue 0.23 0.35 0.10 0.10 0.08 0.16 0.15 0.24 0.12 0.58 
Mouth 0.12 0.27 0.36 0.22 0.25 0.48 0.20 0.20 0.52 0.35 
Salivary glands 0.32 0.07 0.14 0.11 0.17 0.05 0.20 0.31 0.13 0.16 
Tonsil 0.08 0.00 0.06 0.04 0.06 0.00 0.03 0.03 0.00 0.00 
Other oropharynx 0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Nasopharynx 0.29 0.04 0.23 0.00 0.37 0.30 0.58 0.16 0.45 0.39 
Hypopharynx 0.06 0.09 0.07 0.08 0.17 0.14 0.19 0.26 0.14 0.11 
Pharynx unspecified 0.13 0.13 0.23 0.07 0.14 0.17 0.22 0.13 0.10 0.08 
Esophagus 7.37 5.29 7.30 5.25 6.41 4.20 7.23 5.49 8.48 5.95 
Stomach 10.71 3.11 10.68 4.76 11.20 4.52 12.44 5.13 15.00 5.72 
Small intestine 0.23 0.12 0.41 0.21 0.27 0.07 0.43 0.28 0.32 0.29 
Colon 1.78 1.59 1.89 2.36 2.03 2.85 2.75 3.84 3.46 3.74 
Rectum 1.21 1.04 1.23 1.30 1.40 1.75 2.16 1.54 1.98 1.96 
Anus 0.07 0.05 0.20 0.17 0.34 0.04 0.10 0.15 0.00 0.08 
Liver 0.78 0.41 0.66 0.26 1.19 0.64 1.05 0.56 0.81 0.75 
Gallbladder 0.53 0.73 0.37 0.81 0.26 0.84 0.50 0.99 0.59 0.67 
Pancreas 0.60 0.24 1.17 0.61 0.87 0.35 0.97 0.68 1.06 0.67 
Nose, sinuses 0.04 0.00 0.09 0.03 0.19 0.08 0.11 0.04 0.01 0.06 
Larynx 2.14 0.29 1.04 0.23 1.50 0.38 2.13 0.34 2.25 0.33 
Lung, trachea & bronchus 2.58 0.60 3.69 1.40 4.24 0.84 3.91 0.99 5.89 1.32 
Other thoracic organs 0.09 0.05 0.07 0.20 0.26 0.17 0.27 0.21 0.72 0.09 
Bone 0.55 0.44 0.43 0.32 0.66 0.22 0.82 0.45 0.68 0.59 
Melanoma of skin 0.41 0.32 0.68 0.19 0.42 0.53 0.30 0.44 0.31 0.49 
Other skin 5.16 3.85 5.06 4.16 6.74 4.55 8.08 6.01 8.15 6.24 
Mesothelioma 0.02 0.05 0.00 0.04 0.05 0.02 0.00 0.00 0.00 0.11 
Kaposi sarcoma 0.04 0.00 0.09 0.00 0.07 0.08 0.21 0.09 0.10 0.09 
Connective and soft tissue 0.66 0.28 0.23 0.29 0.15 0.54 0.46 0.07 0.59 0.55 
Breast 0.45 7.91 0.56 7.02 0.93 8.25 0.48 12.55 0.31 13.19 
Vulva   0.00   0.08   0.08   0.15   0.04 
Vagina   0.21   0.11   0.15   0.28   0.25 
Cervix uteri   1.26   1.08   1.47   2.40   1.96 
Corpus uteri   0.60   0.59   0.58   0.84   0.68 
Uterus unspecified   0.33   0.19   0.55   0.79   0.91 
Ovary   0.85   0.94   1.25   2.22   1.53 
Other female genitalia   0.17   0.12   0.08   0.06   0.10 
Placenta   0.00   0.00   0.00   0.00   0.04 
Penis 0.03   0.07   0.00   0.11   0.11   
Prostate 2.09   2.33   3.35   3.52   3.98   
Testis 0.44   0.30   0.48   0.97   0.93   
Other male genitalia 0.00   0.00   0.00   0.00   0.03   
Kidney 0.56 0.36 0.56 0.47 1.06 0.62 1.24 0.75 0.91 0.75 
Renal pelvis 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.00 
Ureter 0.00 0.00 0.00 0.00 0.00 0.04 0.06 0.00 0.00 0.00 
Bladder 3.62 0.68 3.84 0.90 5.39 1.38 5.37 1.01 6.55 1.32 
Other urinary organs 0.00 0.00 0.04 0.00 0.03 0.00 0.00 0.00 0.00 0.00 
Eye 0.06 0.04 0.03 0.14 0.12 0.15 0.18 0.25 0.09 0.13 
Brain, nervous system 1.35 1.62 1.22 0.85 1.24 1.28 1.70 1.50 1.31 0.96 
Thyroid 0.50 1.01 0.37 1.49 0.35 1.15 0.27 1.62 0.65 1.02 
Adrenal gland 0.00 0.00 0.00 0.07 0.03 0.02 0.00 0.00 0.00 0.00 
Other endocrine 0.15 0.08 0.04 0.00 0.02 0.07 0.02 0.08 0.02 0.02 
Hodgkin disease 0.79 0.50 0.90 0.21 1.03 0.45 1.12 0.67 1.02 0.84 
Non-Hodgkin lymphoma 2.07 1.12 1.98 0.85 2.23 1.09 3.28 1.59 3.17 1.58 
Immunoproliferative 0.05 0.00 0.00 0.04 0.06 0.00 0.00 0.00 0.00 0.00 
Multiple myeloma 0.42 0.11 0.81 0.48 1.20 0.37 0.79 0.59 1.48 0.77 
Lymphoid leukemia 0.54 0.12 0.99 0.24 0.49 0.58 0.71 0.36 0.37 0.40 
Myeloid leukemia 0.22 0.15 0.29 0.29 0.21 0.31 0.32 0.30 0.27 0.17 
Leukemia unspecified 1.35 1.27 2.00 1.24 1.83 1.74 2.23 1.38 2.54 1.77 
Other and unspecified 2.40 1.90 2.22 2.00 3.11 1.90 2.85 2.07 4.03 2.48 
All sites 53.89 40.22 55.64 42.76 63.02 47.74 70.98 60.39 80.59 62.74 
All sites excluding skin 48.73 36.37 50.58 38.60 56.27 43.19 62.91 54.38 72.45 56.51 
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Appendix Table 23. Age-standardized rate (ASR) by site and year in four provinces of 
Gilan, Mazandaran, Golestan and Kerman, male (before correction for elderly ages or 
unknown age cases) 
 ASR of each cancer site by year 
 1996 1997 1998 1999 2000 
1 Stomach 10.71 Stomach 10.68 Stomach 11.20 Stomach 12.44 Stomach 15.00
2 Esophagus 7.37 Esophagus 7.30 Other skin 6.74 Other skin 8.08 Esophagus 8.48 
3 Other skin 5.16 Other skin 5.06 Esophagus 6.41 Esophagus 7.23 Other skin 8.15 
4 Bladder 3.62 Bladder 3.84 Bladder 5.39 Bladder 5.37 Bladder 6.55 
5 Lung, trachea & bronchus 2.58 Lung, trachea & bronchus 3.69 Lung, trachea & bronchus 4.24 Lung, trachea & bronchus 3.91 Lung, trachea & bronchus 5.89 
6 Larynx 2.14 Prostate 2.33 Prostate 3.35 Prostate 3.52 Prostate 3.98 
7 Prostate 2.09 Leukemia unspecified 2.00 Non-Hodgkin lymphoma 2.23 Non-Hodgkin lymphoma 3.28 Colon 3.46 
8 Non-Hodgkin lymphoma 2.07 Non-Hodgkin lymphoma 1.98 Colon 2.03 Colon 2.75 Non-Hodgkin lymphoma 3.17 
9 Colon 1.78 Colon 1.89 Leukemia unspecified 1.83 Leukemia unspecified 2.23 Leukemia unspecified 2.54 
10 Brain, nervous system 1.35 Rectum 1.23 Larynx 1.50 Rectum 2.16 Larynx 2.25 
11 Leukemia unspecified 1.35 Brain, nervous system 1.22 Rectum 1.40 Larynx 2.13 Rectum 1.98 
12 Rectum 1.21 Pancreas 1.17 Brain, nervous system 1.24 Brain, nervous system 1.70 Multiple myeloma 1.48 
13 Hodgkin disease 0.79 Larynx 1.04 Multiple myeloma 1.20 Kidney 1.24 Brain, nervous system 1.31 
14 Liver 0.78 Lymphoid leukemia 0.99 Liver 1.19 Hodgkin disease 1.12 Pancreas 1.06 
15 Connective& soft tissue 0.66 Hodgkin disease 0.90 Kidney 1.06 Liver 1.05 Hodgkin disease 1.02 
16 Pancreas 0.60 Multiple myeloma 0.81 Hodgkin disease 1.03 Pancreas 0.97 Testis 0.93 
17 Lip 0.58 Melanoma of skin 0.68 Breast 0.93 Testis 0.97 Lip 0.93 
18 Kidney 0.56 Liver 0.66 Pancreas 0.87 Bone 0.82 Kidney 0.91 
19 Bone 0.55 Lip 0.60 Bone 0.66 Multiple myeloma 0.79 Liver 0.81 
20 Lymphoid leukemia 0.54 Kidney 0.56 Lymphoid leukemia 0.49 Lymphoid leukemia 0.71 Other thoracic organs 0.72 
21 Gallbladder 0.53 Breast 0.56 Testis 0.48 Nasopharynx 0.58 Bone 0.68 
22 Thyroid 0.50 Bone 0.43 Melanoma of skin 0.42 Gallbladder 0.50 Thyroid 0.65 
23 Breast 0.45 Small intestine 0.41 Nasopharynx 0.37 Breast 0.48 Gallbladder 0.59 
24 Testis 0.44 Gallbladder 0.37 Lip 0.35 Connective& soft tissue 0.46 Connective& soft tissue 0.59 
25 Multiple myeloma 0.42 Thyroid 0.37 Thyroid 0.35 Small intestine 0.43 Mouth 0.52 
26 Melanoma of skin 0.41 Mouth 0.36 Anus 0.34 Myeloid leukemia 0.32 Nasopharynx 0.45 
27 Salivary glands 0.32 Testis 0.30 Small intestine 0.27 Lip 0.31 Lymphoid leukemia 0.37 
28 Nasopharynx 0.29 Myeloid leukemia 0.29 Other thoracic organs 0.26 Melanoma of skin 0.30 Small intestine 0.32 
29 Small intestine 0.23 Pharynx unspecified 0.23 Gallbladder 0.26 Other thoracic organs 0.27 Breast 0.31 
30 Tongue 0.23 Connective& soft tissue 0.23 Mouth 0.25 Thyroid 0.27 Melanoma of skin 0.31 
31 Myeloid leukemia 0.22 Nasopharynx 0.23 Myeloid leukemia 0.21 Pharynx unspecified 0.22 Myeloid leukemia 0.27 
32 Other endocrine 0.15 Anus 0.20 Nose, sinuses 0.19 Kaposi sarcoma 0.21 Hypopharynx 0.14 
33 Pharynx unspecified 0.13 Salivary glands 0.14 Salivary glands 0.17 Mouth 0.20 Salivary glands 0.13 
34 Mouth 0.12 Tongue 0.10 Hypopharynx 0.17 Salivary glands 0.20 Tongue 0.12 
35 Other thoracic organs 0.09 Kaposi sarcoma 0.09 Connective& soft tissue 0.15 Hypopharynx 0.19 Penis 0.11 
36 Tonsil 0.08 Nose, sinuses 0.09 Pharynx unspecified 0.14 Eye 0.18 Kaposi sarcoma 0.10 
37 Anus 0.07 Other thoracic organs 0.07 Eye 0.12 Tongue 0.15 Pharynx unspecified 0.10 
38 Hypopharynx 0.06 Penis 0.07 Tongue 0.08 Nose, sinuses 0.11 Eye 0.09 
39 Eye 0.06 Hypopharynx 0.07 Kaposi sarcoma 0.07 Penis 0.11 Other male genitalia 0.03 
40 Immunoproliferative 0.05 Tonsil 0.06 Tonsil 0.06 Anus 0.10 Other endocrine 0.02 
41 Nose, sinuses 0.04 Other endocrine 0.04 Immunoproliferative 0.06 Ureter 0.06 Renal pelvis 0.02 
42 Kaposi sarcoma 0.04 Other urinary organs 0.04 Mesothelioma 0.05 Tonsil 0.03 Nose, sinuses 0.01 
43 Penis 0.03 Eye 0.03 Other urinary organs 0.03 Other endocrine 0.02 Tonsil 0.00 
44 Other oropharynx 0.03 Other oropharynx 0.00 Adrenal gland 0.03 Other oropharynx 0.00 Other oropharynx 0.00 
45 Mesothelioma 0.02 Mesothelioma 0.00 Other endocrine 0.02 Mesothelioma 0.00 Anus 0.00 
46 Other male genitalia 0.00 Other male genitalia 0.00 Other oropharynx 0.00 Other male genitalia 0.00 Mesothelioma 0.00 
47 Renal pelvis 0.00 Renal pelvis 0.00 Penis 0.00 Renal pelvis 0.00 Ureter 0.00 
48 Ureter 0.00 Ureter 0.00 Other male genitalia 0.00 Other urinary organs 0.00 Other urinary organs 0.00 
49 Other urinary organs 0.00 Adrenal gland 0.00 Renal pelvis 0.00 Adrenal gland 0.00 Adrenal gland 0.00 
50 Adrenal gland 0.00 Immunoproliferative 0.00 Ureter 0.00 Immunoproliferative 0.00 Immunoproliferative 0.00 
 Other& unspecified 2.40 Other& unspecified 2.22 Other& unspecified 3.11 Other& unspecified 2.85 Other& unspecified 4.03 
 All sites 53.89 All sites 55.64 All sites 63.02 All sites 70.98 All sites 80.59
 All sites excluding skin 48.73 All sites excluding skin 50.58 All sites excluding skin 56.27 All sites excluding skin 62.91 All sites excluding skin 72.45
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Appendix Table 24. Age-standardized rate (ASR) by site and year in four provinces of 
Gilan, Mazandaran, Golestan and Kerman, female (before correction for elderly ages or 
unknown age cases) 
 ASR of each cancer site by year 
 1996 1997 1998 1999 2000 
1 Breast 7.91 Breast 7.02 Breast 8.25 Breast 12.55 Breast 13.19
2 Esophagus 5.29 Esophagus 5.25 Other skin 4.55 Other skin 6.01 Other skin 6.24
3 Other skin 3.85 Stomach 4.76 Stomach 4.52 Esophagus 5.49 Esophagus 5.95
4 Stomach 3.11 Other skin 4.16 Esophagus 4.20 Stomach 5.13 Stomach 5.72
5 Brain, nervous system 1.62 Colon 2.36 Colon 2.85 Colon 3.84 Colon 3.74
6 Colon 1.59 Thyroid 1.49 Rectum 1.75 Cervix uteri 2.40 Cervix uteri 1.96
7 Leukemia unspecified 1.27 Lung, trachea & bronchus 1.40 Leukemia unspecified 1.74 Ovary 2.22 Rectum 1.96
8 Cervix uteri 1.26 Rectum 1.30 Cervix uteri 1.47 Thyroid 1.62 Leukemia unspecified 1.77
9 Non-Hodgkin lymphoma 1.12 Leukemia unspecified 1.24 Bladder 1.38 Non-Hodgkin lymphoma 1.59 Non-Hodgkin lymphoma 1.58
10 Rectum 1.04 Cervix uteri 1.08 Brain, nervous system 1.28 Rectum 1.54 Ovary 1.53
11 Thyroid 1.01 Ovary 0.94 Ovary 1.25 Brain, nervous system 1.50 Lung, trachea & bronchus 1.32
12 Ovary 0.85 Bladder 0.90 Thyroid 1.15 Leukemia unspecified 1.38 Bladder 1.32
13 Gallbladder 0.73 Non-Hodgkin lymphoma 0.85 Non-Hodgkin lymphoma 1.09 Bladder 1.01 Thyroid 1.02
14 Bladder 0.68 Brain, nervous system 0.85 Gallbladder 0.84 Gallbladder 0.99 Brain, nervous system 0.96
15 Lung, trachea & bronchus 0.60 Gallbladder 0.81 Lung, trachea & bronchus 0.84 Lung, trachea & bronchus 0.99 Uterus unspecified 0.91
16 Corpus uteri 0.60 Pancreas 0.61 Liver 0.64 Corpus uteri 0.84 Hodgkin disease 0.84
17 Lip 0.52 Corpus uteri 0.59 Kidney 0.62 Uterus unspecified 0.79 Multiple myeloma 0.77
18 Hodgkin disease 0.50 Multiple myeloma 0.48 Corpus uteri 0.58 Kidney 0.75 Kidney 0.75
19 Bone 0.44 Kidney 0.47 Lymphoid leukemia 0.58 Pancreas 0.68 Liver 0.75
20 Liver 0.41 Bone 0.32 Uterus unspecified 0.55 Hodgkin disease 0.67 Corpus uteri 0.68
21 Kidney 0.36 Myeloid leukemia 0.29 Connective& soft tissue 0.54 Multiple myeloma 0.59 Gallbladder 0.67
22 Tongue 0.35 Connective& soft tissue 0.29 Melanoma of skin 0.53 Liver 0.56 Pancreas 0.67
23 Uterus unspecified 0.33 Liver 0.26 Mouth 0.48 Bone 0.45 Bone 0.59
24 Melanoma of skin 0.32 Lymphoid leukemia 0.24 Hodgkin disease 0.45 Melanoma of skin 0.44 Tongue 0.58
25 Larynx 0.29 Larynx 0.23 Larynx 0.38 Lymphoid leukemia 0.36 Connective& soft tissue 0.55
26 Connective& soft tissue 0.28 Mouth 0.22 Multiple myeloma 0.37 Larynx 0.34 Melanoma of skin 0.49
27 Mouth 0.27 Small intestine 0.21 Pancreas 0.35 Salivary glands 0.31 Lip 0.45
28 Pancreas 0.24 Hodgkin disease 0.21 Myeloid leukemia 0.31 Myeloid leukemia 0.30 Lymphoid leukemia 0.40
29 Vagina 0.21 Other thoracic organs 0.20 Nasopharynx 0.30 Lip 0.29 Nasopharynx 0.39
30 Other female genitalia 0.17 Uterus unspecified 0.19 Lip 0.23 Vagina 0.28 Mouth 0.35
31 Myeloid leukemia 0.15 Melanoma of skin 0.19 Bone 0.22 Small intestine 0.28 Larynx 0.33
32 Pharynx unspecified 0.13 Anus 0.17 Other thoracic organs 0.17 Hypopharynx 0.26 Small intestine 0.29
33 Lymphoid leukemia 0.12 Lip 0.16 Pharynx unspecified 0.17 Eye 0.25 Vagina 0.25
34 Small intestine 0.12 Eye 0.14 Tongue 0.16 Tongue 0.24 Myeloid leukemia 0.17
35 Multiple myeloma 0.11 Other female genitalia 0.12 Vagina 0.15 Other thoracic organs 0.21 Salivary glands 0.16
36 Hypopharynx 0.09 Salivary glands 0.11 Eye 0.15 Mouth 0.20 Eye 0.13
37 Other endocrine 0.08 Vagina 0.11 Hypopharynx 0.14 Nasopharynx 0.16 Hypopharynx 0.11
38 Salivary glands 0.07 Tongue 0.10 Vulva 0.08 Vulva 0.15 Mesothelioma 0.11
39 Anus 0.05 Hypopharynx 0.08 Other female genitalia 0.08 Anus 0.15 Other female genitalia 0.10
40 Other thoracic organs 0.05 Vulva 0.08 Nose, sinuses 0.08 Pharynx unspecified 0.13 Other thoracic organs 0.09
41 Mesothelioma 0.05 Pharynx unspecified 0.07 Kaposi sarcoma 0.08 Kaposi sarcoma 0.09 Kaposi sarcoma 0.09
42 Nasopharynx 0.04 Adrenal gland 0.07 Other endocrine 0.07 Other endocrine 0.08 Anus 0.08
43 Eye 0.04 Mesothelioma 0.04 Small intestine 0.07 Connective& soft tissue 0.07 Pharynx unspecified 0.08
44 Tonsil 0.00 Immunoproliferative 0.04 Salivary glands 0.05 Other female genitalia 0.06 Nose, sinuses 0.06
45 Other oropharynx 0.00 Tonsil 0.04 Anus 0.04 Nose, sinuses 0.04 Vulva 0.04
46 Nose, sinuses 0.00 Nose, sinuses 0.03 Ureter 0.04 Tonsil 0.03 Placenta 0.04
47 Kaposi sarcoma 0.00 Other oropharynx 0.00 Mesothelioma 0.02 Other oropharynx 0.00 Other endocrine 0.02
48 Vulva 0.00 Nasopharynx 0.00 Adrenal gland 0.02 Mesothelioma 0.00 Tonsil 0.00
49 Placenta 0.00 Kaposi sarcoma 0.00 Tonsil 0.00 Placenta 0.00 Other oropharynx 0.00
50 Renal pelvis 0.00 Placenta 0.00 Other oropharynx 0.00 Renal pelvis 0.00 Renal pelvis 0.00
51 Ureter 0.00 Renal pelvis 0.00 Placenta 0.00 Ureter 0.00 Ureter 0.00
52 Other urinary organs 0.00 Ureter 0.00 Renal pelvis 0.00 Other urinary organs 0.00 Other urinary organs 0.00
53 Adrenal gland 0.00 Other urinary organs 0.00 Other urinary organs 0.00 Adrenal gland 0.00 Adrenal gland 0.00
54 Immunoproliferative 0.00 Other endocrine 0.00 Immunoproliferative 0.00 Immunoproliferative 0.00 Immunoproliferative 0.00
 Other& unspecified 1.90 Other& unspecified 2.00 Other& unspecified 1.90 Other& unspecified 2.07 Other& unspecified 2.48
 All sites 40.22 All sites 42.76 All sites 47.74 All sites 60.39 All sites 62.74
 All sites excluding skin 36.37 All sites excluding skin 38.60 All sites excluding skin 43.19 All sites excluding skin 54.38 All sites excluding skin 56.51
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Incidence rates after correction for elderly ages or cases of 
unknown age 
Appendix Table 25. Age-standardized rate (ASR) by province and sex (after corrections) 
ASR (per 100,000)  
All 5 provinces Ardebil Kerman Mazandaran Gilan Golestan Site 
Both Male Female Male Female Male Female Male Female Male Female Male Female
Lip 0.60 0.80 0.37 0.00 0.00 0.66 0.22 0.80 0.37 0.87 0.11 1.39 1.39 
Tongue 0.41 0.33 0.49 0.74 1.21 0.41 0.34 0.51 0.43 0.06 0.42 0.11 0.75 
Mouth 0.46 0.43 0.46 0.56 0.00 0.49 0.47 0.43 0.55 0.50 0.37 0.14 0.60 
Salivary glands 0.24 0.24 0.20 0.19 0.27 0.47 0.33 0.28 0.31 0.19 0.15 0.00 0.03 
Tonsil 0.09 0.09 0.07 0.21 0.40 0.13 0.00 0.00 0.05 0.07 0.07 0.18 0.00 
Other oropharynx 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.02 0.00 0.00 0.00 
Nasopharynx 0.47 0.64 0.28 0.36 0.13 0.28 0.32 1.29 0.48 0.53 0.25 0.10 0.00 
Hypopharynx 0.20 0.18 0.22 0.34 0.17 0.22 0.04 0.21 0.41 0.10 0.17 0.11 0.18 
Pharynx unspecified 0.24 0.26 0.20 0.91 0.45 0.00 0.07 0.13 0.12 0.25 0.18 0.54 0.44 
Esophagus 10.77 12.13 8.89 18.34 16.68 3.13 1.84 13.69 10.78 9.76 5.85 23.60 16.91 
Stomach 16.46 22.54 9.33 54.82 28.48 10.33 5.07 20.81 8.16 24.93 9.58 17.78 5.48 
Small intestine 0.39 0.48 0.27 0.15 0.08 0.41 0.36 0.47 0.33 0.77 0.29 0.12 0.09 
Colon 4.00 3.87 4.03 5.96 3.94 2.56 2.98 3.82 3.88 4.83 5.50 2.48 2.91 
Rectum 2.18 2.33 1.98 0.99 1.47 2.26 2.29 2.55 1.60 2.85 2.37 1.82 1.77 
Anus 0.19 0.24 0.13 0.40 0.48 0.26 0.24 0.29 0.07 0.14 0.05 0.18 0.00 
Liver 1.15 1.36 0.89 1.85 2.34 1.66 0.88 1.07 0.56 1.49 1.04 0.93 0.39 
Gallbladder 0.90 0.62 1.15 0.63 2.32 0.88 2.05 0.93 0.72 0.32 0.90 0.16 0.69 
Pancreas 1.14 1.32 0.88 0.87 0.93 1.04 0.96 1.35 0.78 1.73 1.03 1.25 0.49 
Nose, sinuses 0.17 0.22 0.12 0.25 0.24 0.05 0.12 0.30 0.15 0.32 0.16 0.03 0.00 
Larynx 1.76 2.90 0.46 1.16 0.24 3.68 0.67 4.20 0.51 2.41 0.50 1.02 0.13 
Lung, trachea & bronchus 4.23 6.50 1.63 8.60 3.27 7.62 2.62 8.39 1.33 5.26 1.12 1.48 0.73 
Other thoracic organs 0.27 0.34 0.19 0.14 0.17 0.79 0.47 0.18 0.13 0.40 0.12 0.05 0.15 
Bone 0.81 0.98 0.63 2.35 1.48 1.13 0.59 0.65 0.55 0.91 0.48 0.64 0.52 
Melanoma of skin 0.54 0.60 0.46 0.30 0.19 1.27 0.69 0.58 0.49 0.29 0.26 0.31 0.69 
Other skin 9.39 10.46 7.87 14.23 9.46 13.27 12.29 9.05 6.75 10.01 6.55 7.68 5.92 
Mesothelioma 0.04 0.04 0.04 0.00 0.00 0.00 0.04 0.04 0.03 0.09 0.05 0.03 0.05 
Kaposi sarcoma 0.10 0.15 0.05 0.18 0.00 0.08 0.00 0.13 0.00 0.25 0.14 0.09 0.04 
Connective and soft tissue 0.61 0.66 0.54 0.48 0.34 0.76 0.76 1.02 0.59 0.54 0.64 0.09 0.06 
Breast 7.21 1.05 13.30 0.75 8.43 0.57 16.61 1.28 14.01 1.36 13.02 0.86 10.96 
Vulva   0.12  0.14  0.17  0.11  0.03  0.19 
Vagina   0.27  0.25  0.11  0.18  0.29  0.62 
Cervix uteri   2.25  0.93  3.02  2.33  1.84  2.76 
Corpus uteri   1.04  0.40  0.75  0.87  1.68  0.99 
Uterus unspecified   1.05  3.83  0.60  0.81  0.76  1.02 
Ovary   1.99  1.65  2.04  1.71  2.28  2.12 
Other female genitalia   0.13  0.00  0.33  0.03  0.12  0.18 
Placenta   0.01  0.05  0.00  0.00  0.00  0.05 
Penis  0.07  0.15  0.09  0.05  0.02  0.10  
Prostate  5.62  5.14  3.64  5.00  8.65  5.36  
Testis  0.95  0.72  0.77  0.91  1.41  0.57  
Other male genitalia  0.01  0.00  0.00  0.02  0.00  0.00  
Kidney 1.00 1.25 0.71 2.41 0.00 0.95 0.55 0.83 0.70 1.64 1.07 1.01 0.59 
Renal pelvis 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.03 0.00 
Ureter 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.06 
Bladder 4.72 7.50 1.55 8.58 2.46 7.48 1.83 6.39 1.20 9.33 1.59 5.34 1.37 
Other urinary organs 0.02 0.02 0.02 0.00 0.08 0.06 0.00 0.02 0.00 0.00 0.05 0.00 0.00 
Eye 0.16 0.10 0.22 0.03 0.34 0.31 0.52 0.06 0.18 0.04 0.12 0.00 0.00 
Brain, nervous system 1.97 2.18 1.73 4.17 3.09 2.64 2.02 2.88 1.83 1.08 1.47 0.95 0.79 
Thyroid 1.32 0.69 1.93 0.65 1.27 0.84 2.49 0.55 1.21 0.83 2.82 0.46 1.35 
Adrenal gland 0.01 0.01 0.02 0.00 0.00 0.02 0.04 0.00 0.01 0.00 0.02 0.00 0.00 
Other endocrine 0.07 0.09 0.06 0.28 0.08 0.05 0.08 0.15 0.10 0.06 0.03 0.00 0.00 
Hodgkin disease 0.94 1.21 0.65 0.47 0.46 1.88 0.81 1.46 0.75 0.88 0.53 0.71 0.56 
Non-Hodgkin lymphoma 2.58 3.44 1.65 2.81 0.69 5.90 2.72 3.32 2.03 2.52 0.92 2.27 1.30 
Immunoproliferative 0.01 0.01 0.01 0.00 0.00 0.05 0.04 0.00 0.00 0.00 0.00 0.00 0.00 
Multiple myeloma 0.88 1.16 0.56 0.25 0.13 1.80 1.03 1.17 0.73 1.26 0.43 0.62 0.06 
Lymphoid leukemia 0.57 0.73 0.39 0.46 0.37 1.68 1.01 0.75 0.31 0.41 0.20 0.16 0.12 
Myeloid leukemia 0.31 0.33 0.29 0.29 0.24 0.76 0.60 0.31 0.41 0.14 0.09 0.13 0.02 
Leukemia unspecified 2.03 2.24 1.75 0.79 0.96 3.07 2.62 2.87 2.00 2.17 1.49 1.14 1.12 
Other and unspecified 3.89 4.54 3.24 6.80 6.86 4.04 3.37 3.99 2.82 5.05 2.85 2.78 2.42 
All sites 92.32 103.83 76.76 149.71 107.72 90.48 79.93 105.01 74.39 106.32 72.13 84.90 69.05 
All sites excluding skin 82.93 93.38 68.88 135.50 98.26 77.22 67.69 95.95 67.63 96.31 65.57 77.22 63.11 
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Appendix Table 26. Age-standardized rate (ASR) by cancer site, year and sex in four 
provinces (corrected for cases of unknown age and under-registration in elderly ages) 
ASR by Year and Sex in 4 Provinces  (Gilan, Mazandaran, Golestan and Kerman) 
1996 1997 1998 1999 2000 Site 
Male Female Male Female Male Female Male Female Male Female 
Lip 0.57 0.57 0.62 0.18 0.37 0.27 0.46 0.35 1.10 0.40 
Tongue 0.23 0.44 0.10 0.15 0.08 0.16 0.23 0.33 0.18 0.53 
Mouth 0.06 0.30 0.35 0.29 0.25 0.48 0.16 0.20 0.55 0.51 
Salivary glands 0.30 0.07 0.14 0.14 0.18 0.05 0.20 0.34 0.13 0.20 
Tonsil 0.11 0.00 0.06 0.04 0.07 0.00 0.04 0.04 0.00 0.00 
Other oropharynx 0.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Nasopharynx 0.34 0.06 0.30 0.00 0.48 0.30 0.59 0.24 0.46 0.39 
Hypopharynx 0.06 0.09 0.08 0.10 0.20 0.16 0.14 0.32 0.15 0.12 
Pharynx unspecified 0.13 0.13 0.29 0.08 0.14 0.17 0.17 0.13 0.11 0.09 
Esophagus 7.71 5.93 8.15 6.17 7.56 5.22 8.56 6.24 9.60 6.62 
Stomach 12.70 3.56 12.90 5.39 13.71 5.42 14.23 6.11 16.44 6.66 
Small intestine 0.34 0.16 0.50 0.20 0.35 0.10 0.47 0.28 0.36 0.29 
Colon 1.98 1.87 2.15 2.54 2.19 2.99 3.10 4.41 3.82 4.22 
Rectum 1.23 1.21 1.57 1.43 1.60 1.86 2.73 1.61 2.34 1.98 
Anus 0.11 0.05 0.16 0.14 0.38 0.04 0.05 0.11 0.00 0.08 
Liver 0.91 0.42 0.91 0.25 1.36 0.77 1.18 0.67 1.00 0.86 
Gallbladder 0.45 0.80 0.40 1.04 0.34 0.94 0.50 1.18 0.58 0.71 
Pancreas 0.55 0.35 1.54 0.68 1.04 0.47 1.18 0.76 1.37 0.95 
Nose, sinuses 0.07 0.00 0.04 0.05 0.24 0.12 0.15 0.04 0.01 0.07 
Larynx 2.46 0.30 1.28 0.27 2.05 0.38 2.52 0.41 2.51 0.40 
Lung, trachea & bronchus 2.73 0.73 4.67 1.65 4.90 1.02 4.24 1.18 6.61 1.56 
Other thoracic organs 0.09 0.05 0.15 0.22 0.19 0.22 0.31 0.25 0.78 0.09 
Bone 0.62 0.64 0.43 0.30 0.68 0.22 0.85 0.40 0.78 0.66 
Melanoma of skin 0.42 0.28 0.67 0.20 0.41 0.58 0.49 0.47 0.34 0.52 
Other skin 5.45 4.38 5.78 4.54 7.93 5.14 8.36 6.85 8.78 6.97 
Mesothelioma 0.02 0.05 0.00 0.05 0.05 0.02 0.00 0.00 0.00 0.11 
Kaposi sarcoma 0.04 0.00 0.12 0.00 0.07 0.08 0.19 0.07 0.10 0.07 
Connective and soft tissue 0.73 0.34 0.27 0.32 0.18 0.87 0.53 0.12 0.57 0.55 
Breast 0.44 8.54 0.49 7.75 0.94 9.47 0.66 13.31 0.37 13.92 
Vulva  0.00  0.03  0.08  0.20  0.04 
Vagina  0.21  0.18  0.16  0.32  0.32 
Cervix uteri  1.29  1.19  1.42  2.55  2.12 
Corpus uteri  0.69  0.60  0.67  0.94  0.76 
Uterus unspecified  0.37  0.21  0.62  0.82  0.99 
Ovary  1.14  1.05  1.32  2.43  1.80 
Other female genitalia  0.18  0.12  0.08  0.07  0.10 
Placenta  0.00  0.00  0.00  0.00  0.04 
Penis 0.03  0.07  0.00  0.11  0.00  
Prostate 3.76  4.66  5.46  4.48  4.48  
Testis 0.52  0.30  0.54  1.04  0.89  
Other male genitalia 0.00  0.00  0.00  0.00  0.04  
Kidney 0.51 0.37 0.66 0.50 1.24 0.68 1.36 0.82 1.05 0.78 
Renal pelvis 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.05 0.00 
Ureter 0.00 0.00 0.00 0.00 0.00 0.04 0.00 0.00 0.00 0.00 
Bladder 4.38 0.82 4.41 0.92 6.66 1.51 6.21 1.30 7.58 1.45 
Other urinary organs 0.00 0.00 0.04 0.00 0.04 0.00 0.00 0.00 0.00 0.00 
Eye 0.07 0.07 0.03 0.15 0.16 0.18 0.16 0.31 0.05 0.14 
Brain, nervous system 1.44 1.60 1.29 0.90 1.31 1.36 1.90 1.54 1.50 1.02 
Thyroid 0.53 1.50 0.44 1.63 0.74 1.79 0.27 1.78 0.66 1.13 
Adrenal gland 0.00 0.00 0.00 0.07 0.03 0.02 0.00 0.00 0.00 0.00 
Other endocrine 0.18 0.08 0.07 0.00 0.02 0.10 0.02 0.08 0.02 0.02 
Hodgkin disease 0.93 0.48 0.94 0.20 1.11 0.45 1.15 0.69 1.10 0.86 
Non-Hodgkin lymphoma 2.28 1.19 1.95 0.86 2.51 1.23 3.58 1.88 3.38 1.69 
Immunoproliferative 0.05 0.00 0.00 0.05 0.00 0.00 0.00 0.00 0.00 0.00 
Multiple myeloma 0.60 0.16 0.96 0.50 1.35 0.40 0.95 0.74 1.52 0.77 
Lymphoid leukemia 0.53 0.16 1.13 0.29 0.51 0.61 0.73 0.46 0.44 0.34 
Myeloid leukemia 0.28 0.18 0.29 0.31 0.28 0.40 0.41 0.25 0.30 0.17 
Leukemia unspecified 1.43 1.23 2.16 1.28 1.93 1.92 2.39 1.62 2.74 1.87 
Other and unspecified 2.73 2.03 2.23 2.05 3.56 2.15 3.30 2.37 4.23 2.78 
All sites 61.02 45.12 65.51 47.04 75.32 54.67 80.26 67.62 89.10 68.66 
All sites excluding skin 55.57 40.73 59.73 42.50 67.38 49.54 71.90 60.77 80.31 61.68 
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Method of calculating adjusted relative age-standardized rate 
 
Appendix Table 27. Calculation of relative age-standardized ratio (RASR) and adjusted 
relative age-standardized rate (ARASR) from age-standardized rate (ASR) 
Cancer 
Site Age-standardized rate (ASRCi_y)* 
Ci ASRCi_1 ASRCi_2  ASRCi_3 … ASRCi_k 
C1 ASRC1_1 ASRC1_2  ASRC1_3 … ASRC1_k 
C2 ASRC2_1 ASRC2_2  ASRC2_3 … ASRC2_k 
C3 ASRC3_1 ASRC3_2  ASRC3_3 … ASRC3_k 
… … …  … … … 
Cn ASRCn_1 ASRCn_2  ASRCn_3 … ASRCn_k 
Leukemia ASRLeukemia_1 ASRLeukemia_2  ASRLeukemia_3 … ASRLeukemia_k 
       
 Relative age-standardized ratio (RASRCi_y = ASRCi_y / ASRLeukemia_y) 
Ci RASRCi_1 RASRCi_2  RASRCi_3 … RASRCi_k 
C1 RASRC1_1 = ASRC1_1/ASRLeukemia_1 RASRC1_2 = ASRC1_2/ASRLeukemia_2  RASRC1_3 … RASRC1_k 
C2 RASRC2_1 = ASRC2_1/ASRLeukemia_1 RASRC2_2  RASRC2_3 … RASRC2_k 
C3 RASRC3_1 RASRC3_2  RASRC3_3 … RASRC3_k 
… … …  … … … 
Cn RASRCn_1 RASRCn_2  RASRCn_3 … RASRCn_k 
       
 
Adjusted relative age-standardized rate (ARASRCi_y = RASRCi_y × Sum(ASRCi_1, ASRCi_2, …, ASRCi_k) / Sum(RASRCi_1, 
RASRCi_2,…,RASRCi_k) 
Ci ARASRCi_1 ARASRCi_2  ARASRCi_3 … ARASRCi_k 
C1 
ARASRC1_1= RASRC1_1 × ∑ ASRC1_1,...,C1_k / ∑ RASRC1_1…C1_k 
ARASRC1_2= RASRC1_2  × ∑ ASRC1_1…C1_k / ∑ RASRC1_2…C1_k  ARASRC1_3 … ARASRC1_k 
C2 
ARASRC2_1= RASRC2_1 ×  ∑ ASRC2_1…C2_k / ∑ RASRC2_...C2_k ARASRC2_2  ARASRC2_3 … ARASRC2_k 
C3 ARASRC3_1 ARASRC3_2  ARASRC3_3 … ARASRC3_k 
… … …  … … … 
Cn ARASRCn_1  ARASRCn_2   ARASRCn_3 … ARASRCn_k 
* “Ci” is the cancer site (C1 to Cn; for example C16 is Stomach) and “y” is the calendar year (1 to k). 
Time trend in Finland 
 
 
Appendix Figure 6. Time trend of age-standardized rate (ASR) of leukemia in Finns 
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Appendix Figure 7. Age-standardized rate (ASR), relative age-standardized ratio 
(RASR) and adjusted relative age-standardized rate (ARASR) of four leading cancers 
in Finnish men 
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Appendix Figure 8. Time trend of age-standardized rate (ASR) and adjusted relative age-
standardized rate (ARASR) of cancer, Finland and fitted linear regression line 
 
 
Appendices 
193 
Comparison between Iran and the rest of the world 
 
 
Appendix Figure 9. Comparison between age-standardized rate (/100,000 person-years) of 
cancers in Iran and World 
 
 
